0001493152-19-012130.txt : 20190813 0001493152-19-012130.hdr.sgml : 20190813 20190813111012 ACCESSION NUMBER: 0001493152-19-012130 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAURIGA SCIENCES, INC. CENTRAL INDEX KEY: 0001142790 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 651102237 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53723 FILM NUMBER: 191018842 BUSINESS ADDRESS: STREET 1: 555 MADISON AVENUE STREET 2: 5TH FLOOR SUITE 506 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 917-796-9926 MAIL ADDRESS: STREET 1: 555 MADISON AVENUE STREET 2: 5TH FLOOR SUITE 506 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Immunovative, Inc. DATE OF NAME CHANGE: 20120503 FORMER COMPANY: FORMER CONFORMED NAME: Novo Energies Corp DATE OF NAME CHANGE: 20090626 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC WINE AGENCIES INC DATE OF NAME CHANGE: 20040622 10-Q 1 form10-q.htm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2019

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission file number 000-53723

 

 

TAURIGA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Florida   30-0791746

(State or other jurisdiction of

incorporation or organization)

   (I.R.S. Employer
Identification No.)

 

555 Madison Avenue, 5th Floor

New York, NY 10022

(Address of principal executive offices) (Zip Code)

 

(917) 796-9926

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Exchange Act:

None

 

Securities registered under Section 12(g) of the Exchange Act:

 

Common Stock, $.00001 Par Value

(Title of class)

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [  ] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or, an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company”, in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [  ]
Non-accelerated filer [  ]   Smaller reporting company [X]
Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of August 13, 2019, the registrant had 76,145,090 shares of its Common Stock, $0.00001 par value, outstanding.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   TAUG   OTCQB

 

 

 

 
 

 

TABLE OF CONTENTS

 

      Pages
       
PART I. FINANCIAL STATEMENTS    
       
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:   F-1
       
  Condensed Consolidated Balance Sheets as of June 30, 2019 and March 31, 2019 (unaudited)   F-1
       
  Condensed Consolidated Statements of Operations for the three months ended June 30, 2019 and 2018 (unaudited)   F-2
       
  Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three months ended June 30, 2019 and year ended March 31, 2019 (unaudited)   F-3
       
  Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2019 and 2018 (unaudited)   F-4
       
  Notes to Condensed Consolidated Financial Statements (unaudited)   F-5
       
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   3
       
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK   16
       
Item 4. CONTROLS AND PROCEDURES   17
       
PART II. OTHER INFORMATION    
       
Item 1. LEGAL PROCEEDINGS   19
       
Item 1A. RISK FACTORS   19
       
Item 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS   22
       
Item 3. DEFAULTS UPON SENIOR SECURITIES   27
       
Item 4. MINE SAFETY DISCLOSURES   27
       
Item 5. OTHER INFORMATION   27
       
Item 6. EXHIBITS   28

 

2
 

 

PART I. FINANCIAL STATEMENTS

 

TAURIGA SCIENCES, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN US$)

(UNAUDITED)

 

   June 30, 2019   March 31, 2019 
        
ASSETS          
Current assets:          
Cash  $15,247   $385,943 
Assets from discontinued operations   -    581 
Accounts receivable   28,028    - 
Investment - trading securities   444,785    350,400 
Investment - other   92,900    72,500 
Inventory asset   138,606    10,872 
Prepaid expenses and other current assets   85,675    127,520 
Total current assets   805,241    947,816 
           
Lease right of use asset   9,071    - 
Property and equipment, net   12,778    13,010 
           
Total assets  $827,090   $960,826 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current liabilities:          
Notes payable, net of discounts  $235,420   $213,875 
Accounts payable   27,168    34,703 
Accrued interest   16,946    30,780 
Accrued expenses   18,588    - 
Liabilites from discontinued operations   -    5,522 
Liability for common stock to be issued   -    172,500 
Lease liability - current portion   7,300    - 
Deferred revenue   162    - 
Total current liabilities   305,584    457,380 
           
Lease liability - net of current portion   2,171    - 
           
Total liabilities   307,755    457,380 
           
Stockholders’ equity (deficit):          
Common stock, par value $0.00001; 100,000,000 shares authorized, 72,925,920 and 68,123,326 outstanding at June 30, 2019 and March 31, 2019, respectively   729    681 
Additional paid-in capital   56,665,512    55,991,704 
Accumulated deficit   (56,146,906)   (55,488,939)
Accumulated other comprehensive income   -    - 
Total stockholders’ equity (deficit)   519,335    503,446 
           
Total liabilities and stockholders’ equity (deficit)  $827,090   $960,826 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-1
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN US$)

(UNAIDITED)

 

   For the three months ended 
   June 30, 
   2019   2018 
         
Revenues  $44,377   $- 
Cost of goods sold   29,418    - 
           
Gross profit   14,959    - 
           
Operating expenses          
Marketing and advertising   130,548    - 
Research and development   3,852    - 
General and administrative   628,841    222,038 
Depreciation and amortization expense   232    259 
Total operating expenses   763,473    222,297 
           
Loss from operations   (748,514)   (222,297)
           
Other income (expense)          
Interest expense   (121,814)   (23,496)
Unrealized gain on trading securities   94,385    78,170 
Gain on the extinguishment of debt   113,467    - 
Gain on disposal of discontinued operations   4,941    - 
Loss on exchange from bitcoin   -    (37)
Unrealized loss on digital currency   -    (5,572)
Gain (loss) on sale of trading securities   -    340,020 
Foreign exchange   (29)   - 
Total other income (expense)   90,950    389,085 
           
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND LOSS FROM DISCONTINUED OPERATIONS        (657,564  )        166,788   
           
INCOME (LOSS) FROM DISCONTINUED OPERATIONS   -    - 
           
Net income (loss)   (657,564)   166,788 
           
Net income (loss) attributable to non-controlling interest   -    - 
Net income (loss) attributable to controlling interest   (657,564)   166,788 
           
Net income (loss) attributable to common shareholders  $(657,564)  $166,788 
Income (loss) per share - basic and diluted - Continuing operations  $(0.012)  $0.003 
Income (loss) per share - basic and diluted - Discontinuing operations  $-   $- 
Weighted average number of shares outstanding - basic   55,767,119    53,662,728 
           
Income (loss) per share - fully diluted  $(0.012)  $0.003 
Weighted average number of shares outstanding - fully diluted   55,767,119    59,359,187 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-2
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND THE YEAR ENDED MARCH 31, 2019

(UNAUDITED)

 

   Number of      

Additional

paid-in

   Accumulated  

Accumulated
other

comprehensive

  

Non-

Controlling

  

Total

stockholders’

 
   shares   Amount   capital   deficit   income (loss)   Interest   deficit 
                             
Balance at March 31, 2018   52,264,476    523    54,680,382    (54,391,500)   8,042    (2,196)   295,251 
Shares issued for note conversion at $0.002888 per share   1,985,754    20    57,319    -    -    -    57,339 
Stock-based compensation vesting   -    -    43,221    -    -    -    43,221 
Stock issued for services at $0.345 to $0.42   130,000    1    (1)   -    -    -    - 
Reclassification of other comprehensive income to additional paid in capital   -    -    8,042    -    (8,042)   -    - 
Net loss for the three months ended June 30, 2018   -    -    -    166,788    -         166,788 
                                    
Balance at June 30, 2018   54,380,230    544    54,788,963    (54,224,712)   -    (2,196)   562,599 
                                    
Stock-based compensation vesting   -    -    132,055    -    -    -    132,055 
Net loss for the three months ended September 30, 2018   -    -    -    (265,552)   -         (265,552)
                                    
Balance at September 30, 2018   54,380,230    544    54,921,018    (54,490,264)   -    (2,196)   429,102 
                                    
Shares issued for note conversion at $0.0245 per share   1,000,000    10    24,490    -    -    -    24,500 
Stock-based compensation vesting   -    -    11,769    -    -    -    11,769 
Stock issued for services at $0.0269   1,750,000    18    (18)   -    -    -    - 
Net loss for the three months ended December 31, 2018   -    -    -    (377,982)   -         (377,982)
                                    
Balance at December 31, 2018   57,130,230    572    54,957,259    (54,868,246)   -    (2,196)   87,389 
                                    
Issuance of shares via private placement at $0.02 to $0.06 per share   5,686,667    56    301,144    -    -    -    301,200 
Issuances of commitment shares - debt financing at $0.042 per share   500,000    5    20,995    -    -    -    21,000 
Shares issued for note conversion at $0.0357 to $0.0452 per share   2,960,762    30    118,849    -    -    -    118,879 
Stock-based compensation vesting   -    -    109,660    -    -    -    109,660 
Stock issued for services at $0.0495   1,250,000    12    (12)   -    -    -    - 
Shares issued for settlement of contingent liability at $0.0405   500,000    5    74,995    -    -    -    75,000 
Shares issued for settlement of debt at $0.2091   95,667    1    20,003    -    -    -    20,004 
Recognition of benficial conversion feature of convertible notes   -    -    388,811    -    -    -    388,811 
Non-controlling interest   -    -    -    -    -    2,196    2,196 
Net loss for the year ended March 31, 2019   -    -    -    (620,693)   -         (620,693)
                                    
Balance at March 31, 2019   68,123,326   $681   $55,991,704   $(55,488,939)  $-   $-   $503,446 
                                    
Issuance of shares via private placement at $0.06 to $0.07 per share   714,286    7    44,993    -    -    -    45,000 
Issuances of commitment shares - debt financing at $0.19 per share   750,000    8    142,492    -    -    -    142,500 
Shares issued for note conversion at $0.04725 per share   888,308    9    41,964    -    -    -    41,973 
Stock-based compensation vesting   -    -    375,720    -    -    -    375,720 
Stock issued for services at $0.07 to $0.16   2,450,000    24    (24)   -    -    -    - 
Shares issued for settlement of debt   -    -    -    -    -    -    - 
Recognition of benficial conversion feature of convertible notes   -    -    68,663    -    -    -    68,663 
Cumulative affect of adoption of Lease standard ASC 842   -    -    -    (403)   -    -    (403)
Net loss for the three months ended June 30, 2019   -    -    -    (657,564)   -         (657,564)
                                    
Balance at June 30, 2019   72,925,920   $729   $56,665,512   $(56,146,906)  $-   $-   $519,335 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-3
 

 

TAURIGA SCIENCES, INC. AND SUBSDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN US$)

(UNAUDITED)

 

   For the three months ended 
   June 30, 
   2019   2018 
         
Cash flows from operating activities          
Net income (loss)  $(657,564)  $166,788 
Adjustments to reconcile net loss to cash used in operating activities:          
Amortization of original issue discount   8,673    3,561 
Non-cash lease operating lease expense   (3)   - 
Unrealized loss on digital currency   -    5,572 
Depreciation and amortization   232    259 
Gain on extinguishment of debt   (113,468)   - 
Amortization of debt discount   101,535    - 
Common stock issued and issuable for services (including stock-based compensation)   375,720    43,221 
Gain on disposal of discontinued operation   (4,941)   - 
(Gain) loss on sale of trading securities   -    (339,810)
Unrealized gain on trading securities   (94,385)   (78,170)
(Increase) decrease in assets          
Prepaid expenses   41,845    31,450 
Inventory   (127,734)   - 
Proceeds (purchase) of trading securities, net   -    128,983 
Accounts receivable   (28,028)   - 
Increase (decrease) in liabilities          
Accounts payable   (7,535)   22,224 
Deferred revenue   162    - 
Accrued expenses   18,588    12,134 
Accrued interest   11,607    19,906 
Cash used in operating activities   (475,296)   16,118 
           
Cash flows from investing activities          
Contribution into Ice + Jam   -    - 
Proceeds (purchase) of digital currency, net   -    (7,831)
Investment - other   (20,400)   - 
Purchase of property and equipment   -    (10,086)
Cash provided by (used in) investing activities   (20,400)   (17,917)
           
Cash flows from financing activities          
Repayment of principal on notes payable to individuals and companies   -    - 
Proceeds from the sale of common stock (including to be issued)   15,000    - 
Proceeds from notes payable to individuals and companies   110,000    25,000 
Cash provided by financing activities   125,000    25,000 
Net increase in cash   (370,696)   23,201 
           
Cash, beginning of period   385,943    12,291 
Cash, end of period  $15,247   $35,492 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Interest Paid  $-   $- 
Taxes Paid  $-   $- 
           
NON CASH ITEMS          
Recognition of lease liability and right of use asset at inception  $12,066   $- 
Conversion of notes payable and accrued interest for common stock  $41,973   $200,718 
Original issue discount on notes payable and debentures  $10,000   $- 
Recognition of debt discount  $68,663   $- 
Reclassification of other comprehensive income to additional paid in capital  $-   $8,042 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-4
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS

 

The unaudited condensed consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain certain information included in the Company’s annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the March 31, 2019 Form 10-K filed with the SEC, including the audited consolidated financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these condensed consolidated financial statements are reasonable, the accuracy of the amounts is in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company later in the year.

 

These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary to present fairly the operations and cash flows for the periods presented.

 

Nature of Business

 

Tauriga Sciences, Inc. (the “Company”) is a Florida corporation. The Company has, over time, moved into that of a diversified life sciences technology company, with its mission to operate a revenue generating business, while continuing to evaluate potential acquisition candidates operating in the life sciences technology space.

 

TAURI-GUMTM

 

In October 2018, the Company’s management, along with its board of directors, began to explore the possibility of launching a cannabidiol (“CBD”) infused gum product line into the commercial marketplace. After several weeks of diligence, discussions with various parties and exploratory meetings, the Company made the determination to move forward with this business opportunity.

 

To begin this process, during the quarter ended December 31, 2018, the Company began discussions with a Maryland based chewing gum manufacturer - Per Os Biosciences LLC (“Per Os Bio”), which consummated in a manufacturing agreement in late December 2018 to launch and bring to market a white label line of CBD infused chewing gum under the brand name Tauri-Gum™. We have filed for trademark protection with the United States Patent and Trademark Office for our CBD infused chewing product line, including applications filed in April 2019 for TAURI-GUMMITM and TAURI-GUMMIESTM.

 

Under the terms of the agreement, Per Os Bio has committed to produce the Tauri-GumTM based on the following criteria:

 

  A. By composition, the CBD Gum will contain 10 mg of CBD Isolate
  B. The initial production run will be mint flavor exclusively
  C. This proprietary CBD Gum will be manufactured under U.S. Patent # 9,744,128 (“Method for manufacturing medicated chewing gum without cooling”)
  D. Each Production Batch, including the initial production run, is estimated to yield 70,000 gum tablets or 8,700 Units (each Unit contains 8 gum tablets).
  E. Integrated Quality Control Procedures: Each production batch will be tested by a 3rd Party for CBD label content, THC content (0%), and clear for microbiology.
  F. The packaging, for retail marketplace, will consist of 8 count (gum tablet count) blister card labeled (the “Pack(s)”) with Lot # as well as Expiration Date.
  G. Outer sleeve in the Company’s artwork and graphic design(s) and label copy
  H. Shipping System: Bulk packed 266 Packs per master case (“Palletized”)

 

F-5
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Nature of Business (Continued)

 

TAURI-GUMTM (Continued)

 

Under terms of the Agreement, the Company has committed to provide the following to Per Os Bio:

 

  A. Each product order will consist of exactly 8,700 Packs (unless otherwise agreed upon by both parties).
  B. ½ of initial production invoice due within 3 days of execution of Manufacturing Agreement (this has already been paid by the Company).
  C. Provide graphic design artwork, logo, and label design to Per Os Bio.
  D. Trademark has been successfully filed with U.S.P.T.O.
  E. To implement Kosher Certification Process
  F. Procure appropriate Product & Liability insurance policy
  G. Acquire legal opinion with respect to the confirmation of the legality to sell this CBD Gum – on the Federal Statute Level.

 

The Company gum formulation includes distinctive features: allergen free, gluten free, vegan, kosher (K-Star certification), and incorporates a proprietary manufacturing process. See our “Risk Factors” contained in this Annual Report, including with respect, but not limited, to Federal laws and regulations that govern CBD and cannabis.

 

The Company E-commerce website is www.taurigum.com. The Company has also secured storage space near its New York City headquarters.

 

During the first quarter of fiscal year 2020, the Company began production of Blood Orange flavor of Tauri-GumTM. The Company plans to offer Pomegranate flavored Tauri-GumTM in the near term, which will be in addition to their mint and blood orange flavored products.

 

On April 9, 2019, the Company announced that it is developing a special miniaturized version of Tauri-GumTM for sale at airport retail stores. The Company envisions this Airport version consisting of a miniaturized blister pack (containing three pieces of its CBD Infused gum), with an anticipated retail price of $6.99 per unit.

 

The Company is also working on developing CBD Gum-Infused Lollipops and gummi products.

 

Tauri-GumTM Distribution Agreements

 

E&M Ice Cream Company

 

On April 1, 2019, the Company entered into a comprehensive distribution agreement with E&M Ice Cream Company (“E&M”) to establish Tauri-GumTM in the marketplace (the “E&M Distribution Agreement”). The Company has supported the Tauri-GumTM commercial launch with substantial levels of both financial resources and marketing support. The Company had both received payment for and delivered the product for its previously announced $54,000 Tauri-GumTM purchase order during March 2019, and re-orders in the first quarter of fiscal 2020. The Company has agreed to issue a one-time issuance of 1,000,000 restricted shares of the Company’s common stock, and to tender a one-time cash payment of $125,000 to E&M. This $125,000 cash component was paid in full to E&M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. The Company is awaiting issuance instructions from E&M to issue the shares

 

F-6
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Tauri-GumTM Distribution Agreements (Continued)

 

South Florida Region Distribution Agreement

 

On April 8, 2019, the Company entered into a non-exclusive distribution agreement with IRM Management Corporation (“IRM”), an established medical practice management firm (the “IRM Distribution Agreement”). The purpose of the IRM Distribution Agreement is to target our Tauri-Gum™ product to the South Florida based medical market, including chiropractors, orthopedists, as well as prospective retail customers in this geographic area.

 

Under terms of this IRM Distribution Agreement, the Company will work closely with IRM to promote Tauri-Gum™. In connection with this IRM Distribution Agreement, the Company has also agreed to a one-time issuance of 450,000 shares of the Company’s restricted common stock and a cash stipend of $10,000 to IRM. As of the date of this report, only $2,000 of the $10,000 cash stipend has been paid. The value of the shares will be reflected in stock-based compensation based on the grant date of April 8, 2019.

 

North Eastern United States Distribution Agreement

 

On April 30, 2019, the Company, entered into a non-exclusive comprehensive distribution agreement with Sai Krishna LLC (“SKL”), a New Jersey based distributor, with relationships in the Northeast region of the United States and Asia, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line in the applicable regions.

 

In connection with the SKL Agreement, the Company has agreed to issue a one-time issuance of an aggregate of 1,000,000 restricted common shares the Company’s stock, which are subject to the customary resale and transfer restrictions imposed under the rules and regulations of the Securities and Exchange Commission. The restricted equity issuance to SKL was issued in accordance with the following schedule: (i) to Mr. Mahesh Lekkala, 500,000 restricted shares the Company’s common stock within ten (10) business days of April 30, 2019; and (ii) to SKL, 500,000, which were permitted to be immediately allocated by SKL to persons within its organization and, as such, (a) 250,000 of such shares shall be issued to SKL within ten (10) business days of April 30, 2019, and the additional issuance of (b) 250,000 of such shares shall be issued to SKL within ten (10) business days of August 1, 2019, which shares were issued on August 1, 2019. Other than the payment terms for Tauri-GumTM product purchased and distributed under the terms of the Agreement, there is no additional cash payment currently due or owing by the Company thereunder. The value of the shares is reflected as stock-based compensation with a grant date of April 30, 2019. All but 250,000 shares are expensed on this date, with those 250,000 shares valued over the term of the one-year agreement.

 

On May 11, 2019, the Company entered into a sub-agreement pursuant to the SKL distribution agreement whereby Ms. Neelima Lekkala was appointed Vice President of Distribution & Marketing. This contract has a one-year term and is and may be extended based upon mutual agreement. Ms. Lekkala shall focus her efforts on the expansion of Tauri-GumTM as well as revenue growth, acquisition of new customers, establishment of professional marketing materials & protocols, logistics improvement(s) and fulfillment services. Ms. Lekkala is deeded a non-affiliate and does not carry any type of fiduciary liability. Ms. Lekkala’s compensation includes 250,000 shares of the Company’s restricted common stock deemed fully earned and vested upon the execution of her consulting agreement. These shares were issued May 20, 2019, having a value of $18,275 based on the closing price of the Company’s stock on that day ($0.0731 per share). Additionally, Ms. Lekkala will receive a 30% commission on total gross sales through the sale of the Tauri-GumTM product line which can be paid in either stock or cash at the election of Ms. Lekkala.

 

F-7
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Tauri-GumTM Distribution Agreements (Continued)

 

Windmill Health Distribution Agreement

 

On June 28, 2019, the Company entered into a distribution agreement with Windmill Health Products, LLC (“Windmill Health”), a New Jersey based distributor, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line. Simultaneous with the Company’s entry into the Windmill Health agreement, Windmill Health placed an initial purchase order with us totaling $46,848, split evenly between packages of the Mint flavored and Blood-Orange flavored chewing gum product lines. The Company did not contribute any capital or issue any equity to Windmill Health in connection with the Windmill Health distribution agreement

 

Food and Drug Administration

 

On May 31, 2019, the U. S. Food and Drug Administration (“FDA”) held public hearings to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The hearing came approximately five months after the Agricultural Improvement Act of 2018 (more commonly known as the Farm Bill), went into effect and removed industrial hemp from the Schedule I prohibition under the Controlled Substances Act (CSA) (industrial hemp means cannabis plants and derivatives that contain no more than 0.3 percent tetrahydrocannabinol, or THC, on a dry weight basis).

 

Though the Farm Bill removed industrial hemp from the Schedule I list, the Farm Bill preserved the regulatory authority of the FDA over cannabis and cannabis-derived compounds used in food and pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act. The FDA has been clear that it intends to use this authority to regulate cannabis and cannabis-derived products, including CBD, in the same manner as any other food or drug ingredient. In addition to holding the hearing, the agency had requested comments by July 2, 2019 regarding any health and safety risks of CBD use, and how products containing CBD are currently produced and marketed, which comment period was then extended by two weeks following July 2nd.

 

2019 Increase in Authorized Shares

 

On July 26, 2019, the Company held a meeting of its board of directors. The matters voted on and approved at the meeting included an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock, $0.00001 par value per share from 100,000,000 to 400,000,000 shares (the “Authorized Shares Increase”). In this regard, a Preliminary Proxy Statement which was filed with the Securities and Exchange Commission on July 29, 2019.

 

2018 Reverse Stock Split

 

On July 8, 2018, the Company implemented a Reverse Stock Split with a ratio of 1-for-75 (which became effective July 9, 2018). The par value and other terms of the common stock were not affected by the Reverse Stock Split. In addition, the amendment to the Company’s articles of incorporation that effected the Reverse Stock Split simultaneously reduced the number of authorized shares of Common Stock from 7,500,000,000 to 100,000,000.

 

The Reverse Stock Split affected all issued and outstanding shares of common stock, as well as common stock underlying stock options, warrants and other convertible securities outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split has reduced the number of outstanding shares of the common stock outstanding prior to the Reverse Stock Split from 4,078,179,672 shares to 54,380,230 shares immediately following the Reverse Stock Split. No fractional shares were issued as a result of the Reverse Stock Split, and any such stockholders whose number of post-split shares would have resulted in a fractional number had his/her/its shares rounded up to the next number of shares. On July 30, 2018, the Company’s stock began trading on the OTC:QB.

 

All references set forth in this annual report to number of shares or per share data have been presented on a post reverse stock-split basis.

 

F-8
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Cupuaçu Butter Lip Balm

 

On December 23, 2016, the Company entered into a non-exclusive, 12-month license agreement (the “License Agreement”) with Cleveland, Ohio based cosmetics products company Ice + Jam LLC (“Ice + Jam”) to market Ice + Jam’s proprietary cupuaçu butter lip balm, sold under the trademark HerMan® which launched during the quarter ended December 31, 2017.During February of 2018, the Company’s strategy with respect to the HerMan® product was negatively impacted by a series of product defects relating to the twisting mechanism of the lip balm tube. As a result of this and the concomitant halting of selling efforts, the Company had no sales of the HerMan® product during the three months ended June 30, 2019 or the year ended March 31, 2019. The Company has removed the product from the website and the remaining inventory was written off as it was determined that the units were not usable. The Company has discontinued this operation as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.

 

Honeywood

 

Following the termination of a proposed 2014 merger between the Company and California-based Honeywood LLC (“Honeywood”), a developer of a topical medicinal cannabis product, on August 1, 2017, the Company entered into a Debt Conversion Agreement, whereby the Company agreed to convert an $170,000 note receivable due from Honeywood, including accrued interest into a 5% membership interest in Honeywood.

 

The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320-10-35-28, “Investments—Debt and Equity Securities”, a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: a) the investment experiences a recovery of fair value up to (or beyond) its cost; or b) the entity recognizes an other-than-temporary impairment loss. At the time of the Honeywood Conversion Agreement, the receivable balance under the note of $199,119 had been fully written off by the Company in a prior period. As a result of the Honeywood Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this period.

 

Pilus Energy

 

On January 28, 2014, the Company acquired Pilus Energy, LLC (“Pilus”), an Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that create electricity while consuming polluting molecules from wastewater.

 

On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus back to Open Therapeutics for consideration of the termination of 80% of the unexercised portion of the warrants to purchase the Company’s common stock. Open Therapeutics agreed to pay to the Company 20% of the net profit generated Pilus Energy from its previous year’s earnings, if any. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish a $75,000 contingent liability, whereby Open Therapeutics was to receive the first $75,000 of net profit earned from the operations of Pilus Energy in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share).

 

F-9
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Tauriga Biz Dev Corp

 

On January 4, 2018, the Company announced that its Board of Directors unanimously approved the formation a wholly-owned subsidiary focused on acquiring interest(s) in patents and other intellectual property. This subsidiary, incorporated in Delaware, was named Tauriga IP Acquisition Corp. On March 25, 2018, the Company changed the name to Tauriga Biz Dev Corp. (“Tauriga BDC”).

 

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink Charging Co. (“Blink”) (Nasdaq: BLNK) to be a non-exclusive independent sales representative. Under the terms of this agreement with Blink, the Company is permitted to solicit orders from potential customers for electric vehicle (“EV”) charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company’s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The rest of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.

 

As of June 30, 2019, Tauriga BDC has not installed any of these machines in any locations and no revenue has been generated through the Blink contract.

 

Tauriga Sciences Limited

 

On June 10, 2019, the Company formed a wholly owned subsidiary, Tauriga Sciences Limited, with the registrar of Companies for Northern Ireland. Tauriga Sciences Limited is a private limited Company. The entity was established in conjunction with online merchant services. In conjunction to this new entity the Company entered into a two-year lease commencing on June 11, 2019 and expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).

 

Going Concern

 

During the fourth quarter of the year ended March 31, 2019, the Company began sales and marketing efforts for its Mint flavored Tauri-GumTM product. During the three months ended March 31, 2019, the Company recognized sales of $57,134 and recognized a gross profit of $20,006, which has continued into the first fiscal quarter ended June 30, 2019 where the Company recognized revenue of $44,377 and a gross profit of $14,959. During the first quarter of fiscal year 2020, the Company has entered into multiple distribution agreements and has engaged an independent contractor to act as Vice President of Distribution and Marketing. Although the Company’s working capital surplus of $499,657 at June 30, 2019, has remained constant in the past year, the Company still believes that there is uncertainty with respect to continuing as a going concern.

 

F-10
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 1 – BASIS OF OPERATIONS (CONTINUED)

 

Going Concern (Continued)

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

The Company, in the short term, intends to continue funding its operations either through cash-on-hand or through financing alternatives. Management’s plans with respect to this include raising capital through equity markets to fund future operations as well as the possible sale of its remaining marketable securities which had a market value of $444,785 at June 30, 2019. In the event the Company cannot raise additional capital to fund and/or expand operations or fails to raise adequate capital and generate adequate sales revenue, it could result in the Company having to curtail or cease operations. Currently, the Company has a limited amount of shares of common stock available to issue under its articles of incorporation and has initiated the process of increasing the authorized stock.

 

Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues in the short term there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations to achieve profitability thereby eliminating its reliance on alternative sources of funding. Although management believes that the Company is in a stronger position it has been in in several years, there is still no guarantee that profitable operations with sufficient cashflow to sustain operations can or will be achieved without the need of alternative financing, which is limited. These matters still raise significant doubt about the Company’s ability to continue as a going concern as determined by management. The Company believes that there is uncertainty with respect to continuing as a going concern until the operating business can achieve more than nominal sales and profitable operations and sustain cash flow to operate the Company for a period of twelve months. In the event the Company does need to raise additional capital to fund operations or engage in a transaction, failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreements or ownership interests in life science companies and generate adequate revenues, or the agreements entered into recently are unsuccessful, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern as determined by management. However, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Condensed Consolidated Financial Statements

 

The condensed consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga BDC and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of June 30, 2019, there is no activity in any of the Company’s subsidiaries other than Tauriga BDC holding the electric car chargers and the leasehold interest in Tauriga Sciences Limited.

 

F-11
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of HerMan® using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company’s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.

 

As of June 30, 2019, the Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.

 

During the three months ended March 31, 2019, the Company recognized its first sales of Tauri-GumTM, primarily vis-à-vis its entry in the E&M Distribution Agreement.

 

The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company’s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized revenue from operations in the amount of $44,377 during the three months ended June 30, 2019 compared to no revenue for the same period in the prior year. All revenue is from the sale of the Company’s Tauri-GumTM product line and there were accounts receivable of $28,028 currently outstanding for these sales.

 

The Company recognized no revenue from discontinued operations during the three months ended June 30, 2018 which was related to the sales of the HERMAN® lip balm product.

 

F-12
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Sales Refunds

 

The Company’s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-GumTM distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of June 30, 2019 however will monitor the refunds to estimate whether a reserve will be required.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Equivalents

 

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At June 30, 2019, the Company’s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At June 30, 2019 and March 31, 2019, the Company had a cash balance of $15,247 and $385,943, respectively. The Company’s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of June 30, 2019 and March 31, 2019.

 

Investment in Trading Securities

 

Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss.

 

For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.

 

Investment – Cost Method

 

Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of June 30, 2019, the Company has not impaired any of their cost method investments.

 

F-13
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Inventory

 

Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfillment center is also included in the total inventory cost. Shipping of product upon sale for online sales is paid by the customer upon ordering for orders of single packs of Tauri-GumTM. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of June 30, 2019, the Company’s inventory on hand had a value of $138,606. The Company also has paid deposits in the amount of $52,500 to the manufacturer, Per Os Bio, towards orders not received as of June 30, 2019. Amounts paid to Per Os Bio for Tauri-GumTM are classified as deposits (other current asset) on the Company’s condensed consolidated balance sheet until the goods are available for sale. The Company has not established any inventory reserve on the Tauri-GumTM as of June 30, 2019.

 

Property and Equipment

 

Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

 

Intangible Assets

 

Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.

 

Net Income (Loss) Per Common Share

 

The Company computes per share amounts in accordance with FASB ASC Topic 260 “Earnings per Share” (“EPS”), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the three months ended June 30, 2019, basic and fully diluted earnings per share were the same as the Company had losses in this period.

 

Stock-Based Compensation

 

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation,” which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

 

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

 

F-14
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Stock-Based Compensation (Continued)

 

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

 

Impairment of Long-Lived Assets

 

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it’s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

 

Research and Development

 

The Company expenses research and development costs as incurred. Research and development costs were $3,852 for the three months ended June 30, 2019 compared to no expense during the same period in the prior year. The Company is continually evaluating products and technologies in the natural wellness space, including its Tauri-GumTM product including new flavor formulations and other CBD delivery products, as well as any intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.

 

Fair Value Measurements

 

ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.

 

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

 

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

 

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

 

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

Financial instruments classified as Level 1 – quoted prices in active markets include cash.

 

F-15
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Fair Value Measurements (Continued)

 

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.

 

Share settled debt

 

The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.

 

ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer’s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer’s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer’s shares (e.g. net share settled written put options, net share settled forward purchase contracts).

 

Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.

 

The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15-day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.

 

Income Taxes

 

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.

 

F-16
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Income Taxes (Continued)

 

Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

 

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

 

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of June 30, 2019.

 

Recent Accounting Pronouncements

 

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.

 

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842).” The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

 

The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. Early adoption is permitted. The Company has adopted this standard as of April 1, 2019 (See Note 6).

 

There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or operating results.

 

Subsequent Events

 

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.

 

F-17
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 3– INVENTORY

 

Inventory from continuing operations

 

Inventory value by product as of:

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Tauri-GumTM  $138,606   $10,872 
           
Total Inventory  $138,606   $10,872 

 

At June 30, 2019, deposits to Per Os Bio in the amount of $52,500 for the manufacturing costs of Tauri-GumTM have been classified as a deposit (prepaid expenses other current assets) on the Company’s condensed consolidated balance sheet, as the goods are not yet available for sale.

 

At March 31, 2019, the Company had deposits to Per Os Bio in the amount of $105,000 for the manufacturing costs of Tauri-GumTM for goods not yet available for sale.

 

NOTE 4– DISCONTINUED OPERATIONS

 

On March 31, 2019, the Company decided to discontinue operations relative to its HERMAN© Lip balm product line. After much effort the Company was unable to resolve manufacturing issues as it related to it its lip balm tube mechanism. The Company did not believe that these issues will be resolvable without a substantial investment of time and money. Therefore, the Company exchanged its 50% ownership in Ice+Jam, LLC for the balance of the non-controlling interest as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.

 

The Company had no revenue or expenses from discontinued operations during the three months ended June 30, 2018.

 

TAURIGA SCIENCES, INC. AND SUBSIDIARY

BALANCE SHEETS FROM DISCONTINUED OPERATIONS

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Assets from discontinued operations  $       -   $581 
           
Liabilities from discontinued operations  $-   $5,522 

 

NOTE 5– PROPERTY AND EQUIPMENT

 

The Company’s property and equipment is as follows:

 

   June 30, 2019 (unaudited)   March 31, 2019   Estimated Life
            
Computers, office furniture and other equipment  $69,808   $69,808   3-5 years
              
Less: accumulated depreciation   (57,030)   (56,798)   
              
Net  $12,778    13,010    

 

F-18
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 5– PROPERTY AND EQUIPMENT (CONTINUED)

 

On June 29, 2018, the Company purchased four Blink Level 2 – 40” pedestal chargers for permanent placement in one or more retail locations whereby the Company will share revenue from these electric car vehicle charging units with such location owner. No depreciation expense has been recorded for the charging units as of June 30, 2019 due to the fact that they have not been placed in service.

 

Depreciation expense for the three months ended June 30, 2019 and 2018 was $232 and $259, respectively.

 

During the year ended March 31, 2019 the Company disposed of computer equipment valued at $1,632 recognizing a loss on disposal of $907.

 

NOTE 6 – OPERATING LEASE

 

The Company has adopted ASU No. 2016-02, Leases (Topic 842), as of April 1, 2019 and will account for the new lease in terms of the right of use assets and offsetting lease liability obligations for this new lease under this pronouncement. In accordance with ASC 842 - Leases, effective April 1, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $7,492 and $7,895, respectively, as of April 1, 2019. The Company is recording these at present value, in accordance with the standard, using a discount rate of 8% which is representative of the last borrowing rates for notes issued to a non-related party. The right of use asset is composed of the sum of all lease payments, at present value, and is amortized straight line over the life of the expected lease term. For the expected term of the lease the Company will use the initial term of the two-year lease. If the Company does elect to exercise its option to extend the lease for additional years, that election will be treated as a lease modification and the lease will be reviewed for remeasurement. This lease will be treated as an operating lease under the new standard.

 

The Company has chosen to implement this standard using the modified retrospective model approach with a cumulative-effect adjustment, which does not require the Company to adjust the comparative periods presented when transitioning to the new guidance on April 1, 2019. The Company has also elected to utilize the transition related practical expedients permitted by the new standard. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a modified retrospective approach. Adoption of the new standard resulted in the recording of additional net lease assets and lease liabilities of approximately $7,492 and $7,895 as of April 1, 2019, respectively. The difference between the additional lease assets and lease liabilities, net of the deferred tax impact, will be recorded as an adjustment to retained earnings. The standard is not expected to materially impact our consolidated net earnings and had no impact on cash flows.

 

Corporate office – New York

 

On December 1, 2017, the Company relocated its corporate headquarters from Danbury, Connecticut to New York, New York. The Company has entered into a two-year lease at $1,010 per month for the term of the lease. The lease right of use asset for this lease at adoption was $7,492 and will be amortized on a straight-line basis over the remaining term of the lease. For the three months ended June 30, 2019 the Company recorded a lease expense of $2,810. As of June 30, 2019, the value of the unamortized lease right of use asset is $4,683. As of June 30, 2019, the Company’s lease liability was $4,984.

 

Barcelona office

 

On June 11, 2019 the Company entered into a two-year lease, expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate will be recorded as gain or loss on currency translation.

 

F-19
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 6 – OPERATING LEASE (CONTINUED)

 

The lease right of use asset, at inception, of $27,050 amortized on a straight-line basis over the term of the lease. The present value of the New York corporate office lease had an initial present value of $22,476 at December 1, 2017. The Barcelona office lease value had an initial present value of $4,573. For the three months ended June 30, 2019 the Company recorded a lease expense of $3,149. As of June 30, 2019, the value of the unamortized lease right of use asset is $9,071. As of June 30, 2019, the Company’s lease liability was $9,471.

 

Maturity of Operating Lease Liability for fiscal year ended June 30,
2020  $6,665 
2021  $2,288 
2022  $518 
      
Total lease payments  $9,471 

 

The following chart shows the Company’s operating lease cost at June 30, 2019 and 2018:

 

   For the three months ended 
   June 30, 2019   June 30, 2018 
         
Amortization of right of lease asset  $2,996   $- 
Lease interest cost   153    - 
Total Lease cost  $3,149   $- 

 

The following chart shows the Company’s operating lease liability at June 30, 2019.

 

Discounted Operating Lease liability at inception - December 1, 2017  $27,050 
Financing cost   1,055 
Less lease payments made   (18,204)
Cumulative effect of adoption of ASC 842   (430)
Operating lease liability at June 30, 2019   9,471 
Less Lease Liability current portion   (7,300)
Lease Liability at June 30, 2019 – long-term  $2,171 

 

F-20
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 7 – INTANGIBLE ASSETS

 

Patents:

 

Pilus Energy, LLC

 

The Company, through the acquisition of Pilus Energy on January 28, 2014, acquired a patent to develop cleantech energy using proprietary microbiological solution that creates electricity while consuming polluting molecules from wastewater.

 

On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus to Open Therapeutics. Open Therapeutics agreed to terminate and cancel 80% of the unexercised portion of Open Therapeutics agreed to pay to the Company 20% of the net profit generated by Pilus Energy from its previous year’s earnings, if any. The first $75,000 of such payments were to be retained by Pilus Energy as additional consideration for the sale, which was reflected as a contingent liability on the Company’s consolidated balance sheet. The Company further agreed it would vote its 20% membership interest in Pilus Energy in the same manner that Open Therapeutics votes its membership interest on all matters for which a member vote is required. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.

 

The Company had fully impaired the value of the patents prior to the sale, and the warrants canceled as a result of this transaction was valueless as there is no intrinsic value to them. The Company recorded no gain or loss. Upon Open Therapeutics achieving profitability with respect to this technology, the Company will be the beneficiary of a profit split as noted in the agreement and will recognize revenue from that in the future.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company’s consolidated financial statements. 

 

NOTE 8 – NOTES PAYABLE

 

Notes payable and convertible notes consisted of the following as of:

 

      June 30, 2019   March 31, 2019 
            
Alternative Strategy Partners PTE Ltd.  (a)  $-   $90,000 
GS Capital Partners LLC - Oct 2018  (b)   140,000    180,000 
GS Capital Partners LLC - Mar 2019  (c)   300,000    300,000 
GS Capital Partners LLC - May 2019  (d)   60,000    - 
GS Capital Partners LLC - Jun 2019  (e)   60,000    - 
Total notes payable and convertible notes     $560,000   $570,000 
Less - note discounts      (324,580)   (356,125)
Less - current portion of these notes      (235,420)   (213,875)
Total notes payable and convertible notes, net discounts – long-term     $-   $- 

 

F-21
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 8 – NOTES PAYABLE (CONTINUED)

 

(a) Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. (“ASP”) to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. (“Eishin”), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company’s balance sheet, the $113,468 liability has been removed from the Company’s balance sheet, as is reflected in the Company’s financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.
   
(b) On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 60% instead of 70% while that “chill” is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227.

 

F-22
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 8 – NOTES PAYABLE (CONTINUED)

 

(c) On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company’s consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.
   
(d) On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

F-23
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 8 – NOTES PAYABLE (CONTINUED)

 

(d) In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.
   
(e) On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.
   
  In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $118.
   
  During the year ended March 31, 2019, the Company issued 5,946,516 shares of common stock to holders of convertible notes to retire $187,000 in principal and $13,718 of accrued interest (at an average conversion price of $0.03375 per share) under the convertible notes.  
   
  During the three months ended June 30, 2019, the Company issued 888,308 shares of common stock to holders of convertible notes to retire $40,000 and $1,973 of note principal and accrued interest, respectively.  

 

F-24
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 8 – NOTES PAYABLE (CONTINUED)

 

  Interest expense for the three months ended June 30, 2019 was $121,814 compared to $23,496 for the prior year. Accrued interest at June 30, 2019 and March 31, 2019 was $16,946 and $30,780, respectively.  

 

NOTE 9 – RELATED PARTIES

 

As a result of the Company’s joint venture with Ice + Jam, a receivable and a payable was recorded on the Company’s books. As of December 31, 2018, these amounts represented cash Ice + Jam collected from sales of HerMan® through their website in the amount of $581 and a payable in the amount of $5,522 for expenses incurred through the operation of the business. As of March 31, 2019, these assets and liabilities were reflected in assets and liabilities from discontinued operations.

 

In conjunction with and consideration for a July 22, 2019, 10% convertible note, in the amount of $55,000, under a Securities Purchase Agreement the Company entered into with Jefferson Street Capital, LLC, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.

 

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Common Stock

 

As of June 30, 2019, the Company is authorized to issue 100,000,000 shares of its common stock. As of June 30, 2019 and August 13, 2019, there were 72,925,920 and 75,895,090 shares, respectively of common stock issued and outstanding which includes all adjustments for fractional shares.

 

On July 26, 2019, the Company’s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.

 

Fiscal Year 2019

 

During the year ended March 31, 2019 the Company issued 3,130,000 shares of its restricted common stock to consultants under consulting agreements.

 

During the year ended March 31, 2019, the Company issued 5,946,516 shares of restricted common stock to noteholders for the conversion of debt and accrued interest having a value of $200,718 (at an average conversion price of $0.03375 per share).

 

During the year ended March 31, 2019, the Company issued 5,686,667 shares of common stock ($0.02 to $0.06 per share) for aggregate proceeds of $301,200.

 

During the year ended March 31, 2019, the Company issued 500,000 commitment shares for debt financing ($0.042 per share) valued at $21,000.

 

During the year ended March 31, 2019, the Company issued 95,667 shares for the settlement of debt $20,004.

 

F-25
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT) (CONTINUED)

 

Common Stock (Continued)

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company’s consolidated financial statements.

 

Fiscal Year 2020

 

During the three months ended June 30, 2019, the Company issued 1,200,000 shares under distribution agreements.

 

During the three months ended June 30, 2019, the Company issued 888,308 shares for conversion of debt in the amount of $40,000 as well as accrued interest in the amount of $1,964 ($0.04725).

 

During the three months ended June 30, 2019, the Company issued 250,000 shares issued to Vice President of Distribution and Marketing.

 

During the three months ended June 30, 2019, the Company issued 1,000,000 shares issued for services rendered

 

During the three months ended June 30, 2019, the Company issued 750,000 shares for debt commitment in the amount of $142,500 ($0.19 per share). The shares were recorded as a liability to issue shares at March 31, 2019 on the Company’s balance sheet.

 

During the three months ended June 30, 2019, the Company issued 714,286 shares under stock purchase agreements in consideration for $45,000 (average of $0.063 per share) to accredited investors that are unrelated third parties.

 

In connection with some of the consulting agreements and board advisory agreements the Company has entered into, as the following clauses are part of the compensation arrangements: (a) the consultant will be reimbursed for all reasonable out of pocket expenses and (b) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant’s performance. The Company recognized $375,720 and $43,221 in stock-based compensation expense related to these agreements in the three months ended June 30, 2019 and 2018.

 

F-26
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT) (CONTINUED)

 

Warrants for Common Stock

 

The following table summarizes warrant activity for the three months and year ended June 30, 2019 and March 31, 2019:

 

       Weighted   Average    
       Average   Remaining  Aggregate 
       Exercise   Contractual  Intrinsic 
   Shares   Price   Term  Value 
                
Outstanding at March 31, 2018   1,433,611   $1.06   3.02 Years  $- 
                   
Granted   -    -       - 
Expired   (223,335)   0.2843         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable March 31, 2019   1,210,276   $1.2   1.28 Years  $- 
                   
Granted   -    -       - 
Expired   (389,344)   0.75         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable June 30, 2019   820,932   $1.41   1.41 Years  $        - 

 

During the year ended March 31, 2019, 213,334 warrants expired which were issued in conjunction with a one-year 5% convertible note in the amount of $80,000 with GS Capital Partners, LLC. The five-year cashless warrants had an exercise price of $0.2625 per share. These warrants were cancelled as part of the convertible note agreement which the Company entered into with GS Capital Partners, LLC on March 14, 2019 in the amount of $300,000 (See Note 8 section c).

 

During the year ended March 31, 2019, 10,001 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.

 

During the three months ended June 30, 2019, 389,344 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.

 

F-27
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT) (CONTINUED)

 

Stock Options

 

On February 1, 2012, the Company awarded to each of two executives’, one current and one former, options to purchase 66,667 common shares, an aggregate of 133,334 shares. These options vested immediately and were for services performed.

 

The following table summarizes option activity for the year and three months ended June 30, 2019 and March 31, 2019:

 

   Shares   Weighted-
Average
Exercise
Price		   Weighted
Average
Remaining
Contractual
Term		  Aggregate
Intrinsic
Value		 
                
Outstanding at March 31, 2018   133,334   $7.50   3.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding at March 31, 2019   133,334   $7.50   2.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding and exercisable at June 30, 2019   133,334   $7.50   2.60 Years  $— 

 

NOTE 11 – PROVISION FOR INCOME TAXES

 

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

 

The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for the three months and years ended June 30, 2019 March 31, 2019:

 

   June 30, 2019   March 31,2019 
Federal income taxes at statutory rate   21.00%   21.00%
State income taxes at statutory rate   0.00%   0.00%
Temporary differences   8.99%   1.48%
Permanent differences   0.17%   0.24%
Impact of Tax Reform Act   0.00%   (167.44)%
Change in valuation allowance   (30.16)%   144.72%
Totals   0.00%   0.00%

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.

 

F-28
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 11 – PROVISION FOR INCOME TAXES (CONTINUED)

 

   As of   As of 
   June 30, 2019   March 31, 2019 
Deferred tax assets:          
Net operating losses before non-deductible items  $3,763,732   $3,685,807 
Loss on disposal of fixed assets   355    355 
Stock-based compensation   288,492    209,591 
Unrealized gains or losses on investments   (24,079)   (4,258)
Total deferred tax assets   4,028,500    3,891,495 
Less: Valuation allowance   (4,028,500)   (3,891,495)
           
Net deferred tax assets  $-   $- 

 

At June 30, 2019, the Company had a U.S. net operating loss carryforward in the approximate amount of $17.9 million available to offset future taxable income through 2038. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. The valuation allowance increased by $137,005 in the three months ended June 30, 2019 and decreased by $1,516,710 in the year ended March 31, 2019. The net decreases were the result of the tax effects of the Tax Cuts and Jobs Act (the “TCJA”) offset by taxable losses net of timing differences in each of the years.

 

On December 22, 2017, Public Law 115-97, informally referred to as the TCJA was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. The effective rate for the year ended March 31, 2018 was 31% as the rate was changed effective January 1, 2018 to the lower rate. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. Given the significant complexity of the TCJA and anticipated additional implementation guidance from the Internal Revenue Service, further implications of the TCJA may be identified in future periods. The Company has adjusted their NOLs and valuation allowances to account for the changes brought about by the TCJA for the three months and year ended June 30, 2019 and March 31, 2019, respectively.

 

F-29
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 12 – INVESTMENTS

 

Trading securities

 

For investments in securities of other companies that are owned, the Company records them at fair value with unrealized gains and losses reflected in other operating income or loss. For investments in these securities that are sold by us, the Company recognizes the gains and losses attributable to these securities investments as realized gains or losses in other operating income or loss on a first in first out basis.

 

Investment in Trading Securities:

 

At March 31, 2019                         
Company     Beginning
of Period
Cost		   Purchases  

Sales

Proceeds

  

End of

Period

Cost

  

Fair

Value

   Realized
Gain (Loss)		   Unrealized
Gain (Loss)		 
Green Innovations Ltd (GNIN)*  (a)  $-    -   $-   $-   $-   $-   $- 
VistaGen Therapeutics Inc (VTGN)  (b)   490,117    349,498    (517,485)   287,500    294,400    (34,630)   6,900 
Blink Charging Co (BLNK)  (c)   190,350    151,666    (367,142)   -    -    25,126    - 
Blink Charging Co (BLNKW) (Warrants)  (c)   900    162,215    (468,496)   -    -    305,381    - 
Aytu BioScience Inc (AYTU)  (d)   82,270    100,030    (144,094)   -    -    (38,206)   - 
Lightbridge Corp. (LTBR)  (e)   37,511    299,028    (276,159)   -    -    (60,380)   - 
Pulmatrix Inc. (PULM)  (f)   -    204,802    (183,737)   -    -    (21,065)   - 
Axovant Sciences Ltd. (AXON)  (g)   -    103,938    (98,433)   -    -    (5,505)   - 
Basanite Inc. (BASA)  (h)   -    42,998    (10,821)   30,000    56,000    (2,177)   26,000 
Achieve Life Sciences (ACHV)  (i)   -    177,356    (112,221)   -    -    (65,135)   - 
Decision Diagnostics (DECN)  (j)   -    20,479    (16,893)   -    -    (3,586)   - 
Totals     $801,148   $1,612,010   $(2,195,481)  $317,500   $350,400   $99,823   $32,900*

 

At June 30, 2019                         
Company     Beginning of Period Cost   Purchases   Sales Proceeds   End of Period Cost   Fair Value   Realized Gain (Loss)   Unrealized Gain (Loss) 
VistaGen Therapeutics Inc (VTGN)  (b)   287,500           -            -    287,500    166,865          -    (120,635)
Basanite Inc. (BASA)  (h)   30,000    -    -    30,000    277,920    -    247,920 
Totals     $317,500   $-   $-   $317,500   $444,785   $-   $127,285**

 

* Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.

 

**This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.

 

F-30
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 12 – INVESTMENTS (CONTINUED)

 

Trading securities (Continued)
   
(a) During the year ended March 31, 2018, the Company’s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company’s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.
   
(b) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company’s broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(c) The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company’s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
   
(d) On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.
   
(e) On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380.
   
(f) During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.

 

F-31
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 12 – INVESTMENTS (CONTINUED)

 

Trading securities (Continued)
   
(g) During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
   
(h) On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(i) During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135.
   
(j) During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.

 

At June 30, 2019, the Company held warrants for AYTU to purchase 5,555 common shares at a strike price of $10.80 with an expiration of March 6, 2023. The strike price and number of shares were adjusted for the August 10, 2018, 1 for 20 reverse stock-split. At June 30, 2019, these warrants were out of the money by $9.13 per share and are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.

 

At June 30, 2019, the Company currently holds warrants for VTGN to purchase 320,000 shares of common stock at a strike price of $1.50 per share with an expiration of December 13, 2022 and warrants for VTGN to purchase 230,000 shares of common stock at a strike price of $1.50 per share with an expiration of February 28, 2022. At June 30, 2019, these warrants were out of the money by $0.25 per share. Since these warrants are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.

 

Digital Currency

 

During the year ended March 31, 2019, the Company purchased. Groestlcoin cryptocurrency (Crypto Currency Code: GRS). The purchase of this currency cannot be executed directly using $USD. The Company must purchase Bitcoin (BTC) and then purchase the Groestlcoin cryptocurrency by using BTC. This two-step process triggers the potential recognition of realized gains or losses on the purchase of Groestlcoin.

 

On April 2, 2018, the Company completed a purchase in the Groestlcoin cryptocurrency in the aggregate amount of $8,000 for 11,922.81 units ($0.6569 per unit).

 

On July 15, 2018, the Company sold all of its 39,862 units of Groestlcoin cryptocurrency converting it into 4.17 units of BTC having a value of $32,230. On August 20, 2018, the Company converted its BTC to gold bullion and silver coins at a value of $26,783.

 

On August 25, 2018, the Company sold all gold and silver commodities held for a sum of $24,046, recognizing a loss on the transaction of $2,737.

 

During the year ended March 31, 2019, had an unrealized loss on digital currency of $3,143 prior to the conversion to the gold and silver.

 

During the three months ended June 30, 2019, the Company had no digital currency activity.

 

F-32
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 12 – INVESTMENTS (CONTINUED)

 

Equity investments

 

Honeywood

 

Effective August 1, 2017, the Company entered into a Debt Conversion Agreement in respect to a secured promissory note issued following the unwinding of the Honeywood acquisition (See NOTE 1), whereby the Company agreed to convert the entire principal and accrued but unpaid interest due under the note into a 5% membership interest in Honeywood.

 

The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with FASB ASC 320-10-35-28, “Investments—Debt and Equity Securities,” a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: (a) the investment experiences a recovery of fair value up to (or beyond) its cost; or (b) the entity recognizes an other-than-temporary impairment loss. At the time of the Debt Conversion Agreement the receivable balance of $199,119 had been fully written off by the Company in a prior period. As a result of this Debt Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this year.

 

Cost investments

 

Küdzoo, Inc.

 

On September 4, 2018, the Company invested $15,000 in Küdzoo, Inc. (“Küdzoo”), a privately held company. Küdzoo is the developer of a mobile application that rewards students for their grades and achievements with deals and opportunities. The investment is recorded at cost and represents 0.2% of the value of Küdzoo based on a pre-money valuation of $7,500,000.

 

On March 21, 2019, the Company invested $22,500 in Küdzoo. This investment was recorded at cost and represents 0.22% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000. On April 8, 2019, the Company invested another $20,400, which was recorded at cost representing a 0.42% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.

 

The Company tested the investment value for Küdzoo as of March 31, 2019 for impairment. It was noted that the value of the company has increased based on recent equity raises in which the Company took part in. As a result of the new equity raises, the Company does not believe there is any impairment of this investment as of June 30, 2019.

 

On April 8, 2019, the Company invested $20,400, in Küdzoo, Inc., a private Company in which the Company had previously invested $37,500. The $20,400 investment was recorded at cost representing a 0.2% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.

 

Serendipity

 

On October 31, 2018, the Company invested $35,000 in Serendipity Brands LLC (dba Serendipity Ice Cream Co.) (“Serendipity”), a privately held Company. Serendipity is an ice cream distribution company providing wholesale distribution to retail customers. The investment was recorded at cost and represents 0.24% of the value of Serendipity based on a pre-money valuation of approximately $14 million.

 

The Company tested the investment value for Serendipity as of March 31, 2019 for impairment. It was noted that the value of the company has maintained its value through reviews of their financial performance, therefore, the Company does not believe there is any impairment of this investment as of June 30, 2019.

 

F-33
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 13 – FAIR VALUE MEASUREMENTS

 

The following summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019:

 

   June 30, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $444,785   $-   $-   $444,785 
Cost method investment – Küdzoo  $-   $-   $57,900   $57,900 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 

 

   March 31, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $350,400   $-   $-   $350,400 
Cost method investment – Küdzoo  $-   $-   $37,500   $37,500 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 

 

NOTE 14 – CONCENTRATIONS

 

During the three months and year ended June 30, 2019 and March 31, 2019, we have one supplier for 100% of our product who is also the manufacturer of Tauri-GumTM.

 

For the three months ended June 30, 2019, one customer accounted for 23.96% of product sales from continuing operations. For the year ended March 31, 2019, one customer accounted for 97% of product sales from continuing operations.

 

NOTE 15 – SUBSEQUENT EVENTS

 

Subsequent to June 30, 2019, the Company issued additional shares of common stock as follows; (i) 250,000 shares for commitment shares relative to convertible note issued; (ii) 250,000 shares under a distribution agreement dated April 30, 2019; and (iii) 2,719,170 shares in conversion of convertible notes of $75,000 and accrued interest of $4,373.

 

F-34
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 15 – SUBSEQUENT EVENTS (CONTINUED)

 

Convertible Notes

 

On July 22, 2019, the Company and Jefferson Street Capital, LLC (“Jefferson Street”) consummated entry into a Securities Purchase Agreement where the Company has borrowed $55,000 ($50,000 with original issuance discount reflected) at 10% annual interest under a term of nine-months in the form of a convertible note. The note is convertible into restricted stock of the Company. In connection with this agreement, the Company issued 250,000 commitment shares having a value of $10,500 ($0.042 per share, the closing price of our common stock on the day preceding the note) which will be reflected as interest expense in the Company’s condensed consolidated statement of operations during the three months ended June 30, 2019. The restricted stock was valued at the closing price on July 22, 2019. Legal fees of $2,000 were deducted from cash proceeds of the note payable to investor’s counsel, and a $5,000 original issue discount recognized. The Company received cash proceeds of $48,000 at closing. Under the Jefferson Street note, the Company is required initially to reserve 1,000,000 shares of its common stock, and thereafter to increase the reserve up to 15,000,000 shares upon the increase in the Company’s authorized common shares (per a charter amendment via shareholder meeting and approval as approved by the Board of Directors on July 26, 2019), but up to six times the number of shares required for a full conversion. The Company has 75 days from the date of this note to have this increased effectuated. The noteholder may, at any time, at its option, convert all or any amount of the principal face amount of the note then outstanding into shares of the Company’s common stock at a conversion price for each share of Common Stock equal to 65% of the lowest volume weighted average price for the Company’s common stock during the previous fifteen trading day period as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future, including the day upon which a notice of conversion is received by the Company. If the Company fails to maintain the share reserve at the required amounts, or to attain shareholder approval within 75 days of July 22, 2019, this will be considered an Event of Default. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note; however, the Company maintains the option to repay the note in cash within the first 180 days beginning on July 22, 2019 to avoid such default provision triggering event, as more fully described below.

 

During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date.

 

Upon an event of default (as defined and described in the note), among other default penalties, the Company shall pay the Default Amount (as defined in the agreement) as well as incur annual interest at a default interest rate of 24% per annum.

 

In consideration of Jefferson Street loaning the Company the proceeds under this note, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.

 

F-35
 

 

TAURIGA SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

(US$)

 

NOTE 15 – SUBSEQUENT EVENTS (CONTINUED)

 

Other

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

On July 26, 2019, the Company’s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.

 

On August 12, 2019, the Company received $47,500 net proceeds for the second of two notes (the “Back-End Note”) under a December 20, 2018 security purchase agreement with Adar Alef, LLC whereby the Company issued two 8% convertible redeemable notes in the cumulative principal amount of $110,000. Both notes were for $55,000 and had funded with net proceeds of $47,500, after the deduction of $5,000 for OID and $2,500 in legal fees. The first note was previously funded on December 24, 2018. The Back-End Note was initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the “Note Receivable”). The terms of the Back-End Note required cash funding prior to any conversion thereunder. The Note Receivable was due December 20, 2019, unless certain conditions were not met, in which case both the Back-End Note and the Note Receivable may both have been cancelled. The Back-End Note has a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under the Back-End Note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 50% instead of 60% while that “chill” is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. This Back-End Note may not be repaid. The note holder may redeem this note at any time after the first six months.

 

F-36
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations describes the principal factors affecting the results of operations, liquidity and capital resources of the Company and critical accounting estimates. This discussion should be read in conjunction with the accompanying quarterly unaudited Condensed Consolidated Financial Statements contained in this Form 10-Q and our Annual Report on Form 10-K, for the year ended March 31, 2019 (“Annual Report”). Our Annual Report includes additional information about our significant accounting policies, practices and the transactions that underlie our financial results, as well as a detailed discussion of the most significant risks and uncertainties associated with our financial and operating results.

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors”, set forth in Part II, Item 1A of this Form 10-Q and in our other SEC filings. We disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

 

Business Overview

 

Tauriga Sciences, Inc. (the “Company”, “Tauriga” or “us”) is a Florida corporation, with its principal place of business being located at 555 Madison Avenue, Fifth Floor, New York, NY 10022. The Company has, over time, moved into a diversified life sciences technology company, with its mission to operate a revenue generating business, while continuing to evaluate potential acquisition candidates operating in the life sciences technology space.

 

TAURI-GUMTM

 

In October 2018, the Company’s management, along with its board of directors, began to explore the possibility of launching a cannabidiol (“CBD”) infused gum product line into the commercial marketplace. After several weeks of diligence, discussions with various parties and exploratory meetings, the Company made the determination to move forward with this business opportunity.

 

3
 

 

To begin this process, during the quarter ended December 31, 2018, the Company began discussions with a Maryland based chewing gum manufacturer - Per Os Biosciences LLC (“Per Os Bio”), which consummated in a manufacturing agreement in late December 2018 to launch and bring to market a white label line of CBD infused chewing gum under the brand name Tauri-GumTM. We have filed for trademark protection with the United States Patent and Trademark Office for our CBD infused chewing product line, including applications filed in April 2019 for TAURI-GUMMITM and TAURI-GUMMIESTM.

 

Under the terms of the agreement, Per Os Bio has committed to produce the Tauri-GumTM based on the following criteria:

 

  A. By composition, the CBD Gum will contain 10 mg of CBD Isolate
  B. The initial production run will be mint flavor exclusively
  C. This proprietary CBD Gum will be manufactured under U.S. Patent # 9,744,128 (“Method for manufacturing medicated chewing gum without cooling”)
  D. Each Production Batch, including the initial production run, is estimated to yield 70,000 gum tablets or 8,700 Units (each Unit contains 8 gum tablets).
  E. Integrated Quality Control Procedures: Each production batch will be tested by a 3rd Party for CBD label content, THC content (0%), and clear for microbiology.
  F. The packaging, for retail marketplace, will consist of 8 count (gum tablet count) blister card labeled (the “Pack(s)”) with Lot # as well as Expiration Date.
  G. Outer sleeve in the Company’s artwork and graphic design(s) and label copy
  H. Shipping System: Bulk packed 266 Packs per master case (“Palletized”)

 

Under terms of the Agreement, the Company has committed to provide the following to Per Os Bio:

 

  A. Each product order will consist of exactly 8,700 Packs (unless otherwise agreed upon by both parties).
  B. ½ of initial production invoice due within 3 days of execution of Manufacturing Agreement (this has already been paid by the Company).
  C. Provide graphic design artwork, logo, and label design to Per Os Bio.
  D. Trademark has been successfully filed with U.S.P.T.O.
  E. To implement Kosher Certification Process
  F. Procure appropriate Product & Liability insurance policy
  G. Acquire legal opinion with respect to the confirmation of the legality to sell this CBD Gum – on the Federal Statute Level.

 

The Company’s gum formulation includes distinctive features: allergen free, gluten free, vegan, kosher (K-Star certification), and incorporates a proprietary manufacturing process. See our “Risk Factors” contained in the Annual Report, including with respect, but not limited, to Federal laws and regulations that govern CBD and cannabis.

 

4
 

 

The Company’s E-commerce website is www.taurigum.com. The Company has also secured storage space near its New York City headquarters.

 

During the first quarter of fiscal year 2020, the Company began production of Blood Orange flavor of Tauri-GumTM. The Company plans to offer Pomegranate flavored Tauri-GumTM in the near term, which will be in addition to their mint and blood orange flavored products.

 

On April 9, 2019, the Company announced that it is developing a special miniaturized version of Tauri-GumTM for sale at airport retail stores. The Company envisions this Airport version consisting of a miniaturized blister pack (containing three pieces of its CBD Infused gum), with an anticipated retail price of $6.99 per unit.

 

The Company is also working on developing CBD Gum-Infused Lollipops and gummi products.

 

The Company has entered into the following agreements with distributors to arrange for the distribution of this product line:

 

E&M Distribution Agreement

 

On April 1, 2019, the Company entered into a comprehensive distribution agreement with E&M Ice Cream Company (“E&M”) to establish Tauri-GumTM in the marketplace (the “E&M Distribution Agreement”). The Company has supported the Tauri-GumTM commercial launch with substantial levels of both financial resources and marketing support. The Company had both received payment for and delivered the product for its previously announced $54,000 Tauri-GumTM purchase order during March 2019, and re-orders in the first quarter of fiscal 2020. The Company has agreed to issue a one-time issuance of 1,000,000 restricted shares of the Company’s common stock, and to tender a one-time cash payment of $125,000 to E&M. This $125,000 cash component was paid in full to E&M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. The Company is awaiting issuance instructions from E&M to issue the shares.

 

South Florida Region Distribution Agreement

 

On April 8, 2019, the Company entered into a non-exclusive distribution agreement with IRM Management Corporation (“IRM”), an established medical practice management firm (the “IRM Distribution Agreement”). The purpose of the IRM Distribution Agreement is to target our Tauri-GumTM product to the South Florida based medical market, including chiropractors, orthopedists, as well as prospective retail customers in this geographic area.

 

5
 

 

Under terms of this IRM Distribution Agreement, the Company will work closely with IRM to promote Tauri-GumTM. In connection with this IRM Distribution Agreement, the Company has also agreed to a one-time issuance of 450,000 shares of the Company’s restricted common stock and a cash stipend of $10,000 to IRM. As of the date of this report, only $2,000 of the $10,000 cash stipend has been paid. The value of the restricted shares will be reflected in stock-based compensation based on the grant date of April 8, 2019.

 

North Eastern United States Distribution Agreement

 

On April 30, 2019, the Company, entered into a non-exclusive comprehensive distribution agreement with Sai Krishna LLC (“SKL”), a New Jersey based distributor, with relationships in the Northeast region of the United States and Asia, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line in the applicable regions.

 

In connection with the SKL Agreement, the Company agreed to a one-time issuance of an aggregate of 1,000,000 restricted shares of the Company’s common stock, which are subject to the customary resale and transfer restrictions imposed under the rules and regulations of the Securities and Exchange Commission. The foregoing equity issuance to SKL and the other named persons affiliated with SKL was issued in accordance with the following schedule: (i) to Mr. Mahesh Lekkala, 500,000 restricted shares the Company’s common stock within ten (10) business days of April 30, 2019; and (ii) to SKL, 500,000, which were permitted to be immediately allocated by SKL to persons within its organization and, as such, (a) 250,000 of such shares shall be issued to SKL within ten (10) business days of April 30, 2019, and the additional issuance of (b) 250,000 of such shares shall be issued to SKL within ten (10) business days of August 1, 2019, which shares were issued on August 1, 2019. Other than the payment terms for Tauri-GumTM product purchased and distributed under the terms of the Agreement, there is no additional cash payment due or owing by the Company thereunder. The value of the shares is reflected as stock-based compensation with a grant date of April 30, 2019. All but 250,000 shares were expensed the date of issuance, with those 250,000 shares valued over the term of the one-year agreement.

 

On May 11, 2019, the Company entered into a consulting agreement pursuant to the terms of the SKL distribution agreement, whereby Ms. Neelima Lekkala was appointed Vice President of Distribution & Marketing. This agreement has a one-year term and may be extended based upon mutual agreement of Ms. Lekkala and the Company. Ms. Lekkala will focus her efforts on the expansion of Tauri-GumTM in terms of gross sales and revenue growth through the acquisition of new customers, establishment of professional marketing materials & protocols, logistics improvement(s) and fulfillment services. Ms. Lekkala is not an executive officer of the Company and, therefore, is not deemed to be an affiliate of the Company. Ms. Lekkala’s compensation includes 250,000 shares of the Company’s restricted common stock, which are fully earned and vested upon the execution of her consulting agreement. These shares were issued May 20, 2019, having a value of $18,275 based on the closing price of the Company’s stock on that day. Additionally, Ms. Lekkala will receive a 30% commission on total gross sales through the sale of the Tauri-GumTM product line, which the Company may pay in either stock or cash at the election of Ms. Lekkala.

 

6
 

 

Windmill Health Distribution Agreement

 

On June 28, 2019, the Company entered into a distribution agreement with Windmill Health Products, LLC (“Windmill Health”), a New Jersey based distributor, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line. Simultaneous with the Company’s entry into the Windmill Health agreement, Windmill Health placed an initial purchase order with us totaling $46,848, split evenly between packages of the Mint flavored and Blood-Orange flavored chewing gum product lines. The Company did not contribute any capital or issue any equity to Windmill Health in connection with the Windmill Health distribution agreement.

 

Food and Drug Administration

 

On May 31, 2019, the U. S. Food and Drug Administration (“FDA”) held public hearings to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The hearing came approximately five months after the Agricultural Improvement Act of 2018 (more commonly known as the Farm Bill), went into effect and removed industrial hemp from the Schedule I prohibition under the Controlled Substances Act (CSA) (industrial hemp means cannabis plants and derivatives that contain no more than 0.3 percent tetrahydrocannabinol, or THC, on a dry weight basis).

 

Though the Farm Bill removed industrial hemp from the Schedule I list, the Farm Bill preserved the regulatory authority of the FDA over cannabis and cannabis-derived compounds used in food and pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act. The FDA has been clear that it intends to use this authority to regulate cannabis and cannabis-derived products, including CBD, in the same manner as any other food or drug ingredient. In addition to holding the hearing, the agency had requested comments by July 2, 2019 regarding any health and safety risks of CBD use, and how products containing CBD are currently produced and marketed, which comment period was then extended by two weeks following July 2nd. See our Risk Factors for more information about these items.

 

7
 

 

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding, success in developing and marketing its products and the level of competition. These risks and others are described in greater detail in the risk factors set forth in our annual report on 10-K for the year ended March 31, 2019, as supplemented by the risk factors set forth in Item 1A of Part II of this Form 10-Q.

 

2019 Increase in Authorized Shares

 

On July 26, 2019, the Company held a meeting of its board of directors. The matters voted on and approved at the meeting included an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock, $0.00001 par value per share from 100,000,000 to 400,000,000 shares (the “Authorized Shares Increase”). In this regard, a Preliminary Proxy Statement which was filed with the Securities and Exchange Commission on July 29, 2019.

 

2018 Reverse Stock Split

 

On July 8, 2018, the Company implemented a Reverse Stock Split with a ratio of 1-for-75 (which became effective July 9, 2018). The par value and other terms of the common stock were not affected by the Reverse Stock Split. In addition, the amendment to the Company’s articles of incorporation that effected the Reverse Stock Split simultaneously reduced the number of authorized shares of Common Stock from 7,500,000,000 to 100,000,000.

 

All references set forth in this quarterly report to number of shares or per share data have been presented retroactively on a post reverse stock-split basis, including any common stock equivalents, have been retroactively adjusted in these condensed consolidated financial statements for all periods presented to reflect the 1-for-75 Reverse Stock Split.

 

See also the Risk Factors relating to any prospective changes to the Company’s articles of incorporation.

 

Cupuaçu Butter Lip Balm

 

On December 23, 2016, the Company entered into a non-exclusive, 12-month license agreement (the “License Agreement”) with Cleveland, Ohio based cosmetics products company Ice + Jam LLC (“Ice + Jam”) to market Ice + Jam’s proprietary cupuaçu butter lip balm, sold under the trademark HerMan® which launched during the quarter ended December 31, 2017.During February of 2018, the Company’s strategy with respect to the HerMan® product was negatively impacted by a series of product defects relating to the twisting mechanism of the lip balm tube. As a result of this and the concomitant halting of selling efforts, the Company had no sales of the HerMan® product during the three months ended June 30, 2019 or the year ended March 31, 2019. The Company has removed the product from the website and the remaining inventory was written off as it was determined that the units were not usable. The Company has discontinued this operation as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.

 

8
 

 

Honeywood

 

Following the termination of a proposed 2014 merger between the Company and California-based Honeywood LLC (“Honeywood”), a developer of a topical medicinal cannabis product, on August 1, 2017, the Company entered into a Debt Conversion Agreement, whereby the Company agreed to convert an $170,000 note receivable due from Honeywood, including accrued interest into a 5% membership interest in Honeywood.

 

The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320-10-35-28, “Investments—Debt and Equity Securities”, a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: a) the investment experiences a recovery of fair value up to (or beyond) its cost; or b) the entity recognizes an other-than-temporary impairment loss. At the time of the Honeywood Conversion Agreement, the receivable balance under the Note of $199,119 had been fully written off by the Company in a prior period. As a result of the Honeywood Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this period.

 

Pilus Energy

 

On January 28, 2014, the Company acquired Pilus Energy, LLC (“Pilus”), an Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that create electricity while consuming polluting molecules from wastewater.

 

On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus back to Open Therapeutics for consideration of the termination of 80% of the unexercised portion of the warrants to purchase the Company’s common stock. Open Therapeutics agreed to pay to the Company 20% of the net profit generated Pilus Energy from its previous year’s earnings, if any. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish a $75,000 contingent liability, whereby Open Therapeutics was to receive the first $75,000 of net profit earned from the operations of Pilus Energy in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share).

 

Tauriga Biz Dev Corp.

 

On January 4, 2018, the Company announced that its Board of Directors unanimously approved the formation a wholly-owned subsidiary focused on acquiring interest(s) in patents and other intellectual property. This subsidiary, incorporated in Delaware, was named Tauriga IP Acquisition Corp. On March 25, 2018, the Company changed the name to Tauriga Biz Dev Corp.

 

9
 

 

On March 29, 2018 the Company, through Tauriga Biz Dev Corp., entered into an independent sales representative agreement with Blink Charging Company (NASDAQ: BLNK) (“BLINK”). Under this agreement the Company will be a non-exclusive independent sales representative. The Company will act on behalf of BLINK to solicit orders from potential customers for EV (“Electric Vehicle”) Stations placement. Tauriga Biz Dev Corp. will be compensated upon contracting and as long as the Company’s acquired prospect remains under contract. This arrangement has the potential to earn both short term as well as long term recurring revenue by helping BLINK expand its national electric vehicle charging infrastructure and network. This sales agreement is a three-tier model based on whether Tauriga Biz Dev Corp. contracts the new customer to purchase equipment outright from BLINK or enter into one of two revenue-sharing agreements. In the case Tauriga Biz Dev Corp. effectuates a sale of BLINK equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga Biz Dev Corp. secures a revenue sharing agreement with a customer where BLINK remains the owner, Tauriga Biz Dev Corp. will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four BLINK Level – 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The rest of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs. The Company has not yet secured the location for installation of these units.

 

As of June 30, 2019, Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.

 

Tauriga Sciences Limited

 

On June 10, 2019, the Company formed a wholly owned subsidiary, Tauriga Sciences Limited, with the registrar of Companies for Northern Ireland. Tauriga Sciences Limited is a private limited Company. The entity was established in conjunction with online merchant services. In conjunction to this new entity the Company entered into a two-year lease commencing on June 11, 2019 and expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).

 

10
 

 

RESULTS OF OPERATIONS

 

Three months ended June 30, 2019 compared to the three months ended June 30, 2018

 

The results of operations included herein contain only those operations that are part of our continuing operations. For discussion regarding our past operations which have since been disposed of, please refer to our Annual Report.

 

Revenue

 

During March 2019, the Company began to realize sales of Tauri-GumTM with recognized gross revenue of $57,134. Revenues for the three months ended June 30, 2019 were $44,377. The Company’s sales came from online, distributors and wholesale clients. For the purposes of sales by sales channel segmentation, distributor sales include sales to customers that were distributors.

 

Sales of Tauri-GumTM by sales channel for the three months ended June 30,

 

   2019   2018 
Distributors  $15,592   $- 
Online  $2,447    - 
Wholesale  $26,338    - 
   $44,377   $- 

 

As Tauri-GumTM sales were first recognized in March 2019, there was no revenue recognized during the three months ended June 30, 2018.

 

On March 29, 2018 the Company, through Tauriga Biz Dev Corp., entered into an independent sales representative agreement with BLINK. Under this agreement the Company will be a non-exclusive independent sales representative. The Company will act on behalf of BLINK to solicit orders from potential customers for EV Stations placement. Tauriga Biz Dev Corp. will be compensated upon contracting and as long as the Company’s acquired prospect remains under contract. This arrangement has the potential to earn both short term as well as long term recurring revenue by helping BLINK expand its national electric vehicle charging infrastructure and network. This sales agreement is a three-tier model based on whether Tauriga Biz Dev Corp. contracts the new customer to purchase equipment outright from BLINK or enter into one of two revenue-sharing agreements. In the case Tauriga Biz Dev Corp. effectuates a sale of BLINK equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga Biz Dev Corp. secures a revenue sharing agreement with a customer where BLINK remains the owner, Tauriga Biz Dev Corp. will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

Commissions earned under this contract with Tauriga Biz Dev Corp. will be recorded as revenue when earned. Based on a binding agreement in place between BLINK and the referral provided by the Company, revenue will be recorded based on equipment value purchased or placed in service as well as the length of the contract. The Company is currently working towards its goal of generating potential revenue deriving from this Reseller Agreement with BLINK. For the three months ended June 30, 2019 and 2018, there has been no sales and no revenue generated from this product line.

 

11
 

 

Cost of Goods Sold

 

For the three months ended June 30, 2019, the Company had cost of goods sold in the amount of $29,418 as a result of sales of Tauri-GumTM to online customers, distributors and wholesale clients. For the purposes of cost of goods sold segmentation distributor cost of goods sold includes sales to customers that were distributors.

 

Cost of Goods Sold by sales channel for Tauri-GumTM for the three months ended June 30, 2019 and 2018 were:

 

   2019   2018 
Distributor  $11,340   $- 
Online  $858    - 
Wholesale  $17,220    - 
   $29,418   $- 

 

As Tauri-GumTM sales were first recognized in March 2019, there was no cost of goods sold recognized during the three months ended June 30, 2018.

 

Operating Expenses

 

Marketing and advertising expense

 

For the three months ended June 30, 2019, marketing and advertising expense from continuing operations was $130,548 compared to none for the same period in the prior year, respectively, due to a payment under a distribution agreement in the amount of $125,000.

 

Research and development

 

For the three months ended June 30, 2019, research and development expense was $3,852 compared to none for the same period in the prior year. The current year increased expense was due to the Tauri-GumTM increased spending on product design.

 

General and Administrative Expense

 

For the three months ended June 30, 2019 and 2018, general and administrative expenses were $628,841 and $222,038, respectively. This increase of $406,803 was primarily attributable to $332,501 increase in stock based compensation and $45,417 of increased consulting expense.

 

12
 

 

Depreciation and amortization

 

For the three months ended June 30, 2019 and 2018, depreciation and amortization expense was $232 an $259, respectively. Depreciation expense decrease of $27 was due to depreciation expense on old computer equipment was slightly higher than its replacement.

 

Interest Expense

 

For the three months ended June 30, 2019 and 2018, interest expense was $121,814 and $23,496, respectively. Interest expense increase of $98,318 was due to an increase in interest carry cost of $8,046 due to a much higher debt level as well as increased debt discount amortization of $106,647 offset by a prepayment penalty on a convertible note in the amount of $16,657.

 

Net Income (Loss)

 

The Company generated a net loss from continuing operations of $657,564 for the three months ended June 30, 2019 compared net income of $166,788 during the three months ended June 30, 2018. This difference was largely due to a gain on the sale of trading securities in the amount of $340,020 ad well as lower general and administrative expense in the amount of $406,803 as well as lower interest expense of $98,318.

 

Liquidity and Capital Resources

 

At June 30, 2019, we had cash of $15,247 and $444,785 of securities compared to March 31, 2019 of $385,943 and $350,400 of trading securities. We have historically met our cash needs through a combination of proceeds from private placements of our securities, loans and convertible notes. Our cash requirements are generally for purchases of inventory as well as selling, general and administrative activities. We believe that our cash balance is not sufficient to finance our cash requirements for expected operational activities, capital improvements, and partial repayment of debt through the next 12 months.

 

For operating activities, we used cash of $475,296 for the three months ended June 30, 2019 compared to $16,118 cash provided during the three months ended June 30, 2018. The principal elements of cash flow from operations for the three months ended June 30, 2019 were $375,720 common stock issued and issuable for services (including stock based compensation), offset by an increase in inventory $127,734 and an unrealized gain on trading securities in the amount of $94,385.

 

13
 

 

During the three months ended June 30, 2018, principal elements of cash flow from operations were realized and unrealized gains on the sale of marketable securities of $339,810 and $78,170, respectively, offset by purchases of trading securities in the amount of $128,983,stock-based compensation expense of $43,221 and net income of $166,788, and a reduction in accrued expense (including interest) in the amount of $54,264.

 

Cash used in investing activities during the three months ended June 30, 2019 and 2018 was $20,400 and $17,917, respectively. During 2019, the Company invested $20,400 in a private Company. During 2018, the Company purchased equipment for $10,086 as well as purchased digital currency in the amount of $7,831.

 

Cash provided by in financing activities during the three months ended June 30, 2019 and 2018 was $125,000 and $25,000, respectively. During 2019, the Company had proceeds from the sale of common stock in the amount of $15,000 and $110,000 proceeds from notes payable. During 2018, the Company had $25,000 proceeds from notes payable.

 

As of June 30, 2019, current assets exceeded our current liabilities by $499,657 compared to $490,436 at March 31, 2019. During 2019, the Company’s decrease in net assets was commensurate to the decrease in current liabilities. At June 30, 2019, current assets were $805,241 compared to $947,816. The Company’s current assets decrease was largely due to a decrease in the cash balance decreased by $370,696 offset by an increase in inventory of $127,734 and an increase in trading securities $94,385. At June 30, 2019, current liabilities were $305,584 compared to $457,380 at March 31, 2019. The Company’s decrease in current liabilities was mainly due to a decrease in the liability to issue stock of $172,500.

 

Going Concern

 

During the fourth quarter of the year ended March 31, 2019, the Company began sales and marketing efforts for its Mint flavored Tauri-GumTM product. During the three months ended March 31, 2019, the Company recognized sales of $57,134 and recognized a gross profit of $20,006, which has continued into the first fiscal quarter ended June 30, 2019 where the Company recognized revenue of $44,377 and a gross profit of $14,959. During the first quarter of fiscal year 2020, the Company has entered into multiple distribution agreements and has engaged an independent contractor to act as Vice President of Distribution and Marketing. Although the Company’s working capital surplus of $499,657 at June 30, 2019 has remained consistent in the past year, the Company still believes that there is uncertainty with respect to continuing as a going concern.

 

14
 

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

The Company, in the short term, intends to continue funding its operations either through cash-on-hand or through financing alternatives. Management’s plans with respect to this include raising capital through equity markets to fund future operations, as well as the possible sale of its remaining marketable securities (which had a market value of $444,785 at June 30, 2019). In the event the Company cannot raise additional capital to fund and/or expand operations or fails to raise adequate capital and generate adequate sales revenues, it could result in the Company having to curtail or cease operations. Currently, the Company has a limited amount of shares of common stock available to issue under its articles of incorporation and has initiated the process of increasing the authorized stock.

 

Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues in the short term, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations to achieve profitability thereby eliminating its reliance on alternative sources of funding. Although management believes that the Company is in a stronger position than it has been in in several years, there is still no guarantee that profitable operations with sufficient cashflow to sustain operations can or will be achieved without the need of alternative financing, which is limited. These matters still raise significant doubt about the Company’s ability to continue as a going concern as determined by management. The Company believes that there is uncertainty with respect to continuing as a going concern until the operating business can achieve more than nominal sales and profitable operations and sustain cash flow to operate the Company for a period of twelve months. In the event the Company does need to raise additional capital to fund operations or engage in a transaction, failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreements or ownership interests in life science companies and generate adequate revenues, or the agreements entered into recently are unsuccessful, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern as determined by management. However, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

15
 

 

Contractual Obligations

 

On December 1, 2017, the Company relocated its corporate headquarters from Danbury, Connecticut to New York, New York, and entered into a two-year lease for its New York City location at $1,010 per month for the term of the lease.

 

On June 11, 2019, the Company entered into a two-year lease, expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).

 

Per Os Bio has contracted with the Company as the sole manufacturer of its Tauri-GumTM and are under contract to produce our product when ordered at approximately $6 per blister pack. Per OS is also required to have each batch independently tested to ensure that each piece of chewing gum must contain 10 milligrams (“mg”) of CBD Isolate, has 0% THC Content and is clear for all microbiology.

 

Off-Balance Sheet Arrangements

 

As of June 30, 2019, the Company had one off-balance sheet arrangement as defined in Item 303(a)(4) of Regulation S-K.

 

On December 20, 2018, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued two 8% convertible redeemable notes in the cumulative principal amount of $110,000. The first 8% note for $55,000 was funded with net proceeds of $47,500, after the deduction of $5,000 for OID and $2,500 in legal fees. The second 8% note (the “Back-End Note”) is initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the “Note Receivable”). The terms of the Back-End Note require cash funding prior to any conversion thereunder. The Note Receivable is due December 20, 2019, unless certain conditions are not met, in which case both the Back-End Note and the Note Receivable may both be cancelled. Both the First Note and the Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under both the First Note and the Back-End Note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 50% instead of 60% while that “chill” is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this Note is in effect, the Company may redeem this Note by paying to the Holder an amount equal to 140% of the face amount plus any accrued interest. This Note may not be prepaid after the six-month anniversary of the Issuance Date. The back-end note may not be repaid. The note holder may redeem this note at any time after the first six months.

 

On August 12, 2019, ADAR ALEF, LLC funded this note, satisfying the note receivable and eliminating any further off-balance sheet arrangements. The Company will record this note in notes payable on it condensed consolidated balance sheet.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.

 

Not applicable

 

16
 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean a company’s controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its chief executive and chief financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC’s rules and forms and that information required to be disclosed is accumulated and communicated to the chief executive and chief financial officer to allow timely decisions regarding disclosure.

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are not effective as of such date. The Chief Executive Officer and Chief Financial Officer have determined that the Company continues to have the following deficiencies which represent a material weakness:

 

  1. Lack of oversight by independent directors in the establishment and monitoring of required internal controls and procedures;
     
  2. Lack of functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;
     
  3. Insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting and to allow for proper monitoring controls over accounting;
     
  4. Insufficient written policies and procedures over accounting transaction processing and period end financial disclosure and reporting processes.

 

17
 

 

To remediate our internal control weaknesses, management would need to implement the following measures:

 

  ● The Company would need to add sufficient number of independent directors to the board and appoint an audit committee.
     
  ● The Company would need to add sufficient knowledgeable accounting personnel to properly segregate duties and to affect a timely, accurate preparation of the financial statements.
     
  ● Upon the hiring of additional accounting personnel, the Company would need to develop and maintain adequate written accounting policies and procedures.

 

Currently, management does not have the resources nor will it in the near to mid-term future to accomplish all of these goals.

 

The additional hiring is contingent upon the Company’s efforts to obtain additional funding through equity or debt and the results of its operations, however, has added consultants to assist in the remediation of the weaknesses identified. Management expects to secure funds in the coming fiscal year but provides no assurances that it will be able to do so.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on the Effectiveness of Controls

 

The Company’s management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of the control system must reflect that there are resource constraints and that the benefits must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

18
 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of August 13, 2019, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.

 

ITEM 1A. RISK FACTORS.

 

Investing in our common stock is subject to a number of risks and uncertainties. You should carefully consider the risk factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2019, in other reports we file with the SEC, and as set forth in certain updated or additional risk factor below.

 

Federal regulation and enforcement may adversely affect the implementation of cannabis laws and regulations may negatively impact our business operations, revenues and profits.

 

Currently, there are 33 states in the United States, plus the District of Columbia, that have laws and/or regulations that recognize, in one form or another, medical benefits or other uses for CBD infused or cannabis related products. These states have also passed laws governing the use and sale of cannabis products and others are considering similar legislation. Our Tauri-GumTM product line does not contain psychoactive substances also present in the cannabis plant, such as Tetrahydrocannabinol or THC.

 

Nonetheless, at least some provisions of these state laws are in direct conflict with the United States Federal Controlled Substances Act (21 U.S.C. § 811) (“CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug, which is viewed as having a high potential for abuse, has no currently-accepted use for medical treatment in the U.S., and lacks acceptable safety for use under medical supervision. Under the CSA, the policies and regulations of the federal government and its agencies are that cannabis has no medical benefit and a range of activities including cultivation and the personal use of cannabis is prohibited. Uncertainty remains the rule under the CSA. There is disagreement between the government and the courts regarding the precise scope of the CSA. Some courts have held that CBD is excluded from the CSA, which they believe, only covers the THC chemical. Others have held that CBD is covered by the CSA when it is derived from the cannabis plant. On December 20, 2018, the Agricultural Improvement Act of 2018 (the “2018 Farm Bill”) legalized the cultivation and production of hemp, a variation on the cannabis plant that contains CBD but less than 0.3% THC (the psychoactive chemical of the cannabis plant), providing at least some certainty about sources of legal CBD.

 

Unless and until Congress amends the CSA to clarify precisely what is covered by the CSA, as to the timing or scope of any such potential amendments there can be no assurance, there is a risk that federal authorities may enforce current federal law against us despite our efforts to source our products from legal sources, and we may be deemed to be producing and/or dispensing marijuana-based products in violation of federal law. Active enforcement of the current federal regulatory position on cannabis may thus directly or indirectly, and adversely, affect our business, operations, revenues and any profits. The risk of strict enforcement of the CSA in light of Congressional activity, judicial holdings, and stated federal policy remains uncertain.

 

In an effort to provide guidance to federal law enforcement, the DOJ had previously issued guidance regarding marijuana enforcement to all United States Attorneys in a memorandum from then Attorney General David Ogden on October 19, 2009, in a memorandum from Deputy Attorney General James Cole on June 29, 2011 and in a memorandum from Deputy Attorney General James Cole on August 29, 2013. Each memorandum provided that the DOJ is committed to the enforcement of the CSA, but, the DOJ is also committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and rational way; however, on January 4, 2018, the U.S. Attorney General of the Department of Justice revoked the Ogden Memo and the Cole Memos.

 

19
 

 

The DOJ has not historically devoted resources to prosecuting individuals whose conduct is limited to possession of small amounts of marijuana for use on private property but has relied on state and local law enforcement to address marijuana activity. In the event the DOJ reverses its stated policy and begins strict enforcement of the CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there may be a direct and adverse impact to our business and our revenue and profits. Furthermore, H.R. 83, enacted by Congress on December 16, 2014, provides that none of the funds made available to the DOJ pursuant to the 2015 Consolidated and Further Continuing Appropriations Act may be used to prevent certain states from implementing their own laws that authorized the use, distribution, possession, or cultivation of medical marijuana.

 

Under the 2018 Farm Bill, the U.S. Food and Drug Administration (FDA) has been given the authority to regulate CBD when incorporated into a food, drug, or cosmetic substance. Immediately following the passage of the 2018 Farm Bill, the FDA signaled its intent to use this power. The FDA sought public comments through July 16, 2019 and has not issued any guidance, rules, or regulations regarding the use of CBD in foods, drugs, or cosmetics since closing the comment period. Because our product is included in food, FDA rules and regulations limiting our ability to source, manufacture, and sell the product, or limiting the consumer’s ability to purchase and use the produce, could severely impact our revenues and profits.

 

New York City has implemented an embargo on food and beverage CBD products.

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

Variations in state and local regulation, and enforcement in states that have legalized cannabis, may restrict cannabis-related activities, which may negatively impact our revenues and prospective profits.

 

Individual state and local laws do not always conform to the federal standard or to other states’ laws. States and local governmental entities that have decriminalized marijuana have created legal regimes, structures, and rules related to the use, cultivation, manufacture, distribution, transportation, and sale of medical cannabis and related products. These legal regimes often require companies to apply for and be awarded a license in order to operate a cannabis business operation. We plan to operate our cannabis business as a white label operation, however, if we are deemed to be operating our business without a required license this could impact our ability to maintain this business or subject us to significant penalties, fees, fines, or other financial consequences. If our partners lose their license this could also significantly impact our revenues as a result of lost profits while we sought out new partners or waiting for current partners to become compliant.

 

State and local laws and regulations are also still in flux as states and local agencies figure out how best to regulate new products. State and local laws may change in unexpected ways that could result in our partners losing their license, us or our partners being forced to change our or their products or services, or raise prices, all of which could impact our revenues and prospective profits.

 

State or local laws may prohibit white labeling, which would force us to abandon our current business strategy with regard to our CBD products or rework our current relationships with our partners, which would significantly impact our revenues and prospective profits.

 

20
 

 

Laws regarding the transportation of Cannabis may change

 

Transportation of cannabis or cannabis containing products is governed by both state and federal law. The interaction between these two legal regimes creates legal and practice difficulties in getting products to market. Changes in state law related to the transportation of cannabis may significantly impact our ability to get products to market or may raise the cost of doing so, which would impact our revenue and potential profits. Both state and federal law make it illegal to transport cannabis products across state lines. Any accidental or intentional transportation of our products across state lines could, therefore, result in significant consequences including loss of a state issues license or permit, financial penalties, seizure of our products, and prosecution for the illegal transportation of a Schedule I substance. These consequences may impact our revenues, potential profits, or ability to continue operating in this line of business.

 

We may be classified as an inadvertent investment company.

 

We are not primarily engaged in the business of investing, reinvesting, or trading in securities, and we do not hold ourselves out as being engaged in those activities. Under the Investment Company Act of 1940, as amended (the “1940 Act”), however, a company may be deemed an investment company under section 3(a)(1)(C) of the 1940 Act if the value of its investment securities is more than 40% of its total assets (exclusive of government securities and cash items) on a consolidated basis.

 

As a result of our December 13, 2017 purchase of shares of Vistagen Therapeutics Inc. (NASDAQ: VTGN), and the subsequent investments the Company has made in public and privately held companies in the subsequent period, the investment securities presently held by us exceeds 40% of our total assets, exclusive of cash items and, accordingly, we are currently an inadvertent investment company. As of June 30, 2019 the Company holds common stock in two companies and warrants exercisable for common stock in two companies. An inadvertent investment company can avoid being classified as an investment company if it can rely on one of the exclusions under the 1940 Act. One such exclusion, Rule 3a-2 under the 1940 Act, allows an inadvertent investment company a grace period of one year from the earlier of (a) the date on which an issuer owns securities and/or cash having a value exceeding 50% of the issuer’s total assets on either a consolidated or unconsolidated basis and (b) the date on which an issuer owns or proposes to acquire investment securities having a value exceeding 40% of the value of such issuer’s total assets (exclusive of government securities and cash items) on an unconsolidated basis. We have taken actions to cause the investment securities held by us to be less than 40% of our total assets, and will continue to evaluate other feasible actions towards this end, which may include acquiring assets with our cash on hand, consummating a significant merger/acquisition transaction, or liquidating our investment securities. We also may seek a no-action letter from the SEC if we are unable to acquire sufficient non-securities assets or liquidate sufficient investment securities in a timely manner.

 

As Rule 3a-2 is available to a company no more than once every three years, and assuming no other exclusion were available to us, we would have to keep within the 40% limit for at least three years after we cease being an inadvertent investment company. This may limit our ability to make certain investments or enter into joint ventures that could otherwise have a positive impact on our earnings. In any event, we do not intend to become an investment company engaged in the business of investing and trading securities.

 

Classification as an investment company under the 1940 Act requires registration with the SEC. If an investment company fails to register, it would have to stop doing almost all business, and its contracts would become voidable. Registration is time consuming and restrictive and would require a restructuring of our operations, and we would be very constrained in the kind of business we could do as a registered investment company. Further, we would become subject to substantial regulation concerning management, operations, transactions with affiliated persons and portfolio composition, and would need to file reports under the 1940 Act regime. The cost of such compliance would result in the Company incurring substantial additional expenses and could result in the complete cessation of our operations, and the failure to register if required would have a materially adverse impact to conduct our operations.

 

We may need to increase our authorized shares of common stock under our articles of incorporation

 

We have started the process to amend our articles of incorporation to increase the number of shares of common stock that we are authorized to issue, reserve or otherwise offer by the filing of a preliminary proxy statement with the Securities and Exchange Commission. Such an amendment to our articles of incorporation will require that the Company hold a meeting of its stockholders, reach quorum at such meeting (either in person or by proxy), which, under applicable Florida statute, in part requires the vote of a minimum of 50% plus one of our issued and outstanding shares of common stock as of the record date set for such stockholder meeting, the approval of a majority of the stockholders eligible to cast a vote at such stockholder meeting, and the satisfaction of such other rules and regulations for noticing and holding such a stockholder meeting under the Florida Business Corporation Act, pursuant to Regulation 14A of the SEC, and such other applicable rules and regulations.

 

The failure to obtain such necessary approval to increase our authorized common stock could materially and negatively impact the Company and its stockholders, including a decrease in the price of our trading common stock, triggering a default and/or cross-default under our outstanding debt and convertible instruments (if not timely cured), a significant decrease in the conversion price and increase in the number of shares of common stock issuable thereunder, a default annual interest rate of 24%, among other material negative impacts. The complete terms of our purchase agreement, convertible debt instruments and related agreements are included as exhibits to our SEC filings.

 

21
 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

During May and June 2019, the Company issued additional shares of common stock as follows: (i) 1,450,000 shares under distribution agreements ; (ii) 888,308 shares for conversion of debt; (iii) 250,000 shares issued to Vice President of Distribution and Marketing; (iv) 1,000,000 shares issued for services rendered; (v) 750,000 shares for debt commitment and (vi) 714,286 shares under stock purchase agreements in consideration for $45,000 (average of $0.063 per share) to accredited investors that are unrelated third parties.

 

During the three months ended June 30, 2019 and subsequently (up to this report date), the Company issued 1,450,000 shares under distribution agreements. Under our North Eastern United States Distribution Agreement (SKL Agreement) the Company issued one-time issuance of an aggregate of 1,000,000 restricted common shares the Company’s stock, which are subject to the customary resale and transfer restrictions imposed under the rules and regulations of the Securities and Exchange Commission. The restricted equity issuance to SKL was issued in accordance with the following schedule: (i) to Mr. Mahesh Lekkala, 500,000 restricted shares the Company’s common stock within ten (10) business days of April 30, 2019; and (ii) to SKL, 500,000, which were permitted to be immediately allocated by SKL to persons within its organization and, as such, (a) 250,000 of such shares shall be issued to SKL within ten (10) business days of April 30, 2019, and the additional issuance of (b) 250,000 of such shares shall be issued to SKL within ten (10) business days of August 1, 2019. Other than the payment terms for Tauri-GumTM product purchased and distributed under the terms of the Agreement, there is no additional cash payment currently due or owing by the Company thereunder. The value of the shares is reflected as stock-based compensation with a grant date of April 30, 2019. All but 250,000 shares are expensed on this date, with those 250,000 shares valued over the term of the one-year agreement. The Company issued 450,000 shares pursuant to the South Florida Region Distribution Agreement (IRM Distribution Agreement). Under this agreement, the Company will work closely with IRM to promote Tauri-GumTM. Under the agreement IRM received restricted common stock and a cash stipend of $10,000. As of the date of this report, only $2,000 of the $10,000 cash stipend has been paid. The value of the restricted shares will be reflected in stock-based compensation based on the grant date of April 8, 2019.

 

On April 1, 2019, the Company entered into a comprehensive distribution agreement with E&M to establish Tauri-GumTM in the marketplace. The Company has supported the Tauri-GumTM commercial launch with substantial levels of both financial resources and marketing support. The Company has agreed to issue a one-time issuance of 1,000,000 restricted shares of the Company’s common stock, and to tender a one-time cash payment of $125,000 to E&M. This $125,000 cash component was paid in full to E&M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. The Company is awaiting issuance instructions from E&M to issue the shares.

 

During the three months ended June 30, 2019, the Company issued 888,308 shares for conversion of debt in the amount of $40,000 as well as accrued interest in the amount of $1,964 ($0.04725). On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock pursuant to an October 25, 2018, one-year $180,000 convertible note bearing 8% interest.

 

22
 

 

During the three months ended June 30, 2019, the Company issued 250,000 shares issued to Vice President of Distribution and Marketing. On May 11, 2019, the Company entered into a sub-agreement pursuant to the SKL distribution agreement whereby Ms. Neelima Lekkala was appointed Vice President of Distribution & Marketing. This contract has a one-year term and is and may be extended based upon mutual agreement. Ms. Lekkala shall focus her efforts on the expansion of Tauri-GumTM as well as revenue growth, acquisition of new customers, establishment of professional marketing materials & protocols, logistics improvement(s) and fulfillment services. Ms. Lekkala is deeded a non-affiliate and does not carry any type of fiduciary liability. Ms. Lekkala’s compensation includes 250,000 shares of the Company’s restricted common stock deemed fully earned and vested upon the execution of her consulting agreement. These shares were issued May 20, 2019, having a value of $18,275 based on the closing price of the Company’s stock on that day ($0.0731 per share). Additionally, Ms. Lekkala will receive a 30% commission on total gross sales through the sale of the Tauri-GumTM product line which can be paid in either stock or cash at the election of Ms. Lekkala.

 

During the three months ended June 30, 2019, the Company issued 1,000,000 shares issued for services rendered to one consultant. This consultant integral part of the launch of Tauri-GumTM through coordination efforts and introductions to parties necessary to the ongoing success of our product.

 

During the three months ended June 30, 2019, the Company issued 750,000 shares for debt commitment in the amount of $142,500 ($0.19 per share) pursuant to the March 14, 2019,12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.

 

As previously reported, on Form 8-K, filed on April 12, 2019, during late February of 2019, the Company commenced a strategic private placement, the primary purpose of which was intended finance the following operational matters related to our Tauri-Gum™ product: increasing production of our product inventory, funding of research & development initiatives, entering into distribution agreements, augmenting our digital artwork and graphic design projects, formulating a special miniaturized airport version of Tauri-Gum™, and for general corporate and working capital purposes. On April 12, 2019, the Company executed a Securities Purchase Agreement (the private placement “SPA”) with a number of individual and institutional “accredited investors” (within the meaning of Rule 501 of Regulation D under the Securities Act of 1933, as amended, the “Act”) to consummate the private placement resulting in aggregate gross proceeds to the Company of $335,200. A number of the investors include an owner of a Northeastern supermarket chain, as well as executives in the food distribution and medical practice management networks. Pursuant to the terms of the SPA, the Company was contractually obligated to issue 4,366,667 shares of its restricted common stock pursuant to Regulation D of the Act. No warrants were offered or issued in connection with this above-referenced private placement. While the Company had been offered greater aggregate gross proceeds on the same foregoing terms, it determined to accept only the private placement capital noted above, being mindful of dilution and maintaining shareholder value through the execution of its business plan and initiatives. The revised number of shares that were issued during the year ended March 31, 2019 was 4,686,667 for proceeds of $218,200.

 

23
 

 

Additionally, under the SPA, during the three months ended June 30, 2019, the Company also issued 714,286 shares of restricted stock in consideration for $45,000 (average of $0.063 per share) to accredited investors that are unrelated third parties. The funds were also used for inventory and the start up of Tauri-Gum™, and for general corporate and working capital purposes.

 

On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled.

 

24
 

 

On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled.

 

25
 

 

On July 22, 2019, the Company and Jefferson Street Capital, LLC (“Jefferson Street”) consummated entry into a Securities Purchase Agreement where the Company will borrow $55,000 at 10% annual interest under a term of nine-months in the form of a convertible note. The note is convertible into restricted stock of the Company. In connection with this agreement, the Company issued 250,000 commitment shares having a value of $10,500 ($0.042 per share) which will be reflected as interest expense in the Company’s condensed consolidated statement of operations during the three months ended September 30, 2019. The restricted stock was valued at the closing price on July 22, 2019. Legal fees of $2,000 will be deducted from cash proceeds of the note payable to investor’s counsel, and there is a $5,000 original issue discount recognized. The Company received cash proceeds of $48,000. Under the note, the Company is required initially to reserve 1,000,000 shares of its common stock, and thereafter to increase the reserve up to 15,000,000 shares upon the increase in the Company’s authorized common shares that was approved by the Board of Directors on July 26, 2019, but up to six times the number of shares required for a full conversion. The Company has 75 days from the date of this note to have this increased effectuated. The noteholder may, at any time, at its option, convert all or any amount of the principal face amount of the note then outstanding into shares of the Company’s common stock at a conversion price for each share of Common Stock equal to 65% of the lowest volume weighted average price for the Company’s common stock during the previous fifteen trading day period as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future, including the day upon which a notice of conversion is received by the Company. If the Company fails to maintain the share reserve at the required amounts, post the proxy period as defined in the agreement then that will be considered an Event of Default. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note.

 

During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date.

 

Upon an event of default (as defined and described in the note), among other default penalties, the Company shall pay the Default Amount (as defined in the agreement) as well as incur annual interest at a default interest rate of 24% per annum.

 

In consideration of Jefferson Street loaning the Company the proceeds under this note, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.

 

26
 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable

 

ITEM 5. OTHER INFORMATION.

 

On July 22, 2019, the Company and Jefferson Street Capital, LLC (“Jefferson Street”) consummated entry into a Securities Purchase Agreement where the Company has borrowed $55,000 ($50,000 with original issuance discount reflected) at 10% annual interest under a term of nine-months in the form of a convertible note. The note is convertible into restricted stock of the Company. In connection with this agreement, the Company issued 250,000 commitment shares having a value of $10,500 ($0.042 per share, the closing price of our common stock on the day preceding the note which will be reflected as interest expense in the Company’s condensed consolidated statement of operations during the three months ended September 30, 2019. The restricted stock was valued at the closing price on July 22, 2019. Legal fees of $2,000 were deducted from cash proceeds of the note payable to investor’s counsel, and a $5,000 original issue discount recognized. The Company received cash proceeds of $48,000 at closing. Under the Jefferson Street note, the Company is required initially to reserve 1,000,000 shares of its common stock, and thereafter to increase the reserve up to 15,000,000 shares upon the increase in the Company’s authorized common shares (per a charter amendment via shareholder meeting and approval as approved by the Board of Directors on July 26, 2019), but up to six times the number of shares required for a full conversion. The Company has 75 days from the date of this note to have this increased effectuated. The noteholder may, at any time, at its option, convert all or any amount of the principal face amount of the note then outstanding into shares of the Company’s common stock at a conversion price for each share of Common Stock equal to 65% of the lowest volume weighted average price for the Company’s common stock during the previous fifteen trading day period as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future, including the day upon which a notice of conversion is received by the Company. If the Company fails to maintain the share reserve at the required amounts, or to attain shareholder approval within 75 days of July 22, 2019, this will be considered an Event of Default (among other default provisions contained in the Jefferson Capital note). This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note, and may trigger a cross default of the Company’s other outstanding convertible debt agreements; however, the Company maintains the option to repay the note in cash within the first 180 days beginning on July 22, 2019 to avoid such default provision triggering event, as more fully described below.

 

During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date.

 

Upon an event of default (as defined and described in the note), among other default penalties, the Company shall pay the Default Amount (as defined in the agreement) as well as incur annual interest at a default interest rate of 24% per annum.

 

In consideration of Jefferson Street loaning the Company the proceeds under this note, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.

 

27
 

 

ITEM 6. EXHIBITS.

 

Exhibit 10.1  

GS Capital Partners, LLC Securities Purchase Agreement dated June 21, 2019 (filed on form 10-K on June 29, 2019)

     

Exhibit 10.2

  

GS Capital Partners, LLC Securities Purchase Agreement dated May 23, 2019 (filed on form 10-K on June 29, 2019)

     
Exhibit 10.3   GS Capital, LLC Convertible note dated May 23, 2019 for $60,000 (filed on form 10-K on June 29, 2019)
     
Exhibit 10.4   GS Capital Partners, LLC Convertible note dated June 21, 2019 for $60,000 (filed on form 10-K on June 29, 2019)
     
Exhibit 10.5   Jefferson St. Capital LLC Securities Purchase Agreement note dated July 22, 2019 for $55,000 (filed herewith)
     
Exhibit 10.6   Jefferson St. Capital, LLC Convertible note dated July 22, 2019 for $55,000 (filed herewith)
     
Exhibit 10.7  

Distribution Agreement between the Company and E&M Ice Cream Co., dated April 1, 2019 (filed on current report 8-K on April 15, 2019)

     

Exhibit 10.8

 

   Distribution Agreement between the Company and IRM Management Corporation, dated April 8, 2019 (filed on current report 8-K on April 15, 2019)
     

Exhibit 10.9

 

   Securities Purchase Agreement (Form of Private Placement), dated April 12, 2019 (filed on current report 8-K on April 15, 2019)
     

Exhibit 10.10

 

  

Distribution Agreement between the Company and Windmill Health, dated June 28, 2019 (filed on current report 8-K on July 5, 2019)

     

Exhibit 10.11

   Changes in Registrant’s Certifying Accountant (filed on current report 8-K on July 18, 2019)
     
Exhibit 10.12   Agreement with Vice President of Distribution & Marketing date May 11, 2019 (filed herewith)
     
Exhibit 10.13   Back-end 8% note having a face-value of $55,000 with ADAR ALEF, LLC due December 20, 2019 funded on August 12, 2019 (filed on form 10-Q on January 29, 2019)
     
Exhibit 31.1   Certification of Chief Executive Officer of Tauriga Sciences, Inc. Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
Exhibit 31.2   Certification of Principal Accounting Officer of Tauriga Sciences, Inc. Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
Exhibit 32.1   Certification of Principal Executive Officer of Tauriga Sciences, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
     
Exhibit 32.2   Certification of Principal Accounting Officer of Tauriga Sciences, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63

 

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

Exhibit 101    
     
101.INS   - XBRL Instance Document
     
101.SCH   - XBRL Taxonomy Extension Schema Document
     
101.CAL   - XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   - XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   - XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   - XBRL Taxonomy Extension Presentation Linkbase Document

 

28
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TAURIGA SCIENCES, INC.
  (Registrant)
     
Date: August 13, 2019 By: /s/ Seth M. Shaw
    Seth M. Shaw
    Chief Executive Officer
     
  By: /s/ Kevin P. Lacey
    Kevin P. Lacey
    Chief Financial Officer

 

29
 

 GRAPHIC 2 logo_001.jpg begin 644 logo_001.jpg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
M"]32[12X%( HHHH !UH'6@=:3O0!..@HH'044 5_X:>. ME-QQ2YXH ***,^U !11GVHS[4 %##-&:<>* (@"#3@>,8%+UHQ0 *!_=%-QU M&33^U(1SF@!G(&*0CYN*EZ]J0+\V: $\OBD*\<\T\FFGF@!OEDXIXXI,E>E* M/4T +NR::0,8Q3OPH_"@",YQBG <2E $6?<49]Q4ODI M1Y*4 19]Q1D^HJ7R4H\E* (LGU%&3ZBI?)2CR4H AR?6CGUJ;R4H\E* (LGU M%("1W%3>2E'DI0!#D^HHR?45-Y*4>2E $1)/<4F3ZBIO)2CR4H AY]:7)]:E M\E*/)2@"')]11D^HJ;R4H\E* (L^XHS[BI?)2CR4H BS[BC)]14ODI1Y*4 1 7#.>HHR?:I?)04>2M !GBBG;!10!__]D! end EX-10.5 3 ex10-5.htm

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 22, 2019, by and between TAURIGA SCIENCES INC., a Florida corporation, with its address at 555 Madison Avenue, 5th Floor, New York, New York 10022 (the “Company”), and JEFFERSON STREET CAPITAL LLC, a New Jersey limited liability company, with its address at 900 Monroe Street, Suite 908, Hoboken, New Jersey 07030 (the “Buyer”).

 

WHEREAS:

 

A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”); and

 

B. Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a convertible note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $55,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, $0.00001 par value per share, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

 

NOW THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1. Purchase and Sale of Note.

 

a. Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto. In connection with the issuance of the Note, the Company shall issue 250,000 shares of Common Stock (the “Commitment Shares”) to Buyer as a commitment fee. The Commitment Shares shall be earned on the date of this Agreement.

 

b. Form of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

 

   
 

 

c. Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon, Eastern Standard Time on or about July 22, 2019, or such other mutually agreed upon time. The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 

2. Buyer’s Representations and Warranties. The Buyer represents and warrants to the Company that:

 

a. Investment Purpose. As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Note (such shares of Common Stock being collectively referred to herein as the “Conversion Shares” and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

 

b. Accredited Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

 

c. Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

 

d. Information. The Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.

 

e. Legends. The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act; or may be sold pursuant to an applicable exemption from registration, the Conversion Shares may bear a restrictive legend in substantially the following form:

 

“THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE ISSUER OF SUCH SECURITIES RECEIVES AN OPINION OF COUNSEL TO THE BUYER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY ACCEPTABLE TO THE ISSUER’S TRANSFER AGENT, THAT SUCH SECURITIES MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.”

 

 2 
 

 

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to an exemption from registration without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected. The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144, at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note; provided such opinion complies with the Irrevocable Transfer Agent Instructions (as defined herein).

 

f. Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

 

3. Representations and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a. Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted. “Subsidiaries” means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest.

 

 3 
 

 

b. Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c. Capitalization. As of July 12, 2019, the authorized common stock of the Company consists of 100,000,000 authorized shares of Common Stock, $0.00001 par value per share, of which 72,925,920 shares are issued and outstanding; and 15,000,000 shares shall be reserved for issuance upon conversion of the Note (the “Reserved Amount”). All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and non-assessable. The Buyer acknowledges that the Company shall have seventy-five (75) calendar days from the Closing Date (the “Proxy Period”) to effectuate the Reserved Amount for the Buyer with its Transfer Agent. There shall be no Event of Default (as defined below) if during the Proxy Period the Company is unable to issue the Buyer more than 1,000,000 shares of Common Stock for conversion of the Note.

 

d. Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

e. No Conflicts. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect). The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. “Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial condition or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements or instruments to be entered into in connection herewith.

 

 4 
 

 

f. SEC Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934 Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”). Upon written request the Company will deliver to the Buyer true and complete copies of the SEC Documents, except for such exhibits and incorporated documents. As of their respective dates or if amended, as of the dates of the amendments, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof). As of their respective dates or if amended, as of the dates of the amendments, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods involved and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). The Company is subject to the reporting requirements of the 1934 Act.

 

g. Absence of Certain Changes. Since September 30, 2018, except as set forth in the SEC Documents, there has been no material adverse change and no material adverse development in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status of the Company or any of its Subsidiaries.

 

h. Absence of Litigation. Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

 5 
 

 

i. No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

 

j. No Brokers. The Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

k. No Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment Company”). The Company is not controlled by an Investment Company.

 

l. Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default under Section 3.4 of the Note.

 

4. COVENANTS.

 

a. Best Efforts. The Company shall use its best efforts to satisfy timely each of the conditions described in Section 7 of this Agreement.

 

b. Form D; Blue Sky Laws. The Company agrees to timely make any filings required by federal and state laws as a result of the closing of the transactions contemplated by this Agreement.

 

c. Use of Proceeds. The Company shall use the proceeds for general working capital purposes.

 

d. Expenses. At the Closing, the Company shall pay the Buyer’s legal counsel $2,000.00 in connection with the preparation of this Agreement and the related transaction documents. Such fee shall be deducted from the funding amount delivered at Closing and paid to the Buyer’s legal counsel.

 

e. Corporate Existence. So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except with the prior written consent of the Buyer.

 

 6 
 

 

f. Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an event of default under Section 3.4 of the Note.

 

g. Failure to Comply with the 1934 Act. So long as the Buyer beneficially owns the Note, the Company shall comply with the reporting requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements of the 1934 Act.

 

h. Trading Activities. Neither the Buyer nor its affiliates has an open short position in the common stock of the Company and the Buyer agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales of or hedging transactions with respect to the common stock of the Company.

 

i. Right of First Refusal. Unless it shall have first delivered to the Buyer, at least forty eight (48) hours prior to the closing of such Future Offering (as defined herein), written notice describing the proposed Future Offering (“ROFR Notice”), including the terms and conditions thereof, identity of the proposed purchaser and proposed definitive documentation to be entered into in connection therewith, and providing the Buyer an option during the forty eight (48) hour period following delivery of such notice to purchase the securities being offered in the Future Offering on the same terms as contemplated by such Future Offering (the limitations referred to in this sentence and the preceding sentence are collectively referred to as the “Right of First Refusal”), the Company will not conduct any equity (or debt with an equity component) financing in an amount less than $150,000 (“Future Offering(s)”) during the period beginning on the Closing Date and ending nine (9) months following the Closing Date. In the event the terms and conditions of a proposed Future Offering are amended in any respect after delivery of the notice to the Buyer concerning the proposed Future Offering, the Company shall deliver a new notice to the Buyer describing the amended terms and conditions of the proposed Future Offering and the Buyer thereafter shall have an option during the forty eight (48) hour period following delivery of such new notice to purchase the securities being offered on the same terms as contemplated by such proposed Future Offering, as amended.

 

 7 
 

 

5. Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered in the name of the Buyer or its nominee, for the Conversion Shares in such amounts as specified from time to time by the Buyer to the Company upon conversion of the Note in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”). In the event that the Company proposes to replace its transfer agent, the Company shall provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to this Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount as such term is defined in the Note) signed by the successor transfer agent to Company and the Company. Prior to registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant to an exemption from registration, all such certificates shall bear the restrictive legend specified in Section 2(e) of this Agreement. The Company warrants that: (i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and this Agreement; and (iii) it will not fail to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any Conversion Shares issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and/or this Agreement. If the Buyer provides the Company and the Company’s transfer agent, at the cost of the Buyer, with an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the 1933 Act, the Company shall permit the transfer, and, in the case of the Conversion Shares, promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified by the Buyer. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.

 

6. Conditions to the Company’s Obligation to Sell. The obligation of the Company hereunder to issue and sell the Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

 

a. The Buyer shall have executed this Agreement and delivered the same to the Company.

 

b. The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

 

c. The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

 

d. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

 8 
 

 

7. Conditions to The Buyer’s Obligation to Purchase. The obligation of the Buyer hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

 

a. The Company shall have executed this Agreement and delivered the same to the Buyer.

 

b. The Company shall have delivered to the Buyer the duly executed Note (in such denominations as the Buyer shall request) in accordance with Section 1(b) above.

 

c. The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Buyer, shall have been delivered to and acknowledged in writing by the Company’s Transfer Agent.

 

d. The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. The Buyer shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer including, but not limited to certificates with respect to the Board of Directors’ resolutions relating to the transactions contemplated hereby.

 

e. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

f. No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not limited to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.

 

g. The Conversion Shares shall have been authorized for quotation on an exchange or electronic quotation system and trading in the Common Stock on such exchange or electronic quotation system shall not have been suspended by the SEC or an exchange or electronic quotation system.

 

 9 
 

 

h. The Buyer shall have received an officer’s certificate described in Section 3(d) above, dated as of the Closing Date and the Buyer shall have been delivered the Commitment Shares on the Closing Date.

 

8. Governing Law; Miscellaneous.

 

a. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in New York and the county of Nassau. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and Buyer waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement, the Note or any related document or agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

b. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.

 

c. Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

 

d. Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

e. Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

 10 
 

 

f. Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be as set forth in the heading of this Agreement. Each party shall provide notice to the other party of any change in address.

 

g. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

 

h. Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to indemnify and hold harmless the Buyer and all of its officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

i. Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

 11 
 

 

j. No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

k. Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

 

 12 
 

 

IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

 

TAURIGA SCIENCES INC.  
     
By:  
Name: Seth Shaw  
Title: Chief Executive Officer  

 

JEFFERSON STREET CAPITAL LLC

 

By:    
Name: Brian Goldberg  
Title: Managing Member  

 

AGGREGATE SUBSCRIPTION AMOUNT:

 

Aggregate Principal Amount of Note:  $55,000.00 
Aggregate Purchase Price:  $50,000.00 

 

 13 
 

 

 EX-10.6 4 ex10-6.htm

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

Principal Amount: $55,000.00

Purchase Price: $50,000.00

   Issue Date: July 22, 2019

 

CONVERTIBLE PROMISSORY NOTE

 

FOR VALUE RECEIVED, Tauriga Sciences, Inc., a Florida corporation (hereinafter called the “Borrower”), hereby promises to pay to the order of Jefferson Street Capital LLC, a New Jersey limited liability company, or registered assigns (the “Holder”) the sum of $55,000.00 together with any interest as set forth herein, on April 22, 2020 (the “Maturity Date”), and to pay interest on the unpaid principal balance hereof at the rate of ten percent (10%)(the “Interest Rate”) per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twenty four percent (24%) per annum from the due date thereof until the same is paid (“Default Interest”). Interest shall be computed on the basis of a 365 day year and the actual number of days elapsed. Interest shall commence accruing on the Issue Date but shall not be payable until the Note becomes payable (whether at Maturity Date or upon acceleration or by prepayment). All payments due hereunder (to the extent not converted into common stock, $0.00001 par value per share (the “Common Stock”) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note. Each capitalized term used herein, and not otherwise defined, shall have the meaning ascribed thereto in that certain Securities Purchase Agreement dated the date hereof, pursuant to which this Note was originally issued (the “Purchase Agreement”).

 

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

 

   
 

 

The following terms shall apply to this Note:

 

ARTICLE I. CONVERSION RIGHTS

 

1.1 Conversion Right. The Holder shall have the right from time to time, and at any time following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount (as defined in Article III), each in respect of the remaining outstanding amount of this Note to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the “Conversion Price”) determined as provided herein (a “Conversion”); provided, however, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the “Notice of Conversion”), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the “Conversion Date”); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term “Conversion Amount” means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) at the Holder’s option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder’s option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder’s option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

 

1.2 Conversion Price. The conversion price (the “Conversion Price”) (subject to equitable adjustments by the Borrower relating to the Borrower’s securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events) shall equal the lesser of (i) 65% multiplied by the lowest volume weighted average price (as defined below) for the Common Stock during the previous fifteen (15) Trading Day period before the Issue Date of this Note (representing a discount rate of 35%), or (ii) the Variable Conversion Price (as defined herein). The “Variable Conversion Price” shall mean, 65% multiplied by the Market Price (as defined herein) (representing a discount rate of 35%). “Market Price” means the lowest volume weighted average price for the Common Stock during the fifteen (15) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTC Markets, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. The Borrower shall be responsible for the fees of its transfer agent and all DTC fees associated with any such issuance. Holder shall be entitled to deduct $500.00 from the conversion amount in each Notice of Conversion to cover Holder’s deposit fees associated with each Notice of Conversion.

 

 2 
 

 

1.3 Authorized Shares. The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement. The Borrower is required at all times to have authorized and reserved six times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation set forth in Section 1.1 is not in effect)(based on the respective Conversion Price of the Note (as defined in Section 1.2) in effect from time to time, initially 15,000,000)(the “Reserved Amount”). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower’s obligations hereunder. The Holder acknowledges that the Borrower shall have seventy-five (75) calendar days from the Issue Date (the “Proxy Period”) to effectuate the Reserved Amount for the Holder with its Transfer Agent. There shall be no Event of Default (as defined below) if during the Proxy Period the Borrower is unable to issue the Holder more than 1,000,000 shares of Common Stock for conversion of the Note. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note.

 

If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

 

1.4 Method of Conversion.

 

(a) Mechanics of Conversion. As set forth in Section 1.1 hereof, from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

 

(b) Surrender of Note Upon Conversion. Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

 

 3 
 

 

(c) Delivery of Common Stock Upon Conversion. Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within two (2) business days after such receipt (the “Deadline”) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower’s obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

 

(d) Delivery of Common Stock by Electronic Transfer. In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder’s Prime Broker with DTC through its Deposit and Withdrawal at Custodian (“DWAC”) system.

 

(e) Failure to Deliver Common Stock Prior to Deadline. Without in any way limiting the Holder’s right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder$2,000 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the “Fail to Deliver Fee”); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

 

1.5 Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Borrower or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (“Rule 144”); or (iii) such shares are transferred to an “affiliate” (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

 

 4 
 

 

Any restrictive legend on certificates representing shares of Common Stock issuable upon conversion of this Note shall be removed and the Borrower shall issue to the Holder a new certificate therefore free of any transfer legend if the Borrower or its transfer agent shall have received an opinion of counsel from Holder’s counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that (i) a public sale or transfer of such Common Stock may be made without registration under the Act, which opinion shall be accepted by the Company so that the sale or transfer is effected; or (ii) in the case of the Common Stock issuable upon conversion of this Note, such security is registered for sale by the Holder under an effective registration statement filed under the Act; or otherwise may be sold pursuant to an exemption from registration. In the event that the Company does not reasonably accept the opinion of counsel provided by the Holder with respect to the transfer of Securities pursuant to an exemption from registration (such as Rule 144), at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.

 

1.6 Effect of Certain Events.

 

(a) Effect of Merger, Consolidation, Etc. At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). “Person” shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

 

(b) Adjustment Due to Merger, Consolidation, Etc. If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof. The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

 

 5 
 

 

(c) Adjustment Due to Distribution. If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower’s shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a “Distribution”), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution.

 

1.7 Prepayment. Notwithstanding anything to the contrary contained in this Note, at any time during the periods set forth on the table immediately following this paragraph (the “Prepayment Periods”), the Borrower shall have the right, exercisable on not more than three (3) Trading Days prior written notice to the Holder of the Note to prepay the outstanding Note (principal and accrued interest), in full, in accordance with this Section 1.7. Any notice of prepayment hereunder (an “Optional Prepayment Notice”) shall be delivered to the Holder of the Note at its registered addresses and shall state: (1) that the Borrower is exercising its right to prepay the Note, and (2) the date of prepayment which shall be not more than three (3) Trading Days from the date of the Optional Prepayment Notice. On the date fixed for prepayment (the “Optional Prepayment Date”), the Borrower shall make payment of the Optional Prepayment Amount (as defined below) to Holder, or upon the direction of the Holder as specified by the Holder in a writing to the Borrower (which direction shall to be sent to Borrower by the Holder at least one (1) business day prior to the Optional Prepayment Date). If the Borrower exercises its right to prepay the Note, the Borrower shall make payment to the Holder of an amount in cash equal to the percentage (“Prepayment Percentage”) as set forth in the table immediately following this paragraph opposite the applicable Prepayment Period, multiplied by the sum of: (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note to the Optional Prepayment Date plus (y) Default Interest, if any, on the amounts referred to in clauses (w) and (x) plus (z) any amounts owed to the Holder pursuant to Section 1.4 hereof (the “Optional Prepayment Amount”). If the Borrower delivers an Optional Prepayment Notice and fails to pay the Optional Prepayment Amount due to the Holder of the Note within two (2) business days following the Optional Prepayment Date, the Borrower shall forever forfeit its right to prepay the Note pursuant to this Section 1.7.

 

Prepayment Period  Prepayment Percentage 
1. The period beginning on the Issue Date and ending on the date which is ninety (90) days following the Issue Date.   120%
2. The period beginning on the date which is ninety-one (91) days following the Issue Date and ending on the date which is one hundred eighty (180) days following the Issue Date.   133%

 

 6 
 

 

After the expiration of one hundred eighty (180) days following the Issue Date, the Borrower shall have no right of prepayment.

 

ARTICLE II. CERTAIN COVENANTS

 

2.1 Sale of Assets. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder’s written consent, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may be conditioned on a specified use of the proceeds of disposition.

 

ARTICLE III. EVENTS OF DEFAULT

 

If any of the following events of default (each, an “Event of Default”) shall occur:

 

3.1 Failure to Pay Principal and Interest. The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

 

3.2 Conversion and the Shares. The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for two (2) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower’s transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

 

3.3 Breach of Covenants. The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

 

3.4 Breach of Representations and Warranties. Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

 

 7 
 

 

3.5 Receiver or Trustee. The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

 

3.6 Bankruptcy. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

 

3.7 Delisting of Common Stock. The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

 

3.8 Failure to Comply with the Exchange Act. The Borrower shall fail to comply with the reporting requirements of the Exchange Act; and/or the Borrower shall cease to be subject to the reporting requirements of the Exchange Act.

 

3.9 Liquidation. Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

 

3.10 Cessation of Operations. Any cessation of operations by Borrower or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower’s ability to continue as a “going concern” shall not be an admission that the Borrower cannot pay its debts as they become due.

 

3.11 Financial Statement Restatement. The restatement of any financial statements filed by the Borrower with the SEC at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

 

3.12 Replacement of Transfer Agent. In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

 

3.13 Cross-Default. Notwithstanding anything to the contrary contained in this Note or the other related or companion documents, a breach or default by the Borrower of any covenant or other term or condition contained in any of the Other Agreements, after the passage of all applicable notice and cure or grace periods, shall, at the option of the Holder, be considered a default under this Note and the Other Agreements, in which event the Holder shall be entitled (but in no event required) to apply all rights and remedies of the Holder under the terms of this Note and the Other Agreements by reason of a default under said Other Agreement or hereunder. “Other Agreements” means, collectively, all agreements and instruments between, among or by: (1) the Borrower, and, or for the benefit of, (2) the Holder and any affiliate of the Holder, including, without limitation, promissory notes; provided, however, the term “Other Agreements” shall not include the related or companion documents to this Note. Each of the loan transactions will be cross-defaulted with each other loan transaction and with all other existing and future debt of Borrower to the Holder.

 

 8 
 

 

3.14 Reserve Under Transfer Agent Letter. If, seventy five (75) calendar days from the Issue Date the Borrower has failed to (i) increase its authorized shares of Common Stock by at least an additional 100,000,000 shares and (ii) reserve the Holder at least six times the amount of shares issuable to the Holder upon full conversion of the Note pursuant to that certain Irrevocable Transfer Agent Instruction Letter dated July 22, 2019, by and among the Holder, ClearTrust LLC (the Borrower’s Transfer Agent), and the Borrower (substantially in the form attached hereto as Exhibit B, the “Transfer Agent Letter”).

 

3.15 Unavailability of Rule 144. If, at any time on or after the date which is 180 days after the Issue Date, the Holder is unable to (i) obtain a standard “144 legal opinion letter” from an attorney reasonably acceptable to the Holder, the Holder’s brokerage firm (and respective clearing firm), and the Borrower’s transfer agent in order to facilitate the Holder’s conversion of any portion of the Note into free trading shares of the Borrower’s Common Stock pursuant to Rule 144, and (ii) thereupon deposit such shares into the Holder’s brokerage account.

 

Upon the occurrence and during the continuation of any Event of Default specified in Section 3.1 (solely with respect to failure to pay the principal hereof or interest thereon when due at the Maturity Date), the Note shall become immediately due and payable and the Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the Default Amount (as defined herein). UPON THE OCCURRENCE AND DURING THE CONTINUATION OF ANY EVENT OF DEFAULT SPECIFIED IN SECTION 3.2, 3.14 and 3.15 THE NOTE SHALL BECOME IMMEDIATELY DUE AND PAYABLE AND THE BORROWER SHALL PAY TO THE HOLDER, IN FULL SATISFACTION OF ITS OBLIGATIONS HEREUNDER, AN AMOUNT EQUAL TO: (Y) THE DEFAULT AMOUNT (AS DEFINED HEREIN); MULTIPLIED BY (Z) TWO (2).

 

Upon the occurrence and during the continuation of any Event of Default specified in Sections 3.1 (solely with respect to failure to pay the principal hereof or interest thereon when due on this Note or upon acceleration), 3.3, 3.4, 3.7, 3.8, 3.10, 3.11, 3.12, and/or 3.13 exercisable through the delivery of written notice to the Borrower by such Holders (the “Default Notice”), and upon the occurrence of an Event of Default specified the remaining sections of Articles III (other than failure to pay the principal hereof or interest thereon at the Maturity Date specified in Section 3,1 hereof), the Note shall become immediately due and payable and the Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the greater of (i) 150% times the sum of (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note to the date of payment (the “Mandatory Prepayment Date”) plus (y) Default Interest, if any, on the amounts referred to in clauses (w) and/or (x) plus (z) any amounts owed to the Holder pursuant to Section 1.4(e) hereof (the then outstanding principal amount of this Note to the date of payment plus the amounts referred to in clauses (x), (y) and (z) shall collectively be known as the “Default Amount”) and all other amounts payable hereunder shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including, without limitation, legal fees and expenses, of collection, and the Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

 

If the Borrower fails to pay the Default Amount within five (5) business days of written notice that such amount is due and payable, then the Holder shall have the right at any time, so long as the Borrower remains in default (and so long and to the extent that there are sufficient authorized shares), to require the Borrower, upon written notice, to immediately issue, in lieu of the Default Amount, the number of shares of Common Stock of the Borrower equal to the Default Amount divided by the Conversion Price then in effect.

 

 9 
 

 

ARTICLE IV. MISCELLANEOUS

 

4.1 Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

 

4.2 Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

 

If to the Borrower, to:

 

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, New York 10022

Attn: Seth Shaw, Chief Executive Officer

 

If to the Holder:

 

Jefferson Street Capital LLC 900

Monroe Street, Suite 908

Hoboken, New Jersey 07030

Attn: Brian Goldberg, Managing Member

 

4.3 Amendments. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

 10 
 

 

4.4 Most Favored Nation. During the period where any monies are owed to the Holder pursuant to this Note, if the Borrower engages in any future financing transactions with a third party investor, the Borrower will provide the Holder with written notice (the “MFN Notice”) thereof promptly but in no event less than 10 days prior to closing any financing transactions. Included with the MFN Notice shall be a copy of all documentation relating to such financing transaction and shall include, upon written request of the Holder, any additional information related to such subsequent investment as may be reasonably requested by the Holder. In the event the Holder determines that the terms of the subsequent investment are preferable to the terms of the securities of the Borrower issued to the Holder pursuant to the terms of the Purchase Agreement, the Holder will notify the Borrower in writing. Promptly after receipt of such written notice from the Holder, the Borrower agrees to amend and restate the Securities (which may include the conversion terms of this Note), to be identical to the instruments evidencing the subsequent investment. Notwithstanding the foregoing, this Section 4.4 shall not apply in respect of (i) an Exempt Issuance, or (ii) an underwritten public offering of Common Stock. “Exempt Issuance” means the issuance of: (a) shares of Common Stock or options to employees, officers, consultants, advisors or directors of the Borrower pursuant to any stock or option plan duly adopted for such purpose by a majority of the members of the Board of Directors or a majority of the members of a committee of directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of this Note and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date hereof, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Borrower, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Borrower and in which the Borrower receives benefits in addition to the investment of funds, but shall not include a transaction in which the Borrower is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

 

4.5 Assignability. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an “accredited investor” (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be pledged as collateral in connection with a bona fide margin account or other lending arrangement; and may be assigned by the Holder without the consent of the Borrower.

 

4.6 Cost of Collection. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys’ fees.

 

4.7 Governing Law. This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of New York or in the federal courts located in the Eastern District of New York. The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

 11 
 

 

4.8 Purchase Agreement. By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

 

4.9 Remedies. The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

 

4.10 Personal Guaranty. In consideration of the Holder loaning the Purchase Price to the Borrower, which such amount will personally benefit Seth Shaw (the “Guarantor”), as the Guarantor is an officer and member of the board of directors of the Borrower and will receive substantial material consideration as a direct result of the payment of the Purchase Price by the Holder to the Borrower, plus other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Guarantor personally guarantees the prompt, full and complete payment of the outstanding principal amount, interest, default interest (if any) and applicable fees (if any), owing by the Borrower to the Holder under this Note. Notwithstanding the foregoing, the terms and conditions of this Section 4.10 shall be immediately extinguished and of no further force or effect upon the Borrower effectuating the Transfer Agent Letter and reserving for the Holder at least six times the amount of shares of Common Stock issuable upon full conversion of the Note.

 

 12 
 

 

IN WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer this on July 22, 2019

 

TAURIGA SCIENCES INC.  
     
By:    
Name: Seth Shaw  
Title: Chief Executive Officer  

 

ACKNOWLEDGED AND AGREED IN PERSONAL CAPACITY PURSUANT TO SECTION 4.10  
   
   
Seth Shaw, an individual  

 

 13 
 

 

EXHIBIT A -- NOTICE OF CONVERSION

 

The undersigned hereby elects to convert $ ___________ principal amount of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (“Common Stock”) as set forth below, of Tauriga Sciences, Inc., a Florida corporation (the “Borrower”) according to the conditions of the convertible note of the Borrower dated as of July 22, 2019 (the “Note”), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

 

Box Checked as to applicable instructions:

 

  [  ] The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).
     
    Name of DTC Prime Broker:
    Account Number:
     
  [  ] The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

 

[Insert Name and Address of Holder Here]

 

Date of conversion:        
Applicable Conversion Price:  $ 
Number of shares of common stock to be issued
pursuant to conversion of the Notes:		     
Amount of Principal Balance due remaining
under the Note after this conversion:		     

 

JEFFERSON STREET CAPITAL LLC  
     
By:    
Name: Brian Goldberg  
Title: Managing Member Date:  

 

 14 
 

 EX-10.12 5 ex10-12.htm

 

TAURIGA SCIENCES INC. (OTCQB: TAUG)

555 Madison Avenue, 5” Floor

New York, NY 10022

Attn: Seth M. Shaw, Chief Executive Officer

SUB-AGREEMENT FOR NEELIMA LEKKALA {Pursuant to April 30, 2019

Distribution Agreement Entered into Between Tauriga Sciences Inc.& Sai Krishna LLC}

Ms. Neelima Lekalla 27 Wingate Dfive

Livingston, NJ 07039 SS # XXX-XX-4076

May 11, 2019

 

This (this “Agreement”), dated as of May 11, 2019 (the “Effective Date”), by and between Tauriga Sciences Inc. (“TAUG”), located in New York, NY 10022 (the “Company”), and Ms. Neelima Lekkala (“Ms. Lekkala”) located in Livingston, NJ 07039 is a sub-agreement — Pursuant to Section IV, Item # 1 (page #4), of the effective April 30, 2019 effective date Distribution Agreement — referenced above - entered into between Tauriga Sciences Inc. and Sai Krishna LLC.

 

1. Term.

 

(a) This Agreement shall continue for a period of twelve (12) months from the Effective Date (or May 11, 2020). The is agreement may be extended, at that time, based on mutual consent and agreement.

 

2. Position and Responsibilities

 

(a) Position. Company hereby retains Ms. Lekkala to assume the position of Vice President of Distribution & Marketing. This appointment shall be deemed a non-affilate position and shall not carry any type of fiduciary liability (as assumed by Officers and Directors).

 

(b) Activities. Ms. Lekkala shall focus her efforts on the expansion of Tauri-Gum as well as revenue growth, acquisition of new customers, establishment of professional marketing materials & protocols, logistics improvement(s), and fulfillment services

 

(c) No Conflict. Except as set forth in Section 2(b), Vice President (“VP”) will not engage in any activity that creates an actual conflict of interest with Company, regardless of whether such activity is prohibited by Company’s conflict of interest guidelines or this Agreement, and VP agrees to notify the Board of Directors before engaging in any activity that creates a potential conflict of interest with Company. Specifically and except as set forth in Section 2(b) of this Agreement, VP shall not engage in any activity that is in direct competition with the Company or serve in any capacity (including, but not limited to, as a consultant, advisor or Board Member) in any company or entity that competes directly with the Company, as reasonably determined by a majority of Company’s disinterested board members, without the approval of the Board of Directors Members.

 

 
   

 

3. Compensation and Benefits.

 

  (a) Vice Presidents Fee. Set Forth in Section IV, Item # 1, of the above-referenced April 30, Distribution Agreement — Please see below:

 

“1. Retention of Neelima Lekkala as Vice President of Distribution and Marketing. In consideration for the inherent market leverage afforded by SKL’s extensive existing relationships with dozens of spirits stores, convenient stores, pharmacies, wholesalers, etc. in the NJ and Northeast Region USA Markets, Tauriga has agreed to assist SKL’s effort — with the hiring of Neelima Lekkala (“Mrs. Lekkala”) as Vice President (“VP”) of Distribution and Marketing. There will be a separate agreement provided to Mrs. Lekkala formalize this arrangement. Her Compensation will be: 250,000 shares of TAUG (fully earned and vested upon execution of her SPECIFIC agreement — which is, of course, separate from this one), 30% commission (this can be requested by Ms. Lekkala in terms of either all cash, all stock, or a combination of both) of the total gross sales that Mrs. Lekkala generates (through the sale of Tauri-Gum product line), and she is entitled to cash reimbursement from the Company (once invoiced) for activities directly relating to the sale of Tauri-Gum.”

 

(b) CASH COMPONENT: The Company reserves the right to pay VP some cash payment(s) from time to time, on a “per invoice basis” — based on mutual agreement.

 

(c) Expenses. The Company shall reimburse VP for all reasonable business expenses incurred in the performance of his duties hereunder in accordance with Company’s expense reimbursement guidelines. INVOICE REQUIRED

 

(d) Indemnification. Company will indemnify and defend VP against any liability incurred in the performance of the Services to the fullest extent authorized in Company’s Certificate of Incorporation, as amended, bylaws, amended, and applicable law

 

4. ALL OTHER MATERIAL TERMS & CONDITIONS

 

Reverts to terms and conditions of above-referenced April 30, 2019 Agreement

 

5. Date of Agreement. The parties have duly executed this Agreement as of the date first written above: May 11, 2019 EFFECTIVE DATE

 

  By: x        
  Vice President — Distribution and Marketing
  Ms. Neelima Lekkala
   
  Bv: x
  Tauriga Sciences Inc
  CEO Mr Seth M Shaw

 

 
   

 

 

 EX-31.1 6 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002)

 

I, Seth M. Shaw, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Tauriga Sciences, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 13, 2019

 

  /s/ Seth M. Shaw
  Seth M. Shaw
  Chief Executive Officer

 

 
 

 EX-31.2 7 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002)

 

I, Kevin P. Lacey, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Tauriga Sciences, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 13, 2019

 

  /s/ Kevin P. Lacey
  Kevin P. Lacey
  Chief Financial Officer

 

 
 

 EX-32.1 8 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the quarterly report of Tauriga Sciences, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Seth M. Shaw, Chief Executive Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

Date: August 13, 2019

 

  /s/ Seth M. Shaw
  Seth M. Shaw
  Chief Executive Officer

 

A certification furnished pursuant to this Item will not be deemed “filed” for purposes of section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the small business issuer specifically incorporates it by reference.

 

 
 

 EX-32.2 9 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the quarterly report of Tauriga Sciences, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin P. Lacey, Chief Financial Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

Date: August 13, 2019

 

  /s/ Kevin P. Lacey
  Kevin P. Lacey
  Chief Financial Officer

 

A certification furnished pursuant to this Item will not be deemed “filed” for purposes of section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the small business issuer specifically incorporates it by reference.

 

 
 

 EX-101.INS 10 taug-20190630.xml XBRL INSTANCE FILE 0001142790 2019-06-30 0001142790 2019-03-31 0001142790 2019-04-01 2019-06-30 0001142790 us-gaap:FairValueInputsLevel3Member 2019-06-30 0001142790 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001142790 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001142790 TAUG:TransferAgreementMember TAUG:OpenTherapeuticsMember 2016-12-22 0001142790 TAUG:GSCapitalPartnersLLCMember 2019-03-31 0001142790 TAUG:GSCapitalPartnersLLCMember 2018-04-01 2019-03-31 0001142790 us-gaap:WarrantMember 2018-03-31 0001142790 TAUG:GreenInnovationsLtdMember 2018-03-31 0001142790 TAUG:GreenInnovationsLtdMember 2017-04-01 2018-03-31 0001142790 stpr:NY 2017-11-29 2017-12-02 0001142790 2017-12-21 2017-12-22 0001142790 TAUG:VistaGenTherapeuticsIncMember 2019-06-30 0001142790 TAUG:VistaGenTherapeuticsIncMember 2019-04-01 2019-06-30 0001142790 us-gaap:CommonStockMember 2018-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001142790 us-gaap:RetainedEarningsMember 2018-03-31 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001142790 us-gaap:NoncontrollingInterestMember 2018-03-31 0001142790 stpr:NY 2017-12-02 0001142790 TAUG:AytuBioScienceIncMember 2018-03-31 0001142790 TAUG:LightbridgeCorpMember 2017-04-01 2018-03-31 0001142790 TAUG:LightbridgeCorpMember 2018-03-31 0001142790 TAUG:BlinkChargingCoMember us-gaap:CommonStockMember 2018-03-31 0001142790 TAUG:BlinkChargingCoMember us-gaap:CommonStockMember srt:MaximumMember 2017-04-01 2018-03-31 0001142790 TAUG:BlinkChargingCoMember TAUG:WarrantsMember 2017-04-01 2018-03-31 0001142790 TAUG:BlinkChargingCoMember TAUG:WarrantsMember 2018-03-31 0001142790 TAUG:AytuBioScienceIncMember us-gaap:CommonStockMember 2018-03-01 2018-03-02 0001142790 TAUG:AytuBioScienceIncMember us-gaap:CommonStockMember 2018-03-06 2018-03-08 0001142790 TAUG:LightbridgeCorpMember us-gaap:CommonStockMember 2018-03-11 2018-03-12 0001142790 TAUG:VistaGenTherapeuticsIncMember us-gaap:CommonStockMember 2017-12-11 0001142790 TAUG:VistaGenTherapeuticsIncMember us-gaap:CommonStockMember 2017-12-10 2017-12-11 0001142790 TAUG:VistaGenTherapeuticsIncMember us-gaap:CommonStockMember 2018-03-25 2018-03-26 0001142790 TAUG:HoneywoodMember TAUG:OwnershipMember 2017-08-01 0001142790 us-gaap:WarrantMember 2018-04-01 2019-03-31 0001142790 TAUG:ComputersOfficeFurnitureAndOtherEquipmentMember srt:MinimumMember 2019-04-01 2019-06-30 0001142790 TAUG:ComputersOfficeFurnitureAndOtherEquipmentMember srt:MaximumMember 2019-04-01 2019-06-30 0001142790 us-gaap:SubsequentEventMember 2019-07-26 0001142790 2018-04-01 2018-06-30 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:ConsultingAgreementsMember 2018-04-01 2019-03-31 0001142790 TAUG:OneCurrentExecutiveMember 2012-01-30 2012-02-01 0001142790 TAUG:OneFormerExecutiveMember 2012-01-30 2012-02-01 0001142790 TAUG:ExecutivesMember 2012-01-30 2012-02-01 0001142790 us-gaap:WarrantMember 2019-03-31 0001142790 TAUG:GroestlcoinMember 2018-04-01 2019-03-31 0001142790 TAUG:GreenInnovationsLtdMember 2019-03-31 0001142790 TAUG:GreenInnovationsLtdMember 2018-04-01 2019-03-31 0001142790 TAUG:VistaGenTherapeuticsIncMember 2019-03-31 0001142790 TAUG:VistaGenTherapeuticsIncMember 2018-04-01 2019-03-31 0001142790 TAUG:BlinkChargingCoMember 2019-03-31 0001142790 TAUG:BlinkChargingCoMember 2018-04-01 2019-03-31 0001142790 TAUG:BlinkChargingCoWarrantsMember 2019-03-31 0001142790 TAUG:BlinkChargingCoWarrantsMember 2018-04-01 2019-03-31 0001142790 TAUG:AytuBioScienceIncMember 2019-03-31 0001142790 TAUG:AytuBioScienceIncMember 2018-04-01 2019-03-31 0001142790 TAUG:LightbridgeCorpMember 2019-03-31 0001142790 TAUG:LightbridgeCorpMember 2018-04-01 2019-03-31 0001142790 TAUG:PulmatrixIncPULMMember 2019-03-31 0001142790 TAUG:PulmatrixIncPULMMember 2018-04-01 2019-03-31 0001142790 TAUG:AxovantSciencesLtdAXONMember 2019-03-31 0001142790 TAUG:AxovantSciencesLtdAXONMember 2018-04-01 2019-03-31 0001142790 us-gaap:FairValueInputsLevel1Member 2019-03-31 0001142790 us-gaap:FairValueInputsLevel2Member 2019-03-31 0001142790 us-gaap:FairValueInputsLevel3Member 2019-03-31 0001142790 TAUG:ConvertibleNotesMember 2018-04-01 2019-03-31 0001142790 TAUG:ConvertibleNotesMember 2019-03-31 0001142790 TAUG:AlternativeStrategyPartnersPTELtdMember 2019-03-31 0001142790 TAUG:GSCapitalPartnersLLCOctTwoThousandAndEighteenMember 2019-03-31 0001142790 TAUG:NonConvertibleDebentureMember 2015-09-23 0001142790 TAUG:NonConvertibleDebentureMember 2015-09-21 2015-09-23 0001142790 TAUG:NonConvertibleDebentureMember TAUG:CompanyMember 2015-09-21 2015-09-23 0001142790 TAUG:NonConvertibleDebentureMember TAUG:ConsultantMember 2015-09-21 2015-09-23 0001142790 TAUG:NonConvertibleDebentureMember TAUG:EishinIncMember 2015-09-21 2015-09-23 0001142790 TAUG:NonConvertibleDebentureMember 2019-06-30 0001142790 TAUG:HoneywoodConversionAgreementMember 2019-06-30 0001142790 2018-06-28 2018-06-29 0001142790 TAUG:IceJamLLCMember 2018-12-31 0001142790 TAUG:IceJamLLCMember 2018-12-30 2018-12-31 0001142790 TAUG:BlinkChargingCoMember TAUG:BalanceSheetCashMember 2018-03-31 0001142790 TAUG:BlinkChargingCoMember 2018-02-13 2018-02-14 0001142790 TAUG:AytuBioScienceIncMember us-gaap:CommonStockMember 2017-04-01 2018-03-31 0001142790 TAUG:PulmatixIncPULMMember 2018-04-01 2019-03-31 0001142790 TAUG:PulmatixIncPULMMember 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:NoteHoldersMember 2018-04-01 2019-03-31 0001142790 2019-01-01 2019-03-31 0001142790 TAUG:GSCapitalPartnersLLCMayTwoThousandAndNineteenMember 2019-03-31 0001142790 TAUG:GroestlcoinMember 2018-04-01 2018-04-02 0001142790 TAUG:GroestlcoinMember 2018-04-02 0001142790 TAUG:GroestlcoinMember 2018-07-14 2018-07-15 0001142790 2018-08-24 2018-08-25 0001142790 TAUG:KudzooIncMember TAUG:OwnershipMember 2018-09-04 0001142790 TAUG:AchieveLifeSciencesACHVMember 2019-03-31 0001142790 TAUG:AchieveLifeSciencesACHVMember 2018-04-01 2019-03-31 0001142790 TAUG:DecisionDiagnosticsDECNMember 2019-03-31 0001142790 TAUG:DecisionDiagnosticsDECNMember 2018-04-01 2019-03-31 0001142790 TAUG:VistaGenTherapeuticsIncMember TAUG:RestrictedCommonStockMember 2018-04-01 2019-03-31 0001142790 TAUG:KudzooIncMember 2018-09-03 2018-09-04 0001142790 2018-08-19 2018-08-20 0001142790 TAUG:ComputersOfficeFurnitureAndOtherEquipmentMember 2019-03-31 0001142790 TAUG:ComputersOfficeFurnitureAndOtherEquipmentMember 2019-06-30 0001142790 TAUG:BlinkChargingCoMember us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001142790 TAUG:BlinkChargingCoMember us-gaap:WarrantMember 2018-04-01 2018-06-30 0001142790 TAUG:TransferAgreementMember TAUG:OpenTherapeuticsMember 2019-01-12 0001142790 TAUG:TransferAgreementMember TAUG:OpenTherapeuticsMember 2019-01-09 2019-01-12 0001142790 us-gaap:ComputerEquipmentMember 2018-04-01 2019-03-31 0001142790 TAUG:SerendipityBrandsLLCMember TAUG:OwnershipMember 2018-10-31 0001142790 TAUG:SerendipityBrandsLLCMember 2018-10-28 2018-10-31 0001142790 TAUG:BasaniteIncBASAMember 2019-03-31 0001142790 TAUG:BlinkChargingCoMember us-gaap:CommonStockMember 2018-06-30 0001142790 TAUG:BlinkChargingCoMember us-gaap:WarrantMember 2018-06-30 0001142790 TAUG:BasaniteIndustriesIncMember 2018-07-04 2018-07-05 0001142790 TAUG:BasaniteIndustriesIncMember 2018-07-05 0001142790 TAUG:BasaniteIndustriesIncMember 2018-07-01 2018-07-31 0001142790 TAUG:BasaniteIndustriesIncMember 2018-07-31 0001142790 TAUG:BasaniteIndustriesIncMember TAUG:RestrictedCommonStockMember 2018-07-07 2018-07-09 0001142790 TAUG:BasaniteIndustriesIncMember TAUG:RestrictedCommonStockMember 2018-07-09 0001142790 us-gaap:FairValueInputsLevel1Member TAUG:KudzooMember 2019-03-31 0001142790 us-gaap:FairValueInputsLevel2Member TAUG:KudzooMember 2019-03-31 0001142790 us-gaap:FairValueInputsLevel3Member TAUG:KudzooMember 2019-03-31 0001142790 TAUG:KudzooMember 2019-03-31 0001142790 us-gaap:FairValueInputsLevel1Member TAUG:SerendipityBrandsMember 2019-03-31 0001142790 us-gaap:FairValueInputsLevel2Member TAUG:SerendipityBrandsMember 2019-03-31 0001142790 us-gaap:FairValueInputsLevel3Member TAUG:SerendipityBrandsMember 2019-03-31 0001142790 TAUG:SerendipityBrandsMember 2019-03-31 0001142790 TAUG:TransferAgreementMember TAUG:OpenTherapeuticsMember TAUG:OwnershipMember 2016-12-22 0001142790 TAUG:DebtConversionAgreementMember TAUG:HoneywoodLLCMember TAUG:OwnershipMember 2017-08-01 0001142790 us-gaap:CommonStockMember 2019-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001142790 us-gaap:RetainedEarningsMember 2019-03-31 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001142790 us-gaap:NoncontrollingInterestMember 2019-03-31 0001142790 2019-04-07 2019-04-09 0001142790 TAUG:EAndMDistributionAgreementMember 2019-04-01 2019-04-02 0001142790 TAUG:SouthFloridaRegionDistributionAgreementMember 2019-04-07 2019-04-08 0001142790 TAUG:SouthFloridaRegionDistributionAgreementMember 2019-04-08 0001142790 TAUG:NorthEasternUnitedStatesDistributionAgreementMember 2019-04-29 2019-04-30 0001142790 TAUG:IcePlusJamLLCMember 2019-03-31 0001142790 TAUG:TauriGumTMMember 2019-03-31 0001142790 TAUG:NorthEasternUnitedStatesDistributionAgreementMember TAUG:MrMaheshLekkalaMember TAUG:WithinTenBusinessDaysOfAprilThirtyTwoThousandNineteenMember 2019-04-29 2019-04-30 0001142790 TAUG:NorthEasternUnitedStatesDistributionAgreementMember TAUG:SaiKrishnaLLCMember 2019-04-29 2019-04-30 0001142790 TAUG:NorthEasternUnitedStatesDistributionAgreementMember TAUG:SaiKrishnaLLCMember TAUG:WithinTenBusinessDaysOfAprilThirtyTwoThousandNineteenMember 2019-04-29 2019-04-30 0001142790 TAUG:NorthEasternUnitedStatesDistributionAgreementMember TAUG:SaiKrishnaLLCMember TAUG:WithinTenBusinessDaysOfAugustOneTwoThousandNineteenMember 2019-04-29 2019-04-30 0001142790 TAUG:OneYearAgreementMember TAUG:SaiKrishnaLLCMember 2019-04-29 2019-04-30 0001142790 TAUG:SKLDistributionAgreementMember 2019-05-10 2019-05-11 0001142790 TAUG:SKLDistributionAgreementMember TAUG:MsNeelimaLekkalaMember 2019-05-10 2019-05-11 0001142790 TAUG:SKLDistributionAgreementMember TAUG:MsNeelimaLekkalaMember 2019-05-19 2019-05-20 0001142790 TAUG:SKLDistributionAgreementMember TAUG:MsNeelimaLekkalaMember 2019-05-20 0001142790 us-gaap:AccountingStandardsUpdate201602Member 2019-04-02 0001142790 TAUG:GSCapitalPartnersLLCMarchTwoThousandAndNineteenMember 2019-03-31 0001142790 TAUG:NonConvertibleDebentureMember 2019-04-01 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCMember 2019-03-14 0001142790 TAUG:FiscalYearTwoThousandNineteenMember us-gaap:CommonStockMember 2018-04-01 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:CommonStockOneMember 2018-04-01 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:CommonStockTwoMember 2018-04-01 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:OpenTherapeuticsMember 2019-01-12 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:OpenTherapeuticsMember 2019-01-09 2019-01-12 0001142790 TAUG:SecuritiesPurchaseAgreementMember 2019-03-31 0001142790 TAUG:KudzooIncMember TAUG:OwnershipMember 2019-03-21 0001142790 TAUG:KudzooIncMember 2019-03-20 2019-03-21 0001142790 TAUG:OwnershipMember 2019-04-08 0001142790 2019-04-07 2019-04-08 0001142790 us-gaap:AccountsReceivableMember TAUG:OneSupplierMember 2018-04-01 2019-03-31 0001142790 TAUG:SalesRevenueMember TAUG:OneCustomerMember 2018-04-01 2019-03-31 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember TAUG:SecuritiesPurchaseAgreementMember 2019-05-23 2019-05-24 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember TAUG:SecuritiesPurchaseAgreementMember 2019-05-24 0001142790 TAUG:GSCapitalNoteMember TAUG:SecuritiesPurchaseAgreementMember 2019-05-23 2019-05-24 0001142790 country:ES 2019-06-11 0001142790 country:ES 2019-06-09 2019-06-11 0001142790 country:ES TAUG:EURMember 2019-06-09 2019-06-11 0001142790 TAUG:TauriGumTMMember 2019-06-30 0001142790 srt:MaximumMember 2019-06-30 0001142790 TAUG:BasaniteIncBASAMember 2018-04-01 2019-03-31 0001142790 2018-03-31 0001142790 2018-06-30 0001142790 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001142790 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001142790 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001142790 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001142790 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001142790 us-gaap:CommonStockMember 2018-06-30 0001142790 us-gaap:CommonStockMember 2018-09-30 0001142790 us-gaap:CommonStockMember 2018-12-31 0001142790 us-gaap:CommonStockMember 2019-06-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001142790 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001142790 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001142790 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001142790 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001142790 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001142790 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001142790 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001142790 us-gaap:RetainedEarningsMember 2018-06-30 0001142790 us-gaap:RetainedEarningsMember 2018-09-30 0001142790 us-gaap:RetainedEarningsMember 2018-12-31 0001142790 us-gaap:RetainedEarningsMember 2019-06-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001142790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-10-01 2018-12-31 0001142790 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001142790 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-06-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-09-30 0001142790 us-gaap:NoncontrollingInterestMember 2018-12-31 0001142790 2018-07-01 2018-09-30 0001142790 2018-10-01 2018-12-31 0001142790 2018-09-30 0001142790 2018-12-31 0001142790 srt:MinimumMember 2018-04-01 2018-06-30 0001142790 srt:MinimumMember 2019-01-01 2019-03-31 0001142790 srt:MinimumMember 2019-04-01 2019-06-30 0001142790 srt:MaximumMember 2018-04-01 2018-06-30 0001142790 srt:MaximumMember 2019-01-01 2019-03-31 0001142790 srt:MaximumMember 2019-04-01 2019-06-30 0001142790 us-gaap:WarrantMember 2019-04-01 2019-06-30 0001142790 TAUG:EAndMDistributionAgreementMember 2018-04-01 2019-03-31 0001142790 TAUG:WindmillHealthDistributionAgreementMember 2019-06-26 2019-06-28 0001142790 2018-07-08 0001142790 2018-07-07 2018-07-08 0001142790 2019-04-01 2019-04-02 0001142790 TAUG:DebtConversionAgreementMember TAUG:HoneywoodLLCMember 2017-07-31 2017-08-01 0001142790 TAUG:TauriGumTMMember 2019-03-31 0001142790 2018-04-01 2019-03-31 0001142790 2019-04-02 0001142790 stpr:NY 2019-04-01 2019-06-30 0001142790 stpr:NY 2019-06-30 0001142790 country:ES 2019-06-30 0001142790 TAUG:ConvertibleNotesMember 2019-04-01 2019-06-30 0001142790 TAUG:GSCapitalNoteMember 2019-04-01 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCJuneTwoThousandAndNineteenMember 2019-03-31 0001142790 TAUG:AlternativeStrategyPartnersPTELtdMember 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCOctTwoThousandAndEighteenMember 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCMarchTwoThousandAndNineteenMember 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCMayTwoThousandAndNineteenMember 2019-06-30 0001142790 TAUG:GSCapitalPartnersLLCJuneTwoThousandAndNineteenMember 2019-06-30 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember 2018-10-25 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember 2018-10-24 2018-10-25 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember 2019-06-06 2019-06-07 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember 2019-06-30 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-03-13 2019-03-14 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-03-14 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2018-04-01 2019-03-31 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-03-31 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-06-30 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-06-27 0001142790 TAUG:ConvertibleDebentureMember TAUG:GSCapitalPartnersLLCMember 2019-06-26 2019-06-27 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember TAUG:SecuritiesPurchaseAgreementMember 2019-06-20 2019-06-21 0001142790 TAUG:ConvertibleNoteMember TAUG:GSCapitalPartnersLLCMember TAUG:SecuritiesPurchaseAgreementMember 2019-06-21 0001142790 us-gaap:SubsequentEventMember TAUG:ConvertibleNoteMember TAUG:SecuritiesPurchaseAgreementMember TAUG:JeffersonStreetCapitalLLCMember srt:ChiefExecutiveOfficerMember 2019-07-22 0001142790 us-gaap:SubsequentEventMember 2019-08-13 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:NoteHoldersMember 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember us-gaap:CommonStockMember srt:MinimumMember 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember us-gaap:CommonStockMember srt:MaximumMember 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandNineteenMember TAUG:CommonStockOneMember 2019-03-31 0001142790 TAUG:FiscalYearTwoThousandTwentyMember TAUG:DistributionAgreementsMember 2019-04-01 2019-06-30 0001142790 TAUG:FiscalYearTwoThousandTwentyMember 2019-04-01 2019-06-30 0001142790 TAUG:FiscalYearTwoThousandTwentyMember 2019-06-30 0001142790 TAUG:FiscalYearTwoThousandTwentyMember srt:VicePresidentMember 2019-04-01 2019-06-30 0001142790 TAUG:FiscalYearTwoThousandTwentyMember TAUG:StockPurchaseAgreementsMember TAUG:AccreditedInvestorsMember 2019-04-01 2019-06-30 0001142790 TAUG:FiscalYearTwoThousandTwentyMember TAUG:StockPurchaseAgreementsMember TAUG:AccreditedInvestorsMember 2019-03-31 0001142790 TAUG:SecuritiesPurchaseAgreementMember 2019-06-30 0001142790 us-gaap:WarrantMember 2019-06-30 0001142790 country:US 2019-06-30 0001142790 country:US 2019-04-01 2019-06-30 0001142790 us-gaap:FairValueInputsLevel1Member TAUG:KudzooMember 2019-06-30 0001142790 us-gaap:FairValueInputsLevel2Member TAUG:KudzooMember 2019-06-30 0001142790 us-gaap:FairValueInputsLevel3Member TAUG:KudzooMember 2019-06-30 0001142790 TAUG:KudzooMember 2019-06-30 0001142790 us-gaap:FairValueInputsLevel1Member TAUG:SerendipityBrandsMember 2019-06-30 0001142790 us-gaap:FairValueInputsLevel2Member TAUG:SerendipityBrandsMember 2019-06-30 0001142790 us-gaap:FairValueInputsLevel3Member TAUG:SerendipityBrandsMember 2019-06-30 0001142790 TAUG:SerendipityBrandsMember 2019-06-30 0001142790 us-gaap:AccountsReceivableMember TAUG:OneSupplierMember 2019-04-01 2019-06-30 0001142790 TAUG:SalesRevenueMember TAUG:OneCustomerMember 2019-04-01 2019-06-30 0001142790 TAUG:BasaniteIncBASAMember 2019-06-30 0001142790 TAUG:BasaniteIncBASAMember 2019-04-01 2019-06-30 0001142790 TAUG:VistaGenTherapeuticsIncMember 2018-03-31 0001142790 TAUG:VistaGenTherapeuticsIncMember 2017-04-01 2018-03-31 0001142790 TAUG:BasaniteIndustriesIncMember 2019-04-01 2019-06-30 0001142790 TAUG:AYTUBioscienceMember us-gaap:CommonStockMember 2019-06-30 0001142790 TAUG:AYTUBioscienceMember us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001142790 TAUG:AYTUBioscienceMember us-gaap:WarrantMember 2019-06-30 0001142790 TAUG:VistaGenTherapeuticsIncMember us-gaap:CommonStockMember 2019-06-30 0001142790 TAUG:VistaGenTherapeuticsIncMember TAUG:CommonStockOneMember 2019-06-30 0001142790 TAUG:VistaGenTherapeuticsIncMember us-gaap:WarrantMember 2019-06-30 0001142790 TAUG:GroestlcoinMember 2019-06-30 0001142790 TAUG:KudzooIncMember TAUG:OwnershipMember 2019-04-08 0001142790 TAUG:KudzooIncMember 2019-04-07 2019-04-08 0001142790 TAUG:KudzooIncMember 2019-03-31 0001142790 us-gaap:SubsequentEventMember TAUG:DistributionAgreementsMember 2019-07-01 2019-08-10 0001142790 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember 2019-07-01 2019-08-10 0001142790 us-gaap:SubsequentEventMember TAUG:DistributionAgreementsMember 2019-08-10 0001142790 us-gaap:SubsequentEventMember TAUG:JeffersonStreetCapitalLLCMember us-gaap:ConvertibleDebtMember 2019-07-22 0001142790 us-gaap:SubsequentEventMember TAUG:JeffersonStreetCapitalLLCMember us-gaap:ConvertibleDebtMember 2019-07-21 2019-07-22 0001142790 us-gaap:SubsequentEventMember TAUG:JeffersonStreetCapitalLLCMember us-gaap:ConvertibleDebtMember TAUG:UponIncreaseOfAuthorizedCommonSharesMember 2019-07-22 0001142790 us-gaap:NoncontrollingInterestMember 2019-06-30 0001142790 TAUG:TauriGumTMMember 2019-06-30 0001142790 TAUG:GSCapitalNoteMember 2019-06-30 0001142790 TAUG:GSCapitalNoteMember TAUG:SecuritiesPurchaseAgreementMember 2019-05-24 0001142790 2019-08-13 0001142790 us-gaap:AccountingStandardsUpdate201602Member country:ES 2019-06-11 0001142790 country:ES 2017-12-03 2019-06-30 0001142790 TAUG:NewYorkCorporateOfficeLeaseMember 2017-11-29 2017-12-01 0001142790 TAUG:BarcelonaOfficeLeaseMember 2019-04-01 2019-06-30 0001142790 us-gaap:SubsequentEventMember TAUG:SecuritiesPurchaseAgreementMember TAUG:AdarAlefLLCMember TAUG:EightPercentageConvertibleRedeemableNotesMember 2019-08-12 0001142790 us-gaap:SubsequentEventMember TAUG:SecuritiesPurchaseAgreementMember TAUG:AdarAlefLLCMember TAUG:EightPercentageConvertibleRedeemableNoteOneMember 2019-08-12 0001142790 us-gaap:SubsequentEventMember TAUG:SecuritiesPurchaseAgreementMember TAUG:AdarAlefLLCMember TAUG:EightPercentageConvertibleRedeemableNoteTwoMember 2019-08-12 0001142790 us-gaap:SubsequentEventMember TAUG:SecuritiesPurchaseAgreementMember TAUG:AdarAlefLLCMember TAUG:EightPercentageConvertibleRedeemableNoteTwoMember 2019-08-11 2019-08-12 0001142790 us-gaap:SubsequentEventMember TAUG:SecuritiesPurchaseAgreementMember TAUG:AdarAlefLLCMember TAUG:EightPercentageConvertibleRedeemableNotesMember 2019-08-11 2019-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR TAURIGA SCIENCES, INC. 10-Q 2019-06-30 false --03-31 Non-accelerated Filer <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activity for the three months and year ended June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Average</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Remaining</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Aggregate</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Exercise</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Contractual</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Intrinsic</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 40%">Outstanding at March 31, 2018</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,433,611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 13%; text-align: center">3.02 Years</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(223,335</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.2843</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable March 31, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,210,276</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1.2</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">1.28 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">-</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(389,344</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.75</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">820,932</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1.41</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">1.41 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes option activity for the year and three months ended June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br />Average <br />Exercise <br />Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Weighted <br />Average <br />Remaining <br />Contractual <br />Term</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br />Intrinsic <br />Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 40%">Outstanding at March 31, 2018</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">133,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 13%; text-align: center">3.85 Years</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Outstanding at March 31, 2019</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133,334</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">2.85 Years</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding and exercisable at June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">133,334</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">2.60 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> 5686667 500000 95667 5686667 714286 750000 1200000 250000 714286 250000 280000 48000 0.1150 0.08 0.08 0.080 0.08 0.10 0.10 0.08 5000 11750 20000 5000 50000 5000 0.00001 0.00001 100000000 100000000 400000000 7500000000 72925920 75895090 72925920 68123326 75895090 2020-05-23 2020-03-13 2020-06-21 16946 30780 8227 8219 4373 118 500 14959 20006 763473 222297 628841 222038 -748514 -222297 121814 23496 110000 25000 90000 75000 15000 90000 47500 15247 385943 -41845 -31450 11607 19906 -7535 22224 -20400 -17917 45000 301200 301200 21000 20004 56 7 301144 44993 142500 45000 15000 125000 25000 80000 180000 60000 180000 300000 60000 55000 75000 55000 10086 1.04 0.38 1.03 2.60 0.52 4.03 0.046 0.0495 3.69 0.13 0.075 0.0731 0.0495 0.19 0.03375 0.02 0.06 0.042 0.04725 0.063 0.042 75000 75000 75000 0001142790 23468 -475296 16118 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Notes payable and convertible notes consisted of the following as of:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Alternative Strategy Partners PTE Ltd.</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(a)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">GS Capital Partners LLC - Oct 2018</td><td>&#160;</td> <td style="text-align: center">(b)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">180,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">GS Capital Partners LLC - Mar 2019</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">GS Capital Partners LLC - May 2019</td><td>&#160;</td> <td style="text-align: center">(d)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">GS Capital Partners LLC - Jun 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(e)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total notes payable and convertible notes</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">560,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">570,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less - note discounts</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(324,580</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(356,125</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less - current portion of these notes</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(235,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(213,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total notes payable and convertible notes, net discounts &#8211; long-term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. (&#8220;ASP&#8221;) to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. (&#8220;Eishin&#8221;), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company&#8217;s balance sheet, the $113,468 liability has been removed from the Company&#8217;s balance sheet, as is reflected in the Company&#8217;s financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(b)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC &#8220;chill&#8221; on its shares, the conversion price shall be decreased to 60% instead of 70% while that &#8220;chill&#8221; is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(c)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company&#8217;s consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company&#8217;s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC &#8220;Chill&#8221; on its shares, the conversion price shall be decreased to 56% instead of 66% while that &#8220;Chill&#8221; is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company&#8217;s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the &#8220;Share Reserve&#8221;) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(e)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company&#8217;s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC &#8220;Chill&#8221; on its shares, the conversion price shall be decreased to 56% instead of 66% while that &#8220;Chill&#8221; is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company&#8217;s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.</font></td></tr></table> 101535 41973 200718 68663 2020 76145090 805241 947816 85675 127520 12778 13010 827090 960826 305584 457380 27168 34703 235420 213875 -56146906 -55488939 56665512 55991704 729 681 827090 960826 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s property and equipment is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 40%">Computers, office furniture and other equipment</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">69,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">69,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 20%; text-align: center">3-5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">As of</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">As of</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating losses before non-deductible items</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,763,732</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,685,807</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss on disposal of fixed assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">288,492</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">209,591</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unrealized gains or losses on investments</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,079</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,028,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,891,495</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,028,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,891,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following summarizes the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify">Investment-trading securities</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">444,785</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">444,785</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cost method investment &#8211; K&#252;dzoo</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">57,900</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">57,900</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost method investment &#8211; Serendipity Brands</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify">Investment-trading securities</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">350,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">350,400</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cost method investment &#8211; K&#252;dzoo</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost method investment &#8211; Serendipity Brands</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr></table> 307755 457380 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 &#8211; BASIS OF OPERATIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The unaudited condensed consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain certain information included in the Company&#8217;s annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the March 31, 2019 Form 10-K filed with the SEC, including the audited consolidated financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these condensed consolidated financial statements are reasonable, the accuracy of the amounts is in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company later in the year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary to present fairly the operations and cash flows for the periods presented.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Nature of Business</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Tauriga Sciences, Inc. (the &#8220;Company&#8221;) is a Florida corporation. The Company has, over time, moved into that of a diversified life sciences technology company, with its mission to operate a revenue generating business, while continuing to evaluate potential acquisition candidates operating in the life sciences technology space.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>TAURI-GUM<sup>TM</sup></u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">In October 2018, the Company&#8217;s management, along with its board of directors, began to explore the possibility of launching a cannabidiol (&#8220;CBD&#8221;) infused gum product line into the commercial marketplace. After several weeks of diligence, discussions with various parties and exploratory meetings, the Company made the determination to move forward with this business opportunity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">To begin this process, during the quarter ended December 31, 2018, the Company began discussions with a Maryland based chewing gum manufacturer - Per Os Biosciences LLC (&#8220;Per Os Bio&#8221;), which consummated in a manufacturing agreement in late December 2018 to launch and bring to market a white label line of CBD infused chewing gum under the brand name Tauri-Gum&#8482;. We have filed for trademark protection with the United States Patent and Trademark Office for our CBD infused chewing product line, including applications filed in April 2019 for TAURI-GUMMI<sup>TM</sup> and TAURI-GUMMIES<sup>TM</sup>.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under the terms of the agreement, Per Os Bio has committed to produce the Tauri-Gum<sup>TM</sup> based on the following criteria:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">A.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">By composition, the CBD Gum will contain 10 mg of CBD Isolate</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">B.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The initial production run will be mint flavor exclusively</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">C.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">This proprietary CBD Gum will be manufactured under U.S. Patent # 9,744,128 (&#8220;Method for manufacturing medicated chewing gum without cooling&#8221;)</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">D.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Each Production Batch, including the initial production run, is estimated to yield 70,000 gum tablets or 8,700 Units (each Unit contains 8 gum tablets).</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">E.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Integrated Quality Control Procedures: Each production batch will be tested by a 3<sup>rd</sup> Party for CBD label content, THC content (0%), and clear for microbiology.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">F.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The packaging, for retail marketplace, will consist of 8 count (gum tablet count) blister card labeled (the &#8220;Pack(s)&#8221;) with Lot # as well as Expiration Date.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">G.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Outer sleeve in the Company&#8217;s artwork and graphic design(s) and label copy</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">H.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shipping System: Bulk packed 266 Packs per master case (&#8220;Palletized&#8221;)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under terms of the Agreement, the Company has committed to provide the following to Per Os Bio:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">A.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Each product order will consist of exactly 8,700 Packs (unless otherwise agreed upon by both parties).</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">B.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#189; of initial production invoice due within 3 days of execution of Manufacturing Agreement (this has already been paid by the Company).</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">C.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Provide graphic design artwork, logo, and label design to Per Os Bio.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">D.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Trademark has been successfully filed with U.S.P.T.O.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">E.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">To implement Kosher Certification Process</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">F.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Procure appropriate Product &#38; Liability insurance policy</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">G.</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Acquire legal opinion with respect to the confirmation of the legality to sell this CBD Gum &#8211; on the Federal Statute Level.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The Company gum formulation includes distinctive features: allergen free, gluten free, vegan, kosher (K-Star certification), and incorporates a proprietary manufacturing process. See our &#8220;Risk Factors&#8221; contained in this Annual Report, including with respect, but not limited, to Federal laws and regulations that govern CBD and cannabis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company E-commerce website is www.taurigum.com. The Company has also secured storage space near its New York City headquarters.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the first quarter of fiscal year 2020, the Company began production of Blood Orange flavor of Tauri-Gum<sup>TM</sup>. The Company plans to offer Pomegranate flavored Tauri-Gum<sup>TM</sup> in the near term, which will be in addition to their mint and blood orange flavored products.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 9, 2019, the Company announced that it is developing a special miniaturized version of Tauri-Gum<sup>TM</sup> for sale at airport retail stores. The Company envisions this Airport version consisting of a miniaturized blister pack (containing three pieces of its CBD Infused gum), with an anticipated retail price of $6.99 per unit.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The Company is also working on developing CBD Gum-Infused Lollipops and gummi products.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Tauri-Gum<sup>TM </sup>Distribution Agreements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>E&#38;M Ice Cream Company</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 1, 2019, the Company entered into a comprehensive distribution agreement with E&#38;M Ice Cream Company (&#8220;E&#38;M&#8221;) to establish Tauri-Gum<sup>TM</sup> in the marketplace (the &#8220;E&#38;M Distribution Agreement&#8221;). The Company has supported the Tauri-Gum<sup>TM</sup> commercial launch with substantial levels of both financial resources and marketing support. The Company had both received payment for and delivered the product for its previously announced $54,000 Tauri-Gum<sup>TM</sup> purchase order during March 2019, and re-orders in the first quarter of fiscal 2020. The Company has agreed to issue a one-time issuance of 1,000,000 restricted shares of the Company&#8217;s common stock, and to tender a one-time cash payment of $125,000 to E&#38;M. This $125,000 cash component was paid in full to E&#38;M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. The Company is awaiting issuance instructions from E&#38;M to issue the shares</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>South Florida Region Distribution Agreement</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 8, 2019, the Company entered into a non-exclusive distribution agreement with IRM Management Corporation (&#8220;IRM&#8221;), an established medical practice management firm (the &#8220;IRM Distribution Agreement&#8221;). The purpose of the IRM Distribution Agreement is to target our Tauri-Gum&#8482; product to the South Florida based medical market, including chiropractors, orthopedists, as well as prospective retail customers in this geographic area.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under terms of this IRM Distribution Agreement, the Company will work closely with IRM to promote Tauri-Gum&#8482;. In connection with this IRM Distribution Agreement, the Company has also agreed to a one-time issuance of 450,000 shares of the Company&#8217;s restricted common stock and a cash stipend of $10,000 to IRM. As of the date of this report, only $2,000 of the $10,000 cash stipend has been paid. The value of the shares will be reflected in stock-based compensation based on the grant date of April 8, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>North Eastern United States Distribution Agreement</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 30, 2019, the Company, entered into a non-exclusive comprehensive distribution agreement with Sai Krishna LLC (&#8220;SKL&#8221;), a New Jersey based distributor, with relationships in the Northeast region of the United States and Asia, with the intention of increasing and accelerating market penetration of the Company&#8217;s Tauri-Gum<sup>TM</sup> product line in the applicable regions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the SKL Agreement, the Company has agreed to issue a one-time issuance of an aggregate of 1,000,000 restricted common shares the Company&#8217;s stock, which are subject to the customary resale and transfer restrictions imposed under the rules and regulations of the Securities and Exchange Commission. The restricted equity issuance to SKL was issued in accordance with the following schedule: (i) to Mr. Mahesh Lekkala, 500,000 restricted shares the Company&#8217;s common stock within ten (10) business days of April 30, 2019; and (ii) to SKL, 500,000, which were permitted to be immediately allocated by SKL to persons within its organization and, as such, (a) 250,000 of such shares shall be issued to SKL within ten (10) business days of April 30, 2019, and the additional issuance of (b) 250,000 of such shares shall be issued to SKL within ten (10) business days of August 1, 2019, which shares were issued on August 1, 2019. Other than the payment terms for Tauri-Gum<sup>TM</sup> product purchased and distributed under the terms of the Agreement, there is no additional cash payment currently due or owing by the Company thereunder. The value of the shares is reflected as stock-based compensation with a grant date of April 30, 2019. All but 250,000 shares are expensed on this date, with those 250,000 shares valued over the term of the one-year agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 11, 2019, the Company entered into a sub-agreement pursuant to the SKL distribution agreement whereby Ms. Neelima Lekkala was appointed Vice President of Distribution &#38; Marketing. This contract has a one-year term and is and may be extended based upon mutual agreement. Ms. Lekkala shall focus her efforts on the expansion of Tauri-Gum<sup>TM</sup> as well as revenue growth, acquisition of new customers, establishment of professional marketing materials &#38; protocols, logistics improvement(s) and fulfillment services. Ms. Lekkala is deeded a non-affiliate and does not carry any type of fiduciary liability. Ms. Lekkala&#8217;s compensation includes 250,000 shares of the Company&#8217;s restricted common stock deemed fully earned and vested upon the execution of her consulting agreement. These shares were issued May 20, 2019, having a value of $18,275 based on the closing price of the Company&#8217;s stock on that day ($0.0731 per share). Additionally, Ms. Lekkala will receive a 30% commission on total gross sales through the sale of the Tauri-Gum<sup>TM </sup>product line which can be paid in either stock or cash at the election of Ms. Lekkala.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Windmill Health Distribution Agreement</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 28, 2019, the Company entered into a distribution agreement with Windmill Health Products, LLC (&#8220;Windmill Health&#8221;), a New Jersey based distributor, with the intention of increasing and accelerating market penetration of the Company&#8217;s Tauri-Gum<sup>TM </sup>product line. Simultaneous with the Company&#8217;s entry into the Windmill Health agreement, Windmill Health placed an initial purchase order with us totaling $46,848, split evenly between packages of the Mint flavored and Blood-Orange flavored chewing gum product lines. The Company did not contribute any capital or issue any equity to Windmill Health in connection with the Windmill Health distribution agreement</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Food and Drug Administration</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 31, 2019, the U. S. Food and Drug Administration (&#8220;FDA&#8221;) held public hearings to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The hearing came approximately five months after the Agricultural Improvement Act of 2018 (more commonly known as the Farm Bill), went into effect and removed industrial hemp from the Schedule I prohibition under the Controlled Substances Act (CSA) (industrial hemp means cannabis plants and derivatives that contain no more than 0.3 percent tetrahydrocannabinol, or THC, on a dry weight basis).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Though the Farm Bill removed industrial hemp from the Schedule I list, the Farm Bill preserved the regulatory authority of the FDA over cannabis and cannabis-derived compounds used in food and pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FD&#38;C Act) and section 351 of the Public Health Service Act. The FDA has been clear that it intends to use this authority to regulate cannabis and cannabis-derived products, including CBD, in the same manner as any other food or drug ingredient. In addition to holding the hearing, the agency had requested comments by July 2, 2019 regarding any health and safety risks of CBD use, and how products containing CBD are currently produced and marketed, which comment period was then extended by two weeks following July 2<sup>nd</sup>.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>2019 Increase in Authorized Shares</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 26, 2019, the Company held a meeting of its board of directors. The matters voted on and approved at the meeting included an amendment to the Company&#8217;s Articles of Incorporation to increase the number of authorized shares of the Company&#8217;s common stock, $0.00001 par value per share from 100,000,000 to 400,000,000 shares (the &#8220;Authorized Shares Increase&#8221;). In this regard, a Preliminary Proxy Statement which was filed with the Securities and Exchange Commission on July 29, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>2018 Reverse Stock Split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 8, 2018, the Company implemented a Reverse Stock Split with a ratio of 1-for-75 (which became effective July 9, 2018). The par value and other terms of the common stock were not affected by the Reverse Stock Split. In addition, the amendment to the Company&#8217;s articles of incorporation that effected the Reverse Stock Split simultaneously reduced the number of authorized shares of Common Stock from 7,500,000,000 to 100,000,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Reverse Stock Split affected all issued and outstanding shares of common stock, as well as common stock underlying stock options, warrants and other convertible securities outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split has reduced the number of outstanding shares of the common stock outstanding prior to the Reverse Stock Split from 4,078,179,672 shares to 54,380,230 shares immediately following the Reverse Stock Split. No fractional shares were issued as a result of the Reverse Stock Split, and any such stockholders whose number of post-split shares would have resulted in a fractional number had his/her/its shares rounded up to the next number of shares. On July 30, 2018, the Company&#8217;s stock began trading on the OTC:QB.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All references set forth in this annual report to number of shares or per share data have been presented on a post reverse stock-split basis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cupua&#231;u Butter Lip Balm</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On December 23, 2016, the Company entered into a non-exclusive, 12-month license agreement (the &#8220;License Agreement&#8221;) with Cleveland, Ohio based cosmetics products company Ice + Jam LLC (&#8220;Ice + Jam&#8221;) to market Ice + Jam&#8217;s proprietary cupua&#231;u butter lip balm, sold under the trademark <font style="font-variant: small-caps">HerMan&#174;</font> which launched during the quarter ended December 31, 2017.During February of 2018, the Company&#8217;s strategy with respect to the <font style="font-variant: small-caps">HerMan&#174; </font>product was negatively impacted by a series of product defects relating to the twisting mechanism of the lip balm tube. As a result of this and the concomitant halting of selling efforts, the Company had no sales of the <font style="font-variant: small-caps">HerMan&#174; </font>product during the three months ended June 30, 2019 or the year ended March 31, 2019. The Company has removed the product from the website and the remaining inventory was written off as it was determined that the units were not usable. The Company has discontinued this operation as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Honeywood</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Following the termination of a proposed 2014 merger between the Company and California-based Honeywood LLC (&#8220;Honeywood&#8221;), a developer of a topical medicinal cannabis product, on August 1, 2017, the Company entered into a Debt Conversion Agreement, whereby the Company agreed to convert an $170,000 note receivable due from Honeywood, including accrued interest into a 5% membership interest in Honeywood.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with </font><font style="font: 10pt Times New Roman, Times, Serif">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) <font style="background-color: white">320-10-35-28, &#8220;<i>Investments&#8212;Debt and Equity Securities</i>&#8221;, a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: a) the investment experiences a recovery of fair value up to (or beyond) its cost; or b) the entity recognizes an other-than-temporary impairment loss. </font>At the time of the Honeywood Conversion Agreement, the receivable balance under the note of $199,119 had been fully written off by the Company in a prior period. As a result of the Honeywood Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><u>Pilus Energy</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 28, 2014, the Company acquired Pilus Energy, LLC (&#8220;Pilus&#8221;), an Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that create electricity while consuming polluting molecules from wastewater.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus back to Open Therapeutics for consideration of the termination of 80% of the unexercised portion of the warrants to purchase the Company&#8217;s common stock. Open Therapeutics agreed to pay to the Company 20% of the net profit generated Pilus Energy from its previous year&#8217;s earnings, if any. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 12, 2019, the Company and Open Therapeutics agreed to extinguish a $75,000 contingent liability, whereby Open Therapeutics was to receive the first $75,000 of net profit earned from the operations of Pilus Energy in exchange for a one-time issuance of 500,000 restricted shares of Company&#8217;s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><u>Tauriga Biz Dev Corp</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 4, 2018, the Company announced that its Board of Directors unanimously approved the formation a wholly-owned subsidiary focused on acquiring interest(s) in patents and other intellectual property. This subsidiary, incorporated in Delaware, was named Tauriga IP Acquisition Corp. On March 25, 2018, the Company changed the name to Tauriga Biz Dev Corp. (&#8220;Tauriga BDC&#8221;).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink Charging Co. (&#8220;Blink&#8221;) (Nasdaq: BLNK) to be a non-exclusive independent sales representative. Under the terms of this agreement with Blink, the Company is permitted to solicit orders from potential customers for electric vehicle (&#8220;EV&#8221;) charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company&#8217;s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On June 29, 2018, the Company purchased four Blink Level 2 - 40&#8221; pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The rest of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2019, Tauriga BDC has not installed any of these machines in any locations and no revenue has been generated through the Blink contract.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><u>Tauriga Sciences Limited</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On June 10, 2019, the Company formed a wholly owned subsidiary, Tauriga Sciences Limited, with the registrar of Companies for Northern Ireland. Tauriga Sciences Limited is a private limited Company. The entity was established in conjunction with online merchant services. In conjunction to this new entity the Company entered into a two-year lease commencing on June 11, 2019 and expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Catalun&#771;a 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of &#8364;178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Going Concern</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fourth quarter of the year ended March 31, 2019, the Company began sales and marketing efforts for its Mint flavored Tauri-Gum<sup>TM </sup>product. During the three months ended March 31, 2019, the Company recognized sales of $57,134 and recognized a gross profit of $20,006, which has continued into the first fiscal quarter ended June 30, 2019 where the Company recognized revenue of $44,377 and a gross profit of $14,959. During the first quarter of fiscal year 2020, the Company has entered into multiple distribution agreements and has engaged an independent contractor to act as Vice President of Distribution and Marketing. Although the Company&#8217;s working capital surplus of $499,657 at June 30, 2019, has remained constant in the past year, the Company still believes that there is uncertainty with respect to continuing as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA&#8217;s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company, in the short term, intends to continue funding its operations either through cash-on-hand or through financing alternatives. Management&#8217;s plans with respect to this include raising capital through equity markets to fund future operations as well as the possible sale of its remaining marketable securities which had a market value of $444,785 at June 30, 2019. In the event the Company cannot raise additional capital to fund and/or expand operations or fails to raise adequate capital and generate adequate sales revenue, it could result in the Company having to curtail or cease operations. <font style="background-color: white">Currently, the Company has a limited amount of shares of common stock available to issue under its articles of incorporation and has initiated the process of increasing the authorized stock. </font></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues in the short term there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations to achieve profitability thereby eliminating its reliance on alternative sources of funding. Although management believes that the Company is in a stronger position it has been in in several years, there is still no guarantee that profitable operations with sufficient cashflow to sustain operations can or will be achieved without the need of alternative financing, which is limited. These matters still raise significant doubt about the Company&#8217;s ability to continue as a going concern as determined by management. The Company believes that there is uncertainty with respect to continuing as a going concern until the operating business can achieve more than nominal sales and profitable operations and sustain cash flow to operate the Company for a period of twelve months. In the event the Company does need to raise additional capital to fund operations or engage in a transaction, failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreements or ownership interests in life science companies and generate adequate revenues, or the agreements entered into recently are unsuccessful, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern as determined by management. However, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Condensed Consolidated Financial Statements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga BDC and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of June 30, 2019, there is no activity in any of the Company&#8217;s subsidiaries other than Tauriga BDC holding the electric car chargers and the leasehold interest in Tauriga Sciences Limited.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Revenue Recognition</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of <font style="font-variant: small-caps">HerMan&#174; </font>using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company&#8217;s operations or cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company&#8217;s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 29, 2018, the Company purchased four Blink Level 2 - 40&#8221; pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2019, the Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2019, the Company recognized its first sales of Tauri-Gum<sup>TM</sup>, primarily vis-&#224;-vis its entry in the E&#38;M Distribution Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company&#8217;s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized revenue from operations in the amount of $44,377 during the three months ended June 30, 2019 compared to no revenue for the same period in the prior year. All revenue is from the sale of the Company&#8217;s Tauri-Gum<sup>TM </sup>product line and there were accounts receivable of $28,028 currently outstanding for these sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognized no revenue from discontinued operations during the three months ended June 30, 2018 which was related to the sales of the HERMAN&#174; lip balm product.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Sales Refunds</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-Gum<sup>TM</sup> distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of June 30, 2019 however will monitor the refunds to estimate whether a reserve will be required.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Use of Estimates</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Cash Equivalents</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At June 30, 2019, the Company&#8217;s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At June 30, 2019 and March 31, 2019, the Company had a cash balance of $15,247 and $385,943, respectively. The Company&#8217;s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of June 30, 2019 and March 31, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Investment in Trading Securities</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company&#8217;s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Investment &#8211; Cost Method</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of June 30, 2019, the Company has not impaired any of their cost method investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Inventory</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfillment center is also included in the total inventory cost. Shipping of product upon sale for online sales is paid by the customer upon ordering for orders of single packs of Tauri-Gum<sup>TM</sup>. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of June 30, 2019, the Company&#8217;s inventory on hand had a value of $138,606. The Company also has paid deposits in the amount of $52,500 to the manufacturer, Per Os Bio, towards orders not received as of June 30, 2019. Amounts paid to Per Os Bio for Tauri-Gum<sup>TM </sup>are classified as deposits (other current asset) on the Company&#8217;s condensed consolidated balance sheet until the goods are available for sale. The Company has not established any inventory reserve on the Tauri-Gum<sup>TM </sup>as of June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Property and Equipment</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Intangible Assets</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Net Income (Loss) Per Common Share</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company computes per share amounts in accordance with FASB ASC Topic 260 &#8220;<i>Earnings per Share</i>&#8221; (&#8220;EPS&#8221;), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the three months ended June 30, 2019, basic and fully diluted earnings per share were the same as the Company had losses in this period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Stock-Based Compensation</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for Stock-Based Compensation under ASC 718 &#8220;<i>Compensation-Stock Compensation</i>,&#8221; which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, &#8220;E<i>quity-Based Payments to Non-Employees</i>.&#8221; Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders&#8217; equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Reclassifications</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Impairment of Long-Lived Assets</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it&#8217;s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Research and Development</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses research and development costs as incurred. Research and development costs were $3,852 for the three months ended June 30, 2019 compared to no expense during the same period in the prior year. The Company is continually evaluating products and technologies in the natural wellness space, including its Tauri-Gum<sup>TM </sup>product including new flavor formulations and other CBD delivery products, as well as any intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Fair Value Measurements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 820 &#8220;<i>Fair Value Measurements</i>&#8221; defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Financial instruments classified as Level 1 &#8211; quoted prices in active markets include cash.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These consolidated financial instruments are measured using management&#8217;s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Share settled debt</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer&#8217;s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer&#8217;s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer&#8217;s shares (e.g. net share settled written put options, net share settled forward purchase contracts).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15-day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Income Taxes</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 740 &#8220;<i>Income Taxes</i>&#8221; clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Recent Accounting Pronouncements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU No. 2018-07, <i>&#8220;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221; </i>which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, FASB issued ASU 2016-02, &#8220;<i>Leases (Topic 842)</i>.&#8221; The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. Early adoption is permitted. The Company has adopted this standard as of April 1, 2019 (See Note 6).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s consolidated financial position or operating results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Subsequent Events</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 855 &#8220;<i>Subsequent Events</i>&#8221; the Company evaluated subsequent events after the balance sheet date through the date of issuance.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5&#8211; PROPERTY AND EQUIPMENT</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s property and equipment is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated Life</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 40%">Computers, office furniture and other equipment</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">69,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">69,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 20%; text-align: center">3-5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 29, 2018, the Company purchased four Blink Level 2 &#8211; 40&#8221; pedestal chargers for permanent placement in one or more retail locations whereby the Company will share revenue from these electric car vehicle charging units with such location owner. No depreciation expense has been recorded for the charging units as of June 30, 2019 due to the fact that they have not been placed in service.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation expense for the three months ended June 30, 2019 and 2018 was $232 and $259, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019 the Company disposed of computer equipment valued at $1,632 recognizing a loss on disposal of $907.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7 &#8211; INTANGIBLE ASSETS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Patents:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Pilus Energy, LLC</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company, through the acquisition of Pilus Energy on January 28, 2014, acquired a patent to develop cleantech energy using proprietary microbiological solution that creates electricity while consuming polluting molecules from wastewater.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus to Open Therapeutics. Open Therapeutics agreed to terminate and cancel 80% of the unexercised portion of Open Therapeutics agreed to pay to the Company 20% of the net profit generated by Pilus Energy from its previous year&#8217;s earnings, if any. The first $75,000 of such payments were to be retained by Pilus Energy as additional consideration for the sale, which was reflected as a contingent liability on the Company&#8217;s consolidated balance sheet. The Company further agreed it would vote its 20% membership interest in Pilus Energy in the same manner that Open Therapeutics votes its membership interest on all matters for which a member vote is required. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had fully impaired the value of the patents prior to the sale, and the warrants canceled as a result of this transaction was valueless as there is no intrinsic value to them. The Company recorded no gain or loss. Upon Open Therapeutics achieving profitability with respect to this technology, the Company will be the beneficiary of a profit split as noted in the agreement and will recognize revenue from that in the future.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company&#8217;s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company&#8217;s consolidated financial statements.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8 &#8211; NOTES PAYABLE </b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Notes payable and convertible notes consisted of the following as of:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Alternative Strategy Partners PTE Ltd.</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(a)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">GS Capital Partners LLC - Oct 2018</td><td>&#160;</td> <td style="text-align: center">(b)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">180,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">GS Capital Partners LLC - Mar 2019</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">GS Capital Partners LLC - May 2019</td><td>&#160;</td> <td style="text-align: center">(d)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">GS Capital Partners LLC - Jun 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(e)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total notes payable and convertible notes</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">560,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">570,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less - note discounts</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(324,580</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(356,125</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less - current portion of these notes</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(235,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(213,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total notes payable and convertible notes, net discounts &#8211; long-term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. (&#8220;ASP&#8221;) to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. (&#8220;Eishin&#8221;), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company&#8217;s balance sheet, the $113,468 liability has been removed from the Company&#8217;s balance sheet, as is reflected in the Company&#8217;s financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(b)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC &#8220;chill&#8221; on its shares, the conversion price shall be decreased to 60% instead of 70% while that &#8220;chill&#8221; is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(c)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company&#8217;s consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company&#8217;s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC &#8220;Chill&#8221; on its shares, the conversion price shall be decreased to 56% instead of 66% while that &#8220;Chill&#8221; is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company&#8217;s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the &#8220;Share Reserve&#8221;) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(e)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company&#8217;s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC &#8220;Chill&#8221; on its shares, the conversion price shall be decreased to 56% instead of 66% while that &#8220;Chill&#8221; is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company&#8217;s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the &#8220;Share Reserve&#8221;) within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $118.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company issued 5,946,516 shares of common stock to holders of convertible notes to retire $187,000 in principal and $13,718 of accrued interest (at an average conversion price of $0.03375 per share) under the convertible notes.&#160;&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 888,308 shares of common stock to holders of convertible notes to retire $40,000 and $1,973 of note principal and accrued interest, respectively.&#160;&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Interest expense for the three months ended June 30, 2019 was $121,814 compared to $23,496 for the prior year. Accrued interest at June 30, 2019 and March 31, 2019 was $16,946 and $30,780, respectively.&#160;&#160;</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9 &#8211; RELATED PARTIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">As a result of the Company&#8217;s joint venture with Ice + Jam, a receivable and a payable was recorded on the Company&#8217;s books. As of December 31, 2018, these amounts represented cash Ice + Jam collected from sales of <font style="font-variant: small-caps">HerMan&#174; </font>through their website in the amount of $581 and a payable in the amount of $5,522 for expenses incurred through the operation of the business. As of March 31, 2019, these assets and liabilities were reflected in assets and liabilities from discontinued operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In conjunction with and consideration for a July 22, 2019, 10% convertible note, in the amount of $55,000, under a Securities Purchase Agreement the Company entered into with Jefferson Street Capital, LLC, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company&#8217;s authorized shares within the 75 days from the date of the note as indicated in the agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10 &#8211; STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2019, the Company is authorized to issue 100,000,000 shares of its common stock. As of June 30, 2019 and August 13, 2019, there were 72,925,920 and 75,895,090 shares, respectively of common stock issued and outstanding which includes all adjustments for fractional shares.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 26, 2019, the Company&#8217;s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Fiscal Year 2019</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019 the Company issued 3,130,000 shares of its restricted common stock to consultants under consulting agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company issued 5,946,516 shares of restricted common stock to noteholders for the conversion of debt and accrued interest having a value of $200,718 (at an average conversion price of $0.03375 per share).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company issued 5,686,667 shares of common stock ($0.02 to $0.06 per share) for aggregate proceeds of $301,200.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company issued 500,000 commitment shares for debt financing ($0.042 per share) valued at $21,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company issued 95,667 shares for the settlement of debt $20,004.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company&#8217;s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company&#8217;s consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Fiscal Year 2020</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 1,200,000 shares under distribution agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 888,308 shares for conversion of debt in the amount of $40,000 as well as accrued interest in the amount of $1,964 ($0.04725).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 250,000 shares issued to Vice President of Distribution and Marketing.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 1,000,000 shares issued for services rendered</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 750,000 shares for debt commitment in the amount of $142,500 ($0.19 per share). The shares were recorded as a liability to issue shares at March 31, 2019 on the Company&#8217;s balance sheet.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company issued 714,286 shares under stock purchase agreements in consideration for $45,000 (average of $0.063 per share) to accredited investors that are unrelated third parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with some of the consulting agreements and board advisory agreements the Company has entered into, as the following clauses are part of the compensation arrangements: (a) the consultant will be reimbursed for all reasonable out of pocket expenses and (b) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant&#8217;s performance. The Company recognized $375,720 and $43,221 in stock-based compensation expense related to these agreements in the three months ended June 30, 2019 and 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Warrants for Common Stock</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activity for the three months and year ended June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Weighted</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Average</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Remaining</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Aggregate</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Exercise</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">Contractual</td><td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">Intrinsic</td><td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 40%">Outstanding at March 31, 2018</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,433,611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 13%; text-align: center">3.02 Years</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(223,335</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.2843</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable March 31, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,210,276</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1.2</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">1.28 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">-</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(389,344</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.75</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">820,932</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1.41</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">1.41 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, 213,334 warrants expired which were issued in conjunction with a one-year 5% convertible note in the amount of $80,000 with GS Capital Partners, LLC. The five-year cashless warrants had an exercise price of $0.2625 per share. These warrants were cancelled as part of the convertible note agreement which the Company entered into with GS Capital Partners, LLC on March 14, 2019 in the amount of $300,000 (See Note 8 section c).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, 10,001 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, 389,344 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Stock Options</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 1, 2012, the Company awarded to each of two executives&#8217;, one current and one former, options to purchase 66,667 common shares, an aggregate of 133,334 shares. These options vested immediately and were for services performed.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes option activity for the year and three months ended June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br />Average <br />Exercise <br />Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Weighted <br />Average <br />Remaining <br />Contractual <br />Term</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br />Intrinsic <br />Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 40%">Outstanding at March 31, 2018</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">133,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 13%; text-align: center">3.85 Years</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Outstanding at March 31, 2019</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133,334</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">2.85 Years</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding and exercisable at June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">133,334</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">2.60 Years</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 11 &#8211; PROVISION FOR INCOME TAXES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company&#8217;s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company&#8217;s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company&#8217;s effective tax rate for financial statement purposes for the three months and years ended June 30, 2019 March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Federal income taxes at statutory rate</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes at statutory rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Temporary differences</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.99</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.48</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.17</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.24</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impact of Tax Reform Act</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(167.44</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30.16</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">144.72</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">As of</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">As of</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating losses before non-deductible items</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,763,732</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,685,807</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss on disposal of fixed assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">288,492</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">209,591</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unrealized gains or losses on investments</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,079</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,028,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,891,495</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,028,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,891,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At June 30, 2019, the Company had a U.S. net operating loss carryforward in the approximate amount of $17.9 million available to offset future taxable income through 2038. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. The valuation allowance increased by $137,005 in the three months ended June 30, 2019 and decreased by $1,516,710 in the year ended March 31, 2019. The net decreases were the result of the tax effects of the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) offset by taxable losses net of timing differences in each of the years.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">On December 22, 2017, Public Law 115-97, informally referred to as the TCJA was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. The effective rate for the year ended March 31, 2018 was 31% as the rate was changed effective January 1, 2018 to the lower rate. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. </font><font style="font: 10pt Times New Roman, Times, Serif">Given the significant complexity of the TCJA and anticipated additional implementation guidance from the Internal Revenue Service, further implications of the TCJA may be identified in future periods. The Company has adjusted their NOLs and valuation allowances to account for the changes brought about by the TCJA for the three months and year ended June 30, 2019 and March 31, 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 12 &#8211; INVESTMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Trading securities</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For investments in securities of other companies that are owned, the Company records them at fair value with unrealized gains and losses reflected in other operating income or loss. For investments in these securities that are sold by us, the Company recognizes the gains and losses attributable to these securities investments as realized gains or losses in other operating income or loss on a first in first out basis.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Investment in Trading Securities:</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6"><font style="font: 10pt Times New Roman, Times, Serif"><b>At March 31, 2019</b></font></td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beginning<br /> of Period<br /> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Purchases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Sales</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Proceeds</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>End of</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Cost</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Fair</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Realized<br /> Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br /> Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Green Innovations Ltd (GNIN)*</td><td>&#160;</td> <td style="text-align: center">(a)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 33%">VistaGen Therapeutics Inc (VTGN)</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(b)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">490,117</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">349,498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(517,485</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">294,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(34,630</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">6,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Blink Charging Co (BLNK)</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">190,350</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">151,666</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(367,142</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25,126</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Blink Charging Co (BLNKW) (Warrants)</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">162,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(468,496</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">305,381</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Aytu BioScience Inc (AYTU)</td><td>&#160;</td> <td style="text-align: center">(d)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">82,270</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,030</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(144,094</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(38,206</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lightbridge Corp. (LTBR)</td><td>&#160;</td> <td style="text-align: center">(e)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,511</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">299,028</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(276,159</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60,380</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pulmatrix Inc. (PULM)</td><td>&#160;</td> <td style="text-align: center">(f)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">204,802</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(183,737</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(21,065</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Axovant Sciences Ltd. (AXON)</td><td>&#160;</td> <td style="text-align: center">(g)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">103,938</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(98,433</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,505</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basanite Inc. (BASA)</td><td>&#160;</td> <td style="text-align: center">(h)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,998</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10,821</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,177</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Achieve Life Sciences (ACHV)</td><td>&#160;</td> <td style="text-align: center">(i)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">177,356</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(112,221</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(65,135</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Decision Diagnostics (DECN)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(j)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,586</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">801,148</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,195,481</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">99,823</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,900</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6" style="font-weight: bold">At June 30, 2019</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beginning of Period Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Purchases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Sales Proceeds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">End of Period Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Realized Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 33%">VistaGen Therapeutics Inc (VTGN)</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(b)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">166,865</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(120,635</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Basanite Inc. (BASA)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(h)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">277,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">247,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">444,785</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127,285</td><td style="padding-bottom: 2.5pt; text-align: left">**</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">* Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">**This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u></u></b></font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2018, the Company&#8217;s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company&#8217;s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(b)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company&#8217;s broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company&#8217;s broker of record.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(c)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company&#8217;s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(e)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380. </font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(f) </font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(g)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(h) </font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company&#8217;s broker of record.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(i)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135. </font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(j)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At June 30, 2019, the Company held warrants for AYTU to purchase 5,555 common shares at a strike price of $10.80 with an expiration of March 6, 2023. The strike price and number of shares were adjusted for the August 10, 2018, 1 for 20 reverse stock-split. At June 30, 2019, these warrants were out of the money by $9.13 per share and are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At June 30, 2019, the Company currently holds warrants for VTGN to purchase 320,000 shares of common stock at a strike price of $1.50 per share with an expiration of December 13, 2022 and warrants for VTGN to purchase 230,000 shares of common stock at a strike price of $1.50 per share with an expiration of February 28, 2022. At June 30, 2019, these warrants were out of the money by $0.25 per share. Since these warrants are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Digital Currency</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased. Groestlcoin cryptocurrency (Crypto Currency Code: GRS). The purchase of this currency cannot be executed directly using $USD. The Company must purchase Bitcoin (BTC) and then purchase the Groestlcoin cryptocurrency by using BTC. This two-step process triggers the potential recognition of realized gains or losses on the purchase of Groestlcoin.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 2, 2018, the Company completed a purchase in the Groestlcoin cryptocurrency in the aggregate amount of $8,000 for 11,922.81 units ($0.6569 per unit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 15, 2018, the Company sold all of its 39,862 units of Groestlcoin cryptocurrency converting it into 4.17 units of BTC having a value of $32,230. On August 20, 2018, the Company converted its BTC to gold bullion and silver coins at a value of $26,783.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 25, 2018, the Company sold all gold and silver commodities held for a sum of $24,046, recognizing a loss on the transaction of $2,737.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, had an unrealized loss on digital currency of $3,143 prior to the conversion to the gold and silver.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2019, the Company had no digital currency activity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Equity investments</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Honeywood</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Effective August 1, 2017, the Company entered into a Debt Conversion Agreement in respect to a secured promissory note issued following the unwinding of the Honeywood acquisition (See NOTE 1), whereby the Company agreed to convert the entire principal and accrued but unpaid interest due under the note into a 5% membership interest in Honeywood.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with FASB ASC 320-10-35-28, &#8220;<i>Investments&#8212;Debt and Equity Securities,</i>&#8221; a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: (a) the investment experiences a recovery of fair value up to (or beyond) its cost; or (b) the entity recognizes an other-than-temporary impairment loss. </font><font style="font: 10pt Times New Roman, Times, Serif">At the time of the Debt Conversion Agreement the receivable balance of $199,119 had been fully written off by the Company in a prior period. As a result of this Debt Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Cost investments</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>K&#252;dzoo, Inc.</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On September 4, 2018, the Company invested $15,000 in K&#252;dzoo, Inc. (&#8220;K&#252;dzoo&#8221;), a privately held company. K&#252;dzoo is the developer of a mobile application that rewards students for their grades and achievements with deals and opportunities. The investment is recorded at cost and represents 0.2% of the value of K&#252;dzoo based on a pre-money valuation of $7,500,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 21, 2019, the Company invested $22,500 in K&#252;dzoo. This investment was recorded at cost and represents 0.22% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000. On April 8, 2019, the Company invested another $20,400, which was recorded at cost representing a 0.42% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company tested the investment value for K&#252;dzoo as of March 31, 2019 for impairment. It was noted that the value of the company has increased based on recent equity raises in which the Company took part in. As a result of the new equity raises, the Company does not believe there is any impairment of this investment as of June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 8, 2019, the Company invested $20,400, in K&#252;dzoo, Inc., a private Company in which the Company had previously invested $37,500. The $20,400 investment was recorded at cost representing a 0.2% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Serendipity</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 31, 2018, the Company invested $35,000 in Serendipity Brands LLC (dba Serendipity Ice Cream Co.) (&#8220;Serendipity&#8221;), a privately held Company. Serendipity is an ice cream distribution company providing wholesale distribution to retail customers. The investment was recorded at cost and represents 0.24% of the value of Serendipity based on a pre-money valuation of approximately $14 million.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company tested the investment value for Serendipity as of March 31, 2019 for impairment. It was noted that the value of the company has maintained its value through reviews of their financial performance, therefore, the Company does not believe there is any impairment of this investment as of June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 13 &#8211; FAIR VALUE MEASUREMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following summarizes the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify">Investment-trading securities</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">444,785</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">444,785</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cost method investment &#8211; K&#252;dzoo</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">57,900</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">57,900</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost method investment &#8211; Serendipity Brands</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify">Investment-trading securities</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">350,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">350,400</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cost method investment &#8211; K&#252;dzoo</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost method investment &#8211; Serendipity Brands</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 15 &#8211; SUBSEQUENT EVENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Subsequent to June 30, 2019, the Company issued additional shares of common stock as follows; (i) 250,000 shares for commitment shares relative to convertible note issued; (ii) 250,000 shares under a distribution agreement dated April 30, 2019; and (iii) 2,719,170 shares in conversion of convertible notes of $75,000 and accrued interest of $4,373.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Convertible Notes</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 22, 2019, the Company and Jefferson Street Capital, LLC (&#8220;Jefferson Street&#8221;) consummated entry into a Securities Purchase Agreement where the Company has borrowed $55,000 ($50,000 with original issuance discount reflected) at 10% annual interest under a term of nine-months in the form of a convertible note. The note is convertible into restricted stock of the Company. In connection with this agreement, the Company issued 250,000 commitment shares having a value of $10,500 ($0.042 per share, the closing price of our common stock on the day preceding the note) which will be reflected as interest expense in the Company&#8217;s condensed consolidated statement of operations during the three months ended June 30, 2019. The restricted stock was valued at the closing price on July 22, 2019. Legal fees of $2,000 were deducted from cash proceeds of the note payable to investor&#8217;s counsel, and a $5,000 original issue discount recognized. The Company received cash proceeds of $48,000 at closing. Under the Jefferson Street note, the Company is required initially to reserve 1,000,000 shares of its common stock, and thereafter to increase the reserve up to 15,000,000 shares upon the increase in the Company&#8217;s authorized common shares (per a charter amendment via shareholder meeting and approval as approved by the Board of Directors on July 26, 2019), but up to six times the number of shares required for a full conversion. The Company has 75 days from the date of this note to have this increased effectuated. The noteholder may, at any time, at its option, convert all or any amount of the principal face amount of the note then outstanding into shares of the Company&#8217;s common stock at a conversion price for each share of Common Stock equal to 65% of the lowest volume weighted average price for the Company&#8217;s common stock during the previous fifteen trading day period as reported on the National Quotations Bureau OTC Markets exchange which the Company&#8217;s shares are traded or any exchange upon which the Common Stock may be traded in the future, including the day upon which a notice of conversion is received by the Company. If the Company fails to maintain the share reserve at the required amounts, or to attain shareholder approval within 75 days of July 22, 2019, this will be considered an Event of Default. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note; however, the Company maintains the option to repay the note in cash within the first 180 days beginning on July 22, 2019 to avoid such default provision triggering event, as more fully described below.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon an event of default (as defined and described in the note), among other default penalties, the Company shall pay the Default Amount (as defined in the agreement) as well as incur annual interest at a default interest rate of 24% per annum.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In consideration of Jefferson Street loaning the Company the proceeds under this note, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company&#8217;s authorized shares within the 75 days from the date of the note as indicated in the agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Other</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA&#8217;s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 26, 2019, the Company&#8217;s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 12, 2019, the Company received $47,500 net proceeds for the second of two notes (the &#8220;Back-End Note&#8221;) under a December 20, 2018 security purchase agreement with Adar Alef, LLC whereby the Company issued two 8% convertible redeemable notes in the cumulative principal amount of $110,000. Both notes were for $55,000 and had funded with net proceeds of $47,500, after the deduction of $5,000 for OID and $2,500 in legal fees. The first note was previously funded on December 24, 2018. The Back-End Note was initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the &#8220;Note Receivable&#8221;). The terms of the Back-End Note required cash funding prior to any conversion thereunder. The Note Receivable was due December 20, 2019, unless certain conditions were not met, in which case both the Back-End Note and the Note Receivable may both have been cancelled. The Back-End Note has a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under the Back-End Note are convertible into shares of the Company&#8217;s common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company&#8217;s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC &#8220;chill&#8221; on its shares, the conversion price shall be decreased to 50% instead of 60% while that &#8220;chill&#8221; is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. This Back-End Note may not be repaid. The note holder may redeem this note at any time after the first six months.</p> 444785 350400 444785 350400 232 259 243185 340020 34630 38206 60380 5505 21065 65135 3586 25126 305381 2177 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3&#8211; INVENTORY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Inventory from continuing operations</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Inventory value by product as of:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Tauri-Gum<sup>TM</sup></font></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">138,606</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">10,872</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Inventory</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">138,606</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">10,872</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">At June 30, 2019, deposits to Per Os Bio in the amount of $52,500 for the manufacturing costs of Tauri-Gum<sup>TM</sup> have been classified as a deposit (prepaid expenses other current assets) on the Company&#8217;s condensed consolidated balance sheet, as the goods are not yet available for sale.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">At March 31, 2019, the Company had deposits to Per Os Bio in the amount of $105,000 for the manufacturing costs of Tauri-Gum<sup>TM </sup>for goods not yet available for sale.</font></p> 44377 57134 29418 -8673 -3561 Ratio of 1-for-75 1 for 20 reverse stock split 0 0.05 0.05 0.002 0.0024 0.20 0.05 0.50 0.0022 0.0042 0.20 0.02 138606 10872 10872 138606 -5572 94385 8261 35955 78170 37677 120635 223349 183910 247920 7831 113467 -113467 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Investment in Trading Securities:</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6"><font style="font: 10pt Times New Roman, Times, Serif"><b>At March 31, 2019</b></font></td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beginning<br /> of Period<br /> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Purchases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Sales</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Proceeds</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>End of</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Cost</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Fair</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Realized<br /> Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br /> Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Green Innovations Ltd (GNIN)*</td><td>&#160;</td> <td style="text-align: center">(a)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 33%">VistaGen Therapeutics Inc (VTGN)</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(b)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">490,117</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">349,498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(517,485</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">294,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(34,630</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">6,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Blink Charging Co (BLNK)</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">190,350</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">151,666</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(367,142</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25,126</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Blink Charging Co (BLNKW) (Warrants)</td><td>&#160;</td> <td style="text-align: center">(c)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">162,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(468,496</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">305,381</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Aytu BioScience Inc (AYTU)</td><td>&#160;</td> <td style="text-align: center">(d)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">82,270</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,030</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(144,094</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(38,206</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lightbridge Corp. (LTBR)</td><td>&#160;</td> <td style="text-align: center">(e)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,511</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">299,028</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(276,159</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60,380</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pulmatrix Inc. (PULM)</td><td>&#160;</td> <td style="text-align: center">(f)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">204,802</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(183,737</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(21,065</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Axovant Sciences Ltd. (AXON)</td><td>&#160;</td> <td style="text-align: center">(g)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">103,938</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(98,433</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,505</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basanite Inc. (BASA)</td><td>&#160;</td> <td style="text-align: center">(h)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,998</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10,821</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,177</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Achieve Life Sciences (ACHV)</td><td>&#160;</td> <td style="text-align: center">(i)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">177,356</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(112,221</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(65,135</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Decision Diagnostics (DECN)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(j)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,586</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">801,148</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,195,481</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">99,823</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,900</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6" style="font-weight: bold">At June 30, 2019</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Beginning of Period Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Purchases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Sales Proceeds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">End of Period Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Realized Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized Gain (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 33%">VistaGen Therapeutics Inc (VTGN)</td><td style="width: 1%">&#160;</td> <td style="width: 4%; text-align: center">(b)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">166,865</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(120,635</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Basanite Inc. (BASA)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">(h)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">277,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">247,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">317,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">444,785</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127,285</td><td style="padding-bottom: 2.5pt; text-align: left">**</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">* Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">**This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2018, the Company&#8217;s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company&#8217;s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(b)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company&#8217;s broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company&#8217;s broker of record.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(c)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company&#8217;s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(d)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(e)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company&#8217;s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380. </font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(f) </font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"></td> <td style="font: 10pt Times New Roman, Times, Serif"></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(g)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(h) </font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company&#8217;s broker of record.</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(i)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135. </font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">(j)</font></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.</font></td></tr></table> Q1 581 5522 3130000 5946516 500000 1000000 450000 1000000 500000 500000 250000 250000 250000 18275 500000 true false false 92900 72500 4078179672 54380230 10001 389344 250000 -657564 166788 -620693 166788 -265552 -377982 -620693 -657564 -265552 -377982 90950 389085 3852 -5572 P2Y P2Y 5946516 888308 2650000 888308 2719170 0.03375 121814 23496 560000 570000 90000 180000 300000 140000 300000 60000 60000 110000 55000 55000 324580 356125 0.08 0.24 The note matured in December 2015 The Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. The Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding. The face value of this note plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. The Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. 0.66 0.70 0.68 0.66 375720 43221 20400 0.80 0.80 0.20 142500 187000 21000 5 8 20995 142492 170000 40000 40000 10500 13718 1973 1973 130548 -0.012 0.003 1632 907 349498 151666 162215 100030 299028 204802 103938 177356 20479 42998 1612010 P1Y P1Y P1Y P12M P1Y P9M -657564 166788 -657564 166788 55767119 53662728 55767119 59359187 200718 24750 24750 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Use of Estimates</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Cash Equivalents</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At June 30, 2019, the Company&#8217;s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At June 30, 2019 and March 31, 2019, the Company had a cash balance of $15,247 and $385,943, respectively. The Company&#8217;s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of June 30, 2019 and March 31, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Investment in Trading Securities</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company&#8217;s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Investment &#8211; Cost Method</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of June 30, 2019, the Company has not impaired any of their cost method investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Inventory</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfillment center is also included in the total inventory cost. Shipping of product upon sale for online sales is paid by the customer upon ordering for orders of single packs of Tauri-Gum<sup>TM</sup>. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of June 30, 2019, the Company&#8217;s inventory on hand had a value of $138,606. The Company also has paid deposits in the amount of $52,500 to the manufacturer, Per Os Bio, towards orders not received as of June 30, 2019. Amounts paid to Per Os Bio for Tauri-Gum<sup>TM </sup>are classified as deposits (other current asset) on the Company&#8217;s condensed consolidated balance sheet until the goods are available for sale. The Company has not established any inventory reserve on the Tauri-Gum<sup>TM </sup>as of June 30, 2019.</font></p> Yes false 172500 -657564 166788 -0.012 0.003 10000 52264476 68123326 54380230 54380230 57130230 72925920 500000 750000 888308 250000 250000 1985754 1000000 2960762 888308 41973 57339 118879 20 10 30 9 57319 24490 118849 41964 24500 375720 43221 109660 43221 132055 11769 109660 375720 132055 11769 130000 1750000 1250000 2450000 1000000 1 18 12 24 -1 -18 -12 -24 95667 20004 1 20003 2196 2196 500000 75000 5 74995 8042 -8042 68663 388811 388811 68663 113468 127734 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4&#8211; DISCONTINUED OPERATIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On March 31, 2019, the Company decided to discontinue operations relative to its HERMAN&#169; Lip balm product line. After much effort the Company was unable to resolve manufacturing issues as it related to it its lip balm tube mechanism. The Company did not believe that these issues will be resolvable without a substantial investment of time and money. Therefore, the Company exchanged its 50% ownership in Ice+Jam, LLC for the balance of the non-controlling interest as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had no revenue or expenses from discontinued operations during the three months ended June 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Assets from discontinued operations</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">581</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Liabilities from discontinued operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">5,522</td><td style="text-align: left">&#160;</td></tr></table> 6.99 10000 69808 69808 57030 56798 P3Y P5Y 250000 P1Y 0.30 581 5522 100 9071 7492 7492 4574 9471 7895 7895 4984 9471 4574 108111 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Inventory value by product as of:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Tauri-Gum<sup>TM</sup></font></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">138,606</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">10,872</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Inventory</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">138,606</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">10,872</td><td style="text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>TAURIGA SCIENCES, INC. AND SUBSIDIARY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>BALANCE SHEETS FROM DISCONTINUED OPERATIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Assets from discontinued operations</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">581</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Liabilities from discontinued operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">5,522</td><td style="text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company&#8217;s effective tax rate for financial statement purposes for the three months and years ended June 30, 2019 March 31, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Federal income taxes at statutory rate</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes at statutory rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Temporary differences</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.99</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.48</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.17</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.24</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impact of Tax Reform Act</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(167.44</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30.16</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">144.72</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr></table> 213334 P5Y P5Y P5Y P3Y P5Y P3Y 80000 1964 0.19 375720 43221 300000 66667 66667 133334 133334 133334 7.50 7.50 P2Y10M6D P3Y10M6D P2Y10M6D Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. The effective rate for the year ended March 31, 2018 was 31% as the rate was changed effective January 1, 2018 to the lower rate. 0.2100 0.21 0.2100 0.155 0.08 0.0000 0.0000 0.0000 -1.6744 -0.3016 1.4472 0.0000 0.0000 3763732 3685807 355 355 288492 209591 -24079 -4258 4028500 3891495 45000 320000 208800 5555 320000 230000 0.2625 4.25 1.50 0.77 1.60 0.75 0.75 10.80 9.13 1.50 1.50 0.25 2023-03-06 2022-12-13 2022-02-28 8000 11922.81 0.6569 -37 3143 39862 4.17 32230 26783 24046 2737 15000 35000 37500 37500 35000 35000 22500 20400 57900 57900 35000 35000 20400 37500 7500000 14000000 10200000 10200000 10200000 317500 801148 250000 287500 480000 490117 190350 900 82270 37511 191250 30000 490117 6815 517485 367142 468496 144094 276159 183737 98433 183747 112221 16893 367142 10821 10821 2195481 317500 317500 287500 82270 37511 191250 287500 30000 30000 444785 350400 166865 119947 29250 155295 294400 56000 277920 306207 -34630 25126 305381 -38206 -60380 -21065 -5505 -65135 -3586 -2177 99823 127285 -120635 6900 26000 32900 247920 125 188300 188300 25000 320000 59380 260000 287405 40000 391514 44000 450000 230000 41018 100000 400000 90000 10000 61998 100830 295625 103938 204802 177355 20480 287500 151666 12998 30000 389380 448300 312405 40000 391514 44000 86018 100000 1.33 0.32 0.884 2.46 0.47 2.55 0.038 4.26 0.11 18500250 298800 468496 1.00 0.97 1.00 0.2396 2021-06-30 201 178 55000 55000 (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. The Back-End Note was initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the "Note Receivable'). The terms of the Back-End Note required cash funding prior to any conversion thereunder. The Note Receivable was due December 20, 2019, unless certain conditions were not met, in which case both the Back-End Note and the Note Receivable may both have been cancelled. The Back-End Note has a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under the Back-End Note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 50% instead of 60% while that "chill" is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. This Back-End Note may not be repaid. The note holder may redeem this note at any time after the first six months. 40000 4028500 3891495 94385 78170 8042 0.02 0.06 0.06 0.07 0.19 0.042 0.04725 0.002888 0.0245 0.0357 0.0452 0.0495 0.0269 0.345 0.07 0.42 0.16 125000 2000 52500 105000 0.0899 0.0148 -0.0017 -0.0024 -128983 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Property and Equipment</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Intangible Assets</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Net Income (Loss) Per Common Share</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company computes per share amounts in accordance with FASB ASC Topic 260 &#8220;<i>Earnings per Share</i>&#8221; (&#8220;EPS&#8221;), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the three months ended June 30, 2019, basic and fully diluted earnings per share were the same as the Company had losses in this period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Stock-Based Compensation</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for Stock-Based Compensation under ASC 718 &#8220;<i>Compensation-Stock Compensation</i>,&#8221; which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, &#8220;E<i>quity-Based Payments to Non-Employees</i>.&#8221; Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders&#8217; equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Reclassifications</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Impairment of Long-Lived Assets</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it&#8217;s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Research and Development</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses research and development costs as incurred. Research and development costs were $3,852 for the three months ended June 30, 2019 compared to no expense during the same period in the prior year. The Company is continually evaluating products and technologies in the natural wellness space, including its Tauri-Gum<sup>TM </sup>product including new flavor formulations and other CBD delivery products, as well as any intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Fair Value Measurements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 820 &#8220;<i>Fair Value Measurements</i>&#8221; defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Financial instruments classified as Level 1 &#8211; quoted prices in active markets include cash.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These consolidated financial instruments are measured using management&#8217;s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Share settled debt</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer&#8217;s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer&#8217;s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer&#8217;s shares (e.g. net share settled written put options, net share settled forward purchase contracts).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15-day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Income Taxes</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ASC 740 &#8220;<i>Income Taxes</i>&#8221; clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Recent Accounting Pronouncements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU No. 2018-07, <i>&#8220;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221; </i>which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, FASB issued ASU 2016-02, &#8220;<i>Leases (Topic 842)</i>.&#8221; The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. Early adoption is permitted. The Company has adopted this standard as of April 1, 2019 (See Note 6).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company&#8217;s consolidated financial position or operating results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Subsequent Events</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 855 &#8220;<i>Subsequent Events</i>&#8221; the Company evaluated subsequent events after the balance sheet date through the date of issuance.</font></p> Yes 28028 18588 7300 162 2171 4941 4941 -29 18588 12134 12066 28028 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6 &#8211; OPERATING LEASE </b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has adopted ASU No. 2016-02, <i>Leases (Topic 842)</i>, as of April 1, 2019 and will account for the new lease in terms of the right of use assets and offsetting lease liability obligations for this new lease under this pronouncement. In accordance with ASC 842 - Leases, effective April 1, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $7,492 and $7,895, respectively, as of April 1, 2019. The Company is recording these at present value, in accordance with the standard, using a discount rate of 8% which is representative of the last borrowing rates for notes issued to a non-related party. The right of use asset is composed of the sum of all lease payments, at present value, and is amortized straight line over the life of the expected lease term. For the expected term of the lease the Company will use the initial term of the two-year lease. If the Company does elect to exercise its option to extend the lease for additional years, that election will be treated as a lease modification and the lease will be reviewed for remeasurement. This lease will be treated as an operating lease under the new standard.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has chosen to implement this standard using the modified retrospective model approach with a cumulative-effect adjustment, which does not require the Company to adjust the comparative periods presented when transitioning to the new guidance on April 1, 2019. The Company has also elected to utilize the transition related practical expedients permitted by the new standard. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a modified retrospective approach. Adoption of the new standard resulted in the recording of additional net lease assets and lease liabilities of approximately $7,492 and $7,895 as of April 1, 2019, respectively. The difference between the additional lease assets and lease liabilities, net of the deferred tax impact, will be recorded as an adjustment to retained earnings. The standard is not expected to materially impact our consolidated net earnings and had no impact on cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Corporate office &#8211; New York</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 1, 2017, the Company relocated its corporate headquarters from Danbury, Connecticut to New York, New York. The Company has entered into a two-year lease at $1,010 per month for the term of the lease. The lease right of use asset for this lease at adoption was $7,492 and will be amortized on a straight-line basis over the remaining term of the lease. For the three months ended June 30, 2019 the Company recorded a lease expense of $2,810. As of June 30, 2019, the value of the unamortized lease right of use asset is $4,683. As of June 30, 2019, the Company&#8217;s lease liability was $4,984.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Barcelona office</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 11, 2019 the Company entered into a two-year lease, expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Catalun&#771;a 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of &#8364;178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate will be recorded as gain or loss on currency translation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The lease right of use asset, at inception, of $27,050 amortized on a straight-line basis over the term of the lease. The present value of the New York corporate office lease had an initial present value of $22,476 at December 1, 2017. The Barcelona office lease value had an initial present value of $4,573. For the three months ended June 30, 2019 the Company recorded a lease expense of $3,149. As of June 30, 2019, the value of the unamortized lease right of use asset is $9,071. As of June 30, 2019, the Company&#8217;s lease liability was $9,471.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 72%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="5" style="font-weight: bold">Maturity of Operating Lease Liability for fiscal year ended June 30,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2020</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,665</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,288</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">518</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">9,471</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The following chart shows the Company&#8217;s operating lease cost at June 30, 2019 and 2018:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the three months ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amortization of right of lease asset</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,996</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Lease interest cost</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">The following chart shows the Company&#8217;s operating lease liability at June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Discounted Operating Lease liability at inception - December 1, 2017</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,050</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Financing cost</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,055</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less lease payments made</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(18,204</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cumulative effect of adoption of ASC 842</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability at June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Lease Liability current portion</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Lease Liability at June 30, 2019 &#8211; long-term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,171</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> 519335 503446 523 54680382 -54391500 8042 -2196 681 55991704 -55488939 295251 562599 544 544 572 729 54788963 54921018 54957259 56665512 -54224712 -54490264 -54868246 -56146906 -2196 -2196 -2196 429102 87389 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 72%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td colspan="5" style="font-weight: bold">Maturity of Operating Lease Liability for fiscal year ended June 30,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2020</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,665</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,288</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">518</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">9,471</td><td style="text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The following chart shows the Company&#8217;s operating lease cost at June 30, 2019 and 2018:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the three months ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amortization of right of lease asset</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,996</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Lease interest cost</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">The following chart shows the Company&#8217;s operating lease liability at June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Discounted Operating Lease liability at inception - December 1, 2017</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,050</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Financing cost</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,055</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less lease payments made</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(18,204</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cumulative effect of adoption of ASC 842</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(430</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability at June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Lease Liability current portion</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Lease Liability at June 30, 2019 &#8211; long-term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,171</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> 54000 46848 0.07 499657 52500 4683 2996 27050 9471 3149 153 18204 -430 27050 1055 75000 0.24 0.24 0.24 750000 142500 133334 7.50 P2Y7M6D 1433611 1210276 223335 389344 1.06 1.2 1.2 1.41 1210276 820932 0.2843 0.75 P3Y0M7D P1Y3M11D P1Y3M11D P1Y4M28D 17900000 2038 137005 1516710 5000 1000000 15000000 During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date 44377 -403 -403 0.0405 0.2091 162 -370696 23201 15247 385943 12291 35492 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 14 &#8211; CONCENTRATIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months and year ended June 30, 2019 and March 31, 2019, we have one supplier for 100% of our product who is also the manufacturer of Tauri-Gum<sup>TM</sup>.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended June 30, 2019, one customer accounted for 23.96% of product sales from continuing operations. For the year ended March 31, 2019, one customer accounted for 97% of product sales from continuing operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Condensed Consolidated Financial Statements</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga BDC and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of June 30, 2019, there is no activity in any of the Company&#8217;s subsidiaries other than Tauriga BDC holding the electric car chargers and the leasehold interest in Tauriga Sciences Limited.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Revenue Recognition</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of <font style="font-variant: small-caps">HerMan&#174; </font>using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company&#8217;s operations or cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company&#8217;s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 29, 2018, the Company purchased four Blink Level 2 - 40&#8221; pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2019, the Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2019, the Company recognized its first sales of Tauri-Gum<sup>TM</sup>, primarily vis-&#224;-vis its entry in the E&#38;M Distribution Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company&#8217;s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized revenue from operations in the amount of $44,377 during the three months ended June 30, 2019 compared to no revenue for the same period in the prior year. All revenue is from the sale of the Company&#8217;s Tauri-Gum<sup>TM </sup>product line and there were accounts receivable of $28,028 currently outstanding for these sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognized no revenue from discontinued operations during the three months ended June 30, 2018 which was related to the sales of the HERMAN&#174; lip balm product.</font></p> Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). 2288 518 6665 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Sales Refunds</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-Gum<sup>TM</sup> distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of June 30, 2019 however will monitor the refunds to estimate whether a reserve will be required.</font></p> 213334 28028 3149 1010 2810 22476 4573 3 339810 2000 2500 Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. ("ASP") to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. ("Eishin"), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company's balance sheet, the $113,468 liability has been removed from the Company's balance sheet, as is reflected in the Company's financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019. On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227. On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company's consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled. On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company's common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500. On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company's common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments. This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019. During the year ended March 31, 2018, the Company's investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company's investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125. On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company's broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company's broker of record. The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company's investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381. On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding. On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380. During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding. During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding. On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company's broker of record. During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135. During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586. EX-101.SCH 11 taug-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Operations link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Operating Lease link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Provision for Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Operating Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stockholders' Equity (Deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Provision for Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Basis of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Discontinued Operations - Summary of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Operating Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Operating Lease - Schedule of Maturity of Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Operating Lease - Schedule of Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Operating Lease - Schedule of Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Stockholders' Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Provision for Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Provision for Income Taxes - Schedule of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Investments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Investments - Schedule of Investment in Trading Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 taug-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 taug-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 14 taug-20190630_lab.xml XBRL LABEL FILE Fair Value, Hierarchy [Axis] Level 3 [Member] Level 2 [Member] Level 1 [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Transfer Agreement [Member] Ownership [Axis] Open Therapeutics [Member] Legal Entity [Axis] GS Capital Partners, LLC [Member] Award Type [Axis] Warrants [Member] Green Innovations Ltd (GNIN) [Member] Geographical [Axis] New York [Member] VistaGen Therapeutics, Inc. (VTGN) [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income (Loss) [Member] Non-Controlling Interest [Member] Aytu BioScience Inc (AYTU) [Member] Lightbridge Corp. (LTBR) [Member] Blink Charging Co (BLNK) [Member] Class of Stock [Axis] Range [Axis] Maximum [Member] Warrants [Member] Honeywood [Member] Ownership [Member] Property, Plant and Equipment, Type [Axis] Computers, Office Furniture and Other Equipment [Member] Minimum [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Award Date [Axis] Fiscal Year 2019 [Member] Consulting Agreements [Member] Title of Individual [Axis] One Current Executive [Member] One Former Executive [Member] Executives [Member] Derivative Instrument [Axis] Groestlcoin [Member] Blink Charging Co (BLNKW) (Warrants) [Member] Pulmatrix Inc PULM [Member] Axovant Sciences Ltd AXON [Member] Short-term Debt, Type [Axis] Convertible Notes [Member] Alternative Strategy Partners PTE Ltd [Member] GS Capital Partners LLC - Oct 2018 [Member] Non-Convertible Debenture [Member] Company [Member] Related Party [Axis] Consultant [Member] Eishin, Inc [Member] Honeywood Conversion Agreement [Member] Ice + Jam LLC [Member] Scenario [Axis] Balance Sheet Cash [Member] Pulmatix Inc PULM [Member] Noteholders [Member] GS Capital Partners LLC - May 2019 [Member] Kudzoo, Inc [Member] Achieve Life Sciences (ACHV) [Member] Decision Diagnostics (DECN) [Member] Restricted Common Stock [Member] Computer Equipment [Member] Serendipity Brands LLC [Member] Basanite Inc. (BASA) [Member] Basanite Industries Inc. (BASA) [Member] Kudzoo [Member] Serendipity Brands [Member] Debt Conversion Agreement [Member] Honeywood LLC [Member] Additional Paid-In Capital [Member] Noncontrolling Interest [Member] E&M Distribution Agreement [Member] South Florida Region Distribution Agreement [Member] North Eastern United States Distribution Agreement [Member] Ice+Jam, LLC [Member] Tauri-GumTM [Member] Mr. Mahesh Lekkala [Member] Within Ten (10) Business Days of April 30, 2019 [Member] Sai Krishna LLC (SKL) [Member] Within Ten (10) Business Days of August 1, 2019 [Member] One Year Agreement [Member] SKL Distribution Agreement [Member] Ms. Neelima Lekkala [Member] Adjustments for New Accounting Pronouncements [Axis] ASU No. 2016-02 [Member] GS Capital Partners LLC - March 2019 [Member] Common Stock One [Member] Common Stock Two [Member] Securities Purchase Agreement [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] One Supplier [Member] Sales Revenue [Member] One Customer [Member] Debt Instrument [Axis] Convertible Note [Member] GS Capital Note [Member] Spain [Member] Euro [Member] Windmill Health Distribution Agreement [Member] GS Capital Partners LLC - June 2019 [Member] Convertible Debenture [Member] Jefferson Street Capital, LLC [Member] Chief Executive Officer [Member] Fiscal Year 2020 [Member] Distribution Agreements [Member] Vice President [Member] Stock Purchase Agreements [Member] Accredited Investors [Member] Income Tax Authority [Axis] United States [Member] AYTU Bioscience [Member] Convertible Debt [Member] Upon Increase of Authorized Common Shares [Member] New York Corporate Office Lease [Member] Barcelona Office Lease [Member] Adar Alef, LLC [Member] 8% Convertible Redeemable Notes [Member] 8% Convertible Redeemable Note One [Member] 8% Convertible Redeemable Note Two [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Assets from discontinued operations Accounts receivable Investment - trading securities Investment - other Inventory asset Prepaid expenses and other current assets Total current assets Lease right of use asset Property and equipment, net Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Notes payable, net of discounts Accounts payable Accrued interest Accrued expenses Liabilities from discontinued operations Liability for common stock to be issued Lease liability - current portion Deferred revenue Total current liabilities Lease liability - net of current portion Total liabilities Stockholders' equity (deficit): Common stock, par value $0.00001; 100,000,000 shares authorized, 72,925,920 and 68,123,326 outstanding at June 30, 2019 and March 31, 2019, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Common stock, par value Common stock, shares authorized Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of goods sold Gross profit Operating expenses Marketing and advertising Research and development General and administrative Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense) Interest expense Unrealized gain on trading securities Gain on the extinguishment of debt Gain on disposal of discontinued operations Loss on exchange from bitcoin Unrealized loss on digital currency Gain (loss) on sale of trading securities Foreign exchange Total other income (expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND LOSS FROM DISCONTINUED OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS Net income (loss) Net income (loss) attributable to non-controlling interest Net income (loss) attributable to controlling interest Net income (loss) attributable to common shareholders Income (loss) per share - basic and diluted - Continuing operations Income (loss) per share - basic and diluted - Discontinuing operations Weighted average number of shares outstanding - basic Income (loss) per share - fully diluted Weighted average number of shares outstanding - fully diluted Statement [Table] Statement [Line Items] Balance Balance, shares Shares issued for note conversion Shares issued for note conversion, shares Stock-based compensation vesting Stock issued for services Stock issued for services, shares Reclassification of other comprehensive income to additional paid in capital Issuance of shares via private placement Issuance of shares via private placement, shares Issuances of commitment shares - debt financing Issuances of commitment shares - debt financing, shares Shares issued for settlement of contingent liability at $0.0405 Shares issued for settlement of contingent liability at $0.0405, shares Shares issued for settlement of debt Shares issued for settlement of debt, shares Recognition of beneficial conversion feature of convertible notes Non-controlling interest Cumulative affect of adoption of Lease standard ASC 842 Net loss Balance Balance, shares Statistical Measurement [Axis] Equity issuance price of note conversion Equity issuance price to services Equity issuance price to private placement Equity issuance of commitment shares for debt financing Equity issuance price issuance for settlement of contingent liability Equity issuance price issuance for settlement of debt Statement of Cash Flows [Abstract] Cash flows from operating activities Net income (loss) Adjustments to reconcile net loss to cash used in operating activities: Amortization of original issue discount Non-cash lease operating lease expense Unrealized loss on digital currency Depreciation and amortization Gain on extinguishment of debt Amortization of debt discount Common stock issued and issuable for services (including stock-based compensation) Gain on disposal of discontinued operation (Gain) loss on sale of trading securities Unrealized gain on trading securities (Increase) decrease in assets Prepaid expenses Inventory Proceeds (purchase) of trading securities, net Accounts receivable Increase (decrease) in liabilities Accounts payable Deferred revenue Accrued expenses Accrued interest Cash used in operating activities Cash flows from investing activities Contribution into Ice + Jam Proceeds (purchase) of digital currency, net Investment - other Purchase of property and equipment Cash provided by (used in) investing activities Cash flows from financing activities Repayment of principal on notes payable to individuals and companies Proceeds from the sale of common stock (including to be issued) Proceeds from notes payable to individuals and companies Cash provided by financing activities Net increase in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest Paid Taxes Paid NON CASH ITEMS Recognition of lease liability and right of use asset at inception Conversion of notes payable and accrued interest for common stock Original issue discount on notes payable and debentures Recognition of debt discount Reclassification of other comprehensive income to additional paid in capital Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Inventory Disclosure [Abstract] Inventory Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Property, Plant and Equipment [Abstract] Property and Equipment Leases [Abstract] Operating Lease Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Notes Payable Related Party Transactions [Abstract] Related Parties Equity [Abstract] Stockholders' Equity (Deficit) Income Tax Disclosure [Abstract] Provision for Income Taxes Investments, Debt and Equity Securities [Abstract] Investments Fair Value Disclosures [Abstract] Fair Value Measurements Risks and Uncertainties [Abstract] Concentrations Subsequent Events [Abstract] Subsequent Events Condensed Consolidated Financial Statements Revenue Recognition Sales Refunds Use of Estimates Cash Equivalents Investment in Trading Securities Investment - Cost Method Inventory Property and Equipment Intangible Assets Net Income (Loss) Per Common Share Stock-Based Compensation Reclassifications Impairment of Long-Lived Assets Research and Development Fair Value Measurements Share Settled Debt Income Taxes Recent Accounting Pronouncements Subsequent Events Schedule of Inventory Summary of Discontinued Operations Schedule of Property and Equipment Schedule of Maturity of Operating Lease Liability Schedule of Operating Lease Cost Schedule of Operating Lease Liability Schedule of Notes Payable and Convertible Notes Schedule of Warrants Activity Schedule of Stock Options Activity Schedule of Effective Income Tax Rate Schedule of Deferred Tax Assets Schedule of Investment in Trading Securities Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Retail price, per unit Payment received from delivery of product Restricted common stock issued during period One time cash payment Cash stipend Cash stipend paid Number of shares expensed Term of contract Commission earned, percentage Shares issued price per share Initial purchase order Reverse stock split, description Reverse stock split, shares Reduction in outstanding shares Debt conversion Percentage of membership interest Investment Percentage of membership interest sold Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period Percentage of net profit generated Contingent liability Restricted common stock issued during period, value Variable annual fee, percentage Lease expiration date Lease, description Lease, term of contract Monthly rent payments Sales revenue Accounts receivable Gross profit Working capital Marketable securities Revenue from discontinued operations Refund to customers Cash FDIC insured amount Ownership interest percentage Deposits Research and development costs Deposits Total Inventory Depreciation expense Loss on disposal Property and equipment gross Less: accumulated depreciation Net Property and equipment estimated life Right of use asset Lease liability Debt discount rate Lease term Lease expense Unamortized lease right of use asset Amortization of right of lease asset 2020 2021 2022 Total lease payments Lease interest cost Total Lease cost Discounted Operating Lease liability Financing cost Less lease payments made Cumulative effect of adoption of ASC 842 Operating lease liability Less Lease Liability current portion Lease Liability - long-term Membership interest percentage Extinguishment of contingent liability Number of shares issued from common stock for conversion of debt, shares Debt conversion, description Conversion of convertible debt, amount Conversion of convertible debt, accrued interest Average conversion price per share Interest expense Total notes payable and convertible notes Less - note discounts Less - current portion of these notes Total notes payable and convertible notes, net discounts - long-term Debt principal amount Debt instrument, interest rate Debt maturity date description Proceeds from notes payable Accrued interest Gain on extinguishment of debt Debt Instrument term Percentage of share price multiplied by the lowest closing price Beneficial conversion feature debt discount Default interest rate Debt instrument redemption, description Original issue of discount Conversion of convertible debt, shares Notes maturity date Gross proceeds from convertible debt Number of common stock shares issued Number of common stock issued Cashless warrants Warrant term Debt principal amount cancelled Funded amount Cash collected related party sales Due to related party Common stock authorized Common stock, shares issued Number of shares issued from common stock for conversion of debt Accrued interest Number of common stock shares issued for service Number of common stock shares issued for debt commitment Number of common stock issued for debt commitment Stock issued during period, per share Share-based compensation expense Number of warrants expired Debt term Debt instruments interest rate Warrant exercise price per share Warrant cancelled Warrants shares awarded Options to purchase common shares Shares, Outstanding, Beginning balance Shares, Granted Shares, Expired Shares, Exercised Shares, Cancelled Shares, Outstanding and exercisable, Ending balance Weighted Average Exercise Price, Outstanding, Beginning balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Outstanding and exercisable, Ending balance Weighted Average Remaining Contractual Term, Outstanding, Beginning Weighted Average Remaining Contractual Term, Outstanding and exercisable, Ending Aggregate Intrinsic Value, Outstanding Beginning Aggregate Intrinsic Value, Outstanding and exercisable, Ending Number of Options, Outstanding, Beginning balance Number of Options, Granted Number of Options, Expired Number of Options, Exercised Number of Options, Outstanding, Ending balance Number of Options, Outstanding and exercisable, Ending balance Weighted Average Exercise Price, Outstanding, Beginning balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Outstanding, Ending balance Weighted Average Exercise Price, Outstanding and exercisable, Ending balance Weighted Average Remaining Contractual Term Outstanding, Beginning Weighted Average Remaining Contractual Term Outstanding, Ending Weighted Average Remaining Contractual Term Outstanding and exercisable , Ending Aggregate Intrinsic Value Outstanding, Beginning Aggregate Intrinsic Value Outstanding, Ending Aggregate Intrinsic Value Outstanding and exercisable, Ending Net operating loss carryforward Net operating loss carryforward, expiration year Increase (decrease) in valuation allowance Income tax examination description Federal tax rate Untaxed earnings and profit tax rate Tax rate on remaining balance Federal income taxes at statutory rate State income taxes at statutory rate Temporary differences Permanent differences Impact of Tax Reform Act Change in valuation allowance Totals Deferred tax assets: Net operating losses before non-deductible items Deferred tax assets: Loss on disposal of fixed assets Deferred tax assets: Stock-based compensation Deferred tax assets: Unrealized gains or losses on investments Total deferred tax assets Less: Valuation allowance Net deferred tax assets Warrants purchase of common shares Warrants strike price Warrants expired date Reverse stock split Cumulative purchase amount Purchase of units Purchase of units, price per share Sale of units Conversion into BTC Sale of units value Conversion of BTC Conversion of gold and silver commodities Loss on transaction Unrealized loss on digital currency exchange Investment - digital currency Investment amount Cost investments Pre- money valuation amount Investment of cost at beginning Investment of purchase Investment of sales proceeds Investment of cost at end Investment of fair value Investment of realized gain (loss) Investment of unrealized gain (loss) Investment unrealized gain (loss) Proceeds from investment Investment cost Investment realized gain (loss) Comprehensive gain Number of common stock shares purchased Additional number of common stock purchased Fair value of investment Number of common stock shares purchased value Share issued price per share Number of common stock sold shares Sale of stock price per share Investment of cost net Participated in underwritten public offering amount Sale of warrants purchased Sale of warrant purchased value Fair Value Hierarchy and NAV [Axis] Investment-trading securities Cost method investments Concentration of risk percentage Number of shares issued for debt commitment Debt instrument face amount Original issue discount Debt instrument interest rate Debt instrument term Shares issued, price per share Legal fees Original issue discount deducted from proceeds Proceeds from issuance of convertible debt Common stock reserved for issuance Debt payment terms, description Debt interest rate upon default Notes payable Debt instrument, description AYTU Bioscience [Member] Achieve Life Sciences (ACHV) [Member] Axovant Sciences Ltd AXON [Member] Aytu BioScience Inc (AYTU) [Member] Balance Sheet Cash [Member] Basanite Inc. (BASA) [Member] Basanite Industries Inc. (BASA) [Member] Blink Charging Co (BLNK) [Member] Blink Charging Co (BLNKW) (Warrants) [Member] Common Stock One [Member] Company [Member] Computers, Office Furniture and Other Equipment [Member] Consultant [Member] Consulting Agreements [Member] Conversion of notes payable and accrued interest for common stock. Convertible Note [Member] Convertible Notes [Member] Debt Conversion Agreement [Member] Conversion of convertible debt, accrued interest. Decision Diagnostics (DECN) [Member] Eishin, Inc [Member] Executives [Member] Fiscal Year 2019 [Member] GS Capital Partners LLC [Member] Green Innovations Ltd [Member] Groestlcoin [Member] Honeywood Conversion Agreement [Member] Honeywood LLC [Member] Honeywood [Member] Ice + Jam LLC [Member] Investment - digital currency. Kudzoo, Inc. [Member] Kudzoo [Member] Lightbridge Corp. (LTBR) [Member] Non-Convertible Debenture [Member] Note Holders [Member] Total notes payable and convertible notes, net discounts. One Current Executive [Member] One Former Executive [Member] Open Therapeutics [Member] Ownership [Member] Percentage of net profit generated. Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period. Pulmatix Inc PULM [Member] Pulmatrix Inc PULM [Member] Purchase of digital currency. Recognition of debt discount. Reduction in outstanding shares. Restricted Common Stock [Member] Securities Purchase Agreement [Member] Serendipity Brands LLC [Member] Serendipity Brands [Member] Stock Purchase Agreements [Member] Transfer Agreement [Member] Unrealized gain (loss) on digital currency. Unrealized loss on digital currency. VistaGen Therapeutics, Inc [Member] Warrants [Member] Liability for common stock to be issued. Contribution into Ice + Jam. Original issue discount on notes payable and debentures. Shares issued for note conversion per share, value. Shares issued for settlement of debt. Shares issued for settlement of debt, shares. Non-controlling interest adjustment. Shares issued for settlement of contingent liability. Shares issued for settlement of contingent liability, shares, Reclassification of other comprehensive income to additional paid in capital. Recognition of beneficial conversion feature of convertible notes. Equity issuance price of note conversion. Equity issuance price to services. Equity issuance price to private placement. Share Settled Debt [Policy Text Block] Retail price, per unit. E&M Distribution Agreement [Member] South Florida Region Distribution Agreement [Member] Cash stipend. North Eastern United States Distribution Agreement [Member] Ice+Jam, LLC [Member] Tauri-GumTM [Member] Mr. Mahesh Lekkala [Member] Within Ten (10) Business Days of April 30, 2019 [Member] Sai Krishna LLC (SKL) [Member] Within Ten (10) Business Days of August 1, 2019 [Member] Number of shares expensed. One Year Agreement [Member] SKL Distribution Agreement [Member] Ms. Neelima Lekkala [Member] Commission earned, percentage. GS Capital Partners, LLC - March 2019 [Member] Debt principal amount cancelled. Cashless warrants. Common Stock Two [Member] Equity Issuance Per Share Amount One. Warrant cancelled. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Net operating loss carryforward, expiration year. Untaxed earnings and profit tax rate. Tax rate on remaining balance. Impact of Tax Reform Act. Deferred tax assets: Loss on disposal of fixed assets. Deferred tax assets Unrealized gains or losses on investments. Cumulative purchase amount. Purchase of units. Purchase of units, price per share. Loss on exchange from BTC. Unrealized loss on digital currency exchange. Sale of units. Conversion of cryptocurrency into BTC. Sale of units value. Conversion of BTC into gold bullion and silver coins. Conversion of gold and silver commodities. Loss on transaction. Pre- money valuation amount. Number of common stock shares purchased. Additional number of common stock purchased. Number of common stock shares purchased Value. Participated in underwritten public offering amount. Sale of warrants purchased. Sale of warrant purchased value. One Supplier [Member] Sales Revenue [Member] One Customer [Member] Distribution Agreements [Member] GS Capital Note [Member] Reclassification of other comprehensive income to additional paid in capital. Equity issuance of commitment shares for debt financing. Payment received from delivery of product. One time cash payment. Cash stipend paid. Euro [Member] Recognition of lease liability and right of use asset at inception. Windmill Health Distribution Agreement [Member] Initial purchase order. Variable annual fee, percentage. Working capital. Unamortized lease right of use asset. Amortization of lease right of use asset. Lease interest cost. Cumulative effect of adoption of ASC 842. Discounted operating lease liability. Financing cost. Extinguishment of contingent liability. Alternative Strategy Partners PTE Ltd [Member] GS Capital Partners LLC - Oct 2018 [Member] GS Capital Partners LLC - May 2019 [Member] GS Capital Partners LLC - June 2019 [Member] Default interest rate. Convertible Debenture [Member] Jefferson Street Capital, LLC [Member] Fiscal Year 2020 [Member] Number of common stock shares issued for debt commitment. StockIssuedDuringPeriodSharesIssuedForDebtCommitment. Accredited Investors [Member] Number of options outstanding and exercisable, including both vested and non-vested options. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Aggregate Intrinsic Value Outstanding and exercisable. Number of equity instruments other than options outstanding and exercisable, including both vested and non-vested instruments. Weighted average exercise price, outstanding. Weighted average exercise price, outstanding and exercisable. Weighted average exercise price, granted. Weighted average exercise price, expired. Weighted average exercise price, exercised Weighted average exercise price, cancelled Weighted average remaining contractual term. Weighted average remaining contractual term. Aggregate intrinsic value. Aggregate intrinsic value. Original issue discount deducted from proceeds. Upon Increase Of Authorized Common Shares [Member] Cumulative affect of adoption of Lease standard, Equity issuance price issuance for settlement of contingent liability. Equity issuance price issuance for settlement of debt. Condensed consolidated financial statements [Policy Text Block] Sales refunds [Policy Text Block] Number of warrants expired. New York Corporate Office Lease [Member] Barcelona Office Lease [Member] Non-cash lease operating lease expense. (Gain) loss on sale of trading securities. Second Back-End Note [Member] Adar Alef, LLC [Member] 8% Convertible Redeemable Notes [Member] 8% Convertible Redeemable Note One [Member] 8% Convertible Redeemable Note Two [Member] WarrantsMember Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Accretion (Amortization) of Discounts and Premiums, Investments NoncashLeaseOperatingLeaseExpense UnrealizedLossOnDigitalCurrency Debt and Equity Securities, Gain (Loss) GainLossOnSaleOfTradingSecurities Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Debt Securities, Trading Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Interest Payable, Net Net Cash Provided by (Used in) Operating Activities PurchaseOfDigitalCurrency Payments for (Proceeds from) Investments Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations ReclassificationOfOtherComprehensiveIncomeLossToAdditionalPaidInCapital Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Accounts Receivable, after Allowance for Credit Loss Deposits [Default Label] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Lessee, Operating Lease, Liability, Payments, Due Operating Lease, Cost Operating Lease, Payments Debt Instrument, Unamortized Discount, Current Interest Payable Debt Instrument, Increase, Accrued Interest Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue Effective Income Tax Rate Reconciliation, Deduction, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net EX-101.PRE 15 taug-20190630_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information - shares
 3 Months Ended
Jun. 30, 2019
Aug. 13, 2019
Document And Entity Information    
Entity Registrant Name TAURIGA SCIENCES, INC.  
Entity Central Index Key 0001142790  
Document Type 10-Q  
Document Period End Date Jun. 30, 2019  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Entity Reporting Status Current Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   76,145,090
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2020  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Current assets:    
Cash $ 15,247 $ 385,943
Assets from discontinued operations 581
Accounts receivable 28,028
Investment - trading securities 444,785 350,400
Investment - other 92,900 72,500
Inventory asset 138,606 10,872
Prepaid expenses and other current assets 85,675 127,520
Total current assets 805,241 947,816
Lease right of use asset 9,071
Property and equipment, net 12,778 13,010
Total assets 827,090 960,826
Current liabilities:    
Notes payable, net of discounts 235,420 213,875
Accounts payable 27,168 34,703
Accrued interest 16,946 30,780
Accrued expenses 18,588
Liabilities from discontinued operations 5,522
Liability for common stock to be issued 172,500
Lease liability - current portion 7,300
Deferred revenue 162
Total current liabilities 305,584 457,380
Lease liability - net of current portion 2,171
Total liabilities 307,755 457,380
Stockholders' equity (deficit):    
Common stock, par value $0.00001; 100,000,000 shares authorized, 72,925,920 and 68,123,326 outstanding at June 30, 2019 and March 31, 2019, respectively 729 681
Additional paid-in capital 56,665,512 55,991,704
Accumulated deficit (56,146,906) (55,488,939)
Accumulated other comprehensive income
Total stockholders' equity (deficit) 519,335 503,446
Total liabilities and stockholders' equity (deficit) $ 827,090 $ 960,826
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2019
Mar. 31, 2019
Jul. 08, 2018
Statement of Financial Position [Abstract]      
Common stock, par value $ 0.00001 $ 0.00001  
Common stock, shares authorized 100,000,000 100,000,000 7,500,000,000
Common stock, shares outstanding 72,925,920 68,123,326  
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Income Statement [Abstract]    
Revenues $ 44,377
Cost of goods sold 29,418
Gross profit 14,959
Operating expenses    
Marketing and advertising 130,548
Research and development 3,852
General and administrative 628,841 222,038
Depreciation and amortization expense 232 259
Total operating expenses 763,473 222,297
Loss from operations (748,514) (222,297)
Other income (expense)    
Interest expense (121,814) (23,496)
Unrealized gain on trading securities 94,385 78,170
Gain on the extinguishment of debt 113,467
Gain on disposal of discontinued operations 4,941
Loss on exchange from bitcoin (37)
Unrealized loss on digital currency (5,572)
Gain (loss) on sale of trading securities 340,020
Foreign exchange (29)
Total other income (expense) 90,950 389,085
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND LOSS FROM DISCONTINUED OPERATIONS (657,564) 166,788
INCOME (LOSS) FROM DISCONTINUED OPERATIONS
Net income (loss) (657,564) 166,788
Net income (loss) attributable to non-controlling interest
Net income (loss) attributable to controlling interest (657,564) 166,788
Net income (loss) attributable to common shareholders $ (657,564) $ 166,788
Income (loss) per share - basic and diluted - Continuing operations $ (0.012) $ 0.003
Income (loss) per share - basic and diluted - Discontinuing operations
Weighted average number of shares outstanding - basic 55,767,119 53,662,728
Income (loss) per share - fully diluted $ (0.012) $ 0.003
Weighted average number of shares outstanding - fully diluted 55,767,119 59,359,187
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Non-Controlling Interest [Member]
Total
Balance at Mar. 31, 2018 $ 523 $ 54,680,382 $ (54,391,500) $ 8,042 $ (2,196) $ 295,251
Balance, shares at Mar. 31, 2018 52,264,476          
Shares issued for note conversion $ 20 57,319 57,339
Shares issued for note conversion, shares 1,985,754          
Stock-based compensation vesting 43,221 43,221
Stock issued for services $ 1 (1)
Stock issued for services, shares 130,000          
Reclassification of other comprehensive income to additional paid in capital 8,042 (8,042)
Net loss 166,788 166,788
Balance at Jun. 30, 2018 $ 544 54,788,963 (54,224,712) (2,196) 562,599
Balance, shares at Jun. 30, 2018 54,380,230          
Balance at Mar. 31, 2018 $ 523 54,680,382 (54,391,500) 8,042 (2,196) 295,251
Balance, shares at Mar. 31, 2018 52,264,476          
Balance at Mar. 31, 2019 $ 681 55,991,704 (55,488,939) 503,446
Balance, shares at Mar. 31, 2019 68,123,326          
Balance at Jun. 30, 2018 $ 544 54,788,963 (54,224,712) (2,196) 562,599
Balance, shares at Jun. 30, 2018 54,380,230          
Stock-based compensation vesting 132,055 132,055
Net loss (265,552) (265,552)
Balance at Sep. 30, 2018 $ 544 54,921,018 (54,490,264) (2,196) 429,102
Balance, shares at Sep. 30, 2018 54,380,230          
Shares issued for note conversion $ 10 24,490 24,500
Shares issued for note conversion, shares 1,000,000          
Stock-based compensation vesting 11,769 11,769
Stock issued for services $ 18 (18)
Stock issued for services, shares 1,750,000          
Net loss (377,982) (377,982)
Balance at Dec. 31, 2018 $ 572 54,957,259 (54,868,246) (2,196) 87,389
Balance, shares at Dec. 31, 2018 57,130,230          
Shares issued for note conversion $ 30 118,849 118,879
Shares issued for note conversion, shares 2,960,762          
Stock-based compensation vesting 109,660 109,660
Stock issued for services $ 12 (12)
Stock issued for services, shares 1,250,000          
Issuance of shares via private placement $ 56 301,144 301,200
Issuance of shares via private placement, shares 5,686,667          
Issuances of commitment shares - debt financing $ 5 20,995 21,000
Issuances of commitment shares - debt financing, shares 500,000          
Shares issued for settlement of contingent liability at $0.0405 $ 5 74,995 75,000
Shares issued for settlement of contingent liability at $0.0405, shares 500,000          
Shares issued for settlement of debt $ 1 20,003 20,004
Shares issued for settlement of debt, shares 95,667          
Recognition of beneficial conversion feature of convertible notes 388,811 388,811
Non-controlling interest 2,196 2,196
Net loss (620,693) (620,693)
Balance at Mar. 31, 2019 $ 681 55,991,704 (55,488,939) 503,446
Balance, shares at Mar. 31, 2019 68,123,326          
Shares issued for note conversion $ 9 41,964 41,973
Shares issued for note conversion, shares 888,308          
Stock-based compensation vesting 375,720 375,720
Stock issued for services $ 24 (24)
Stock issued for services, shares 2,450,000          
Reclassification of other comprehensive income to additional paid in capital          
Issuance of shares via private placement $ 7 44,993 45,000
Issuance of shares via private placement, shares 714,286          
Issuances of commitment shares - debt financing $ 8 142,492 142,500
Issuances of commitment shares - debt financing, shares 750,000          
Shares issued for settlement of debt
Shares issued for settlement of debt, shares          
Recognition of beneficial conversion feature of convertible notes 68,663 68,663
Cumulative affect of adoption of Lease standard ASC 842 (403) (403)
Net loss (657,564) (657,564)
Balance at Jun. 30, 2019 $ 729 $ 56,665,512 $ (56,146,906) $ 519,335
Balance, shares at Jun. 30, 2019 72,925,920          
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Equity issuance price of note conversion $ 0.04725   $ 0.0245 $ 0.002888
Equity issuance price to services   $ 0.0495 $ 0.0269  
Equity issuance of commitment shares for debt financing 0.19 0.042    
Equity issuance price issuance for settlement of contingent liability   0.0405    
Equity issuance price issuance for settlement of debt   0.2091    
Minimum [Member]        
Equity issuance price of note conversion   0.0357    
Equity issuance price to services 0.07     0.345
Equity issuance price to private placement 0.06 0.02    
Maximum [Member]        
Equity issuance price of note conversion   0.0452    
Equity issuance price to services 0.16     $ 0.42
Equity issuance price to private placement $ 0.07 $ 0.06    
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Apr. 02, 2019
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2019
Cash flows from operating activities        
Net income (loss)   $ (657,564) $ 166,788  
Adjustments to reconcile net loss to cash used in operating activities:        
Amortization of original issue discount   8,673 3,561  
Non-cash lease operating lease expense   (3)  
Unrealized loss on digital currency   5,572  
Depreciation and amortization   232 259  
Gain on extinguishment of debt   (113,468)  
Amortization of debt discount   101,535  
Common stock issued and issuable for services (including stock-based compensation)   375,720 43,221  
Gain on disposal of discontinued operation $ (4,941) (4,941)  
(Gain) loss on sale of trading securities   (339,810)  
Unrealized gain on trading securities   (94,385) (78,170) $ (223,349)
(Increase) decrease in assets        
Prepaid expenses   41,845 31,450  
Inventory   (127,734)  
Proceeds (purchase) of trading securities, net   128,983  
Accounts receivable   (28,028)  
Increase (decrease) in liabilities        
Accounts payable   (7,535) 22,224  
Deferred revenue   162  
Accrued expenses   18,588 12,134  
Accrued interest   11,607 19,906  
Cash used in operating activities   (475,296) 16,118  
Cash flows from investing activities        
Contribution into Ice + Jam    
Proceeds (purchase) of digital currency, net   (7,831)  
Investment - other   (20,400)  
Purchase of property and equipment   (10,086)  
Cash provided by (used in) investing activities   (20,400) (17,917)  
Cash flows from financing activities        
Repayment of principal on notes payable to individuals and companies    
Proceeds from the sale of common stock (including to be issued)   15,000  
Proceeds from notes payable to individuals and companies   110,000 25,000  
Cash provided by financing activities   125,000 25,000  
Net increase in cash   (370,696) 23,201  
Cash, beginning of period $ 385,943 385,943 12,291 12,291
Cash, end of period   15,247 35,492 $ 385,943
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Interest Paid    
Taxes Paid    
NON CASH ITEMS        
Recognition of lease liability and right of use asset at inception   12,066  
Conversion of notes payable and accrued interest for common stock   41,973 200,718  
Original issue discount on notes payable and debentures   10,000  
Recognition of debt discount   68,663  
Reclassification of other comprehensive income to additional paid in capital   $ 8,042  
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Operations
 3 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Operations

NOTE 1 – BASIS OF OPERATIONS

 

The unaudited condensed consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain certain information included in the Company’s annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the March 31, 2019 Form 10-K filed with the SEC, including the audited consolidated financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these condensed consolidated financial statements are reasonable, the accuracy of the amounts is in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company later in the year.

 

These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary to present fairly the operations and cash flows for the periods presented.

 

Nature of Business

 

Tauriga Sciences, Inc. (the “Company”) is a Florida corporation. The Company has, over time, moved into that of a diversified life sciences technology company, with its mission to operate a revenue generating business, while continuing to evaluate potential acquisition candidates operating in the life sciences technology space.

 

TAURI-GUMTM

 

In October 2018, the Company’s management, along with its board of directors, began to explore the possibility of launching a cannabidiol (“CBD”) infused gum product line into the commercial marketplace. After several weeks of diligence, discussions with various parties and exploratory meetings, the Company made the determination to move forward with this business opportunity.

 

To begin this process, during the quarter ended December 31, 2018, the Company began discussions with a Maryland based chewing gum manufacturer - Per Os Biosciences LLC (“Per Os Bio”), which consummated in a manufacturing agreement in late December 2018 to launch and bring to market a white label line of CBD infused chewing gum under the brand name Tauri-Gum™. We have filed for trademark protection with the United States Patent and Trademark Office for our CBD infused chewing product line, including applications filed in April 2019 for TAURI-GUMMITM and TAURI-GUMMIESTM.

 

Under the terms of the agreement, Per Os Bio has committed to produce the Tauri-GumTM based on the following criteria:

 

  A. By composition, the CBD Gum will contain 10 mg of CBD Isolate
  B. The initial production run will be mint flavor exclusively
  C. This proprietary CBD Gum will be manufactured under U.S. Patent # 9,744,128 (“Method for manufacturing medicated chewing gum without cooling”)
  D. Each Production Batch, including the initial production run, is estimated to yield 70,000 gum tablets or 8,700 Units (each Unit contains 8 gum tablets).
  E. Integrated Quality Control Procedures: Each production batch will be tested by a 3rd Party for CBD label content, THC content (0%), and clear for microbiology.
  F. The packaging, for retail marketplace, will consist of 8 count (gum tablet count) blister card labeled (the “Pack(s)”) with Lot # as well as Expiration Date.
  G. Outer sleeve in the Company’s artwork and graphic design(s) and label copy
  H. Shipping System: Bulk packed 266 Packs per master case (“Palletized”)

 

Under terms of the Agreement, the Company has committed to provide the following to Per Os Bio:

 

  A. Each product order will consist of exactly 8,700 Packs (unless otherwise agreed upon by both parties).
  B. ½ of initial production invoice due within 3 days of execution of Manufacturing Agreement (this has already been paid by the Company).
  C. Provide graphic design artwork, logo, and label design to Per Os Bio.
  D. Trademark has been successfully filed with U.S.P.T.O.
  E. To implement Kosher Certification Process
  F. Procure appropriate Product & Liability insurance policy
  G. Acquire legal opinion with respect to the confirmation of the legality to sell this CBD Gum – on the Federal Statute Level.

 

The Company gum formulation includes distinctive features: allergen free, gluten free, vegan, kosher (K-Star certification), and incorporates a proprietary manufacturing process. See our “Risk Factors” contained in this Annual Report, including with respect, but not limited, to Federal laws and regulations that govern CBD and cannabis.

 

The Company E-commerce website is www.taurigum.com. The Company has also secured storage space near its New York City headquarters.

 

During the first quarter of fiscal year 2020, the Company began production of Blood Orange flavor of Tauri-GumTM. The Company plans to offer Pomegranate flavored Tauri-GumTM in the near term, which will be in addition to their mint and blood orange flavored products.

 

On April 9, 2019, the Company announced that it is developing a special miniaturized version of Tauri-GumTM for sale at airport retail stores. The Company envisions this Airport version consisting of a miniaturized blister pack (containing three pieces of its CBD Infused gum), with an anticipated retail price of $6.99 per unit.

 

The Company is also working on developing CBD Gum-Infused Lollipops and gummi products.

 

Tauri-GumTM Distribution Agreements

 

E&M Ice Cream Company

 

On April 1, 2019, the Company entered into a comprehensive distribution agreement with E&M Ice Cream Company (“E&M”) to establish Tauri-GumTM in the marketplace (the “E&M Distribution Agreement”). The Company has supported the Tauri-GumTM commercial launch with substantial levels of both financial resources and marketing support. The Company had both received payment for and delivered the product for its previously announced $54,000 Tauri-GumTM purchase order during March 2019, and re-orders in the first quarter of fiscal 2020. The Company has agreed to issue a one-time issuance of 1,000,000 restricted shares of the Company’s common stock, and to tender a one-time cash payment of $125,000 to E&M. This $125,000 cash component was paid in full to E&M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. The Company is awaiting issuance instructions from E&M to issue the shares

 

South Florida Region Distribution Agreement

 

On April 8, 2019, the Company entered into a non-exclusive distribution agreement with IRM Management Corporation (“IRM”), an established medical practice management firm (the “IRM Distribution Agreement”). The purpose of the IRM Distribution Agreement is to target our Tauri-Gum™ product to the South Florida based medical market, including chiropractors, orthopedists, as well as prospective retail customers in this geographic area.

 

Under terms of this IRM Distribution Agreement, the Company will work closely with IRM to promote Tauri-Gum™. In connection with this IRM Distribution Agreement, the Company has also agreed to a one-time issuance of 450,000 shares of the Company’s restricted common stock and a cash stipend of $10,000 to IRM. As of the date of this report, only $2,000 of the $10,000 cash stipend has been paid. The value of the shares will be reflected in stock-based compensation based on the grant date of April 8, 2019.

 

North Eastern United States Distribution Agreement

 

On April 30, 2019, the Company, entered into a non-exclusive comprehensive distribution agreement with Sai Krishna LLC (“SKL”), a New Jersey based distributor, with relationships in the Northeast region of the United States and Asia, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line in the applicable regions.

 

In connection with the SKL Agreement, the Company has agreed to issue a one-time issuance of an aggregate of 1,000,000 restricted common shares the Company’s stock, which are subject to the customary resale and transfer restrictions imposed under the rules and regulations of the Securities and Exchange Commission. The restricted equity issuance to SKL was issued in accordance with the following schedule: (i) to Mr. Mahesh Lekkala, 500,000 restricted shares the Company’s common stock within ten (10) business days of April 30, 2019; and (ii) to SKL, 500,000, which were permitted to be immediately allocated by SKL to persons within its organization and, as such, (a) 250,000 of such shares shall be issued to SKL within ten (10) business days of April 30, 2019, and the additional issuance of (b) 250,000 of such shares shall be issued to SKL within ten (10) business days of August 1, 2019, which shares were issued on August 1, 2019. Other than the payment terms for Tauri-GumTM product purchased and distributed under the terms of the Agreement, there is no additional cash payment currently due or owing by the Company thereunder. The value of the shares is reflected as stock-based compensation with a grant date of April 30, 2019. All but 250,000 shares are expensed on this date, with those 250,000 shares valued over the term of the one-year agreement.

 

On May 11, 2019, the Company entered into a sub-agreement pursuant to the SKL distribution agreement whereby Ms. Neelima Lekkala was appointed Vice President of Distribution & Marketing. This contract has a one-year term and is and may be extended based upon mutual agreement. Ms. Lekkala shall focus her efforts on the expansion of Tauri-GumTM as well as revenue growth, acquisition of new customers, establishment of professional marketing materials & protocols, logistics improvement(s) and fulfillment services. Ms. Lekkala is deeded a non-affiliate and does not carry any type of fiduciary liability. Ms. Lekkala’s compensation includes 250,000 shares of the Company’s restricted common stock deemed fully earned and vested upon the execution of her consulting agreement. These shares were issued May 20, 2019, having a value of $18,275 based on the closing price of the Company’s stock on that day ($0.0731 per share). Additionally, Ms. Lekkala will receive a 30% commission on total gross sales through the sale of the Tauri-GumTM product line which can be paid in either stock or cash at the election of Ms. Lekkala.

 

Windmill Health Distribution Agreement

 

On June 28, 2019, the Company entered into a distribution agreement with Windmill Health Products, LLC (“Windmill Health”), a New Jersey based distributor, with the intention of increasing and accelerating market penetration of the Company’s Tauri-GumTM product line. Simultaneous with the Company’s entry into the Windmill Health agreement, Windmill Health placed an initial purchase order with us totaling $46,848, split evenly between packages of the Mint flavored and Blood-Orange flavored chewing gum product lines. The Company did not contribute any capital or issue any equity to Windmill Health in connection with the Windmill Health distribution agreement

 

Food and Drug Administration

 

On May 31, 2019, the U. S. Food and Drug Administration (“FDA”) held public hearings to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The hearing came approximately five months after the Agricultural Improvement Act of 2018 (more commonly known as the Farm Bill), went into effect and removed industrial hemp from the Schedule I prohibition under the Controlled Substances Act (CSA) (industrial hemp means cannabis plants and derivatives that contain no more than 0.3 percent tetrahydrocannabinol, or THC, on a dry weight basis).

 

Though the Farm Bill removed industrial hemp from the Schedule I list, the Farm Bill preserved the regulatory authority of the FDA over cannabis and cannabis-derived compounds used in food and pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act. The FDA has been clear that it intends to use this authority to regulate cannabis and cannabis-derived products, including CBD, in the same manner as any other food or drug ingredient. In addition to holding the hearing, the agency had requested comments by July 2, 2019 regarding any health and safety risks of CBD use, and how products containing CBD are currently produced and marketed, which comment period was then extended by two weeks following July 2nd.

 

2019 Increase in Authorized Shares

 

On July 26, 2019, the Company held a meeting of its board of directors. The matters voted on and approved at the meeting included an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock, $0.00001 par value per share from 100,000,000 to 400,000,000 shares (the “Authorized Shares Increase”). In this regard, a Preliminary Proxy Statement which was filed with the Securities and Exchange Commission on July 29, 2019.

 

2018 Reverse Stock Split

 

On July 8, 2018, the Company implemented a Reverse Stock Split with a ratio of 1-for-75 (which became effective July 9, 2018). The par value and other terms of the common stock were not affected by the Reverse Stock Split. In addition, the amendment to the Company’s articles of incorporation that effected the Reverse Stock Split simultaneously reduced the number of authorized shares of Common Stock from 7,500,000,000 to 100,000,000.

 

The Reverse Stock Split affected all issued and outstanding shares of common stock, as well as common stock underlying stock options, warrants and other convertible securities outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split has reduced the number of outstanding shares of the common stock outstanding prior to the Reverse Stock Split from 4,078,179,672 shares to 54,380,230 shares immediately following the Reverse Stock Split. No fractional shares were issued as a result of the Reverse Stock Split, and any such stockholders whose number of post-split shares would have resulted in a fractional number had his/her/its shares rounded up to the next number of shares. On July 30, 2018, the Company’s stock began trading on the OTC:QB.

 

All references set forth in this annual report to number of shares or per share data have been presented on a post reverse stock-split basis.

 

Cupuaçu Butter Lip Balm

 

On December 23, 2016, the Company entered into a non-exclusive, 12-month license agreement (the “License Agreement”) with Cleveland, Ohio based cosmetics products company Ice + Jam LLC (“Ice + Jam”) to market Ice + Jam’s proprietary cupuaçu butter lip balm, sold under the trademark HerMan® which launched during the quarter ended December 31, 2017.During February of 2018, the Company’s strategy with respect to the HerMan® product was negatively impacted by a series of product defects relating to the twisting mechanism of the lip balm tube. As a result of this and the concomitant halting of selling efforts, the Company had no sales of the HerMan® product during the three months ended June 30, 2019 or the year ended March 31, 2019. The Company has removed the product from the website and the remaining inventory was written off as it was determined that the units were not usable. The Company has discontinued this operation as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.

 

Honeywood

 

Following the termination of a proposed 2014 merger between the Company and California-based Honeywood LLC (“Honeywood”), a developer of a topical medicinal cannabis product, on August 1, 2017, the Company entered into a Debt Conversion Agreement, whereby the Company agreed to convert an $170,000 note receivable due from Honeywood, including accrued interest into a 5% membership interest in Honeywood.

 

The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320-10-35-28, “Investments—Debt and Equity Securities”, a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: a) the investment experiences a recovery of fair value up to (or beyond) its cost; or b) the entity recognizes an other-than-temporary impairment loss. At the time of the Honeywood Conversion Agreement, the receivable balance under the note of $199,119 had been fully written off by the Company in a prior period. As a result of the Honeywood Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this period.

 

Pilus Energy

 

On January 28, 2014, the Company acquired Pilus Energy, LLC (“Pilus”), an Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that create electricity while consuming polluting molecules from wastewater.

 

On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus back to Open Therapeutics for consideration of the termination of 80% of the unexercised portion of the warrants to purchase the Company’s common stock. Open Therapeutics agreed to pay to the Company 20% of the net profit generated Pilus Energy from its previous year’s earnings, if any. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish a $75,000 contingent liability, whereby Open Therapeutics was to receive the first $75,000 of net profit earned from the operations of Pilus Energy in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share).

 

Tauriga Biz Dev Corp

 

On January 4, 2018, the Company announced that its Board of Directors unanimously approved the formation a wholly-owned subsidiary focused on acquiring interest(s) in patents and other intellectual property. This subsidiary, incorporated in Delaware, was named Tauriga IP Acquisition Corp. On March 25, 2018, the Company changed the name to Tauriga Biz Dev Corp. (“Tauriga BDC”).

 

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink Charging Co. (“Blink”) (Nasdaq: BLNK) to be a non-exclusive independent sales representative. Under the terms of this agreement with Blink, the Company is permitted to solicit orders from potential customers for electric vehicle (“EV”) charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company’s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The rest of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.

 

As of June 30, 2019, Tauriga BDC has not installed any of these machines in any locations and no revenue has been generated through the Blink contract.

 

Tauriga Sciences Limited

 

On June 10, 2019, the Company formed a wholly owned subsidiary, Tauriga Sciences Limited, with the registrar of Companies for Northern Ireland. Tauriga Sciences Limited is a private limited Company. The entity was established in conjunction with online merchant services. In conjunction to this new entity the Company entered into a two-year lease commencing on June 11, 2019 and expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).

 

Going Concern

 

During the fourth quarter of the year ended March 31, 2019, the Company began sales and marketing efforts for its Mint flavored Tauri-GumTM product. During the three months ended March 31, 2019, the Company recognized sales of $57,134 and recognized a gross profit of $20,006, which has continued into the first fiscal quarter ended June 30, 2019 where the Company recognized revenue of $44,377 and a gross profit of $14,959. During the first quarter of fiscal year 2020, the Company has entered into multiple distribution agreements and has engaged an independent contractor to act as Vice President of Distribution and Marketing. Although the Company’s working capital surplus of $499,657 at June 30, 2019, has remained constant in the past year, the Company still believes that there is uncertainty with respect to continuing as a going concern.

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

The Company, in the short term, intends to continue funding its operations either through cash-on-hand or through financing alternatives. Management’s plans with respect to this include raising capital through equity markets to fund future operations as well as the possible sale of its remaining marketable securities which had a market value of $444,785 at June 30, 2019. In the event the Company cannot raise additional capital to fund and/or expand operations or fails to raise adequate capital and generate adequate sales revenue, it could result in the Company having to curtail or cease operations. Currently, the Company has a limited amount of shares of common stock available to issue under its articles of incorporation and has initiated the process of increasing the authorized stock.

 

Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues in the short term there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations to achieve profitability thereby eliminating its reliance on alternative sources of funding. Although management believes that the Company is in a stronger position it has been in in several years, there is still no guarantee that profitable operations with sufficient cashflow to sustain operations can or will be achieved without the need of alternative financing, which is limited. These matters still raise significant doubt about the Company’s ability to continue as a going concern as determined by management. The Company believes that there is uncertainty with respect to continuing as a going concern until the operating business can achieve more than nominal sales and profitable operations and sustain cash flow to operate the Company for a period of twelve months. In the event the Company does need to raise additional capital to fund operations or engage in a transaction, failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreements or ownership interests in life science companies and generate adequate revenues, or the agreements entered into recently are unsuccessful, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern as determined by management. However, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies
 3 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Condensed Consolidated Financial Statements

 

The condensed consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga BDC and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of June 30, 2019, there is no activity in any of the Company’s subsidiaries other than Tauriga BDC holding the electric car chargers and the leasehold interest in Tauriga Sciences Limited.

  

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of HerMan® using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company’s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.

 

As of June 30, 2019, the Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.

 

During the three months ended March 31, 2019, the Company recognized its first sales of Tauri-GumTM, primarily vis-à-vis its entry in the E&M Distribution Agreement.

 

The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company’s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized revenue from operations in the amount of $44,377 during the three months ended June 30, 2019 compared to no revenue for the same period in the prior year. All revenue is from the sale of the Company’s Tauri-GumTM product line and there were accounts receivable of $28,028 currently outstanding for these sales.

 

The Company recognized no revenue from discontinued operations during the three months ended June 30, 2018 which was related to the sales of the HERMAN® lip balm product.

 

Sales Refunds

 

The Company’s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-GumTM distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of June 30, 2019 however will monitor the refunds to estimate whether a reserve will be required.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Equivalents

 

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At June 30, 2019, the Company’s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At June 30, 2019 and March 31, 2019, the Company had a cash balance of $15,247 and $385,943, respectively. The Company’s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of June 30, 2019 and March 31, 2019.

 

Investment in Trading Securities

 

Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss.

 

For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.

 

Investment – Cost Method

 

Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of June 30, 2019, the Company has not impaired any of their cost method investments.

 

Inventory

 

Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfillment center is also included in the total inventory cost. Shipping of product upon sale for online sales is paid by the customer upon ordering for orders of single packs of Tauri-GumTM. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of June 30, 2019, the Company’s inventory on hand had a value of $138,606. The Company also has paid deposits in the amount of $52,500 to the manufacturer, Per Os Bio, towards orders not received as of June 30, 2019. Amounts paid to Per Os Bio for Tauri-GumTM are classified as deposits (other current asset) on the Company’s condensed consolidated balance sheet until the goods are available for sale. The Company has not established any inventory reserve on the Tauri-GumTM as of June 30, 2019.

 

Property and Equipment

 

Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

 

Intangible Assets

 

Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.

 

Net Income (Loss) Per Common Share

 

The Company computes per share amounts in accordance with FASB ASC Topic 260 “Earnings per Share” (“EPS”), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the three months ended June 30, 2019, basic and fully diluted earnings per share were the same as the Company had losses in this period.

 

Stock-Based Compensation

 

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation,” which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

 

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

 

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

 

Impairment of Long-Lived Assets

 

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it’s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

 

Research and Development

 

The Company expenses research and development costs as incurred. Research and development costs were $3,852 for the three months ended June 30, 2019 compared to no expense during the same period in the prior year. The Company is continually evaluating products and technologies in the natural wellness space, including its Tauri-GumTM product including new flavor formulations and other CBD delivery products, as well as any intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.

 

Fair Value Measurements

 

ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.

 

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

 

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

 

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

 

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

Financial instruments classified as Level 1 – quoted prices in active markets include cash.

 

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.

 

Share settled debt

 

The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.

 

ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer’s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer’s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer’s shares (e.g. net share settled written put options, net share settled forward purchase contracts).

 

Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.

 

The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15-day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.

 

Income Taxes

 

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.

 

Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

 

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

 

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of June 30, 2019.

 

Recent Accounting Pronouncements

 

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.

 

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842).” The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

 

The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. Early adoption is permitted. The Company has adopted this standard as of April 1, 2019 (See Note 6).

 

There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or operating results.

 

Subsequent Events

 

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory
 3 Months Ended
Jun. 30, 2019
Inventory Disclosure [Abstract]  
Inventory

NOTE 3– INVENTORY

 

Inventory from continuing operations

 

Inventory value by product as of:

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Tauri-GumTM  $138,606   $10,872 
           
Total Inventory  $138,606   $10,872 

 

At June 30, 2019, deposits to Per Os Bio in the amount of $52,500 for the manufacturing costs of Tauri-GumTM have been classified as a deposit (prepaid expenses other current assets) on the Company’s condensed consolidated balance sheet, as the goods are not yet available for sale.

 

At March 31, 2019, the Company had deposits to Per Os Bio in the amount of $105,000 for the manufacturing costs of Tauri-GumTM for goods not yet available for sale.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Discontinued Operations
 3 Months Ended
Jun. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

NOTE 4– DISCONTINUED OPERATIONS

 

On March 31, 2019, the Company decided to discontinue operations relative to its HERMAN© Lip balm product line. After much effort the Company was unable to resolve manufacturing issues as it related to it its lip balm tube mechanism. The Company did not believe that these issues will be resolvable without a substantial investment of time and money. Therefore, the Company exchanged its 50% ownership in Ice+Jam, LLC for the balance of the non-controlling interest as of March 31, 2019. On April 1, 2019, the Company recognized a gain on the disposal of discontinued operations in the amount of $4,941.

 

The Company had no revenue or expenses from discontinued operations during the three months ended June 30, 2018.

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Assets from discontinued operations  $       -   $581 
           
Liabilities from discontinued operations  $-   $5,522 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment
 3 Months Ended
Jun. 30, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment

NOTE 5– PROPERTY AND EQUIPMENT

 

The Company’s property and equipment is as follows:

 

   June 30, 2019 (unaudited)   March 31, 2019   Estimated Life
            
Computers, office furniture and other equipment  $69,808   $69,808   3-5 years
              
Less: accumulated depreciation   (57,030)   (56,798)   
              
Net  $12,778    13,010    

 

On June 29, 2018, the Company purchased four Blink Level 2 – 40” pedestal chargers for permanent placement in one or more retail locations whereby the Company will share revenue from these electric car vehicle charging units with such location owner. No depreciation expense has been recorded for the charging units as of June 30, 2019 due to the fact that they have not been placed in service.

 

Depreciation expense for the three months ended June 30, 2019 and 2018 was $232 and $259, respectively.

 

During the year ended March 31, 2019 the Company disposed of computer equipment valued at $1,632 recognizing a loss on disposal of $907.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease
 3 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Operating Lease

NOTE 6 – OPERATING LEASE

 

The Company has adopted ASU No. 2016-02, Leases (Topic 842), as of April 1, 2019 and will account for the new lease in terms of the right of use assets and offsetting lease liability obligations for this new lease under this pronouncement. In accordance with ASC 842 - Leases, effective April 1, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $7,492 and $7,895, respectively, as of April 1, 2019. The Company is recording these at present value, in accordance with the standard, using a discount rate of 8% which is representative of the last borrowing rates for notes issued to a non-related party. The right of use asset is composed of the sum of all lease payments, at present value, and is amortized straight line over the life of the expected lease term. For the expected term of the lease the Company will use the initial term of the two-year lease. If the Company does elect to exercise its option to extend the lease for additional years, that election will be treated as a lease modification and the lease will be reviewed for remeasurement. This lease will be treated as an operating lease under the new standard.

 

The Company has chosen to implement this standard using the modified retrospective model approach with a cumulative-effect adjustment, which does not require the Company to adjust the comparative periods presented when transitioning to the new guidance on April 1, 2019. The Company has also elected to utilize the transition related practical expedients permitted by the new standard. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a modified retrospective approach. Adoption of the new standard resulted in the recording of additional net lease assets and lease liabilities of approximately $7,492 and $7,895 as of April 1, 2019, respectively. The difference between the additional lease assets and lease liabilities, net of the deferred tax impact, will be recorded as an adjustment to retained earnings. The standard is not expected to materially impact our consolidated net earnings and had no impact on cash flows.

 

Corporate office – New York

 

On December 1, 2017, the Company relocated its corporate headquarters from Danbury, Connecticut to New York, New York. The Company has entered into a two-year lease at $1,010 per month for the term of the lease. The lease right of use asset for this lease at adoption was $7,492 and will be amortized on a straight-line basis over the remaining term of the lease. For the three months ended June 30, 2019 the Company recorded a lease expense of $2,810. As of June 30, 2019, the value of the unamortized lease right of use asset is $4,683. As of June 30, 2019, the Company’s lease liability was $4,984.

 

Barcelona office

 

On June 11, 2019 the Company entered into a two-year lease, expiring on June 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate will be recorded as gain or loss on currency translation.

 

The lease right of use asset, at inception, of $27,050 amortized on a straight-line basis over the term of the lease. The present value of the New York corporate office lease had an initial present value of $22,476 at December 1, 2017. The Barcelona office lease value had an initial present value of $4,573. For the three months ended June 30, 2019 the Company recorded a lease expense of $3,149. As of June 30, 2019, the value of the unamortized lease right of use asset is $9,071. As of June 30, 2019, the Company’s lease liability was $9,471.

 

Maturity of Operating Lease Liability for fiscal year ended June 30,
2020  $6,665 
2021  $2,288 
2022  $518 
      
Total lease payments  $9,471 

 

The following chart shows the Company’s operating lease cost at June 30, 2019 and 2018:

 

   For the three months ended 
   June 30, 2019   June 30, 2018 
         
Amortization of right of lease asset  $2,996   $- 
Lease interest cost   153    - 
Total Lease cost  $3,149   $- 

 

The following chart shows the Company’s operating lease liability at June 30, 2019.

 

Discounted Operating Lease liability at inception - December 1, 2017  $27,050 
Financing cost   1,055 
Less lease payments made   (18,204)
Cumulative effect of adoption of ASC 842   (430)
Operating lease liability at June 30, 2019   9,471 
Less Lease Liability current portion   (7,300)
Lease Liability at June 30, 2019 – long-term  $2,171 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets
 3 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

NOTE 7 – INTANGIBLE ASSETS

 

Patents:

 

Pilus Energy, LLC

 

The Company, through the acquisition of Pilus Energy on January 28, 2014, acquired a patent to develop cleantech energy using proprietary microbiological solution that creates electricity while consuming polluting molecules from wastewater.

 

On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus to Open Therapeutics. Open Therapeutics agreed to terminate and cancel 80% of the unexercised portion of Open Therapeutics agreed to pay to the Company 20% of the net profit generated by Pilus Energy from its previous year’s earnings, if any. The first $75,000 of such payments were to be retained by Pilus Energy as additional consideration for the sale, which was reflected as a contingent liability on the Company’s consolidated balance sheet. The Company further agreed it would vote its 20% membership interest in Pilus Energy in the same manner that Open Therapeutics votes its membership interest on all matters for which a member vote is required. Through June 30, 2019, there has been no activity recorded by Open Therapeutics with respect to Pilus Energy.

 

The Company had fully impaired the value of the patents prior to the sale, and the warrants canceled as a result of this transaction was valueless as there is no intrinsic value to them. The Company recorded no gain or loss. Upon Open Therapeutics achieving profitability with respect to this technology, the Company will be the beneficiary of a profit split as noted in the agreement and will recognize revenue from that in the future.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company’s consolidated financial statements. 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable
 3 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Notes Payable

NOTE 8 – NOTES PAYABLE

 

Notes payable and convertible notes consisted of the following as of:

 

      June 30, 2019   March 31, 2019 
            
Alternative Strategy Partners PTE Ltd.  (a)  $-   $90,000 
GS Capital Partners LLC - Oct 2018  (b)   140,000    180,000 
GS Capital Partners LLC - Mar 2019  (c)   300,000    300,000 
GS Capital Partners LLC - May 2019  (d)   60,000    - 
GS Capital Partners LLC - Jun 2019  (e)   60,000    - 
Total notes payable and convertible notes     $560,000   $570,000 
Less - note discounts      (324,580)   (356,125)
Less - current portion of these notes      (235,420)   (213,875)
Total notes payable and convertible notes, net discounts – long-term     $-   $- 

 

(a) Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. (“ASP”) to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. (“Eishin”), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company’s balance sheet, the $113,468 liability has been removed from the Company’s balance sheet, as is reflected in the Company’s financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.
   
(b) On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 60% instead of 70% while that “chill” is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227.

 

(c) On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company’s consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.
   
(d) On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

(d) In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.
   
(e) On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.
   
  In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $118.
   
  During the year ended March 31, 2019, the Company issued 5,946,516 shares of common stock to holders of convertible notes to retire $187,000 in principal and $13,718 of accrued interest (at an average conversion price of $0.03375 per share) under the convertible notes.  
   
  During the three months ended June 30, 2019, the Company issued 888,308 shares of common stock to holders of convertible notes to retire $40,000 and $1,973 of note principal and accrued interest, respectively.  

 

  Interest expense for the three months ended June 30, 2019 was $121,814 compared to $23,496 for the prior year. Accrued interest at June 30, 2019 and March 31, 2019 was $16,946 and $30,780, respectively.  
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Related Parties
 3 Months Ended
Jun. 30, 2019
Related Party Transactions [Abstract]  
Related Parties

NOTE 9 – RELATED PARTIES

 

As a result of the Company’s joint venture with Ice + Jam, a receivable and a payable was recorded on the Company’s books. As of December 31, 2018, these amounts represented cash Ice + Jam collected from sales of HerMan® through their website in the amount of $581 and a payable in the amount of $5,522 for expenses incurred through the operation of the business. As of March 31, 2019, these assets and liabilities were reflected in assets and liabilities from discontinued operations.

 

In conjunction with and consideration for a July 22, 2019, 10% convertible note, in the amount of $55,000, under a Securities Purchase Agreement the Company entered into with Jefferson Street Capital, LLC, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Deficit)
 3 Months Ended
Jun. 30, 2019
Equity [Abstract]  
Stockholders' Equity (Deficit)

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Common Stock

 

As of June 30, 2019, the Company is authorized to issue 100,000,000 shares of its common stock. As of June 30, 2019 and August 13, 2019, there were 72,925,920 and 75,895,090 shares, respectively of common stock issued and outstanding which includes all adjustments for fractional shares.

 

On July 26, 2019, the Company’s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.

 

Fiscal Year 2019

 

During the year ended March 31, 2019 the Company issued 3,130,000 shares of its restricted common stock to consultants under consulting agreements.

 

During the year ended March 31, 2019, the Company issued 5,946,516 shares of restricted common stock to noteholders for the conversion of debt and accrued interest having a value of $200,718 (at an average conversion price of $0.03375 per share).

 

During the year ended March 31, 2019, the Company issued 5,686,667 shares of common stock ($0.02 to $0.06 per share) for aggregate proceeds of $301,200.

 

During the year ended March 31, 2019, the Company issued 500,000 commitment shares for debt financing ($0.042 per share) valued at $21,000.

 

During the year ended March 31, 2019, the Company issued 95,667 shares for the settlement of debt $20,004.

 

On January 12, 2019, the Company and Open Therapeutics agreed to extinguish the $75,000 contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. The shares were recorded at a value of $24,750 ($0.0495 per share) as a loss on settlement in the Company’s consolidated financial statements.

 

Fiscal Year 2020

 

During the three months ended June 30, 2019, the Company issued 1,200,000 shares under distribution agreements.

 

During the three months ended June 30, 2019, the Company issued 888,308 shares for conversion of debt in the amount of $40,000 as well as accrued interest in the amount of $1,964 ($0.04725).

 

During the three months ended June 30, 2019, the Company issued 250,000 shares issued to Vice President of Distribution and Marketing.

 

During the three months ended June 30, 2019, the Company issued 1,000,000 shares issued for services rendered

 

During the three months ended June 30, 2019, the Company issued 750,000 shares for debt commitment in the amount of $142,500 ($0.19 per share). The shares were recorded as a liability to issue shares at March 31, 2019 on the Company’s balance sheet.

 

During the three months ended June 30, 2019, the Company issued 714,286 shares under stock purchase agreements in consideration for $45,000 (average of $0.063 per share) to accredited investors that are unrelated third parties.

 

In connection with some of the consulting agreements and board advisory agreements the Company has entered into, as the following clauses are part of the compensation arrangements: (a) the consultant will be reimbursed for all reasonable out of pocket expenses and (b) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant’s performance. The Company recognized $375,720 and $43,221 in stock-based compensation expense related to these agreements in the three months ended June 30, 2019 and 2018.

 

Warrants for Common Stock

 

The following table summarizes warrant activity for the three months and year ended June 30, 2019 and March 31, 2019:

 

       Weighted   Average    
       Average   Remaining  Aggregate 
       Exercise   Contractual  Intrinsic 
   Shares   Price   Term  Value 
                
Outstanding at March 31, 2018   1,433,611   $1.06   3.02 Years  $- 
                   
Granted   -    -       - 
Expired   (223,335)   0.2843         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable March 31, 2019   1,210,276   $1.2   1.28 Years  $- 
                   
Granted   -    -       - 
Expired   (389,344)   0.75         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable June 30, 2019   820,932   $1.41   1.41 Years  $        - 

 

During the year ended March 31, 2019, 213,334 warrants expired which were issued in conjunction with a one-year 5% convertible note in the amount of $80,000 with GS Capital Partners, LLC. The five-year cashless warrants had an exercise price of $0.2625 per share. These warrants were cancelled as part of the convertible note agreement which the Company entered into with GS Capital Partners, LLC on March 14, 2019 in the amount of $300,000 (See Note 8 section c).

 

During the year ended March 31, 2019, 10,001 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.

 

During the three months ended June 30, 2019, 389,344 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.

 

Stock Options

 

On February 1, 2012, the Company awarded to each of two executives’, one current and one former, options to purchase 66,667 common shares, an aggregate of 133,334 shares. These options vested immediately and were for services performed.

 

The following table summarizes option activity for the year and three months ended June 30, 2019 and March 31, 2019:

 

   Shares   Weighted-
Average
Exercise
Price		   Weighted
Average
Remaining
Contractual
Term		  Aggregate
Intrinsic
Value		 
                
Outstanding at March 31, 2018   133,334   $7.50   3.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding at March 31, 2019   133,334   $7.50   2.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding and exercisable at June 30, 2019   133,334   $7.50   2.60 Years  $— 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Provision for Income Taxes
 3 Months Ended
Jun. 30, 2019
Income Tax Disclosure [Abstract]  
Provision for Income Taxes

NOTE 11 – PROVISION FOR INCOME TAXES

 

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

 

The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for the three months and years ended June 30, 2019 March 31, 2019:

 

   June 30, 2019   March 31,2019 
Federal income taxes at statutory rate   21.00%   21.00%
State income taxes at statutory rate   0.00%   0.00%
Temporary differences   8.99%   1.48%
Permanent differences   0.17%   0.24%
Impact of Tax Reform Act   0.00%   (167.44)%
Change in valuation allowance   (30.16)%   144.72%
Totals   0.00%   0.00%

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.

 

   As of   As of 
   June 30, 2019   March 31, 2019 
Deferred tax assets:          
Net operating losses before non-deductible items  $3,763,732   $3,685,807 
Loss on disposal of fixed assets   355    355 
Stock-based compensation   288,492    209,591 
Unrealized gains or losses on investments   (24,079)   (4,258)
Total deferred tax assets   4,028,500    3,891,495 
Less: Valuation allowance   (4,028,500)   (3,891,495)
           
Net deferred tax assets  $-   $- 

 

At June 30, 2019, the Company had a U.S. net operating loss carryforward in the approximate amount of $17.9 million available to offset future taxable income through 2038. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. The valuation allowance increased by $137,005 in the three months ended June 30, 2019 and decreased by $1,516,710 in the year ended March 31, 2019. The net decreases were the result of the tax effects of the Tax Cuts and Jobs Act (the “TCJA”) offset by taxable losses net of timing differences in each of the years.

 

On December 22, 2017, Public Law 115-97, informally referred to as the TCJA was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. The effective rate for the year ended March 31, 2018 was 31% as the rate was changed effective January 1, 2018 to the lower rate. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. Given the significant complexity of the TCJA and anticipated additional implementation guidance from the Internal Revenue Service, further implications of the TCJA may be identified in future periods. The Company has adjusted their NOLs and valuation allowances to account for the changes brought about by the TCJA for the three months and year ended June 30, 2019 and March 31, 2019, respectively.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Investments
 3 Months Ended
Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Investments

NOTE 12 – INVESTMENTS

 

Trading securities

 

For investments in securities of other companies that are owned, the Company records them at fair value with unrealized gains and losses reflected in other operating income or loss. For investments in these securities that are sold by us, the Company recognizes the gains and losses attributable to these securities investments as realized gains or losses in other operating income or loss on a first in first out basis.

 

Investment in Trading Securities:

 

At March 31, 2019                         
Company     Beginning
of Period
Cost		   Purchases  

Sales

Proceeds

  

End of

Period

Cost

  

Fair

Value

   Realized
Gain (Loss)		   Unrealized
Gain (Loss)		 
Green Innovations Ltd (GNIN)*  (a)  $-    -   $-   $-   $-   $-   $- 
VistaGen Therapeutics Inc (VTGN)  (b)   490,117    349,498    (517,485)   287,500    294,400    (34,630)   6,900 
Blink Charging Co (BLNK)  (c)   190,350    151,666    (367,142)   -    -    25,126    - 
Blink Charging Co (BLNKW) (Warrants)  (c)   900    162,215    (468,496)   -    -    305,381    - 
Aytu BioScience Inc (AYTU)  (d)   82,270    100,030    (144,094)   -    -    (38,206)   - 
Lightbridge Corp. (LTBR)  (e)   37,511    299,028    (276,159)   -    -    (60,380)   - 
Pulmatrix Inc. (PULM)  (f)   -    204,802    (183,737)   -    -    (21,065)   - 
Axovant Sciences Ltd. (AXON)  (g)   -    103,938    (98,433)   -    -    (5,505)   - 
Basanite Inc. (BASA)  (h)   -    42,998    (10,821)   30,000    56,000    (2,177)   26,000 
Achieve Life Sciences (ACHV)  (i)   -    177,356    (112,221)   -    -    (65,135)   - 
Decision Diagnostics (DECN)  (j)   -    20,479    (16,893)   -    -    (3,586)   - 
Totals     $801,148   $1,612,010   $(2,195,481)  $317,500   $350,400   $99,823   $32,900*

 

At June 30, 2019                         
Company     Beginning of Period Cost   Purchases   Sales Proceeds   End of Period Cost   Fair Value   Realized Gain (Loss)   Unrealized Gain (Loss) 
VistaGen Therapeutics Inc (VTGN)  (b)   287,500           -            -    287,500    166,865          -    (120,635)
Basanite Inc. (BASA)  (h)   30,000    -    -    30,000    277,920    -    247,920 
Totals     $317,500   $-   $-   $317,500   $444,785   $-   $127,285**

 

* Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.

 

**This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.

 

(a) During the year ended March 31, 2018, the Company’s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company’s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.
   
(b) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company’s broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(c) The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company’s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
   
(d) On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.
   
(e) On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380.
   
(f) During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.

 

(g) During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
   
(h) On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(i) During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135.
   
(j) During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.

 

At June 30, 2019, the Company held warrants for AYTU to purchase 5,555 common shares at a strike price of $10.80 with an expiration of March 6, 2023. The strike price and number of shares were adjusted for the August 10, 2018, 1 for 20 reverse stock-split. At June 30, 2019, these warrants were out of the money by $9.13 per share and are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.

 

At June 30, 2019, the Company currently holds warrants for VTGN to purchase 320,000 shares of common stock at a strike price of $1.50 per share with an expiration of December 13, 2022 and warrants for VTGN to purchase 230,000 shares of common stock at a strike price of $1.50 per share with an expiration of February 28, 2022. At June 30, 2019, these warrants were out of the money by $0.25 per share. Since these warrants are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.

 

Digital Currency

 

During the year ended March 31, 2019, the Company purchased. Groestlcoin cryptocurrency (Crypto Currency Code: GRS). The purchase of this currency cannot be executed directly using $USD. The Company must purchase Bitcoin (BTC) and then purchase the Groestlcoin cryptocurrency by using BTC. This two-step process triggers the potential recognition of realized gains or losses on the purchase of Groestlcoin.

 

On April 2, 2018, the Company completed a purchase in the Groestlcoin cryptocurrency in the aggregate amount of $8,000 for 11,922.81 units ($0.6569 per unit).

 

On July 15, 2018, the Company sold all of its 39,862 units of Groestlcoin cryptocurrency converting it into 4.17 units of BTC having a value of $32,230. On August 20, 2018, the Company converted its BTC to gold bullion and silver coins at a value of $26,783.

 

On August 25, 2018, the Company sold all gold and silver commodities held for a sum of $24,046, recognizing a loss on the transaction of $2,737.

 

During the year ended March 31, 2019, had an unrealized loss on digital currency of $3,143 prior to the conversion to the gold and silver.

 

During the three months ended June 30, 2019, the Company had no digital currency activity.

 

Equity investments

 

Honeywood

 

Effective August 1, 2017, the Company entered into a Debt Conversion Agreement in respect to a secured promissory note issued following the unwinding of the Honeywood acquisition (See NOTE 1), whereby the Company agreed to convert the entire principal and accrued but unpaid interest due under the note into a 5% membership interest in Honeywood.

 

The Company made an assessment for impairment of its investment in Honeywood at the entity level. During the relationship between the Company and Honeywood, Honeywood had a working capital deficiency and had a history of operating losses. In accordance with FASB ASC 320-10-35-28, “Investments—Debt and Equity Securities,” a Company may not record an impairment loss on the investment but shall continue to evaluate whether the investment is impaired (that is, shall estimate the fair value of the investment) in each subsequent reporting period until either of the following occurs: (a) the investment experiences a recovery of fair value up to (or beyond) its cost; or (b) the entity recognizes an other-than-temporary impairment loss. At the time of the Debt Conversion Agreement the receivable balance of $199,119 had been fully written off by the Company in a prior period. As a result of this Debt Conversion Agreement, the Company deemed the investment to still have no current value. The Company recorded this investment at $0. Thus, no recovery of bad debt and no impairment will be recognized in this year.

 

Cost investments

 

Küdzoo, Inc.

 

On September 4, 2018, the Company invested $15,000 in Küdzoo, Inc. (“Küdzoo”), a privately held company. Küdzoo is the developer of a mobile application that rewards students for their grades and achievements with deals and opportunities. The investment is recorded at cost and represents 0.2% of the value of Küdzoo based on a pre-money valuation of $7,500,000.

 

On March 21, 2019, the Company invested $22,500 in Küdzoo. This investment was recorded at cost and represents 0.22% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000. On April 8, 2019, the Company invested another $20,400, which was recorded at cost representing a 0.42% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.

 

The Company tested the investment value for Küdzoo as of March 31, 2019 for impairment. It was noted that the value of the company has increased based on recent equity raises in which the Company took part in. As a result of the new equity raises, the Company does not believe there is any impairment of this investment as of June 30, 2019.

 

On April 8, 2019, the Company invested $20,400, in Küdzoo, Inc., a private Company in which the Company had previously invested $37,500. The $20,400 investment was recorded at cost representing a 0.2% of the proportionate interest in the outstanding of the Company after this offering based on a pre-money valuation of $10,200,000.

 

Serendipity

 

On October 31, 2018, the Company invested $35,000 in Serendipity Brands LLC (dba Serendipity Ice Cream Co.) (“Serendipity”), a privately held Company. Serendipity is an ice cream distribution company providing wholesale distribution to retail customers. The investment was recorded at cost and represents 0.24% of the value of Serendipity based on a pre-money valuation of approximately $14 million.

 

The Company tested the investment value for Serendipity as of March 31, 2019 for impairment. It was noted that the value of the company has maintained its value through reviews of their financial performance, therefore, the Company does not believe there is any impairment of this investment as of June 30, 2019.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements
 3 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements

NOTE 13 – FAIR VALUE MEASUREMENTS

 

The following summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019:

 

   June 30, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $444,785   $-   $-   $444,785 
Cost method investment – Küdzoo  $-   $-   $57,900   $57,900 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 

 

   March 31, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $350,400   $-   $-   $350,400 
Cost method investment – Küdzoo  $-   $-   $37,500   $37,500 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Concentrations
 3 Months Ended
Jun. 30, 2019
Risks and Uncertainties [Abstract]  
Concentrations

NOTE 14 – CONCENTRATIONS

 

During the three months and year ended June 30, 2019 and March 31, 2019, we have one supplier for 100% of our product who is also the manufacturer of Tauri-GumTM.

 

For the three months ended June 30, 2019, one customer accounted for 23.96% of product sales from continuing operations. For the year ended March 31, 2019, one customer accounted for 97% of product sales from continuing operations.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent Events
 3 Months Ended
Jun. 30, 2019
Subsequent Events [Abstract]  
Subsequent Events

NOTE 15 – SUBSEQUENT EVENTS

 

Subsequent to June 30, 2019, the Company issued additional shares of common stock as follows; (i) 250,000 shares for commitment shares relative to convertible note issued; (ii) 250,000 shares under a distribution agreement dated April 30, 2019; and (iii) 2,719,170 shares in conversion of convertible notes of $75,000 and accrued interest of $4,373.

 

Convertible Notes

 

On July 22, 2019, the Company and Jefferson Street Capital, LLC (“Jefferson Street”) consummated entry into a Securities Purchase Agreement where the Company has borrowed $55,000 ($50,000 with original issuance discount reflected) at 10% annual interest under a term of nine-months in the form of a convertible note. The note is convertible into restricted stock of the Company. In connection with this agreement, the Company issued 250,000 commitment shares having a value of $10,500 ($0.042 per share, the closing price of our common stock on the day preceding the note) which will be reflected as interest expense in the Company’s condensed consolidated statement of operations during the three months ended June 30, 2019. The restricted stock was valued at the closing price on July 22, 2019. Legal fees of $2,000 were deducted from cash proceeds of the note payable to investor’s counsel, and a $5,000 original issue discount recognized. The Company received cash proceeds of $48,000 at closing. Under the Jefferson Street note, the Company is required initially to reserve 1,000,000 shares of its common stock, and thereafter to increase the reserve up to 15,000,000 shares upon the increase in the Company’s authorized common shares (per a charter amendment via shareholder meeting and approval as approved by the Board of Directors on July 26, 2019), but up to six times the number of shares required for a full conversion. The Company has 75 days from the date of this note to have this increased effectuated. The noteholder may, at any time, at its option, convert all or any amount of the principal face amount of the note then outstanding into shares of the Company’s common stock at a conversion price for each share of Common Stock equal to 65% of the lowest volume weighted average price for the Company’s common stock during the previous fifteen trading day period as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future, including the day upon which a notice of conversion is received by the Company. If the Company fails to maintain the share reserve at the required amounts, or to attain shareholder approval within 75 days of July 22, 2019, this will be considered an Event of Default. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note; however, the Company maintains the option to repay the note in cash within the first 180 days beginning on July 22, 2019 to avoid such default provision triggering event, as more fully described below.

 

During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date.

 

Upon an event of default (as defined and described in the note), among other default penalties, the Company shall pay the Default Amount (as defined in the agreement) as well as incur annual interest at a default interest rate of 24% per annum.

 

In consideration of Jefferson Street loaning the Company the proceeds under this note, the Chief Executive Officer has personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty will remain in effect until such time that the Company can reserve at least six times the amount of common shares issuable upon full conversion of the note. The Company anticipates this to occur upon the effectiveness of the increase in the Company’s authorized shares within the 75 days from the date of the note as indicated in the agreement.

 

Other

 

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that the FDA as well as the New York City Council will implement regulations surrounding the CBD industry in a logical and prompt manner. The FDA’s uncertainty surrounding CBD was the initial cause of the New York City ban, and we believe further clarification from the FDA supporting its safety and regulating its labeling will also offer a clearer pathway to the New York City CBD market. The Company is very well positioned in this argument and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants and that it contains 0% THC content. The Company remains confident that this embargo on CBD Edible(s) products will be lifted and/or clarified. As a result of this embargo, the Company has taken the necessary steps to ensure that their marketing efforts are focused on areas outside of New York City, while still maintaining their New York City (the 5 Boroughs) presence.

 

On July 26, 2019, the Company’s Board of Directors approved the (i) increase of the authorized common stock of the Company from 100,000,000 shares to 400,000,000 shares; (ii) the filing of both the preliminary and definitive information statements; and (iii) approved the record date of July 29, 2019.

 

On August 12, 2019, the Company received $47,500 net proceeds for the second of two notes (the “Back-End Note”) under a December 20, 2018 security purchase agreement with Adar Alef, LLC whereby the Company issued two 8% convertible redeemable notes in the cumulative principal amount of $110,000. Both notes were for $55,000 and had funded with net proceeds of $47,500, after the deduction of $5,000 for OID and $2,500 in legal fees. The first note was previously funded on December 24, 2018. The Back-End Note was initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the “Note Receivable”). The terms of the Back-End Note required cash funding prior to any conversion thereunder. The Note Receivable was due December 20, 2019, unless certain conditions were not met, in which case both the Back-End Note and the Note Receivable may both have been cancelled. The Back-End Note has a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under the Back-End Note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 50% instead of 60% while that “chill” is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. This Back-End Note may not be repaid. The note holder may redeem this note at any time after the first six months.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Condensed Consolidated Financial Statements

Condensed Consolidated Financial Statements

 

The condensed consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga BDC and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of June 30, 2019, there is no activity in any of the Company’s subsidiaries other than Tauriga BDC holding the electric car chargers and the leasehold interest in Tauriga Sciences Limited.
Revenue Recognition

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of HerMan® using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. Tauriga BDC will be compensated upon contracting for so long as the Company’s acquired prospect remains under contract. This sales agreement is a three-tier model based on whether Tauriga BDC contracts the new customer to purchase equipment outright from Blink or enter into one of two revenue-sharing agreements. In the case Tauriga BDC effectuates a sale of Blink equipment it will receive a one-time sales commission based on the sales price of the equipment sale. In the case where Tauriga BDC secures a revenue sharing agreement with a customer where Blink remains the owner, Tauriga BDC will be paid an on-going commission based off of gross charger revenue, subject to which party paid for the installation. Commission payments under the revenue sharing agreement are subject to minimum revenue generation hurdles.

 

On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner to will pay for the cost of providing power to these unit as well as installation costs.

 

As of June 30, 2019, the Tauriga BDC has not installed any of these machines in any locations, and no revenue has been generated through the Blink contract.

 

During the three months ended March 31, 2019, the Company recognized its first sales of Tauri-GumTM, primarily vis-à-vis its entry in the E&M Distribution Agreement.

 

The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company’s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized revenue from operations in the amount of $44,377 during the three months ended June 30, 2019 compared to no revenue for the same period in the prior year. All revenue is from the sale of the Company’s Tauri-GumTM product line and there were accounts receivable of $28,028 currently outstanding for these sales.

 

The Company recognized no revenue from discontinued operations during the three months ended June 30, 2018 which was related to the sales of the HERMAN® lip balm product.
Sales Refunds

Sales Refunds

 

The Company’s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-GumTM distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of June 30, 2019 however will monitor the refunds to estimate whether a reserve will be required.
Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash Equivalents

Cash Equivalents

 

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At June 30, 2019, the Company’s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At June 30, 2019 and March 31, 2019, the Company had a cash balance of $15,247 and $385,943, respectively. The Company’s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of June 30, 2019 and March 31, 2019.
Investment in Trading Securities

Investment in Trading Securities

 

Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss.

 

For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.
Investment - Cost Method

Investment – Cost Method

 

Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of June 30, 2019, the Company has not impaired any of their cost method investments.
Inventory

Inventory

 

Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfillment center is also included in the total inventory cost. Shipping of product upon sale for online sales is paid by the customer upon ordering for orders of single packs of Tauri-GumTM. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of June 30, 2019, the Company’s inventory on hand had a value of $138,606. The Company also has paid deposits in the amount of $52,500 to the manufacturer, Per Os Bio, towards orders not received as of June 30, 2019. Amounts paid to Per Os Bio for Tauri-GumTM are classified as deposits (other current asset) on the Company’s condensed consolidated balance sheet until the goods are available for sale. The Company has not established any inventory reserve on the Tauri-GumTM as of June 30, 2019.
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.
Intangible Assets

Intangible Assets

 

Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.
Net Income (Loss) Per Common Share

Net Income (Loss) Per Common Share

 

The Company computes per share amounts in accordance with FASB ASC Topic 260 “Earnings per Share” (“EPS”), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the three months ended June 30, 2019, basic and fully diluted earnings per share were the same as the Company had losses in this period.
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation,” which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

 

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

  

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it’s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Research and Development

Research and Development

 

The Company expenses research and development costs as incurred. Research and development costs were $3,852 for the three months ended June 30, 2019 compared to no expense during the same period in the prior year. The Company is continually evaluating products and technologies in the natural wellness space, including its Tauri-GumTM product including new flavor formulations and other CBD delivery products, as well as any intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.
Fair Value Measurements

Fair Value Measurements

 

ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.

 

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

 

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

 

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

 

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

Financial instruments classified as Level 1 – quoted prices in active markets include cash.

 

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.
Share Settled Debt

Share settled debt

 

The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.

 

ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer’s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer’s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer’s shares (e.g. net share settled written put options, net share settled forward purchase contracts).

 

Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.

 

The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15-day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.
Income Taxes

Income Taxes

 

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.

 

Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

 

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

 

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of June 30, 2019.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.

 

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842).” The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

 

The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. Early adoption is permitted. The Company has adopted this standard as of April 1, 2019 (See Note 6).

 

There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or operating results.
Subsequent Events

Subsequent Events

 

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory (Tables)
 3 Months Ended
Jun. 30, 2019
Inventory Disclosure [Abstract]  
Schedule of Inventory

Inventory value by product as of:

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Tauri-GumTM  $138,606   $10,872 
           
Total Inventory  $138,606   $10,872 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Discontinued Operations (Tables)
 3 Months Ended
Jun. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Summary of Discontinued Operations

TAURIGA SCIENCES, INC. AND SUBSIDIARY

BALANCE SHEETS FROM DISCONTINUED OPERATIONS

 

   June 30, 2019 (unaudited)   March 31, 2019 
         
Assets from discontinued operations  $       -   $581 
           
Liabilities from discontinued operations  $-   $5,522 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Tables)
 3 Months Ended
Jun. 30, 2019
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

The Company’s property and equipment is as follows:

 

   June 30, 2019 (unaudited)   March 31, 2019   Estimated Life
            
Computers, office furniture and other equipment  $69,808   $69,808   3-5 years
              
Less: accumulated depreciation   (57,030)   (56,798)   
              
Net  $12,778    13,010    
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease (Tables)
 3 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Schedule of Maturity of Operating Lease Liability
Maturity of Operating Lease Liability for fiscal year ended June 30,
2020  $6,665 
2021  $2,288 
2022  $518 
      
Total lease payments  $9,471 
Schedule of Operating Lease Cost

The following chart shows the Company’s operating lease cost at June 30, 2019 and 2018:

 

   For the three months ended 
   June 30, 2019   June 30, 2018 
         
Amortization of right of lease asset  $2,996   $- 
Lease interest cost   153    - 
Total Lease cost  $3,149   $- 
Schedule of Operating Lease Liability

The following chart shows the Company’s operating lease liability at June 30, 2019.

 

Discounted Operating Lease liability at inception - December 1, 2017  $27,050 
Financing cost   1,055 
Less lease payments made   (18,204)
Cumulative effect of adoption of ASC 842   (430)
Operating lease liability at June 30, 2019   9,471 
Less Lease Liability current portion   (7,300)
Lease Liability at June 30, 2019 – long-term  $2,171 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable (Tables)
 3 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Schedule of Notes Payable and Convertible Notes

Notes payable and convertible notes consisted of the following as of:

 

      June 30, 2019   March 31, 2019 
            
Alternative Strategy Partners PTE Ltd.  (a)  $-   $90,000 
GS Capital Partners LLC - Oct 2018  (b)   140,000    180,000 
GS Capital Partners LLC - Mar 2019  (c)   300,000    300,000 
GS Capital Partners LLC - May 2019  (d)   60,000    - 
GS Capital Partners LLC - Jun 2019  (e)   60,000    - 
Total notes payable and convertible notes     $560,000   $570,000 
Less - note discounts      (324,580)   (356,125)
Less - current portion of these notes      (235,420)   (213,875)
Total notes payable and convertible notes, net discounts – long-term     $-   $- 

 

(a) Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. (“ASP”) to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. (“Eishin”), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company’s balance sheet, the $113,468 liability has been removed from the Company’s balance sheet, as is reflected in the Company’s financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.
   
(b) On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 60% instead of 70% while that “chill” is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227.

 

(c) On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company’s consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.
   
(d) On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

(d) In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.
   
(e) On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 56% instead of 66% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Deficit) (Tables)
 3 Months Ended
Jun. 30, 2019
Equity [Abstract]  
Schedule of Warrants Activity

The following table summarizes warrant activity for the three months and year ended June 30, 2019 and March 31, 2019:

 

       Weighted   Average    
       Average   Remaining  Aggregate 
       Exercise   Contractual  Intrinsic 
   Shares   Price   Term  Value 
                
Outstanding at March 31, 2018   1,433,611   $1.06   3.02 Years  $- 
                   
Granted   -    -       - 
Expired   (223,335)   0.2843         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable March 31, 2019   1,210,276   $1.2   1.28 Years  $- 
                   
Granted   -    -       - 
Expired   (389,344)   0.75         
Exercised   -    -         
Canceled   -    -         
                   
Outstanding and exercisable June 30, 2019   820,932   $1.41   1.41 Years  $        - 
Schedule of Stock Options Activity

The following table summarizes option activity for the year and three months ended June 30, 2019 and March 31, 2019:

 

   Shares   Weighted-
Average
Exercise
Price		   Weighted
Average
Remaining
Contractual
Term		  Aggregate
Intrinsic
Value		 
                
Outstanding at March 31, 2018   133,334   $7.50   3.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding at March 31, 2019   133,334   $7.50   2.85 Years  $— 
                   
Granted   —    —         
Expired   —    —         
Exercised   —    —         
                   
Outstanding and exercisable at June 30, 2019   133,334   $7.50   2.60 Years  $— 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Provision for Income Taxes (Tables)
 3 Months Ended
Jun. 30, 2019
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate

The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for the three months and years ended June 30, 2019 March 31, 2019:

 

   June 30, 2019   March 31,2019 
Federal income taxes at statutory rate   21.00%   21.00%
State income taxes at statutory rate   0.00%   0.00%
Temporary differences   8.99%   1.48%
Permanent differences   0.17%   0.24%
Impact of Tax Reform Act   0.00%   (167.44)%
Change in valuation allowance   (30.16)%   144.72%
Totals   0.00%   0.00%
Schedule of Deferred Tax Assets

As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.

 

   As of   As of 
   June 30, 2019   March 31, 2019 
Deferred tax assets:          
Net operating losses before non-deductible items  $3,763,732   $3,685,807 
Loss on disposal of fixed assets   355    355 
Stock-based compensation   288,492    209,591 
Unrealized gains or losses on investments   (24,079)   (4,258)
Total deferred tax assets   4,028,500    3,891,495 
Less: Valuation allowance   (4,028,500)   (3,891,495)
           
Net deferred tax assets  $-   $- 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Investments (Tables)
 3 Months Ended
Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment in Trading Securities

Investment in Trading Securities:

 

At March 31, 2019                         
Company     Beginning
of Period
Cost		   Purchases  

Sales

Proceeds

  

End of

Period

Cost

  

Fair

Value

   Realized
Gain (Loss)		   Unrealized
Gain (Loss)		 
Green Innovations Ltd (GNIN)*  (a)  $-    -   $-   $-   $-   $-   $- 
VistaGen Therapeutics Inc (VTGN)  (b)   490,117    349,498    (517,485)   287,500    294,400    (34,630)   6,900 
Blink Charging Co (BLNK)  (c)   190,350    151,666    (367,142)   -    -    25,126    - 
Blink Charging Co (BLNKW) (Warrants)  (c)   900    162,215    (468,496)   -    -    305,381    - 
Aytu BioScience Inc (AYTU)  (d)   82,270    100,030    (144,094)   -    -    (38,206)   - 
Lightbridge Corp. (LTBR)  (e)   37,511    299,028    (276,159)   -    -    (60,380)   - 
Pulmatrix Inc. (PULM)  (f)   -    204,802    (183,737)   -    -    (21,065)   - 
Axovant Sciences Ltd. (AXON)  (g)   -    103,938    (98,433)   -    -    (5,505)   - 
Basanite Inc. (BASA)  (h)   -    42,998    (10,821)   30,000    56,000    (2,177)   26,000 
Achieve Life Sciences (ACHV)  (i)   -    177,356    (112,221)   -    -    (65,135)   - 
Decision Diagnostics (DECN)  (j)   -    20,479    (16,893)   -    -    (3,586)   - 
Totals     $801,148   $1,612,010   $(2,195,481)  $317,500   $350,400   $99,823   $32,900*

 

At June 30, 2019                         
Company     Beginning of Period Cost   Purchases   Sales Proceeds   End of Period Cost   Fair Value   Realized Gain (Loss)   Unrealized Gain (Loss) 
VistaGen Therapeutics Inc (VTGN)  (b)   287,500           -            -    287,500    166,865          -    (120,635)
Basanite Inc. (BASA)  (h)   30,000    -    -    30,000    277,920    -    247,920 
Totals     $317,500   $-   $-   $317,500   $444,785   $-   $127,285**

 

* Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.

 

**This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.

   
(a) During the year ended March 31, 2018, the Company’s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company’s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.
   
(b) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company’s broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(c) The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company’s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
   
(d) On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.
   
(e) On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380.
   
(f) During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.

   
(g) During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
   
(h) On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company’s broker of record.
   
(i) During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135.
   
(j) During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Tables)
 3 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019:

 

   June 30, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $444,785   $-   $-   $444,785 
Cost method investment – Küdzoo  $-   $-   $57,900   $57,900 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 

 

   March 31, 2019 
   Level 1   Level 2   Level 3   Total 
Assets                    
Investment-trading securities  $350,400   $-   $-   $350,400 
Cost method investment – Küdzoo  $-   $-   $37,500   $37,500 
Cost method investment – Serendipity Brands  $-   $-   $35,000   $35,000 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Operations (Details Narrative)
 3 Months Ended 12 Months Ended
Jun. 28, 2019
USD ($)
Jun. 11, 2019
USD ($)
Jun. 11, 2019
EUR (€)
May 20, 2019
$ / shares
shares
May 11, 2019
shares
Apr. 30, 2019
shares
Apr. 09, 2019
$ / shares
Apr. 08, 2019
USD ($)
shares
Apr. 02, 2019
USD ($)
shares
Jan. 12, 2019
USD ($)
$ / shares
shares
Jul. 08, 2018
shares
Jun. 29, 2018
Aug. 01, 2017
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
Mar. 31, 2019
USD ($)
$ / shares
shares
Jul. 26, 2019
shares
Dec. 22, 2016
USD ($)
Retail price, per unit | $ / shares             $ 6.99                        
Common stock, par value | $ / shares                           $ 0.00001 $ 0.00001   $ 0.00001    
Common stock, shares authorized | shares                     7,500,000,000     100,000,000 100,000,000   100,000,000    
Reverse stock split, description                     Ratio of 1-for-75                
Reverse stock split, shares | shares                     4,078,179,672                
Reduction in outstanding shares | shares                     54,380,230                
Gain on disposal of discontinued operations                 $ 4,941         $ 4,941        
Debt conversion                           142,500 $ 21,000        
Variable annual fee, percentage                       0.07              
Sales revenue                           44,377 57,134      
Accounts receivable                           28,028          
Gross profit                           14,959 20,006      
Working capital                           499,657          
Marketable securities                           444,785 $ 350,400   $ 350,400    
Spain [Member]                                      
Lease expiration date   Jun. 30, 2021 Jun. 30, 2021                                
Lease, description   Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).                                
Lease, term of contract   2 years 2 years                                
Monthly rent payments   $ 201                                  
Spain [Member] | Euro [Member]                                      
Monthly rent payments | €     € 178                                
Ownership [Member]                                      
Percentage of membership interest               0.42%                      
Subsequent Event [Member]                                      
Common stock, shares authorized | shares                                   400,000,000  
E&M Distribution Agreement [Member]                                      
Payment received from delivery of product                                 $ 54,000    
Restricted common stock issued during period | shares                 1,000,000                    
One time cash payment                 $ 125,000                    
South Florida Region Distribution Agreement [Member]                                      
Restricted common stock issued during period | shares               450,000                      
Cash stipend               $ 10,000                      
Cash stipend paid               $ 2,000                      
North Eastern United States Distribution Agreement [Member]                                      
Restricted common stock issued during period | shares           1,000,000                          
North Eastern United States Distribution Agreement [Member] | Sai Krishna LLC (SKL) [Member]                                      
Restricted common stock issued during period | shares           500,000                          
North Eastern United States Distribution Agreement [Member] | Within Ten (10) Business Days of April 30, 2019 [Member] | Sai Krishna LLC (SKL) [Member]                                      
Restricted common stock issued during period | shares           250,000                          
North Eastern United States Distribution Agreement [Member] | Within Ten (10) Business Days of August 1, 2019 [Member] | Sai Krishna LLC (SKL) [Member]                                      
Restricted common stock issued during period | shares           250,000                          
North Eastern United States Distribution Agreement [Member] | Mr. Mahesh Lekkala [Member] | Within Ten (10) Business Days of April 30, 2019 [Member]                                      
Restricted common stock issued during period | shares           500,000                          
One Year Agreement [Member] | Sai Krishna LLC (SKL) [Member]                                      
Number of shares expensed | shares           250,000                          
SKL Distribution Agreement [Member]                                      
Term of contract         1 year                            
SKL Distribution Agreement [Member] | Ms. Neelima Lekkala [Member]                                      
Restricted common stock issued during period | shares       18,275 250,000                            
Commission earned, percentage       0.30                              
Shares issued price per share | $ / shares       $ 0.0731                              
Windmill Health Distribution Agreement [Member]                                      
Initial purchase order $ 46,848                                    
Debt Conversion Agreement [Member] | Honeywood LLC [Member]                                      
Debt conversion                         $ 170,000            
Debt Conversion Agreement [Member] | Honeywood LLC [Member] | Ownership [Member]                                      
Percentage of membership interest                         5.00%            
Honeywood Conversion Agreement [Member]                                      
Investment                           $ 0          
Transfer Agreement [Member] | Open Therapeutics [Member]                                      
Percentage of membership interest sold                                     80.00%
Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period                                     80.00%
Percentage of net profit generated                                     20.00%
Contingent liability                                     $ 75,000
Transfer Agreement [Member] | Open Therapeutics [Member]                                      
Restricted common stock issued during period | shares                   500,000                  
Shares issued price per share | $ / shares                   $ 0.0495                  
Contingent liability                   $ 75,000                  
Restricted common stock issued during period, value                   $ 24,750                  
Transfer Agreement [Member] | Open Therapeutics [Member] | Ownership [Member]                                      
Percentage of membership interest                                     20.00%
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of Significant Accounting Policies (Details Narrative)
 3 Months Ended
Jun. 29, 2018
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2018
USD ($)
Variable annual fee, percentage 0.07      
Sales revenue   $ 44,377 $ 57,134
Revenue from discontinued operations    
Refund to customers   100    
Cash FDIC insured amount   250,000    
Cash   15,247 385,943  
Inventory asset   138,606 $ 10,872  
Deposits   52,500    
Research and development costs   $ 3,852  
Maximum [Member]        
Ownership interest percentage   20.00%    
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory (Details Narrative) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Tauri-GumTM [Member]    
Deposits $ 52,500 $ 105,000
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Inventory - Schedule of Inventory (Details) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Total Inventory $ 138,606 $ 10,872
Tauri-GumTM [Member]    
Total Inventory $ 138,606 $ 10,872
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Discontinued Operations (Details Narrative) - USD ($)
 3 Months Ended
Apr. 02, 2019
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2019
Gain on disposal of discontinued operations $ 4,941 $ 4,941  
Ice+Jam, LLC [Member]        
Ownership interest percentage       50.00%
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Discontinued Operations - Summary of Discontinued Operations (Details) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]    
Assets from discontinued operations $ 581
Liabilities from discontinued operations $ 5,522
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2019
Depreciation expense $ 232 $ 259  
Loss on disposal     $ 907
Computer Equipment [Member]      
Loss on disposal     $ 1,632
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
 3 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Less: accumulated depreciation $ (57,030) $ (56,798)
Net 12,778 13,010
Computers, Office Furniture and Other Equipment [Member]    
Property and equipment gross $ 69,808 $ 69,808
Computers, Office Furniture and Other Equipment [Member] | Minimum [Member]    
Property and equipment estimated life 3 years  
Computers, Office Furniture and Other Equipment [Member] | Maximum [Member]    
Property and equipment estimated life 5 years  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease (Details Narrative)
 3 Months Ended 19 Months Ended
Jun. 11, 2019
USD ($)
Jun. 11, 2019
EUR (€)
Dec. 02, 2017
USD ($)
Dec. 01, 2017
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Apr. 02, 2019
USD ($)
Mar. 31, 2019
USD ($)
Right of use asset         $ 9,071   $ 9,071 $ 7,492
Lease liability         $ 9,471   $ 9,471 7,895  
Debt discount rate         8.00%   8.00%    
Lease expense         $ 3,149        
Amortization of right of lease asset         2,996      
New York Corporate Office Lease [Member]                  
Lease expense       $ 22,476          
Barcelona Office Lease [Member]                  
Lease expense         4,573        
New York [Member]                  
Lease liability         4,984   $ 4,984    
Lease term     2 years            
Lease expense     $ 1,010   2,810        
Unamortized lease right of use asset         4,683   4,683    
Spain [Member]                  
Lease liability         $ 9,471   9,471    
Lease term 2 years                
Lease expiration date Jun. 30, 2021 Jun. 30, 2021              
Monthly rent payments $ 201                
Lease, description Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). Monthly rent payments will be approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into).              
Amortization of right of lease asset             $ 27,050    
Spain [Member] | Euro [Member]                  
Monthly rent payments | €   € 178              
ASU No. 2016-02 [Member]                  
Right of use asset               7,492  
Lease liability               $ 7,895  
ASU No. 2016-02 [Member] | Spain [Member]                  
Right of use asset $ 4,574                
Lease liability $ 4,574                
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease - Schedule of Maturity of Operating Lease Liability (Details)
Jun. 30, 2019
USD ($)
Leases [Abstract]  
2020 $ 6,665
2021 2,288
2022 518
Total lease payments $ 9,471
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease - Schedule of Operating Lease Cost (Details) - USD ($)
 3 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Leases [Abstract]    
Amortization of right of lease asset $ 2,996
Lease interest cost 153
Total Lease cost $ 3,149
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Operating Lease - Schedule of Operating Lease Liability (Details) - USD ($)
 3 Months Ended
Jun. 30, 2019
Apr. 02, 2019
Mar. 31, 2019
Leases [Abstract]      
Discounted Operating Lease liability $ 27,050    
Financing cost 1,055    
Less lease payments made (18,204)    
Cumulative effect of adoption of ASC 842 (430)    
Operating lease liability 9,471 $ 7,895  
Less Lease Liability current portion (7,300)  
Lease Liability - long-term $ 2,171  
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets (Details Narrative) - USD ($)
Jan. 12, 2019
Apr. 08, 2019
Dec. 22, 2016
Ownership [Member]      
Ownership interest percentage   0.42%  
Transfer Agreement [Member] | Open Therapeutics [Member]      
Contingent liability $ 75,000    
Extinguishment of contingent liability $ 75,000    
Restricted common stock issued during period 500,000    
Restricted common stock issued during period, value $ 24,750    
Shares issued price per share $ 0.0495    
Transfer Agreement [Member] | Open Therapeutics [Member]      
Membership interest percentage     80.00%
Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period     80.00%
Percentage of net profit generated     20.00%
Contingent liability     $ 75,000
Transfer Agreement [Member] | Ownership [Member] | Open Therapeutics [Member]      
Ownership interest percentage     20.00%
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2019
Accrued interest $ 16,946 $ 30,780   $ 30,780
Conversion of convertible debt, amount 142,500 $ 21,000    
Interest expense $ 121,814   $ 23,496  
GS Capital Note [Member]        
Number of shares issued from common stock for conversion of debt, shares 2,650,000      
Debt conversion, description The Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution, and shall maintain a 2.5 times reserve for the amount then outstanding.      
Accrued interest $ 118      
Convertible Notes [Member]        
Number of shares issued from common stock for conversion of debt, shares 888,308     5,946,516
Conversion of convertible debt, amount $ 40,000     $ 187,000
Conversion of convertible debt, accrued interest $ 1,973     $ 13,718
Average conversion price per share   $ 0.03375   $ 0.03375
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Total notes payable and convertible notes $ 560,000 $ 570,000
Less - note discounts (324,580) (356,125)
Less - current portion of these notes (235,420) (213,875)
Total notes payable and convertible notes, net discounts - long-term
Alternative Strategy Partners PTE Ltd [Member]    
Total notes payable and convertible notes [1] 90,000
GS Capital Partners LLC - Oct 2018 [Member]    
Total notes payable and convertible notes [2] 140,000 180,000
GS Capital Partners LLC - March 2019 [Member]    
Total notes payable and convertible notes [3] 300,000 300,000
GS Capital Partners LLC - May 2019 [Member]    
Total notes payable and convertible notes [4] 60,000
GS Capital Partners LLC - June 2019 [Member]    
Total notes payable and convertible notes [5] $ 60,000
[1] Three-month $180,000 non-convertible debenture dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from Alternative Strategy Partners PTE Ltd. ("ASP") to compensate a consultant. The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc. ("Eishin"), but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of December 31, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. Upon settlement, this note had accrued interest of $23,468. As a result, the Company and ASP, on May 29, 2019, agreed and acknowledged that they shall have no debt, liability or any obligation between them and that the ASP Loan Agreement is immediately retired (except with respect to the assignment and transfer of the Eishin shares noted above). Since the Eishen rights were not valued on the Company's balance sheet, the $113,468 liability has been removed from the Company's balance sheet, as is reflected in the Company's financial statement as a gain on extinguishment of debt in the amount of $113,467 during the three months ended June 30, 2019.
[2] On October 25, 2018, the Company entered into a one-year $180,000 convertible note bearing 8% interest with GS Capital Partners, LLC. The note has an original issue discount of $11,750. A portion of the proceeds will be used to retire the two remaining convertible notes on the books of the Company as of December 31, 2018 with GS Capital Partners, LLC. The face value of this note plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the $108,111 which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. On June 7, 2019, GS Capital Partners, LLC converted $40,000 of principal and $1,973 of accrued interest into 888,308 shares of common stock. Accrued interest as of June 30, 2019 was $8,227.
[3] On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital Partners, LLC, with a maturity date of March 13, 2020. The GS Capital Note carries $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company is obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company's consolidated statement of operations during the year ended March 31,2019. These shares were not issued as of March 31, 2019. The Holder is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. The GS Capital Note may be redeemed by the Company during the first six months from execution, as follows: (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution. At June 30, 2019, this note had accrued interest of $8,219. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled.
[4] On May 24, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of May 23, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on May 24, 2019. The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company's common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. At June 30, 2019, this note had accrued interest of $500.
[5] On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note has a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company's common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) (Parenthetical) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 27, 2019
Jun. 21, 2019
Jun. 07, 2019
May 24, 2019
Mar. 14, 2019
Oct. 25, 2018
Sep. 23, 2015
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2019
Proceeds from notes payable               $ 110,000   $ 25,000  
Gain on extinguishment of debt               (113,467)    
Conversion of convertible debt, amount               142,500 $ 21,000    
Accrued interest               16,946 30,780   $ 30,780
Number of common stock issued               $ 45,000 $ 301,200    
Securities Purchase Agreement [Member]                      
Warrant term               3 years 3 years   3 years
GS Capital Note [Member] | Securities Purchase Agreement [Member]                      
Debt conversion, description       The Company issued irrevocable transfer agent instructions reserving 3,327,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") within 5 days from the date of execution and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled.              
Accrued interest       $ 500              
GS Capital Partners, LLC [Member]                      
Debt principal amount                 $ 80,000   $ 80,000
Debt Instrument term                     1 year
Warrant term                 5 years   5 years
GS Capital Partners, LLC [Member] | Convertible Note [Member] | Securities Purchase Agreement [Member]                      
Debt principal amount   $ 60,000   $ 60,000              
Debt instrument, interest rate   8.00%   8.00%              
Debt Instrument term   1 year   1 year              
Percentage of share price multiplied by the lowest closing price   66.00%   66.00%              
Debt conversion, description   The Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company.   The Company experiences a DTC "Chill" on its shares, the conversion price shall be decreased to 56% instead of 66% while that "Chill" is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company. During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days.              
Default interest rate   0.24   0.24              
Debt instrument redemption, description   (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.   (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company's stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (iv) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.              
Original issue of discount   $ 5,000   $ 5,000              
Notes maturity date   Jun. 21, 2020   May 23, 2020              
Funded amount   $ 55,000   $ 55,000              
Non-Convertible Debenture [Member]                      
Debt principal amount             $ 180,000        
Debt instrument, interest rate             11.50%        
Debt maturity date description             The note matured in December 2015        
Proceeds from notes payable             $ 90,000        
Accrued interest               $ 23,468      
Gain on extinguishment of debt               113,467      
Non-Convertible Debenture [Member] | Consultant [Member]                      
Proceeds from notes payable             15,000        
Non-Convertible Debenture [Member] | Company [Member]                      
Proceeds from notes payable             75,000        
Non-Convertible Debenture [Member] | Eishin, Inc [Member]                      
Proceeds from notes payable             $ 90,000        
Convertible Note [Member] | GS Capital Partners, LLC [Member]                      
Debt principal amount           $ 180,000          
Debt instrument, interest rate           8.00%          
Debt Instrument term           1 year          
Percentage of share price multiplied by the lowest closing price           70.00%          
Debt conversion, description           The face value of this note plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect.          
Beneficial conversion feature debt discount           $ 108,111          
Default interest rate           0.24          
Debt instrument redemption, description           (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest.          
Original issue of discount           $ 11,750          
Conversion of convertible debt, amount     $ 40,000                
Conversion of convertible debt, accrued interest     $ 1,973                
Conversion of convertible debt, shares     888,308                
Accrued interest               8,227      
Convertible Debenture [Member] | GS Capital Partners, LLC [Member]                      
Debt principal amount         $ 300,000            
Debt instrument, interest rate         8.00%            
Debt Instrument term         12 months            
Percentage of share price multiplied by the lowest closing price         68.00%            
Debt instrument redemption, description         (i) if the redemption is within the first 90 days, then for an amount equal to 120% of the unpaid principal amount, with any accrued interest; (ii) if the redemption is after the 91st day, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount, with any accrued interest. The GS Capital Note may not be redeemed after 180 days from the date of execution.            
Original issue of discount         $ 20,000            
Accrued interest               $ 8,219      
Notes maturity date         Mar. 13, 2020            
Gross proceeds from convertible debt         $ 280,000            
Number of common stock shares issued                     750,000
Number of common stock issued                     $ 142,500
Shares issued price per share                 $ 0.19   $ 0.19
Cashless warrants 213,334                    
Warrant term 5 years                    
Debt principal amount cancelled $ 80,000                    
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Related Parties (Details Narrative) - USD ($)
Dec. 31, 2018
Jul. 22, 2019
Ice + Jam LLC [Member]    
Cash collected related party sales $ 581  
Due to related party $ 5,522  
Convertible Note [Member] | Securities Purchase Agreement [Member] | Jefferson Street Capital, LLC [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]    
Debt instrument, interest rate   10.00%
Debt principal amount   $ 55,000
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Deficit) (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 12, 2019
Feb. 01, 2012
Aug. 10, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Mar. 31, 2019
Aug. 13, 2019
Jul. 26, 2019
Mar. 14, 2019
Jul. 08, 2018
Common stock authorized       100,000,000 100,000,000     100,000,000       7,500,000,000
Common stock, shares issued       72,925,920                
Common stock, shares outstanding       72,925,920 68,123,326     68,123,326        
Number of common stock issued       $ 45,000 $ 301,200              
Share-based compensation expense       $ 375,720     $ 43,221          
GS Capital Partners, LLC [Member]                        
Number of warrants expired               213,334        
Debt term               1 year        
Debt instruments interest rate               5.00%        
Debt principal amount         $ 80,000     $ 80,000        
Warrant term         5 years     5 years        
Warrant exercise price per share         $ 0.2625     $ 0.2625        
Warrant cancelled                     $ 300,000  
Common Stock [Member]                        
Number of common stock shares issued       714,286 5,686,667              
Number of common stock issued       $ 7 $ 56              
Number of common stock shares issued for service       2,450,000 1,250,000 1,750,000 130,000          
One Current Executive [Member]                        
Options to purchase common shares   66,667                    
One Former Executive [Member]                        
Options to purchase common shares   66,667                    
Executives [Member]                        
Options to purchase common shares   133,334                    
Securities Purchase Agreement [Member]                        
Warrant term       3 years 3 years     3 years        
Warrant exercise price per share       $ 0.75 $ 0.75     $ 0.75        
Warrants shares awarded       389,344 10,001     10,001        
Fiscal Year 2019 [Member] | Open Therapeutics [Member]                        
Restricted common stock issued during period 500,000                      
Restricted common stock issued during period, value $ 24,750                      
Shares issued price per share $ 0.0495                      
Contingent liability $ 75,000                      
Fiscal Year 2019 [Member] | Common Stock [Member]                        
Number of common stock shares issued               5,686,667        
Number of common stock issued               $ 301,200        
Fiscal Year 2019 [Member] | Common Stock [Member] | Minimum [Member]                        
Shares issued price per share         $ 0.02     $ 0.02        
Fiscal Year 2019 [Member] | Common Stock [Member] | Maximum [Member]                        
Shares issued price per share         0.06     0.06        
Fiscal Year 2019 [Member] | Common Stock One [Member]                        
Shares issued price per share         0.042     $ 0.042        
Number of common stock shares issued               500,000        
Number of common stock issued               $ 21,000        
Fiscal Year 2019 [Member] | Common Stock Two [Member]                        
Number of common stock shares issued               95,667        
Number of common stock issued               $ 20,004        
Fiscal Year 2019 [Member] | Noteholders [Member]                        
Restricted common stock issued during period               5,946,516        
Restricted common stock issued during period, value               $ 200,718        
Shares issued price per share         0.03375     $ 0.03375        
Fiscal Year 2019 [Member] | Consulting Agreements [Member]                        
Restricted common stock issued during period               3,130,000        
Fiscal Year 2020 [Member]                        
Shares issued price per share       $ 0.04725                
Number of shares issued from common stock for conversion of debt, shares       888,308                
Number of shares issued from common stock for conversion of debt       $ 40,000                
Accrued interest       $ 1,964                
Number of common stock shares issued for service       1,000,000                
Number of common stock shares issued for debt commitment       750,000                
Number of common stock issued for debt commitment       $ 142,500                
Stock issued during period, per share       $ 0.19                
Fiscal Year 2020 [Member] | Vice President [Member]                        
Number of common stock shares issued       250,000                
Fiscal Year 2020 [Member] | Distribution Agreements [Member]                        
Number of common stock shares issued       1,200,000                
Fiscal Year 2020 [Member] | Stock Purchase Agreements [Member] | Accredited Investors [Member]                        
Shares issued price per share         $ 0.063     $ 0.063        
Number of common stock shares issued       714,286                
Number of common stock issued       $ 45,000                
Subsequent Event [Member]                        
Common stock authorized                   400,000,000    
Common stock, shares issued                 75,895,090      
Common stock, shares outstanding                 75,895,090      
Subsequent Event [Member] | Distribution Agreements [Member]                        
Number of common stock shares issued     250,000                  
Number of shares issued from common stock for conversion of debt, shares     2,719,170                  
Debt principal amount     $ 75,000                  
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - Warrants [Member] - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Shares, Outstanding, Beginning balance 1,210,276 1,433,611
Shares, Granted
Shares, Expired (389,344) (223,335)
Shares, Exercised
Shares, Cancelled
Shares, Outstanding and exercisable, Ending balance 820,932 1,210,276
Weighted Average Exercise Price, Outstanding, Beginning balance $ 1.2 $ 1.06
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired 0.75 0.2843
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Outstanding and exercisable, Ending balance $ 1.41 $ 1.2
Weighted Average Remaining Contractual Term, Outstanding, Beginning 1 year 3 months 11 days 3 years 7 days
Weighted Average Remaining Contractual Term, Outstanding and exercisable, Ending 1 year 4 months 28 days 1 year 3 months 11 days
Aggregate Intrinsic Value, Outstanding Beginning
Aggregate Intrinsic Value, Outstanding and exercisable, Ending
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Equity [Abstract]    
Number of Options, Outstanding, Beginning balance 133,334 133,334
Number of Options, Granted
Number of Options, Expired
Number of Options, Exercised
Number of Options, Outstanding, Ending balance   133,334
Number of Options, Outstanding and exercisable, Ending balance 133,334  
Weighted Average Exercise Price, Outstanding, Beginning balance $ 7.50 $ 7.50
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Outstanding, Ending balance   $ 7.50
Weighted Average Exercise Price, Outstanding and exercisable, Ending balance $ 7.50  
Weighted Average Remaining Contractual Term Outstanding, Beginning 2 years 10 months 6 days 3 years 10 months 6 days
Weighted Average Remaining Contractual Term Outstanding, Ending   2 years 10 months 6 days
Weighted Average Remaining Contractual Term Outstanding and exercisable , Ending 2 years 7 months 6 days  
Aggregate Intrinsic Value Outstanding, Beginning
Aggregate Intrinsic Value Outstanding, Ending  
Aggregate Intrinsic Value Outstanding and exercisable, Ending  
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Provision for Income Taxes (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 22, 2017
Jun. 30, 2019
Mar. 31, 2019
Increase (decrease) in valuation allowance   $ 137,005 $ 1,516,710
Income tax examination description   Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. The effective rate for the year ended March 31, 2018 was 31% as the rate was changed effective January 1, 2018 to the lower rate.  
Federal tax rate 21.00% 21.00% 21.00%
Untaxed earnings and profit tax rate 15.50%    
Tax rate on remaining balance 8.00%    
United States [Member]      
Net operating loss carryforward   $ 17,900,000  
Net operating loss carryforward, expiration year   2038  
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Provision for Income Taxes - Schedule of Effective Income Tax Rate (Details)
 3 Months Ended 12 Months Ended
Dec. 22, 2017
Jun. 30, 2019
Mar. 31, 2019
Income Tax Disclosure [Abstract]      
Federal income taxes at statutory rate 21.00% 21.00% 21.00%
State income taxes at statutory rate   0.00% 0.00%
Temporary differences   8.99% 1.48%
Permanent differences   0.17% 0.24%
Impact of Tax Reform Act   0.00% (167.44%)
Change in valuation allowance   (30.16%) 144.72%
Totals   0.00% 0.00%
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.19.2
Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Deferred tax assets: Net operating losses before non-deductible items $ 3,763,732 $ 3,685,807
Deferred tax assets: Loss on disposal of fixed assets 355 355
Deferred tax assets: Stock-based compensation 288,492 209,591
Deferred tax assets: Unrealized gains or losses on investments (24,079) (4,258)
Total deferred tax assets 4,028,500 3,891,495
Less: Valuation allowance (4,028,500) (3,891,495)
Net deferred tax assets
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.19.2
Investments (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Apr. 08, 2019
Mar. 21, 2019
Oct. 31, 2018
Sep. 04, 2018
Aug. 25, 2018
Aug. 20, 2018
Jul. 15, 2018
Jul. 08, 2018
Apr. 02, 2018
Jun. 30, 2019
Mar. 31, 2019
Aug. 01, 2017
Reverse stock split               Ratio of 1-for-75        
Conversion of BTC           $ 26,783            
Conversion of gold and silver commodities         $ 24,046              
Loss on transaction         $ 2,737              
Pre- money valuation amount $ 10,200,000                      
Honeywood Conversion Agreement [Member]                        
Investment amount                   $ 0    
Ownership [Member]                        
Ownership interest percentage 0.42%                      
Cost investments $ 20,400                      
Groestlcoin [Member]                        
Cumulative purchase amount                 $ 8,000      
Purchase of units                 11,922.81      
Purchase of units, price per share                 $ 0.6569      
Sale of units             39,862          
Conversion into BTC             4.17          
Sale of units value             $ 32,230          
Unrealized loss on digital currency exchange                     $ 3,143  
Investment - digital currency                      
AYTU Bioscience [Member] | Common Stock [Member]                        
Warrants purchase of common shares                   5,555    
Warrants strike price                   $ 10.80    
Warrants expired date                   Mar. 06, 2023    
Reverse stock split                   1 for 20 reverse stock split    
AYTU Bioscience [Member] | Warrants [Member]                        
Warrants strike price                   $ 9.13    
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock [Member]                        
Warrants purchase of common shares                   320,000    
Warrants strike price                   $ 1.50    
Warrants expired date                   Dec. 13, 2022    
VistaGen Therapeutics, Inc. (VTGN) [Member] | Warrants [Member]                        
Warrants strike price                   $ 0.25    
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock One [Member]                        
Warrants purchase of common shares                   230,000    
Warrants strike price                   $ 1.50    
Warrants expired date                   Feb. 28, 2022    
Honeywood [Member] | Ownership [Member]                        
Ownership interest percentage                       5.00%
Kudzoo, Inc [Member]                        
Cost investments                     $ 37,500  
Pre- money valuation amount $ 10,200,000 $ 10,200,000   $ 7,500,000                
Kudzoo, Inc [Member] | Ownership [Member]                        
Ownership interest percentage 2.00% 0.22%   0.20%                
Cost investments $ 20,400 $ 22,500   $ 15,000                
Serendipity Brands LLC [Member]                        
Pre- money valuation amount     $ 14,000,000                  
Serendipity Brands LLC [Member] | Ownership [Member]                        
Ownership interest percentage     0.24%                  
Cost investments     $ 35,000                  
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.19.2
Investments - Schedule of Investment in Trading Securities (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Mar. 31, 2018
Investment of cost at beginning $ 317,500 $ 801,148  
Investment of purchase 1,612,010  
Investment of sales proceeds (2,195,481)  
Investment of cost at end 317,500 317,500  
Investment of fair value 444,785 350,400  
Investment of realized gain (loss) 99,823  
Investment of unrealized gain (loss) 127,285 [1] 32,900 [2]  
Green Innovations Ltd (GNIN) [Member]      
Investment of cost at beginning   [2],[3] $ 250,000
Investment of purchase [2],[3]    
Investment of sales proceeds   [2],[3] (6,815)
Investment of cost at end [2],[3]    
Investment of fair value [2],[3]    
Investment of realized gain (loss) [2],[3]    
Investment of unrealized gain (loss) [2],[3]    
VistaGen Therapeutics, Inc. (VTGN) [Member]      
Investment of cost at beginning 287,500 [4] 490,117 [4] 490,117
Investment of purchase [4] 349,498  
Investment of sales proceeds [4] (517,485)  
Investment of cost at end [4] 287,500 287,500  
Investment of fair value 166,865 [4] 294,400 [4] 306,207
Investment of realized gain (loss) [4] (34,630)  
Investment of unrealized gain (loss) [4] (120,635) 6,900  
Blink Charging Co (BLNK) [Member]      
Investment of cost at beginning [5]   190,350  
Investment of purchase [5]   151,666  
Investment of sales proceeds [5]   (367,142)  
Investment of cost at end [5]    
Investment of fair value [5]    
Investment of realized gain (loss) [5]   25,126  
Investment of unrealized gain (loss) [5]    
Blink Charging Co (BLNKW) (Warrants) [Member]      
Investment of cost at beginning [5]   900  
Investment of purchase [5]   162,215  
Investment of sales proceeds [5]   (468,496)  
Investment of cost at end [5]    
Investment of fair value [5]    
Investment of realized gain (loss) [5]   305,381  
Investment of unrealized gain (loss) [5]    
Aytu BioScience Inc (AYTU) [Member]      
Investment of cost at beginning   82,270 [6]
Investment of purchase [6]   100,030  
Investment of sales proceeds [6]   (144,094)  
Investment of cost at end   [6] 82,270
Investment of fair value   [6] 119,947
Investment of realized gain (loss) [6]   (38,206)  
Investment of unrealized gain (loss) [6]    
Lightbridge Corp. (LTBR) [Member]      
Investment of cost at beginning   37,511 [7]
Investment of purchase [7]   299,028  
Investment of sales proceeds   (276,159) [7]
Investment of cost at end   [7] 37,511
Investment of fair value   [7] $ 29,250
Investment of realized gain (loss) [7]   (60,380)  
Investment of unrealized gain (loss) [7]    
Pulmatrix Inc PULM [Member]      
Investment of cost at beginning [8]    
Investment of purchase [8]   204,802  
Investment of sales proceeds [8]   (183,737)  
Investment of cost at end [8]    
Investment of fair value [8]    
Investment of realized gain (loss) [8]   (21,065)  
Investment of unrealized gain (loss) [8]    
Axovant Sciences Ltd AXON [Member]      
Investment of cost at beginning [9]    
Investment of purchase [9]   103,938  
Investment of sales proceeds [9]   (98,433)  
Investment of cost at end [9]    
Investment of fair value [9]    
Investment of realized gain (loss) [9]   (5,505)  
Investment of unrealized gain (loss) [9]    
Basanite Inc. (BASA) [Member]      
Investment of cost at beginning [10] 30,000  
Investment of purchase [10] 42,998  
Investment of sales proceeds [10] (10,821)  
Investment of cost at end [10] 30,000 30,000  
Investment of fair value [10] 277,920 56,000  
Investment of realized gain (loss) [10] (2,177)  
Investment of unrealized gain (loss) [10] $ 247,920 26,000  
Achieve Life Sciences (ACHV) [Member]      
Investment of cost at beginning [11]    
Investment of purchase [11]   177,356  
Investment of sales proceeds [11]   (112,221)  
Investment of cost at end [11]    
Investment of fair value [11]    
Investment of realized gain (loss) [11]   (65,135)  
Investment of unrealized gain (loss) [11]    
Decision Diagnostics (DECN) [Member]      
Investment of cost at beginning [12]    
Investment of purchase [12]   20,479  
Investment of sales proceeds [12]   (16,893)  
Investment of cost at end [12]    
Investment of fair value [12]    
Investment of realized gain (loss) [12]   (3,586)  
Investment of unrealized gain (loss) [12]    
[1] This amount represents the cumulative unrealized gain as of June 30, 2019, which includes $94,385 for the three months ended June 30, 2019.
[2] Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.
[3] During the year ended March 31, 2018, the Company's investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company's investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.
[4] On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company's broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company's broker of record.
[5] The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company's investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
[6] On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.
[7] On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380.
[8] During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.
[9] During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
[10] On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of June 30, 2019, the Company had an unrealized gain of $247,920. In conjunction with the investment, the Company agreed to a 12-month resale restriction. BASA is publicly traded on the OTC:Pink. As June 30, 2019, these shares were not on deposit held with the Company's broker of record.
[11] During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135.
[12] During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.19.2
Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 09, 2018
Jul. 05, 2018
Mar. 26, 2018
Mar. 12, 2018
Mar. 08, 2018
Mar. 02, 2018
Feb. 14, 2018
Dec. 11, 2017
Jul. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2019
Mar. 31, 2018
Investment unrealized gain (loss)                   $ 94,385 $ 78,170 $ 223,349  
Proceeds from investment                     2,195,481  
Investment cost                   317,500   801,148  
Investment realized gain (loss)                   340,020    
Fair value of investment                   444,785   350,400  
Investment of cost net                   317,500   317,500  
Green Innovations Ltd (GNIN) [Member]                          
Proceeds from investment                       [1],[2] $ 6,815
Investment cost                       [1],[2] 250,000
Investment realized gain (loss)                         243,185
Comprehensive gain                       125  
Fair value of investment [1],[2]                        
Investment of cost net [1],[2]                        
VistaGen Therapeutics, Inc. (VTGN) [Member]                          
Investment unrealized gain (loss)                         183,910
Proceeds from investment [3]                     517,485  
Investment cost                   287,500 [3]   490,117 [3] 490,117
Investment realized gain (loss)                       $ 34,630  
Number of common stock shares purchased                       59,380  
Fair value of investment                   166,865 [3]   $ 294,400 [3] 306,207
Number of common stock shares purchased value                       $ 61,998  
Share issued price per share                       $ 1.04  
Number of common stock sold shares                       389,380  
Sale of stock price per share                       $ 1.33  
Investment of cost net [3]                   287,500   $ 287,500  
VistaGen Therapeutics, Inc. (VTGN) [Member] | Restricted Common Stock [Member]                          
Investment unrealized gain (loss)                       $ 120,635  
Number of common stock shares purchased                       230,000  
Number of common stock shares purchased value                       $ 287,500  
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock [Member]                          
Investment cost               $ 480,000          
Number of common stock shares purchased               320,000          
Warrants purchase of common shares               320,000          
Warrant term               5 years          
Warrants strike price               $ 1.50          
Additional number of common stock purchased     10,000                    
Blink Charging Co (BLNK) [Member]                          
Proceeds from investment [4]                       367,142  
Investment cost [4]                       190,350  
Fair value of investment [4]                        
Investment of cost net [4]                        
Participated in underwritten public offering amount             $ 18,500,250            
Blink Charging Co (BLNK) [Member] | Warrants [Member]                          
Investment unrealized gain (loss)                         35,955
Fair value of investment                         155,295
Investment of cost net                         191,250
Blink Charging Co (BLNK) [Member] | Balance Sheet Cash [Member]                          
Investment cost                         $ 191,250
Blink Charging Co (BLNK) [Member] | Common Stock [Member]                          
Proceeds from investment                     367,142    
Investment realized gain (loss)                     $ 25,126    
Number of common stock shares purchased                     41,018    
Warrants purchase of common shares                     208,800   45,000
Warrant term                         5 years
Warrants strike price                     $ 0.77   $ 4.25
Number of common stock shares purchased value                     $ 151,666    
Share issued price per share                     $ 3.69    
Number of common stock sold shares                     86,018    
Sale of stock price per share                     $ 4.26    
Sale of warrants purchased                     298,800    
Sale of warrant purchased value                     $ 468,496    
Blink Charging Co (BLNK) [Member] | Common Stock [Member] | Maximum [Member]                          
Additional number of common stock purchased                         90,000
Blink Charging Co (BLNK) [Member] | Warrants [Member]                          
Investment realized gain (loss)                     $ 305,381    
Warrants strike price                     $ 1.60    
Aytu BioScience Inc (AYTU) [Member]                          
Proceeds from investment [5]                       144,094  
Investment cost                       82,270 [5]
Investment realized gain (loss)                       $ 38,206  
Number of common stock shares purchased                       260,000  
Fair value of investment                       [5] 119,947
Number of common stock shares purchased value                       $ 100,830  
Share issued price per share                       $ 0.38  
Number of common stock sold shares                       448,300  
Sale of stock price per share                       $ 0.32  
Investment of cost net                       [5] 82,270
Aytu BioScience Inc (AYTU) [Member] | Common Stock [Member]                          
Investment unrealized gain (loss)                         37,677
Number of common stock shares purchased         188,300 188,300              
Lightbridge Corp. (LTBR) [Member]                          
Investment unrealized gain (loss)                         8,261
Proceeds from investment                       276,159 [6]
Investment cost                       37,511 [6]
Investment realized gain (loss)                       $ 60,380  
Number of common stock shares purchased                       287,405  
Fair value of investment                       [6] 29,250
Number of common stock shares purchased value                       $ 295,625  
Share issued price per share                       $ 1.03  
Number of common stock sold shares                       312,405  
Sale of stock price per share                       $ 0.884  
Investment of cost net                       [6] $ 37,511
Lightbridge Corp. (LTBR) [Member] | Common Stock [Member]                          
Number of common stock shares purchased       25,000                  
Pulmatix Inc PULM [Member]                          
Proceeds from investment [7]                       183,747  
Investment realized gain (loss)                       $ 21,065  
Number of common stock shares purchased                       391,514  
Number of common stock shares purchased value                       $ 204,802  
Share issued price per share                       $ 0.52  
Number of common stock sold shares                       391,514  
Sale of stock price per share                       $ 0.47  
Axovant Sciences Ltd AXON [Member]                          
Proceeds from investment [8]                       $ 98,433  
Investment cost [8]                        
Investment realized gain (loss)                       $ 5,505  
Number of common stock shares purchased                       40,000  
Fair value of investment [8]                        
Number of common stock shares purchased value                       $ 103,938  
Share issued price per share                       $ 2.60  
Number of common stock sold shares                       40,000  
Sale of stock price per share                       $ 2.46  
Investment of cost net [8]                        
Basanite Industries Inc. (BASA) [Member]                          
Investment unrealized gain (loss)                   $ 247,920      
Proceeds from investment                 $ 10,821        
Investment realized gain (loss)                 $ 2,177        
Number of common stock shares purchased   100,000                      
Number of common stock shares purchased value   $ 12,998                      
Share issued price per share   $ 0.13                      
Number of common stock sold shares                 100,000        
Sale of stock price per share                 $ 0.11        
Basanite Industries Inc. (BASA) [Member] | Restricted Common Stock [Member]                          
Number of common stock shares purchased 400,000                        
Number of common stock shares purchased value $ 30,000                        
Share issued price per share $ 0.075                        
Achieve Life Sciences (ACHV) [Member]                          
Proceeds from investment [9]                       112,221  
Investment cost [9]                        
Investment realized gain (loss)                       $ 65,135  
Number of common stock shares purchased                       44,000  
Fair value of investment [9]                        
Number of common stock shares purchased value                       $ 177,355  
Share issued price per share                       $ 4.03  
Number of common stock sold shares                       44,000  
Sale of stock price per share                       $ 2.55  
Investment of cost net [9]                        
Decision Diagnostics (DECN) [Member]                          
Proceeds from investment [10]                       16,893  
Investment cost [10]                        
Investment realized gain (loss)                       $ 3,586  
Number of common stock shares purchased                       450,000  
Fair value of investment [10]                        
Number of common stock shares purchased value                       $ 20,480  
Share issued price per share                       $ 0.046  
Sale of stock price per share                       $ 0.038  
Investment of cost net [10]                        
[1] During the year ended March 31, 2018, the Company's investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company's investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the year ended March 31, 2019, there was a realized gain of $125.
[2] Represents the Unrealized Gain (Loss) at March 31, 2019 for securities being held by the Company. For the year ended March 31, 2019, there was a cumulative unrealized gain on trading securities of $223,349 on these investments.
[3] On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. As of March 31, 2019, these shares were not on deposit with the Company's broker of record. As of June 30, 2019, the Company has an unrealized loss on these shares in the amount of $120,635, and for the year ended March 31, 2019 has recorded a total realized loss of $34,630 in VTGN. As June 30, 2019, these shares were not on deposit held with the Company's broker of record.
[4] The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company's investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
[5] On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the year ended March 31, 2019, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the year ended March 31, 2019, the Company had a realized loss of $38,206 on this holding.
[6] On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 287,405 shares of LTBR for $295,625 (average of $1.03 per share). During the year ended March 31, 2019, the Company sold 312,405 shares of LTBR for $276,159 (average price per share of $0.884) realizing a loss of $60,380.
[7] During the year ended March 31, 2019, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the year ended March 31, 2019, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.
[8] During the year ended March 31, 2019, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the year ended March 31, 2019, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
[9] During the year ended March 31, 2019, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the year ended March 31, 2019, the Company sold all 44,000 shares for $112,221 ($2.55 per share) for a realized loss of $65,135.
[10] During the year ended March 31, 2019, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the year ended March 31, 2019, the Company sold all of its shares for $16,893 ($0.038 per share) for a realized loss of $3,586.
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
Jun. 30, 2019
Mar. 31, 2019
Investment-trading securities $ 444,785 $ 350,400
Kudzoo [Member]    
Cost method investments 57,900 37,500
Serendipity Brands [Member]    
Cost method investments 35,000 35,000
Level 1 [Member]    
Investment-trading securities 444,785 350,400
Level 1 [Member] | Kudzoo [Member]    
Cost method investments
Level 1 [Member] | Serendipity Brands [Member]    
Cost method investments
Level 2 [Member]    
Investment-trading securities
Level 2 [Member] | Kudzoo [Member]    
Cost method investments
Level 2 [Member] | Serendipity Brands [Member]    
Cost method investments
Level 3 [Member]    
Investment-trading securities
Level 3 [Member] | Kudzoo [Member]    
Cost method investments 57,900 37,500
Level 3 [Member] | Serendipity Brands [Member]    
Cost method investments $ 35,000 $ 35,000
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.19.2
Concentrations (Details Narrative)
 3 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Accounts Receivable [Member] | One Supplier [Member]    
Concentration of risk percentage 100.00% 100.00%
Sales Revenue [Member] | One Customer [Member]    
Concentration of risk percentage 23.96% 97.00%
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent Events (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Aug. 12, 2019
Jul. 22, 2019
Aug. 10, 2019
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Jul. 26, 2019
Jul. 08, 2018
Accrued interest       $ 16,946 $ 30,780      
Conversion of convertible debt, amount       $ 142,500 $ 21,000      
Debt interest rate upon default       8.00%        
Common stock, shares authorized       100,000,000 100,000,000     7,500,000,000
Proceeds from notes payable       $ 110,000   $ 25,000    
Notes payable       $ 560,000 $ 570,000      
Subsequent Event [Member]                
Common stock, shares authorized             400,000,000  
Subsequent Event [Member] | Distribution Agreements [Member]                
Number of common stock shares issued     250,000          
Number of shares issued from common stock for conversion of debt, shares     2,719,170          
Debt instrument face amount     $ 75,000          
Accrued interest     $ 4,373          
Subsequent Event [Member] | Convertible Debt [Member]                
Number of shares issued for debt commitment     250,000          
Subsequent Event [Member] | Convertible Debt [Member] | Jefferson Street Capital, LLC [Member]                
Number of shares issued for debt commitment   250,000            
Debt instrument face amount   $ 55,000            
Original issue discount   $ 50,000            
Debt instrument interest rate   10.00%            
Debt instrument term   9 months            
Conversion of convertible debt, amount   $ 10,500            
Shares issued, price per share   $ 0.042            
Legal fees   $ 2,000            
Original issue discount deducted from proceeds   5,000            
Proceeds from issuance of convertible debt   $ 48,000            
Common stock reserved for issuance   1,000,000            
Debt payment terms, description   During the first 180 days, the Company may prepay the principal amount of this note and accrued interest thereon, with a premium as follows: (a) 120% of the prepayment penalty for redemptions in the first 90 days after the note issuance; and (b) 133% of the prepayment amount if such prepayment was made at any time from (91 days after the issuance date until 180 days after the issuance date). The note is not able to be prepaid after 180 days after the issuance date            
Debt interest rate upon default   24.00%            
Subsequent Event [Member] | Convertible Debt [Member] | Jefferson Street Capital, LLC [Member] | Upon Increase of Authorized Common Shares [Member]                
Common stock reserved for issuance   15,000,000            
Subsequent Event [Member] | 8% Convertible Redeemable Note Two [Member] | Securities Purchase Agreement [Member] | Adar Alef, LLC [Member]                
Original issue discount $ 5,000              
Legal fees 2,500              
Proceeds from notes payable 47,500              
Notes payable $ 55,000              
Subsequent Event [Member] | 8% Convertible Redeemable Notes [Member] | Securities Purchase Agreement [Member] | Adar Alef, LLC [Member]                
Debt instrument interest rate 8.00%              
Notes payable $ 110,000              
Debt instrument, description The Back-End Note was initially paid for by an offsetting promissory note issued by Adar Alef, LLC to the Company (the "Note Receivable'). The terms of the Back-End Note required cash funding prior to any conversion thereunder. The Note Receivable was due December 20, 2019, unless certain conditions were not met, in which case both the Back-End Note and the Note Receivable may both have been cancelled. The Back-End Note has a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The face value amount plus accrued interest under the Back-End Note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 60% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 50% instead of 60% while that "chill" is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. This note contains a provision where if the Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period they would be considered in default of this note. This Back-End Note may not be repaid. The note holder may redeem this note at any time after the first six months.              
Subsequent Event [Member] | 8% Convertible Redeemable Note One [Member] | Securities Purchase Agreement [Member] | Adar Alef, LLC [Member]                
Notes payable $ 55,000              
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 325 443 1 true 111 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://tauriga.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://tauriga.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://tauriga.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://tauriga.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) Sheet http://tauriga.com/role/StatementOfStockholdersEquityDeficit Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://tauriga.com/role/StatementOfStockholdersEquityDeficitParenthetical Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://tauriga.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis of Operations Sheet http://tauriga.com/role/BasisOfOperations Basis of Operations Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://tauriga.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Inventory Sheet http://tauriga.com/role/Inventory Inventory Notes 10 false false R11.htm 00000011 - Disclosure - Discontinued Operations Sheet http://tauriga.com/role/DiscontinuedOperations Discontinued Operations Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://tauriga.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Operating Lease Sheet http://tauriga.com/role/OperatingLease Operating Lease Notes 13 false false R14.htm 00000014 - Disclosure - Intangible Assets Sheet http://tauriga.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 00000015 - Disclosure - Notes Payable Notes http://tauriga.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 00000016 - Disclosure - Related Parties Sheet http://tauriga.com/role/RelatedParties Related Parties Notes 16 false false R17.htm 00000017 - Disclosure - Stockholders' Equity (Deficit) Sheet http://tauriga.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 17 false false R18.htm 00000018 - Disclosure - Provision for Income Taxes Sheet http://tauriga.com/role/ProvisionForIncomeTaxes Provision for Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - Investments Sheet http://tauriga.com/role/Investments Investments Notes 19 false false R20.htm 00000020 - Disclosure - Fair Value Measurements Sheet http://tauriga.com/role/FairValueMeasurements Fair Value Measurements Notes 20 false false R21.htm 00000021 - Disclosure - Concentrations Sheet http://tauriga.com/role/Concentrations Concentrations Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://tauriga.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://tauriga.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://tauriga.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Inventory (Tables) Sheet http://tauriga.com/role/InventoryTables Inventory (Tables) Tables http://tauriga.com/role/Inventory 24 false false R25.htm 00000025 - Disclosure - Discontinued Operations (Tables) Sheet http://tauriga.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://tauriga.com/role/DiscontinuedOperations 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Tables) Sheet http://tauriga.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://tauriga.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Operating Lease (Tables) Sheet http://tauriga.com/role/OperatingLeaseTables Operating Lease (Tables) Tables http://tauriga.com/role/OperatingLease 27 false false R28.htm 00000028 - Disclosure - Notes Payable (Tables) Notes http://tauriga.com/role/NotesPayableTables Notes Payable (Tables) Tables http://tauriga.com/role/NotesPayable 28 false false R29.htm 00000029 - Disclosure - Stockholders' Equity (Deficit) (Tables) Sheet http://tauriga.com/role/StockholdersEquityDeficitTables Stockholders' Equity (Deficit) (Tables) Tables http://tauriga.com/role/StockholdersEquityDeficit 29 false false R30.htm 00000030 - Disclosure - Provision for Income Taxes (Tables) Sheet http://tauriga.com/role/ProvisionForIncomeTaxesTables Provision for Income Taxes (Tables) Tables http://tauriga.com/role/ProvisionForIncomeTaxes 30 false false R31.htm 00000031 - Disclosure - Investments (Tables) Sheet http://tauriga.com/role/InvestmentsTables Investments (Tables) Tables http://tauriga.com/role/Investments 31 false false R32.htm 00000032 - Disclosure - Fair Value Measurements (Tables) Sheet http://tauriga.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://tauriga.com/role/FairValueMeasurements 32 false false R33.htm 00000033 - Disclosure - Basis of Operations (Details Narrative) Sheet http://tauriga.com/role/BasisOfOperationsDetailsNarrative Basis of Operations (Details Narrative) Details http://tauriga.com/role/BasisOfOperations 33 false false R34.htm 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://tauriga.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://tauriga.com/role/SummaryOfSignificantAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - Inventory (Details Narrative) Sheet http://tauriga.com/role/InventoryDetailsNarrative Inventory (Details Narrative) Details http://tauriga.com/role/InventoryTables 35 false false R36.htm 00000036 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://tauriga.com/role/Inventory-ScheduleOfInventoryDetails Inventory - Schedule of Inventory (Details) Details 36 false false R37.htm 00000037 - Disclosure - Discontinued Operations (Details Narrative) Sheet http://tauriga.com/role/DiscontinuedOperationsDetailsNarrative Discontinued Operations (Details Narrative) Details http://tauriga.com/role/DiscontinuedOperationsTables 37 false false R38.htm 00000038 - Disclosure - Discontinued Operations - Summary of Discontinued Operations (Details) Sheet http://tauriga.com/role/DiscontinuedOperations-SummaryOfDiscontinuedOperationsDetails Discontinued Operations - Summary of Discontinued Operations (Details) Details 38 false false R39.htm 00000039 - Disclosure - Property and Equipment (Details Narrative) Sheet http://tauriga.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://tauriga.com/role/PropertyAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://tauriga.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 40 false false R41.htm 00000041 - Disclosure - Operating Lease (Details Narrative) Sheet http://tauriga.com/role/OperatingLeaseDetailsNarrative Operating Lease (Details Narrative) Details http://tauriga.com/role/OperatingLeaseTables 41 false false R42.htm 00000042 - Disclosure - Operating Lease - Schedule of Maturity of Operating Lease Liability (Details) Sheet http://tauriga.com/role/OperatingLease-ScheduleOfMaturityOfOperatingLeaseLiabilityDetails Operating Lease - Schedule of Maturity of Operating Lease Liability (Details) Details 42 false false R43.htm 00000043 - Disclosure - Operating Lease - Schedule of Operating Lease Cost (Details) Sheet http://tauriga.com/role/OperatingLease-ScheduleOfOperatingLeaseCostDetails Operating Lease - Schedule of Operating Lease Cost (Details) Details 43 false false R44.htm 00000044 - Disclosure - Operating Lease - Schedule of Operating Lease Liability (Details) Sheet http://tauriga.com/role/OperatingLease-ScheduleOfOperatingLeaseLiabilityDetails Operating Lease - Schedule of Operating Lease Liability (Details) Details 44 false false R45.htm 00000045 - Disclosure - Intangible Assets (Details Narrative) Sheet http://tauriga.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://tauriga.com/role/IntangibleAssets 45 false false R46.htm 00000046 - Disclosure - Notes Payable (Details Narrative) Notes http://tauriga.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://tauriga.com/role/NotesPayableTables 46 false false R47.htm 00000047 - Disclosure - Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) Notes http://tauriga.com/role/NotesPayable-ScheduleOfNotesPayableAndConvertibleNotesDetails Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) Details 47 false false R48.htm 00000048 - Disclosure - Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) (Parenthetical) Notes http://tauriga.com/role/NotesPayable-ScheduleOfNotesPayableAndConvertibleNotesDetailsParenthetical Notes Payable - Schedule of Notes Payable and Convertible Notes (Details) (Parenthetical) Details 48 false false R49.htm 00000049 - Disclosure - Related Parties (Details Narrative) Sheet http://tauriga.com/role/RelatedPartiesDetailsNarrative Related Parties (Details Narrative) Details http://tauriga.com/role/RelatedParties 49 false false R50.htm 00000050 - Disclosure - Stockholders' Equity (Deficit) (Details Narrative) Sheet http://tauriga.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders' Equity (Deficit) (Details Narrative) Details http://tauriga.com/role/StockholdersEquityDeficitTables 50 false false R51.htm 00000051 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) Sheet http://tauriga.com/role/StockholdersEquityDeficit-ScheduleOfWarrantsActivityDetails Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) Details http://tauriga.com/role/StockholdersEquityDeficitTables 51 false false R52.htm 00000052 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) Sheet http://tauriga.com/role/StockholdersEquityDeficit-ScheduleOfStockOptionsActivityDetails Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) Details http://tauriga.com/role/StockholdersEquityDeficitTables 52 false false R53.htm 00000053 - Disclosure - Provision for Income Taxes (Details Narrative) Sheet http://tauriga.com/role/ProvisionForIncomeTaxesDetailsNarrative Provision for Income Taxes (Details Narrative) Details http://tauriga.com/role/ProvisionForIncomeTaxesTables 53 false false R54.htm 00000054 - Disclosure - Provision for Income Taxes - Schedule of Effective Income Tax Rate (Details) Sheet http://tauriga.com/role/ProvisionForIncomeTaxes-ScheduleOfEffectiveIncomeTaxRateDetails Provision for Income Taxes - Schedule of Effective Income Tax Rate (Details) Details 54 false false R55.htm 00000055 - Disclosure - Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) Sheet http://tauriga.com/role/ProvisionForIncomeTaxes-ScheduleOfDeferredTaxAssetsDetails Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) Details 55 false false R56.htm 00000056 - Disclosure - Investments (Details Narrative) Sheet http://tauriga.com/role/InvestmentsDetailsNarrative Investments (Details Narrative) Details http://tauriga.com/role/InvestmentsTables 56 false false R57.htm 00000057 - Disclosure - Investments - Schedule of Investment in Trading Securities (Details) Sheet http://tauriga.com/role/Investments-ScheduleOfInvestmentInTradingSecuritiesDetails Investments - Schedule of Investment in Trading Securities (Details) Details 57 false false R58.htm 00000058 - Disclosure - Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) Sheet http://tauriga.com/role/Investments-ScheduleOfInvestmentInTradingSecuritiesDetailsParenthetical Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) Details 58 false false R59.htm 00000059 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://tauriga.com/role/FairValueMeasurements-SummaryOfCompanysFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 59 false false R60.htm 00000060 - Disclosure - Concentrations (Details Narrative) Sheet http://tauriga.com/role/ConcentrationsDetailsNarrative Concentrations (Details Narrative) Details http://tauriga.com/role/Concentrations 60 false false R61.htm 00000061 - Disclosure - Subsequent Events (Details Narrative) Sheet http://tauriga.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://tauriga.com/role/SubsequentEvents 61 false false All Reports Book All Reports taug-20190630.xml taug-20190630.xsd taug-20190630_cal.xml taug-20190630_def.xml taug-20190630_lab.xml taug-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 82 0001493152-19-012130-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-012130-xbrl.zip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

?]]@TW-!PBE6_.*Q2)!>P;7)N5@F(!;>\=RF1[&P75X/TW+\0WJA5#7 M$S]@9AR P#D.QHF\)%EMLR.60+CI;Q?Y/)93W51U/-\PI MIQ;*DB[=5*79V)'2W>9*(+6;K=G=TYT'$L@EC4?SW%E8^(=7-MVR@; XX+9P MFJOQ=%>E:MH_X-45 C0#D6]8]=G_+-X\U878]I[Y(\ZV,NL_S"J7N^R+E+J= MSK/2!S(@W\[)P3O+',H#VC:-0WD=3+M M_B#"94J"X0-AWCVIQ#(XF7XJ@G[D::B5"S0=F\;"HIN.\%G5K?31GV?QB >: MHTT#A-'-474(OG.Z^CFJ%P\T1YM&/B.?Z_(HB.[H9$[>CSQI:TH)G+FVLQ5T^:9>$X$6_UYD7V*> MGV9>)*ZH'&)89T'B?N196TM&X)S=8XLHZAG3[O(#%P=N^5X75X?\_( M/0?BG+,8QDGHY\D[W$Q?.2T_]/Q4B 2<@'ME:JV^@:BFHPEE/_3D-!80.%5+ M%E=DEY>*FIJY#,PN,!WN=($I;SQ8/$]VBVDM)[NRN&+T(12AUF>4G7ZSR?-JM,&$LD$QWB ?<,7*8#5F?S6KOYKUW5[-6KU+ MBQ(U8-VZ10>H/>[+6FHNL465;E.KNRX#]W!S>THC;QTXR*]"V<,'\Y4D*QBV M=[]HJ[BA+]+]L&M7?2T3PO8!'?7] D.>8'KF=^'A,'>X4&"O<9O\=J MY# C'0+)?A%:@(KU)9@_B:4P0=JO"4!9%]%$$$)R0"6&, M!$*'2!*2'D_%,G >Z](^UAT)+[2[,-3)CM_\L''ZY,T658!.2.*S,#?"&9PY MY!W18VA"/[BM.87L=#(APC)*5BR(M+'7A&_N?AB%Q<1,SXBHWA0)>62>[\5B51;&HFB5(*[QI+8?F:NHHC$W]EE ]S3@7NT;9R&5+ M #((M@D&Y6_Y#G<)_%&L/L_*FHZ[5KGJ"%=)-"3@MVYG^ EAX8-7.&66]ZBN MP^2;6NU2]\*M=9EPC"VX8$WS\KJOJ!Z@V]W5O=RH8$;2AP"#F4>GB-E'#+-: M9AG53BVLGQDE21KY-(R5V]%6.U>A T;O ]41#HGW??>7"$:/,6')-)S#%PDV MFB#=8;8)!7=]=T(&UZ R]8XV"5" $@%WNP&T)F.4RWI]'#I=LE?/5B[8&ZVZ M=RHH9BO5D G[%=P>%\1.,YJ4DC2HSPE 4RT. M(. 0XE;)D[WZ,5G\FAS4!%,WW)XB;,86J.9AB X0.FY!;6FZ?O'2+,_FH[S7 M:SH"?G#K<0+N^(YC$#=3;UX38L7H D)#Z/8_J0:P[)1:I.U@6V M1YAL3DFK[66CLXQS76>8V#GCG#+#A&5Q'XDFQU./W>?5L95BEK;M/,>$@7AA M0B&Q-@Z -Q/K,MZGCGBK?3J_/EU?S!*"(7$WOC8-Y?U\3K.CD-X463)URP70 M>OP1GXA5I$+"_6C;K2(BU.Y8&-R38\K4MTBE;?G^C$^R"DKAPXEER5YETO%%*5IYX_$!PNU-12KLM;*])CQQ-29.%Z^.T&6&_SVZ5"\,BB[= MWP\S61ZT!,/.$=L[GI=X7!)BC3H:W@S5.YVL[?@ XQ8'4PH;RFU/9'\:D@=R M$4[($NCA\6^_JV>RJL_X .-.IZ<8MLQ:EO@)\?-Z(2>A=Q_31&CG)Z?'ZK5# MV8>K]/@D;D Q;--P>Y=@R^0M'">P_53:?/S&OO'#KC=(038$C-N;/8L[9.P;2<7+OZ;Z>A%*^)G+1H03PDB9],8/FSD7$(9NH[YD]*\# M0INAN-U_/W&$^ MOWL61'/E,?[[E/#3D1?)(VH^MA)1,_BI\N@^PJ:/L.DC M;*Q!TD?8]!$V?83-]QYA@] UIB86G.'H@VP0EL[3$PP>-] %V6 L\:B@%-P M;1=ZM!/X<8A0NDI:P77"MGQWC_TX_(1/M@I*0L Z1"+(D92'1:A**'N,W"$,3M/2"LK8= MF& _%.0M0L7-@&+0V&];=;,?"O*VZZN1.X>"O%4F5ON I!3R(F%FGGO/L SR M=A>D1B8]X:#>@B'5:TZG+J6SK*V;W-YZ,4M3M4JX1)>E>S= 4!JSK(&&.M?U M+D6.N][B]:^%KL2QTCCC=DEK5N38D6O7& ()N; MTBT /W"Q$+=Q1OM?X:$O M%H)$#=G_J819%?J^BH4 !_-K(DPQ?IHSH-6-1!=%C^YOT77QUM,:O(,>FT.K MN[U18=C5EGGCD]AC(84K'0--D>[V,,&@=:5[X2_H^AHG<^*'DY $JOJ\BN8= M[[5:X5(3HKO9,#M% N5690.M3O>;(X\OLCZYF1*2'GO)5./AD#7N_@JQT5RG M9G2#.\3;[G>(:[$]PKM"Z6>\.\$6#RV'O9L+%IS:2ZJ7#;I?X;>%1N6D(5K' MZ\@4ZUIM*/<.3:A&HO_B/86S;*82?J5)]SD(@'E+5?2!*_%[QP:BY9*WO#H%5G/P&:.W;.*04N2SX.\(O..&8#'93[ MB&T$.]7_C5*X;:1 .W"4!5L]WZF:7G!W^8#L/OKZZN%O-!(_Z6]BFH\Q?M=U MQI:=+T-K>(%P=9PRI/L,$NB1K<\-^,[B>F.;9.E!CY:";%#!P 6+>3X";=<] MA$O. JA6N X#FC,R%8K8@[@30F?DDJ2CR:WWI P(@CKAATM+O&W/":#^76:" MG]&DY#[+_7+)LI9K *B$^HZ(0:C#0"=&S*8!CPM%=\3RNP5:'7>/K=)3:VG!D8/DY9X$*FFY@\H;8C'TM /YYQN_D9_C?E#'CE% M*8FOLKLH]$>3"6&<4G75WEJ#($:G*3,@6DV-'@!:Q=N]/,DM=2 %7ECY-)7 M$0U[DEN4LI&RK>BQ3_*NI52[*5]]YH4LI^X+\41ZW$4.WFPV\]AS?DZ8>_%S MWWD):&ZY/6GS02] M8IA!/LZ@3!;_94&82-6[(.TOR6!%W*"@;N#%P:!$WW*08."EY;%I/%A1.%+#%;DC7 M[6T^=,&)-8=Q$U):$RD YCJ"0A=SZ@)NS#&JW4T)S%EG5C2?Q_,L37*^#W29 M3Q2=NBYYOM,K"F JYPKY(EXB^K )?H>MW4YR"F"9+:3."!G9;YI ^,913O26 M(2RS!>ZMG=9=^&&K6^SB$>JK6[2C&?;5+;!5M_A'%OR+JDL E)N,$2;YWJ(/ MDEWCS "0H9M-%T5UD)7?8+ :I_<@]!Z$[]:#4)G]UV'R[>CYB,3^ M=.8Q36YW?4^D)RUC^G&:FK;I7E*M33.N[>G&*V",A Y N2#0N0#:0Q#E*;%= ME#%;]8>^+R*ADFOBD_!!K$4Z>R+4PY$]W_@5H\9GEEI[U3,?2IYQW7D=DD61!<>ULJ=T*C4VCR M=!MPCE^3V!&M/=,?FB/:J2%Z%).;;#Z/0L*46]%6.RR[ON1-H!JR;:]NL&B/ MLR2E,[UHJ^W0;/):V4KH!H6+;.^XXMLI_\*[)ZJ+YXI>K@HJU3"5:H@WL&-W M:#"]R>X2\L],9 1\$$9=,Y/IP:;)=#W,H!BGMYKV5M,?R6JZ\1[I#S%@!]P' M& V?V$RC$G*U%8O@+HZR[FI$K@4(^9'%)D:8CRN6<,1LWMP@6F?;E#9W=,31 MOS=*?+"'(Y^0N_0\3O@^F5>Q4FY-LK:X=R68.VS6M"JE)A7TX!YNMB.%K%6@ M[$%E1'O88-Z&=L8/\P;$3]\/A*4A7RH$^?IZS9+FCC8@[>NR96>0D]Z1G>U4 M),9;VS9*Y%R3@)"96*TO:4IN']4!M[7'Z3R&M"8^S9F"D/MH.9^N*77J$-^: MHXP_?3^PE5F"0/OD"+11K/9NUQZ'+_??#W(;7,$6)L=)GO@#1I-2*5JUP@XT MQZVS*WF4*!9NXW9*58&'<7!)8V_]32FW&[QD+@-AZ@[D1LE7@T-W8PFI^N\* M8\R'A1;G0:<.]Y-0U."^RW*!WC-24*G<*%5=7%W&;OJJT1IL@7NB]0MER_L] MRU1:*W(T5\LT_5P=$"R 8\8;>$[H]!;P#WO7>A?5L+]KW<[NW]^UQG;7^N]$ MY/Y,1")REEI%UU<'"L7=TVOL8Q*Q_>'34@&A6YY3QT&'AM&9*(3\U8[ MC!>SY42"FY_5 Z)1A>O5EG+C$[[7AQ38!WE;H"G2W1 F&)*^U4)39L)?T/4U M3N;$#R>PSP@\/ M_.2>I5/*1(G%1560O"B!...#KK/?U T7;<(/!+'CL"E1@J*@\R03&:NO")_B04'_ M)7G,?U)&+)OTQX]H'3Y ,Q5>)->3521?7WFH3-+X[#;NGB-OR!^H$CE?O==+ MTIGG$[ \B-3ON>Z!'T4UY3@]>^=<$>1S++WRGL51Z#ACC*C0D;?'CXV*[C8L MG;;?G*^Q-Z/\Q>?JF[AY5.<5DG3%CY$;CGUKCGK.?_!.E+#%$/5 M&/L&IIX7"%6W=:&K7*@K06^WW3>4UC1#:+BM]JP]_A1[[RX'PL4(^X&<.2>@ M"=GMT<%FZ5/TB&E(AR!R6]0Y=[>=$=5!;=4$/P0;I((':MNY+UAX'\9>E&._ M5&9.2)#Y_(T]X]Q<,>H3$LB$G"= ,.V/&($&?(#PN#5X+(D4!&]<28!?$D4G MQ*"9$@\BY3H7QZHL^,)'7:S!UR0A[(%/.&UL[+U[_ /*=>&96%7#8LF/7;K'..?D# M\,/!Z^#@7__/\R9&3SC+29K\VU?OOGG[%<))F$8D>?RWKS[='2_N3B\OOT)Y M$211$*<)_K>ODO2K__.__]__!]'_^=?_=GR,+@B.H^_161H>7R:K]%_0=;#! MWZ,/.,%94*39OZ"?@KAD?TDO2(PS=)INMC$N,/VA^O#WZ)^^>?L0HN-C"[L_ MX21*LT^WEZW==5%LO__VV\^?/W^3I$_!YS3[+?\F3.W,W:5E%N+6UOWBTP?T M/]^?H?=OW_WY[1^_>XO>O?UW]._OT-G%]3?/*UJ8LZ"@W;/[ZE_U.I_VM,DM^^9__K(<@Q MHDV4Y-\_Y^3?ONH5]?-WWZ39X[?OW[Y]]^U_?+RZ"]=X$QR3A#55B+]JM)@5 MF=Z[/__YS]_R7QM10?+Y(8N;;WSW;0.GM4Q_)1KY'I*%=I&!2<:<;/ M(*4$^Z_C1NR8_>GXW?OC[]Y]\YQ'7S65SVLP2V-\BU>(%_/[XF5+V9L31KZO MZK^M,[R2@XFS[%NF_VV"'VF+1^Q#?V8?>O=']J'_7O_Y*GC \5>(25)**LOU MYX&M6NE;UV!O<$;2Z#R9AWJL[0D^[3M9L4,!^OK.BW"?%D$\"WQ?TSGL:SRO MQCL]]S5-AQ8\KZ9[F@>!78B0)U>OO%YC]L9I)R\Y-KH+\@=LM\^/'(-A^RT;-;W%+D^-/=5_^;:523HB/4*J&_,HW_^Z_? M=I\#0,S+9%L6.2_0=Q_QY@%GI@J1:7BAH!JZE'>B.#RR*3&.&<9%T'?HKY44 M8%:]G\RJ]U!8]7X:J]Z_ E:]MV#5^U? JG>36?4."JO>36/5NU? JG<6K'H' MC%7W] /+U2++*%2\P4FAF8DI9%TR20NWSR&I(!CVZ-"-><-D4;I"/6D4)!&Z M3I/CH/>W>_K// C9ADR^ITE6$92/Q\W6&:<-VU#[E7]IA;/%8X;YMZ5>2"_J M@C0V8!EG='+>*6,!3F!,+8U:\<,ZG3PK>@Z'_M?8V= __;K\G-"5^)IL)0Y& M\KL+?BAA,5((/WIG@@K1N/E;F<-Z@>46)_=KNJK;XK(@8:YV BI)9SY #[5U M 7(Q[^UNQB8P@ JCOO1>^W_>.( M%*1XD71^J80+:FB@,4I(?O9.!34F<;9)I5 E=E@_\.'N--B2(HAO@JQ@GN?J MZE3M"W32SOR!&7+K$]2BWLE@AV],C ]WJ-9 CJ:)#-28(ET%\U0%IJ_9GOM:1+S44,BX)(877)\1 PA M9*C&A*AE]C>)4 TD=+&27"8LZ(,O8J^*2#..J(7=#2,FP-THHI+T3@0K>,(8 MPN113P%1#?3FP_7E]=< EIHL'HS_@])'.@=QQIA-5)7FPSQID_\7\QOORISQ?ZMU^O?QF7I_FK$PX,(?#6 MKO[DOUT'.,8M>(T_HU_2[+=##PP_D;P(/@S7OY=)J!X<# K.!@@KX.T@H97V M3@5KB&.6-#J##8DC.GJ$WZ W/]U_./20,7FFV3JR\[^5=/7,XEO3A/YGKEF* M&'123$F:? M0X(0&-ZHD(VY4LDA+@C,(2VBB+!I-MOD(=%E4N_?:$ECT'&Z5V(#?[!WHE, M0RP;E,+>2JN#F-(Q2=K-.%B4N\5%0!(&.2=@ER?2 ^^R22X*A ME1:>P*D9 <^*AWNN_J$"X+.@%D8W&&USC)R1.F<\!T@_5^ MS%[?J4^;6JR!?[-5!D/*J8AU/.4&T, "JDR@-U=IGD-;#EQ3-J1)0>N(FGZ\ M3 I,:U>_#ZU7<=#FJ4#KUUL7@IRA.2WH4$ MT[;2;EHH19UM5QC MAL5"CGO_+ )S@F*HTZ<>:(T)O%+_>?]N>%%,RX(H_K MXB$CT2,^3;.MFA<*06>LT )M.2&5@L$('30A;**314SX&SHFW9_<'IP-)TSD M=!UDC]0[G:9J-B@$G;%!"[1E@U0*!AMTT,9LX+*H$::$0&].KJY_A#9#:;?& M3N,@SY]Y72XG4FK0]-; M%DBN."3M_>;J4%2 TQR"MC]X;W@9FG$C\]^]M^W'X)ELRHUT5)'\[JJ-I;": M=A[\"**M98C&[5W+''JZT(3DJ.<)8PEG$P0YM'9F,/S9:;L^X>PA;7,!F*K, MQ-C$7<7 M)N3@NIL2P]]A-+ #&'05IHN M)_83BM*?XENH>2?:=*QC_C6:1XCK\JNT#R]6*A/BB MS!)2E!FFI>!;\RT8M6.:;,*9XYI9N-:Q3=3WSL<=0$L"("HK1ZBR@UI#G*35 MN4UK"T"<[T>2Z)O_G-$WR,BY(\MAF:=%LY^JD'2ZN3)![ZRB5* R>&/&)JZ-&HDB/%R=9E$Y(E$I?*>HT+.U9I("[-9&TF%O//%A$S(OL1DV;EN M)WW@1#P)/BVSC$VAGG%8%N1)'E)K$G:WNVP"W.TSJR2]L\(*GK#WG&!4*Z!6 MX^ '#0F^2+,-SNS8H9!U20XMW#XWI()@J*%#)V-&)>^.&.V'-/,.4<89$53P M6@*,!6 TO *5<#6Q%0.VBCW#&6%9'5AUE:1A+>*:"%)69E M:>4;,MX$14:>+Y/P MYM/51S5U5)+..*.'VI)%+@:#)5IL0H1"(\QOPS#Q@]^2>DZ?*.OJ2S@L_=3B M/Y;7FJM26GEW]Z4L8'>7IC3",$AB@5#8>*]44*/#\X Q+6"3VKMUFA7W.-N< MX0?C.;%"",N?? 1**;42_B*Z:[(@@(_OC39<6_N MS[69**U5W8U+TPK3#5%V>C#X- VL,'!UVJA1;_,A(VJ CV2'3G@JR=V\#(O> MR26++&4W4K7'R[/,>,VU;5E(;1)N@PT8))T/W")M-\_:?8RH/79@_:=#L_4Z M37INF0[2.&&QH6I>&A2<,= *>,LUK30,5ME 5"3 :$?55NOP<0Z;;9"\Z(/) M>P).0\4%8(- \/97&,TN@R0+XJ8RP)9?MYBG_F&.ZZ7_3-7)2_\7S9ILB@&W M6<>F%FR8B34XUB\/6BCY?[*M+$(XBUJI0H,NECC5-^U[C0/\&:A@E27(?Y+L-$^5B6( M.*.+ ES+C='O,(@@!S5N=2J%_@%1P<._.C7MM9"[$"=!1E+32R%#.>>OA,A@ M"B^$](6\D\.$3#@+J$4..ST\">A'0WRWQK@X#?*U)GA!(>DN:D$+M0M7D(IY M;WXS-B% H1)&7!HQ<3?A"-;1"+Z#$>QB$0"'(DR)1' 8B,#.FGY(XXC.173[ MFH*0P[U,!<#>_N5( D:SJV")^Y0%7E=R/HY?/@8OP\UY\^V^66;\/G5J5TC] M&ZAZ&S!(-Q^X_?$+M>?DON"/9?3W--5N?-*$'>@5W 03,TH[?NE.!WGTWIU,U#NE[/"I4K\=(+N;PN_3C,[# M<^T^O$[:F=U8B!8,0.FCBYFPE6[_@R^0/_SQ*BR\JV>"']>\_:\4]L$() M6L(-018:0U0 -3QI5%Q2IEJWFS9+/.V4:+=)(#6[!)%\@\3YA&'";,'_5,%V MG@"IZ?7@+&8(!]_S>"@FQ0,9%!SN>5@ [^UY:*1A,,4&HKCG\5!X"?MI@XZT M*PZ9E/M8,?4*0Q2!004E+G7LE^U"XH +_SV_4/X>RK,VT^":'BN_G/98^0'; M:Z^OVH)K+2NTDOL]H8?W;<\72?3QC+#I_4-9V(W#9AUWX=F6\+MX;8,"#"]L MB5*(Z/Y?P6;[+Q]17]/=P'R7EL7Z(DXS$@6W^)&?H4SBU40#[E8#!9;,+ MV0L]FVP#!F'G Q>'86H)U:9090M5QCRQ]S+$-W&96UQU$,5<7G=0@>Q?>1C+ MP&"/&ICDZL,_4+$C%X&]Z]T-W+ MQ/-MP>#G[@40'COF%A$UB=Z\>_LU:@PC9ID]<'CD)@;X+R(\9R==) MH(\6D8FY6^VI079K.E$&!H74P(3U64!0+C5M&[]QX-EH"]O"4Q2Z"2M+E^QP:J/W7 M.21B,,BDQ29[F8,_"N9N(_3'JZD[GP8-=X.?%?1N'-2*PR"+%49A=/SQRM-V MS\?\&N.8; +S>E AZ6Y!J(7:K0BE8C#(H<4FK GS;U MOO=%X9Y>,(W^DPYZ M_&F[BS2[QI\789B6"7OU[B9+$_K/L'KX3O?"Z30;3E] G5.\X;'_! />&;H+ M:C$6H+6!5FE&>?P9=6;0T ZH9YT[E'<%G1T&691_VD9!@:G\']^^U]Y*L=1U MRN$IQ1EPUT81#FO<)7:??L(G['X_?OO>31B +U_M))& TY#F5@&5! M#)>I4P^_EZ!2$8K-$@D]S# MZZYSLH6G.P)0"EL1H"?G@P "3!D!6B%P!!@CTQ* "A_^5D589J0@.+^AQ5T' M.;;9;3 K.;QI85F WIT+@P8,TMC"%.]A-'JH43S YL.^KHC3QDW8ZQLD3=B+ MEBVG\4G A4DORY4T-,#[5J$!>'^2T. M,7D*'F+Y+,@L[F$)J 0M6?4)LF 89@ H)MFIQ%$G#]^IW;]H'YS3:GAV96/H M!B_6B(.AEQFCA>]B&H?-14OG^G?E=AL3G&F/_L9"+D_]Y #[!WY#">\/8XDQ=7A/."DUJVZ9E,,H%A7$7A#+6 1&BRMQB2$L5!#5D@Y.^$_+ MO$@WAAX^%G+9P^4 ^SU\* &CO56P9#V\$00V9V"7H2^3O,A*MDK33!5D@BYG M"&J@_8F!*.6=*49HTOOIG:33EVAU&W%205_OT"JWXB12WBE@A&9ZA-;909*> M U(Q]X= FO:7R,!H?34PS?',7IN> <^; 2/'X3>/Z=.W?$F;O;#QXI^;_V#\ M^.?>4%'_^=?SNU'!^C^X8($(A+5[]U?O+2U $>9]VX D![\8_^E6W85[/[J[ MZCX&U-UI;W[QWG12.,(M]3([^+G(SR2)-B2.?\!!7*PG1F-.4'882#ZQ0+W M<4M-&.R9"E<,#*_T467 4Q2G+-+@+^4@S'UV2(G9CM>($MMB:@-*3$9@<'4' MY/;A),R@HVB2*8^#@W@9?,*SX-#?!)_\(+B7Q\#_@E!F_L0([)TVJA2JUQ/OO-;##_3=[2 W+SRJ!'U3BH[?((S8AJH54&USJ'=T07)PR!FM[MZ0^[] M9^H+7]0.R4+)F4NR+D#KE(P:WADT">:82)5>=6'O_=OW;P^>A%:VP-#D)M;+ MNTM!:P&[RT"K$8;!%@N$POZ^=%VWOZ3%\\>NGZCGNZ'50R+5+H-2RM58I8'8 MC%$2$>],:,X1)HE;TX#$!+.17"/7493G7*[B+%+ !W@4-Z*2]$\0:HK"E MS .VQ8#;@R=!7X1AAB.69>Z2+N=RJJ:AC$;8X5.!!L"]9P(5DC!H8H(GB5RL MY5&K "P,X3()TPV^#YX79;%.,U*\:$(15,(NPQ'T@/LA"7))[TRR@B=D$>3" MB$JC5GR/4=4['4]^4AU/?G)\//E)>CSY"<[QY"?5\>0P:>BAQX]?[C^=D#2O MGBO5#!U2.7>CA@9F-V!(A+PWMPF9,$Q04=3) ALAAKO,IB<=I;*. ]K5<$>A M[**@=^[8H#-LZQ]\W?)IFR9T0,HPG?>R?%Q\//I[^YCI.J"5H78K4[2=.9OI M16I=D+VJ=W+-PRL,5M0 :BQ4>=,:&^WCM-S*P9.TX\^_I-EOIVFV33,ZQF MS6,)& 10P1(34['4C%3025+]<_*X+FYPQFX(!H^X-]FZQ1'&FZ".*]=,>2:; MLS"/_U/U)]X=ZH\>OS@DQ_;0FBS_,PP HZ:ZOQ MDRV\+GJ:,@OI">HBUY!M2;2)B&88 <=1=0JCR19>%T=-R8\,''60#NDL#:M[ M@4ETGA2D>+E,5FFVX:D %@]YD05A(8T_L-)S%]TQH1A=E(>%$@R^34 J1'W4 MJHCJHDH9];0/,!FOS4SG M5R2EXUUT%A2Z]A[)N6YX*Z+&@2"*&YB(. M'B4%&_WNB@Y26 T-!C^":'X9(F&CL9%!3,A+8Y^66<9 MK'Q:G>@%G5% 1/8 MA@TJ.1#$,( 3#M\K<=2_A>#5/=2SFPK6+=ZF69U2ORC'<7UF<<J:/&%*Z: &I"RU2MPMD?2@AT22RP(B MDA:@@D@]'>:) @!$NB QSDZI5WQ,,_6:=B3EEC92B$.V#$0 D42&2\$-+HH: M68^,N-L$<=R\PJ@LV4C*+2.D$(>,&(@ 8H0,EX(17+1[#]/;9+>"<[[!V2,= M S]DZ>=B?9INMD&B=A@*:;TD4J"H@V.GP*^C0JJ-)!M9)/"CW?9T&2 M$[;!7RW9U>65B#HFCQ+LB#F"'"3:J,"I./.,.H5Z6\7G4+3&<6QR-4,AQP.1 M!.!H'.I) "*&!)9J%&*2 )Q'[^V>*HYY618Y>Y&.NCCU:D^KY'@9;5& T6): MHP&(2Q8P5>6CIKP])ZVUWW^:NNH\H$7]&^RN;!&UO5^OQ+N>,]?$ 1! M)1,ZY=Y_O<-7'P%P%0"T81N.=J3I2?JAC !53IA6#"!=QMA,9.';P7NCRNZ7 M^?@-4P9PN;H@29"$A':!M)J%*:*=IJFZO.HWI3#]FW\V>MZY-P.LF*&B5F67 MM%IEU&BCOS;Z0&Z:+O(<%[F!AF,AIZ]P20$.WMX:2( AD126^(;RW?G]'20J MU)O65HP09-T30P%7Y,=($!A-Y.A4YYX!U_D>!FU.@WR]2"+V?\[_5I*G(,;L MC?OB-,BR%SK-_RF(R_'1^41=IW?9IQ1G<+?=1A$,[::@%6A(E6!PK^H\R]49 MR;=I'L0?LK3<7B9A7+(%)OTK;?"")"6.EEMN0C"R,P-(E;M*.JIH[31![*\$%_VO,:%@>5:%;]OK(K@]>^L=O)PN&@& MJ7QO-6MU8+#K/@M8!^J>NU:462+GDD=*F'WR"$)@&*-")J8D8QGM^/+R&!65 M$LI;+1B4619KG'5(58P1Q5P21@6RSY>Q#!BZ*(!IV9(R'1@$8;@2:ON%ND5% M"883#A)L/;@$3GSUNUVEX(M]\P(2&+4:\?DD6<]NF47\I>K3[0O,(RJP5JOXW328P-_ M, /2*8#Q2S8HQQRKTE9E3):=U)3T/T"-BVR7H7BYH9CY_?N_E63+)G+J&9-> MQ>U(: 8_' +5\F X9@%2'/0J%3[8X4;^""506%;Y8JVC]C&PJ4"!Q'R?@/*71V6MTSC"67Y'5I7IY?W7 MX$AK=S"M4_!$3(LC:K4T1/)-.ZR..T4@)]8\5^!-\,)VV?6+/*FD2QIIH/;Y M(Q$#0QPU-B$3,<_AN*U$^3R)3[HO+),&01PM/]H84.^HGM1(,\M2H MQ(%8W5]4\H[]CQ[VR 7)A<$0R810Q:5FZQL&EWKP]Q@]M;-53S/T?<51[6@2 M#,?W4PYA_=E9/6A8E2+I;//YEXLTZUUJNT]/\&6>4PBCRK!5H9J4_!T>J0J@ M/CT::WCGWB28\O.CN&7@<7M>R;-)[2?'\>ZL.\,K3&%%M_@)4S>K9YM*V"7+ M](#[[))+@F&5%IYPA;$61EDE#8,\UBL-WTL,N[6%YT6%\3S)>DDQC(_H[:_" MH(W"GU[3=IPSV/7U (QW8C$LAKQ."8Q_LD5J'OCJ?5J0XU^O3YE[G3>G9?!6 M8-V4UC^!\TN3C[RA'')/.]9^!0?9DX^N^PI_X+$TU/.\B?"*A*3X&LBQ8F_I MJKWS*HBY?:I9#G+X2O-0!@QO%,#$MYF[G8 CM TR],2DT?]X^\U;^C_O_@6] M>_OVZ&WU_U%>)28*V@=UC] _OS_Z\_M_HO__+8_=^N.?CMZ]_^[HN_=_1&F7 MO@@%!?I+F6#TW=LCQ"C!93_2JEFC[]Y5?SJB$_I\BWE.V'@O^;7V<(P013P5 M11#?!"2Z3$Z#+:'^NE>WJIUO"T6G!PO6!1F<,!BUP-#=&JKX6&>CB%C8_3%) M4%CIPJ#@+2X"DN#H/,@2VI/R11B6FS(."AR=53Y=42,VBBXI:%^0/@7-6F H M: U59VHUO2TZC851;$05ZF!&7GML5HNU\&1L,I@O&CW"M?+ KEQ]#++?,,.U2*)%](2S@N1= MJ12%-RFYY)5= ?KDTFN 89@5S#'-6B6^GQIT:C#8=HMSS$)1:)'.Z!@<_9D(0PU\RB MG?1,,VHYG5+9%6$PS=*K@.&;'4YA)E9IU8ZMKP>#/(#[13H++\M11=L9"IO7](+:42H4MIT8D")(P 4[BZQ'0:>>@#: M(R[7:9(.B]%DV=9O.5CHN4U79EF,8?(R@Q*8HI_?PA(PASM,K%].VB.(:=>;79!!VYNLA4X?F\N]#&1 M.UWT2)41G>Y#?<6(%2YGI<.T?.?/S.67)%]7KP*?X0?ER9!9S^GFAFTQ!ML; M)B4PS+1%*FQQ-.Q;8^I4^VH\Y2A5A,%":9JMKM\UN;EXEBY1T'")95_&G6Z@ M[+5"!GLM>[$,IF?LM3BJ[A/55MH\O>ZRN?%2G#^':XJ+QZ2<%.&H*G2"[K*V MZ8!VF=ID4MZY9(0F76#S/;Q*NEIL/Y B3,G.&4$43)#-1\[(([\IRU.2A.,; M+/9JSE@RH1 M9RQT8##('JAFOAC7U(HJQ3K=3 CD4KTP ;X=E5CAI2WTO#ZC MJBJ&]EG5L9)W%DY%*AWNWC &?LTH2 <\S$8\J$N7BS3#Y#%I^A8M=9('87_\ M/\$K*J.>&4ZRX)*@,XK6I^H$=3"DG8YY3-_:0CLJPV"I MY"P7'@MT3^.85TRU":O7R^@Z=G%\L;\_1S>WRI\L[ M^A=$_Q/5VO>+_ZB?"F-F*BMGEW>UH?.SGAT8O5ZZE3&L?*G(J/:G[*C,L>Y] MOVQ^E1@WS*:;!M-+]UL>BQX)NB]5=S4T2]>^@./G94? 1H_)UK_"FF()N(3' MSW#1SJ7X2A,BLK@LLBB(C#V7!7E"Z3R=-CV;8<7S$.Z^8HQ/>:4:@A23, M+8"1RRCH&6./@DEZK1+)T%.QB=6LZWX\Y76151[2J,)P!2V!C^'Y%5"$99)I#8(@^/FY>P- MSGC9V3TG$I=TV-&EZ]K!'JR-$4.QIVU[*(R!62[M6@)%MI.Z,U C%?/1,7I@ M1JKK;Y49^K?N>^!BN>>N(YN8BVF=YV!?>PV[%)95MH]="\.GP'3+PY9OMT[; M?1ABO_T9D\\76Y><#96NX#X/43>+V)@=GW:<5E:64=DE4 ^0^)16B8,BG MQV?O3%=E'+\TCA0&L13]JC]F6*2QG&P%@,2,30-4Y@HXK):NARTVF>^=?'>:<73*09)(UIS6:';\-3@ M'+?"24#_,P0286@["?$\S;":2/B=*M@2Q7)>4+.DR9)]H(LA%9K+/"]Q=)%F MUVF!3].$SD1RDB;-C%SV4N-D;6?71*87J;TM8J_JW??/PRL,"-4,DW +:)5F M**$VV-%A;02(DV+.M2KF69G1/G-3]36.OBOQS>%].=(]L_I %23$L-.^HO"P/08XC]BP;3O+J3FJF#K*8;\XY MPW@,FVJNCJO,SM$':'LR<2*K.@ M3+0!P(7KBV?AP>4&8%%Y(FHI?_ON.Z_E01-W-/F:QURE$0#4-130>O;QZLBK MAVW-W@,OW6YQ& =Y3E8DY-Y^N5*]YGJ?*E[)EJTI]F+6V6)OCY70K@+W8-,[ MP_=<$#'?]M R.ZU0/P+, O6"X7/K"-ISZ[IQ[!I_YK_,F97T= &X='EQ;&L]!*YPDTQ_9#EOOI.V)!&B;D:> KAZW<1!B.#GDM4/53((*R@ 8JBB0 M]63CU7!4#GFG M%6J8H]Y.%PQI)P)6T39GO&4Q^J3@QXXUA8]Y]D"T(@D5 K-!82QS?UTPF[LC M(Z 8+"W@)!X/++P>-LM@[\AIMP=W=[@H8ERE]*S"_A]Y/$#UHKTTN=M4"[X. M\"R+ICK$,ZA[Y^A\S.9CD+RU4W&VL83BQA0*"O0_WG[S]A_?_A,(HE;2NU=1 M8P12:Y0+[BE#H--W)=5JO@EH[N3%&L,.?$*2/":FV?D]P@E8^FK_-^1!C%D0D9=\NUER>!^Q8Y/XQP$Q3,,B[,W[)IG]CD!'XH379B[1! MJ\IH/5 W9GE SJ%H+D^[LHC^L\SY"DU6.68=9Y2UA=\2TZ0 @WZ6*(64#P=* M>J/@SFFY*6/^;.=BM<(A=>R+*-U6?>8*!SF^8U&Z03:^##A5V1F;)A>HI96U M)@Q^384[)EJGCP)N@+FLH#;!_LV-H+RV@A9WI^A/__C>TV4)ZX1N;B]'Z#;= M)*!D^5W81<[7=@/E.P\7"\X3;5HR#GS;G+XN/1CJG(ER!WND)#./S]25TTGG=7- M-J:U\Q5(Q72AZEG-2NY"-559JSJ8($PK13@XL=+P//!.!C@E5 M:?(%.S]QWS)=-A'8\Y48>VK=IXJ@4AL%GW02@>N(U$F#I9 T8X\1;JW4.8I MK+FIHD-NFN 0ZT**BGY9I"J(GDUC+<"L4D"U9M?>@]6L:,9VC)KC[VH2=)%F M;$/THCG\-E> C0U/Y+,OGH*'9@,0*6F-VL1.:7@$VP#?;]"/O4=L_F->G,2. M!GUZT.D%UWE6>VL0Z3VO"':>N/U/N]-J[\Q7G51/M0"0V])S[&GJKXV]FE/N MR72%\ZISFZN&=L\@7U_$Z>=\\9 761"JWD_0JWA)*:0!+TTN))'W3L<)(-4) MARBWF!+B6NBOC1Z07%77N&#H;K+TB40X.GGYE+/PT&7SX-LB+,@3?[W20,$Y MAASGI9]9T%%J^HE6P)!X-G3A_(BQ><79S!]P;A\'1$%KPM,6^\2W+^ <&)G#?,JE'SID9?69?HCO@.DN!RSR ]-0PSS([Y%YLT*\C?Z\O1//-Z M24NX2**;#&](N-"?9EF"]H;73J40ND;/!K\' MGY%'PNZY\]!/%-5&#QC\1KL=#U9INS7_+_E+T;9*3L/?K HPB'_3:D"AVR2T MTD XYE!C'H?4N=/JO^NGI _$JD])AH.8_)V6B_KV97)&*5T$M^]+9<./ M1AQ._,H4L..6ZNOPAV&"GA:,V1/;;J3%J;86[S E$)_;?0A(HGD*TJCE^B*T M11'&-Y\U*E"D\O.[;GY3SFEO:RGX.,Y?+,>[GBEMEI M'!#EDP<3;3A]P7%.\0:O-DXQ (:PP65#\[('I# MDC N^:LNN2*!JW9G\Y#CH^SQNV;L8)/.?)OF05ROF%6OY$F'T;U8=C77FS#> M[K=* %85>4NR"FG>0^"QASNYF%;+%BH>1L46A=@'99 M:-2 PL%):,?,>L,4OVZ7A91;/("KJ-2IMVKT80R^0K&ZI>T/:Q.+UC?K=IK0R'M;.2:O8W'VDM")>]E$F9L\^X,5_^W?Q"3Y[@P'?M-T'?\ MYO>T8HW>^+93AC-3G(A8\+B-@:_IZJ;Z%SLO"[@N5*+251M+VRL_4[!7\TM+ M>2'T;!SJ0/.>EGC'%*R%FD,$L*QCAV\)_9HXO[34\!*?=I)03T6L*T"A[9=SVB+IV2=5A<]#'6S1\:4AQE&.WFPI MMC4?A*6KG2,6V *5MHNP"E.XQ2$F3YHW=^U4_1)671@]6T4]^%158A:VP6M! M%FA52T(E8Q?34%]O,89%N<*:ZD3K;BE]:6A513U*M"?B4M8$O!@.M<);AB,X"Z$*J!$M@%DY; MTKE0Y^6G]&1!U;L'513&Z$1'>O!)J<0L<:5,\!5L&%79(NN!X1K;3T%EJKZW MCU2%,>TBC?7@,U&)6<7$?>4%=7U_5%$C4PS O"\JXZ:]ME.&%FD1Q#I^3L8M MO1RJNPD%FK;5G9<]7'O6&@) 8XN"6M!98P7,ZGXV=-.U9])8V".Y5;F:V12: M/)153*DN-9Y*TET69BW4+N6R5,P[:";11=CG[V!1DD%3=J0>'C9,2R@^I* AU7[UC#8N!]N@C_5I(,TV+1R63Q ME.OCK\^R KBH"1N\Z'NNCS6&@) M:HN"6I!;8\7[2F=GZ*;E<9OM%ARY;_&V'HRJ_/B&DV^UN$NBFD#WZ:B2A38G M,. 47V&KQ:LI *'LVK(+84GUQEISV,WR,9$DHI2+RB#.^1R!72T,$C ,',S1 M!TFHTX1?PE1-HLQZ3N>RML48O=BD5P+C&FV1*M?[W _2-55[MRSL7Y/MW8*E MC'W ];U9(#G]^H6W<))J<5^$-#E)E2Q(^EEXQR'K7IM'M)^&[#R/@3K!W&UB M^2I636K**.GDGTA_VP2*+A'WJ2-_RY-3$J MH!X9SI_#-7L/[)9.I<[Y6XV*"G<-PF47\E/!_6[H%@&LKNRE[(K$Q^V5498> M\ OH_6U%-%DR/F1IN:4:TEP9JJ'/+817T_-G5N[>^OW$[WMXY?.N"++B8'U_ M7OEE$X$CNCIZ)$G"1G^V].?@/24(^EU1$N#3LU[*+R7VQO/VXN+]<7@/)0=\%/)-(%Z8^ MDG(;D2Z%. P^'XB X9,[ \7ULF=L'A-211WS9Q+:6Y)L3DL>U\5R M]2G'/-76@KUT0YG2RQ;?#U&=;\M95/"NQ6V#AN<:\D[:?: 7S\A; MU@\?L2@!W*1[7R:C$I_A![JJHZ.-].;.=!O.R#RW>"V)IQJ 0=Z9J,>D7A)H<,9T1 MD!4)Z_Q=1^H'D:MTA1T-I'/-TK/S+FGX"Q MD[','H.D?NR%3FKR-"91\UK6#6T@MAU$.9'UH\1:Y1MLM/3^4D% M&IS/6VF"H>,DN,(9?;G9!-D+:37 !U*N!\H:18)@^H5_%,,ZVWT\E#)IK)LP%[XD(>P5>%]G6A?J8Y MW60K3M]NGE=$XR.4:A-@^#D/MY!5N/]N9&>&KV\;0ZBR!,YG#@O:#V255(R] M7]W=K.,>L)=*&'6)G6Q"ZB/[*(AEIX'1*Y1)A Q^WD+/\;UENV*,+C#KE< P MTQ:IY$HSUSM"7)/[Z587G(=6EM+>&T\S 8*AEEYVBCY\WMI[SYM^IK)6'P9A M>;29:48\%G)).CG /JV&$F"((X4UID8E!,Z-7>$\Q[A[ 8FC-#DNDY);UM@4 M8,@BG08@5EG %,[UVA3L7!X&QSZD:?29Q#'UJ9=)0>$2%DO%GP&VWG><:,,E M V<5KT_(20; \',.ZC%=&QM\O.RLH,H,[$U-59'->YL6FHZOO]D6970ESJ0& MAJOV6"57YX:DA$&_)J#0RG>JA)WNY6@!#W9HI))@J*2%)SYL]E! ]F+#PAAW M#U72_HBDW^N3BP*EDLD3\4!T= /IB<=;'+.DGS9T&2LV1=;*=>[X_, M:FY3K=H58IAR5:\#AF*60,407*Z&N![J*X)S8:H2VKNU218@,-/2_4U0!\]7 M>S?9IRZ8.!NV%5B\&-SB6,@EU>0 ^VP:2H AC!36F!.5$#C7Q>\^KM,XPEE> M061CO+WCFJ#O-%1P:K$&T8*VRF 8.!6Q$#/8T_\#JJGZY@RO2$@*(.FAVQPB M$^($-1I>\K?8Q@DJQ<$PSHQ1W,7@5Z6H"N35J*1E*E8[Y$TMOZNSWF+ESLNL=!*DW1F?;Z+8A=[Q %U'14&#WP(B#93T%<]J;YIF%# MK^*R)]B [[-9)P^&D18@QZQB*HCK]";%\+R]K&0FEVW0\&C1/ 2G+Y=:I 7-Y= M^9#COY44UOF35X:CE M?9)*?T2C$@9+*W/:AA&O#I<5-\))CJ,NX1*.),F;>)*(%Q5W=C/E,B?N+H7M MI\2=8\<[&?< 7C*(5M90WYPT.1<,=WB+:7]RZ(<7Z+5V42V7A7K;@S M#VH!NO62&EGOG+$$*(S*3 /5*C#\V:<<+U?G>4$VU,^JL@N.A5SZ(SG OK\9 M2GCGAA;6F!%4B*76:L5@D*)^AF[\%JK5V&:IZ_K%&>OBC)^5,2J"(=P4M-+G MJGM:,'C8'115H%-PR3@S\#[-U-)@N&6$J#[@9+FKZU/27@@"#(*= MIGGQ$1=K]L1S>R"K99A6P^WVK!'Z<%=6*0Z&9&:,&I8=(Z:.*GT8[&HSS-F- MG&IQ+^D!+<9'E2R4U/Z6.(%G!E1F<;&CE;TZB'P\%K2SU85&PXFX7U,JGO%U M] N2D )?D2<<:8=3"SV?B0.4Q="E#1"4H/'0%O KR1QP'F0)G5SF-SB[6P<9 MMG.+1BVGE]7LBC"XO:97 3.IL\,I7 W'11-I_X:]N/,UHOJH>F /<3LPN,>A MG 3\.&2SQ4E>O5^RK1\UN>0A K1C,9>O7UC,LN3T1'5^40=GK=/-@.'R?.S2 M*W+'W!3JVX+!ZIN,I!GM<"2-QD]7+:+_+*L5UQG.PXS(7O"=;\;M#'1>(8TJM?\_=8G'*=\+7C^S 82 MK)UG6&FZ#3BP+LHPRL"H!H:=]EA%!UMI5BG^.UT8+&RO#/2"_ZOBV#G7"?I> M+GC8%DMZV<.D#&U78"IP1W=!5.$O;"I^AXLBQNP%:\->J)V*NS 8._!=*(Q> MWKN?FP!26 @Q+52K\2O+,%Q;FR? ]NQ&)>XE8X/5V8UR$8; M3:=VR:JK2WFPY"6AY0WRWQIA% M!2RBB-\;".()Z1&\(/'319Q7M;S+.8,!L N[+KOF4>K7^;K?[)@M:-%:\^*T MX'';&JIN=((^F*! ]\+/X8%"PL^^6>!7B;N#G+DN_WLRR+:GI4RV & M#)WG8]?QNU%D_QX]RX5:ZU#H3D&Q@'!+2BNDG3\6J(8LO!HHB@*BGPZ?CF)C M6C$C,!@U>K9NN:KZF'V&GRD&7/)N>L'Z5+37!L/.R9"G$!:8'^S-V?&#G3/4 MJWA:\RG!*Q9G@CP8]EF U/%M\&82GVB>ILD3G77RL&S^*S3FR9\3^#G(,CK7 MSI?9+7E<6^05FF_/#V=G%EM.Z(G& +)]7@ET7:'118NP($\ 7:X\7)A71!4S MG#?()SKF^88]=84=*T+1)V9:A=@Y=BN*KI=P(ZBV K:KG*]6F$'#[:G_;5!@ MED4G">ETBE?'Q$XRQZ2?[C&_\/*.,=T>P"XQNQ"ZSM :[3WC@9A=:/WA#*]P MEN&(XJO"CA=)U"PM",XG3^0G6?,UQY]19-7T?X(I@-R?@U]'^\8>ISND,/8N M?\,/=&;(K@EVE=#+ 6%%]YFV_+S8,:.X\N6JB?'J:8@#>F^BG;PZ:SXIX6;\?^?R^+-8FCLY(-0=5= M>+X/E]_2620E>H$C+K;X'&31ARS-5>EQYQIS_H3U[ (+[UE/MN2=UWN!+[F> M6\NCL,I-D_/M5L+MHXA_@+E+LGM.0H6S7";XGFPP2^!:]T%9AY9).7.-:HBM M1Q1%O!-&CVO,!"J("BJ)0I9)=UO)'NK1#?J)NX)L<1+), ]^=O_"B M^PU&LXJ I F1\TKD4-."ZW#S@K#[_R^N$$%(*J"2=44 /M:6 7 P&!;38A QT7)A-7',NCG M#V," M>T;G%$]\_7V/L\URU3Q9HICUJ,5=3D)-H/O33)6L=RI9 ASSB0DQ-H6UV,$> MY-ILZ.R3I E+O(@C.KMEEXN#1RP=!S72#I_5,D'NO9RE$O5."SM\XO9;HX P MU^";*[4.#$]3>W[?)]Y$Y5^)Y+]N!5$-_0R7B*7<^9O=#!;3R,3\DX&$S(Q M)PH71=M:%J5,&(A;$>)!V=MI68[Y#W?;6-CIGZ3I?&_-KBC"1II>S3OCIF.5 MO8A'Y>J-L9Q)'J&HRRP*B(WJ7<%146=N!(M6 .T JXHX8>MW; (6>R?CMF)R MM3@\V.$G.S&AG>0R699%7@0)BVBI8,N/\W3R#@]$S;![1Z-J8>\$LD4H4J56 M88%(::=D09>#+K\?BNJV$%MPU/>&<'29Y$56\DB!#4M ]4Z^'+?3A1R?H>_T(8RIQ1H\B6&K[-VOS$4L MG+JW FQK:8/9EB53I&ZGP!0LD-/V7E"GHB(&$GY"C M_3^2),UXSJ^*E1*"G[S9<'I2Y_3BS9X^M->'0S_IF.>[+903I>: MASIV;3^^7'U*\#/]3Y*SEZ\R_IC+JKY6>I^V.RSU@1';P2=)0.<._)5=2HVX MOYJ0'CH>[%ONCGX/7%W=X?&!/N2]W[@HG;Z'E=T'T;;Z(OOSY^J;J$A[.X3M M>6?1?IB' H?\TTU(4['&APUKZM?7-2YNLG1%B@\X8=DVY"?D)@TO/48-7>Y48]1Q,<,%"0*D>>FP48OJOG$1U M6L$VN8MB9)QER>5L98>B]F=K.W_>DLK;G]$)R3M%SY*+ M.D\.J0 K9(8:\ M(.4T-;T M[!#4\-'8ZC@D'7)!BW< M/C6D@M!B670@Q]QI9.LK^4S84]P1WVBH]HQE-=_[V7'TD*YGRE"-JYC+U+O: M!]K^^#G-?J/SB=-@2XI NCP?2SC;Y)!#:_=\%D\==4LT,'16ORJ[]&LO MIV6F"7$R*;F<-=D5H,]JO89W[S\)ID@\)LS"),):'0K/@GQ]<79Y>IGP#'M5 M(+.JY')9IZS2P1V0228(AT,:=-)$$DP8D:3.@LC%/0UKCL*KP0U-TZ$+^7T: MV2Y&$=J!UAG>ICDIJC2)-$9G2/%*7]WLLYO(M\&TRC Z[UV<"4A#%R+1R]&G1X*TQS*!FI#'#WW M_'1471]UVSVM+GD-< 'KH.VSY8J]Q_[O\+J?%)V0WB8M@MCN??;#4C?#8?4X M"'M<>L."G?\>J ZU->*_?N>T&0IVL]A <"-4">M;G29]%0R_]R$@"=L36";L MA&.Y&CR_W+ZF H-PBS L-V7,;D#T733] M=XPE_EU9"^I#PCV9=WQ0N]=*&9WM[L6VFX[QYZIC)/B1 38>@EB;MXD$B M)7N5R'![Z(!M>+";#^#&I@F8Y&A1B=I&G=:"OK;U#2'/Q)!<'T M>QTZY07!?6QJ*V)O/R5!M7JFJW#-=+(NA9V*L^A<2_!MN*Y!WCM))H <*I?V@G*[M[RFEJ@[HDO6TT85)L*5[A^T1-A3&LI M5S$0T"I,-FZWJX'FCMHMW@0DB=CS.1=T5A7$O^!@G-Q_'P9]7TJ=5G#3E,W. MFG?"[ZT(XT[P_NW[MZ^(Y&QJ5I* 5P]) M%@9IS #'=&EEP(Y)S;3+RJ-VPO[&IC%@]?C42$(+K]2BE 5+CN:\:!-$ASJ; M.JUB,LE3?2:^7"VBE&RQU4%AI=2\J *KS:ZIYN1FZY1>3=^20)9O M.G3M=HSB-'D\-D4;';#-'#X:!JX=YX 7,H5)7@S;7S8.Q8SK_)FQKR3YFN<. M677/?VAW":S4G,VJ)A2BG4=9Z,"8.=D#'1-JJ-GD87Y5C[M4KX5U#]WRXK.G M;LE#C,4L@J->N:M1 ,^]3*P ZW?-C1:]DW^OQ1"NEY7,U_;>A:N?@.%9^ 9O MPZS2K/=,,M.(\,/>GDC?WX6!KB;,SS9HY%U?!-#"5C_5#?&1!A-"PPOMXA[+Q0[2G,N?%V.>,QH@_#K&1_J&:4TM.(R3;< MG0#-+%YW(#31@'=OL@OJR0+!EN;+EA?[&'%5M2(5-(E S50 MAWG;!#$PK%)C&_.GD825(NPZ+7!^$[RP?/"*(@Y%7/)#!JY/C/[O8!@A 24/ MMTF8(#O%K-]PC 8#(O\5!D>&GK-WS:N)_M!G7+=7]S?ZF0NE'OS4NM".92;B MEA[/''-FMG>^?>7Z[/]*!)YP*=)*!\@,HC.I:6(5^G<6_ZO5SQ M."Q^9'>?D<='K,J3M+-5$(>RTZK ZJC6SB10@L\MAS#[:G7:X+OZ7'=3Q@79 MQH0.A0\O;'L5Q>EG?I\^3G-VFX2+ >\Y)SC!*Q*2(.Z.N2\P6PC8;478F@+1 M1RP*:]4Q-';@]P8S^'$7Z#3ZP0VK2H?/)=I]W ,&C76%.<.K@/:]_N:+*B;) MH.0T+,RJ (,X,*V&=Z9-@BE.,K@D_-VOJ3M>0':Y)NULP=_-LMS!ZO95488C MO.$*UG'*@"(FYA[0 XN1F!4< 92":J3"?6(ZH20)'2WY'0V^WK88'@_<3MKH MW.IN2G5G95ZL_, "O$W7F?BGQB=#NV,C/PZ8?'X Y;AFVAD-4#\B@2A<]N)[ M_(/C&!BS%/ M8Y3VUN0U_LQ_FGYMM-6$-R9-Q*V^$3JX_CFX'@JK+7\*XA+/::N"?!WC//\YR+) $8\IRKC+.J6 UR65&@EX]\DZ5,(LLA9#GVLY M&(-[@WJ11/R=C7Q9%CG+<$4)K3F8,ZNY'.9M"]'W.B8=[^2:"'3,MUIM+P=Y MF@W:FR;TLHK2/ UH8\4QCE3;AFIYI]NR)MB#'5F5L'>*V"*T"II%8:,%PS.= ME9C-<6\Q?_[Z)L@T*504LDX7L#JX@[6K3- [E6S0"8E;RR3"$:B8ZUO\A),) MQ-'(NR2/$7:?0$IA,"0R(93-C>@\F/J>D"6-SBH=M W82]=Y$(/972OQ?3HL MD>&6HT;!L7,R !]Y*(4T&(89(0I#7HE1D0ZIY6FA?,H7?'SY6"W[%V6Q3C-V MQB!K#8TXO$6Q#5AQ?[VW Y:>1A=7BA0M>*W+7XC[;*S&R!KN56)@NGF>GPZ M(AW9[XEY3Q_(MXSVG#W0UB: Y('3BF^[<_CJ4P=.*L6^,P?"Z"_C>W=AQM() MZW.%3=3U>6]26QS=E4FI(K2IP!300&^;: ]KJK]?I-D=SIY(...82K ;SXW M$_^<8RONB?+*TH$V+.U*4X6-;#:DV(@KNQWL.-O@W*68[<;G'"/>A]1=D<_F M;51E26W,N>4OGRGL3E^]&=_LM2FDB;PZ&Z"Y:P%\T@&S0\Z>_ZUD+P[0S[+C M!5H?Y%"S)Y ?E2E%W"=#T8+MD M9W(Y[X2Q *<>,)L('48(IN Q@'_6Y7-PJT@-1FEH M3+Y_TK;OWIF>4.B$H9 M1NXN68'L\G;U-;WW_%EP#??*'#8^3/.0I)C?L>]\WSU MK[DJ&?U,6TY/M78I[N#,:XXA,+3>!;TJ1!#7ZOM.7:^8"-6?U88*BC+.ICXJ M>.V<9RS@G1LZ5*HV!Q;L)Z5U,W_K3KM. P;YY.4\"-=#V2G=99I=[TYN3C48 M'=X4H]X)ON^2*#I%WFSL!G0%$$'I&O*E[H(A?L1L=G+RTHG4#Z4O6 &J#>\; MV@!K]M-%FO$_JTYZ]OX9IZ$%!ZJDP5G>GK\!IEL=J&#BB]O,;,["\+:U2KLW M#>@*]>S:N$Z3JHCU!FNW?.C=V*B\U;X;8M*G7T6_G%&9>^FK$[[KM/]66^UW M19 5VO-Z=^66;JOF1Z@G?X1.\"-)$G96\!#$;,KYQ?;Q#VP&H0P,/>0'7WE_ M'E7<@7MQ_;77/_;:%E'536NI+[8_\LU^;D89.7O@C[[R?BFIP /WS=X7H>5C M=E):55<]-Q]#O?*N6NT_.AP\>Y]\]=UT5'D'[Z3U][[D(71<2'7/K.6^V+Y) MU_0K3%C.5X?#Z."CK[Q_2BKPP#VT]\4ON8^*Q53UTM-]G76HPG(/NNA>)%'M M9MB3'=+](V\HW 4%>ZOB+J;8.00/&TSGB70:[+<"+'::^'.3N-.G0W/U]SUM M.WGI^3]C=F:%H_J1^<$IO_L&TJ/Y0CR!394[\@@Z*)"VGF%4A7"D6ZN@6J>= MJB.N=>AM:G#^0KX]#074[\![2+:Y82#ROD8 50V3_]M'!.0S-]00 H'X' M#D-UY<([HM^[P]!?(S$ZC#WMY@-T&/)=?#BP?A=.0W(: 73?SD._:F"A>O8 MTW$#..>AO0P M;OP'FHKSP P/1[=Q[&BQTFY_$EG8+ VAF=@NT+<2/3F\/+ M.0JP/50HIRL'WD_]/1S&W.)-0-B.\6F:%%D0%F40LXOM[[V/&AID7XCSF=H4 M?J8Q2EB_PYF,J2Z,WJ8U@'H6$#.A.LEYE4Y&ZZ8!N9RY.+\0![1;,T&8"?VN MG=-.-;,O5Z6:)+U.O_7XF/$@^DM:8I+D).09"STTK0K(E^)Y]!7MRK7(4?S. MHE+TM2"DM&ZD42N.N/S0*WQ)\QHT$@?/J:#^SJNXD6*JIKU<0E%]!-),X-"%5.<1K16_\)0(=2EY'%Q^ MF51Y%?F;\P=J".F77E.?U%35/GNEY#/>5_>'+YM%=_PR4A_4Q>E=(V^JXT!U M+OW2:^IWFJK:9[^3?.:+Z7?JLEGT.UAY#'2OQ/ ?VR(;LA/,, 3@U3V+@EH_ M9"6U H?S_? M3:N\W??F[+X'IS,Z+.VT7GGHD"88:XEY=\^=?_TUK3EFW"UW_.DO?*_N]=T= M=^0+\DE;+(?P!_M$ ,HG[+]J)_F%_7T>VD-2[HONZSXX$"<@V>_QX0DFPWA5 M[F!F)>_5)TS$\,4YAGGE]W7Y&XQWJ$KGV3=, O'*/,.,"MZS7YB X OT"M-+ M?YA;W?^UQ-UEG?=E[S=;%7VW1>[KWI-V=EUX-R"O?__:S47@75# <03>ZP#R M%=\]3G ?S+7[,-G'VM[%\XK$^5373U4+$PJW,.#$.7@K^PYWXCS,7 MM_W!<#N[\%/)P[F%6PS>_8#G@N_-"1S^'NQ^ZF?6->)#^X.YH%ZC=]BM 0[A M*^8A^N(\QT[5L"<_,EZAH"_K^MM/.&=5RBIZBT/ZS_N4_6GRG7P >$#MR!^Z MVO>Y^SD;S)<8\K-K95C?L9VQ8ODO0A^Z#;_ #?[=*V,FI6'FH;&O%>5<8*>D6-(VH'6:/%ZE>7X:9-G+*LU8!:IN MLNL47,YJS<#[H[1:VOM"U!JB<'L#%RAME%!,M5#84SO08*:&V863_8(#Z6TH M>UUGP\'4XK3^VE;1.[_FH)U(M2/JWQHKZ(6:@>';F"NNQHLX3C^S(]HSO,)9 M1D>!X'F1Y[@X7;-QY#)9;-(R*10=<[H9EWYP;B'[WG&J#>^MK1!+TU%A'06,>!K$IWG2#:1'/GX,-23C&,YR'&>&S'D5E&;5< MTM:R"'V6&E3 D-(.IX2#5 L5P3-UIJT>BCI%&-P[7ZWH1)H\X;:8MW0"?(M9 MFY.85+VQN, 1'2WBNR(H2@KD92"LJ+>]6';)X3U619_G>S +IB_LKRSC_E+K M\ Y#9QZ'BL_\E- /X.@\R-B&9TY7BS=9NB*%G,IV*LXFMY;@VSFM0=X[JR: M'-.EUD*X5N.K\BU7/#2%:F#+I#W$.ZD"!F6ETP@[HXT1<$L8I20,JIC@C4ER M7Q,!T8$W:T]<+<([?Y^#C-L#"(N[+_LLE&J\(>T\#5,G4J"\,;,7%^)NCL:* MCZGSO*(PXE8.J[;]=C,);59F*OS4GJ*RY]T-[K$0XP[!Q;^8[G"19I@\)@.) M,T(5,YP4)-BE7LVFH74/V\J8VDU,=E]5=[$LC##'P)MMF@6T@T2U<(CSU]-/ MSG!4AOQH;8>JZQN!QGVQ@%-9WEEPP^<_5WQ.^$FD-CQC%OHQ@6]PM@D2RO%] M$EBQ=+(!?+G9!F&Q7+$?\2K--HMPO)._HRUG"Z]=B]NNR^8:\NZ ]X%>V%GE MHBS+'5O?5=*(BK\>I]L<8HP/-W+Q_&.'GC_I*]#<]HPJFNK7)WS">S\Z;+G& M/:RR /K(3%X1+)B>)"5)'NL#\JGS&KD!_YU#5S S[V7:P"FM@2S,P-,BB(%, MN84^-SD>:Y(%E\2<4;0^,R>H@Z'F=,QC;C86^)E$P&U\C\3H&YRC!S:/P2A) MD^.HFK*S"S^DP)M#3<:%TK%"+9,SDF_3/(B7JPORC*/J)]FT;IJ^LTGWG&*U M$^TIRMYI.A>Q%4F9&79N$M6&V'Q[Q4S5$D#]+?U'\S<6(ISD>!!HG$0G.,$K M4N3R2.33-%>%C1WF4UX]^!XK2^OJ]_ =[YW-0>&L^B5_[..87V!%8<^.JT'B M4Y+A("9_Q]&'@"3Y,KOBX]<%[PC'16?LK.D+]A8TI!U>.'C17OW-X9 MNA5S.WOHD1E$:=9,?N@X0SJC0(<6W7N *F&O[EWY*I]!V6.S/UR9OWUVA7/J[GZ"NG4FKAA(\$!B4A"< MTZ6I;76,M;RR4%X$+0.'*L"=GQ2L[%8/6!]X&E,TR]7/ ;OK62RS6Y81I7>M M4E$39C67O+,M1)]X)AWOL[^)0(7<-I5\CK84S)K=NDE7;&6RH9XO9TL>+0%= M-]8@B6C[8U[_FK^S;D&3(7C1E+L50]GL>9&1WS#:,@,P7$T#C:Z]JU+T2/PQ M*,J,%"]GZGLK]NHN7<_40O4);*L+QA5-!*SD)JZ>JD"1(7;Q@.W&]VO6:1SA M+#__6TF!WV+:67/,?[C;TD%=UF06:O \S!30XS:K):D[H:(H9[('VM(Z+3=E M'+ 3QYMZQ))>%S;(.MN8,L%M]YY4@MY[M0TZ(02A%>_F%0%7.! K&E3+U:>$ MR+#$L(/>[/&DLFY:5\^W[G!&=^4MT _DO?5\E+8 M*AH,A$%R0H;02)"C:JZ)MCBK%AB'2O,5Q#IO,/C97;HK$5272N'"!5$ M)_>GA^^SZAQY@HR/WJO(&C<2@-'."E3:SLQ#1P_EFCM"+5?&#EV+>.C. W"2 MSLQ_A]'$[1Y7^@3!4KXT<2=-:.0C*8+XM,S87;>7\^>07W>0%<9:U6$* MF$F%Z:6"L=*#P:%I8,74,&V<4=P&L7(#**PM(%R;.!#EN@BI$719:37"SFAE M!-P222D)@SHF>&*:MD8>'0LT\71DH @PE/P,[PA !DY3Y_O9TMU3A$*:%Q]Q ML4XC=2BK0=9I+((.[N#X6B;HO;?:H!-GC7FQST!1U59QAC^F"7[I KZ4YT-* M47<;Q'JPW=ZP7,X[#RS "3O"&3Y&&R;?OY\*R)/0V2\[J;[#(3NIIJL8S;42 MA:Q+3Z*%V_+02]2M!@1[V]73G?FA4OW^0WZ>+\&\ER;!0 MPA]P'*W2K'.)BJJ99]\['IR-\?G0#B=I2'&47Y!F[_: M5EX\!21F#VE545-,N&4Q3,*-Z#O!'UHX?(SL.MYFU.5G*5TY69A ML%?HDE64TY3AO:_A=9 7H6N'^DX;:F4$L2KM[;%#Z9C3 MMB3!'8OI86HZ&%NC0&D#FSF74>D5M(T2LJ:=X,ZZ6+*A#*]QDK22GT7![Q&F$/CSH5(J#<=9FC.*A9T^#T^M QY[7Y>8!9\L5C]Y+JBM[_/YV MNXG^00<5Y3T=:U5 PXO\5H^E'@P?, WLS-'&O%=^0#=0%>P VM;)L&M$YI137LBKRS=@%O=$2K-S5,A"))M-KH'F!FL]7;5W MB*\C< /S&- MED 3(3[1@KO \5E%Z^+))ZE[=PCS,0LG)3TC[(FDLF>&3G"9'4K,RM!A4Q95 MSJU)=M9,SV4%5TDZ3GR@@CI*?S 6@T$>+3;50/)YG!SS4/ML W3FM;56W \K M#&MHC2Q ?EBME4+.0 MB;BE.VI<";5:/)O!]>(G]%>F^G^A3!VM)HR_?N6MEJ\LQ+M=TP376?0PI3S9N!C^DEUK>^P Z :0DDTRGPN-?J1I;M-=ZGKK]&7XHNB0WU;_XJB,O MLI+U@?Z>E[3!IEF YK1GHE?O]-4G"/5>]2K-4$0_P3< B<](-5;0KE0702A) MSVN2A>?EC4C%%Y\>V-7\1@.MJ(K%ZM=9PWQ**!BZE/I M((_;;)F11\*.ZWFG8B\]AF#:ZS*A+H9.%]A;P'<%VVOIA@)SP^FTH;>@%793 M]R.U$93YRWP_+-8]SC;FAF-2$(>[^[7&((L/J4:7\$LW@8(Q*?9:._HQ4^6%+)9CSE]&Q& MWS/^F#>.V.V,YI*%;/MP@K*S_=G)!6IW:ZTUO;-G%ES+F12*:A/5K1J;7 8' M[,[]>T+U@HR],<_&+%D'UXC#FT+9@#5<>:(MQ]YHK Z56PM\E0ECE.@%Y)T& M6Y:HL!K;;G&.LR?*TS2[*(LRPY=U492;+)/M.+[T,:^8HZL@TXQX]T.[(I=< M&^DBH[):F>^;-$R'P>KA[+I.@L0FV>JGEM4*;M\@-0%7+W/ZTF"89X0H7>UL M*SF^U,F/J+O,PXQL3>FPCG*]6..0O4,W<2I 8@#<4SH.O6,GV=A%0N669 ME/$J*&-?>T37:8%SRDQVMUG6=/W?X;6,%)VPX\V$6*]B4B"ZT%G7I!'S$Y'A,673.C7* V=-07]%J^N0/6R M@@:A<*N,BJ).%OVUDG8=4E'!#M<$/^$KLL)W%9Q\E_[;:7G]"E(B@;251$M_F-YK6HDC3"P-C(C%9JH4NE:ARHA MIN6W?5Z*DG;H&M1E$JJ:1BX'K%6T((4&H=*H$T=4GO88ZN'\]IB3(&8+PKLU MQL5ID*\5#2(7@]4>6HSCYJB%$9=&3-QS,^1!0@K&HI/%W4+9"A(I:(V@ABBV M027+^L(WZ V3]]T9&O!1R=ZVQ[G:16EDH;:("JBF71H5.$W$_G"Z#K)'DCR> MIJK&D4D!:Q8-1*%!F"QJA-%I2EOBZOI'4"W1W(ZP:Y&A-.B6D4*U;*&?OT9O M&GV_K=7;6UXFJM6C3 A6VV@0*G;!N2RBPKZK?QLD+^IZ[WX%5^$"-%F:*BKC MO8)+%D.R7*U(B"_*C(Y@98872;0LUCACMTNWK*2:)IB@#Z^1IH.7-2.W6YN9.\C(M TYY# 6@-)D4G"7"OQ2!4-KL=^YAAS*]QZ*M= M(@JR =0X%4W!!O=.PW>KM$_P]H\7:*=?A&'&\VE49S@7:=8;-V5M-LL0N!;= MI13Z5XJ3_LD,=X9!9;,[)V/'Z_V4)-_XXP2/7F%UH.ZDHA3$UI1#E#=5%;+# MA 'TRA:XQD]*Q$"W@=$_#AK!KV\<7D%J';:B,;32L-K$!JKT(+/GSUHM0$TD MN24V\MJ&5C,;@-R0UNCUP]0X>/%(&*:\C$IG."0,XAD)'I,T+TB8GYV?JH[E MM-+0&M$,5>R-E0[J*:$W3,WO!M$YR=]WCWZ'U1!R<..JKZ2.^-&;UZI^ MQF')@K%4LX.Q +#*EJ,3:KL5\UK9%R0/@_@7'&3WG]/[=5KF=/I^31)<8)PH MZM]"!U:3V ,6,IAP3<14$0O3]=I6'^[JN&>6:"NAX]K5U:FBB=2BL%K&B'/< M(!_N4*V!&A5$=?RV"YTP4N^:I$^\G"P 1=4L*DE@K6* *30*DT<]!1Y.X[=) M4CJ=B\.4J)R8( &M">3PQ*IOY;Q6^ _LT?G/:1K9KRO-*K":Q!KON(U:17C+ MS!::>B@118 VBVGHZ)K!]X#1(C%5.>CZMJQLGQ5]&>*_!!LUMT>_PZIH.3@A MLUN(T3\@*NB=U5W6LS/RR&9HIV66X21\$:M=)0FL 0PP-?F7CU%4J:"PUO&R MM?1C&?T]3=6[%J/?856_'-RXTBNIHRH"SR?]*R#:BH9;RQ95[+5RK\CCNGC( M2/2(3]-LJZAEJ12LZM9!%-)R=+*("7^#WES=G]SZW0B];K?CZS0"M+1EICI+ MU4K#:AD;J.*5Q.2X?[37:GENH@*S%XOI2D/9+",):$TAAR>[$8IJ0>\UWHNH M&!\-7^.B29TB)H29H NOE:8!'[???@N5\AR10>[FRQ=D>(#IM!8:E*AWO7BL)K!"JN0-:Q5XC&A M=,#>L+2/=I\S))\^H>2_!#$H:; MS6[8==CXK&1O%U&+)-4W\#X_!)<:!RBEGE1E]T&TK;[8?R:F2-N78GJ)T8OV MP]7DDG\:1?S;J%CSG*<4@!]REO&&5O7S91+>?+KZJ'#94BE@M-! %-JTEN61 M1DS:KQOG:#*[-AB+06P$!49Y*V1PFJ%Q%Z;3 Z4DM,;0PQ3;H_-<( X/;G&8 M/B:D$E:+F&".6Z0GSQN%!8HW>Q">6H0ES:5P+I-E6>0%'<[8 M\T]\F),TBEH86KL8D8I-4ZNP=R;33JD>\SVU#DL&P9(:]^Y/*483C2RTMC$! M%9NFT4"#.^8^!Y?NA;3&RYJ"DXP:L)K)%J[P!D"KA]KQ!T9DTAVF(U]$MJ1X M.:&3^T@3[*H6A=9(!IQBZ[0*J-+P'N0AE,&V35Y%@TQM#:\MP9]N'_=V97OH MI(&UB@54H6WX$".Z,+]-=$]9DJ]P9AIL%'*PFD4/4CC:JZ6!C":?D@P',7O[ MZT- DJLTSY>):9UIH0.KA>P!CUNKTT2/5!6]B:GRUXAEM8:P$NW@36VY5]5J M,UN,M168IOJ)T*78A^'AF3K^4"L-JYELH(X;J=$9' [ZOV!IR$4'.?F<5;:Y M1LASQ&+P0&(Z5QSF4[E/3W#U2)M0[T8-6$UA"U>,:JSUA)PP[/SF ='5LFHXBS M-MK2\I4UC0%8;3<3O>W;:[2-Q9B[J+7FI<7[SU=2A\**VEV6:YZR_"F(2RRT MM;TJK%:>C%O[@"?WIJQ9Z^A)?LFP?:O8'#5!;"O%49.5UJMJ-^WADTWK'?D\B;JFO[,1/8WI+X]-CJ1% M])]E=3U-:$"3 JRVLT0KNZS1T^MR$P:M)K0^Q^9E%"K]=SMKGM+Y).JP6G(6 M]JG=,6PMH;@Q]0H:>KJO51IYS8V^DR>6-7WCF8\\Q=3$09Z3%0F#:F7&TT:S MW-(97N,D)T_L;9!T@^_3113QV!.6'(=$ETF=]T86?;.K35@$V5^!)!$] \N, M(RG/VQWVC=.A@5EG^Q%!:Y^NE@C+%(C"ZA/^8[).<()I24@0=^N&"QRP11SO M2H/K6#+:S#0%CBV[E<,0]O70FNROK%:5T7%:2;ZN]L(,EGB^>&F>/K[)2(BK M3,]=10@4L-"!U=;V@(5T>URS>\M\RW2;W-6]AH72=O>IZ\%I(OI_GH("W\1!B*7K*BNM5]!D"LC63;>M]-&V,>!O_EU--]GF:7&3 MQB1\N%62+$S%LH/<;K 82@0G'SNQ=V;P2\;11GA7K\R O<)8P M_XRC.UH>G$_I0C-LP&JG^040=]BI)52;0I4M5!F#V*LNZ;@E^S33:J:\V>Z(LDE(=IR,5C-J,4H MS-BY<"]9#J[E?:589"_MF%9<^ MICIYZ41N@A?VIP5UI-%RRY\6[64(_!FS!W)PM'C"&9UFWN)-0!+Z=WZ;.0B+ M,HA9TN%WXHK5/098C/%7 0(I:W445/HH:PSPRQNU!9[#F=_O2#D %# P>3_S MXQ$+S?_#3?)+\C$YNT]^H/_G[@],91,41UP5/P>;;8R/J-2[7_[IX[OOSOY MO[:E%OS3H*8C:V2> :%)*SV M,<$4(QRJVF<))3JW_5#I^(E>7:UP6'37PZH"L0L]=!4<$U[RR\V6.O?EBOV( MV?BP""6!^S,-P6K0'4LA!!!Q438LLI:OI!$5]]+49WB%LPQ'%,HBSW&1-]G3 M\FV:!_%R=4&HUZA^DFS\V"O#:M(9R,6-H7;5)Y"I#K)57S%0M M :.-AQD.\V7&8&-:_N[I78O&MK$"O-4G%,&B^=$H_R-E0L9G2)AS@G0V_>QD ME9LR#I@?:[/";J3O$*@$836F :6PJ]6*=X_;5)NYGEZL:9ZU8/&]8F\;_0ZK MZN7@="]QL(LX?E@_PMI<(^+K0*NI1&K$'1R?PHQ,7!3),FRV4H/5C-- M STC87#;J'XVAH-8.:CT?H/5)B(P,? U]CR0=+D1+I,BE?DH00)6):O@2;*8 M-NDY6%J.[&5;I"VW>5937WZJ1Q-%#LN1 *P&4*#34MUCPLF.!\N5GN[\=UAU M+0>GISJE=<7OQS2.T$,9Q_R,)(E03N(GGMV(+NJ\M\4'BFZ11'<<$S^LC_C3 M0]H&4BG!;34#8GU3\A8(7/GA41W$>MSJ:FQ2]$*3J M4D6S(%5?$%&KP&H@:[SJBR.##/[U+9)FH\I/B$F7$U!2/'7;V:G!:K])F,=M MV"FC1-ZK%68OLJN&NTGJL)IV%G9A<.P98:%.9<\,;6!FAS9_9FUUFGSGY9T'K+1\7PH :O.5?!D/&\$_5Y^DUUM5CWSIQ.&U0X62(4@%^EU M;;\O K87,5G":M-]TTX&5ENH 6KNBC)9KU5O_Z( VP8\Q-,+6KNPFGB_A?KB MGF 8WGVK%NR$1\=5Z_6+-&-7;R](0G^GBS&!-%,-P&+'3/2F5.'USD5EJ=FW M8+=VV&-::-58\[0EGX881SF+C*'_CLJP.,,Q)6DFOL:DD875CF:@X@X$OP>& M,AQB*A=5H3]1K<1:<%O9\;6JNB<;S.Y>UT!ET\V1"*PF4>*333@+*DG]8+YF MKWAZ2ZE?XV2]7I>C6"X&J_:U&'69B_FHY&_ *KCL>PA%&AS/S> MVA\\)G2%@QRW#Y$MDNB6W55=KC[EF$?A+XI+;DUV*C[7$*SVVK$4AI>58F:P M>YB-ASUDS"8/(F)A[LPL"@HV&:P,^TD/0))H0^+X!QS$Q7I*:C1K35C-/A6V MF/FQTD>5 8C)TRX9#>F*I8E&SR)9\F^)$*R6TB 4;N]5HMTEDI0)>^E0/P49 MJ1XQ3\H@OL!8DS)-(PNK* EEB=PN1)8\.'_]^6#QT-$F)4A\L=^=A,NYN5NDCOR+%JZJ"^RPO^4U^ M> 6NO4>U1A\HCXL%-["Z=T(M):<%^D3 %1EU#M>>S'Y3 Q:(K7,,)I91K1R7JKH@1C)'U/K[#(-DIBXNE8:#K_-1E M_(V0E\^ N(J+%=2-YZ^6V>SMO<=!!AVF3[_X>)-%?VEZN0ZFD;WD!+\?#O6P)UP4.B?<;B<\BDMRIRWR 5=!%52 MJF6S,<;FH 0N+EWA&N*"0X5S 5)+>.TXO\#F0EZ ;UI.:2D[N3UYX4!Y7/RX@5TGJ98B0DR-?/Y3['Z( MBS!((!IR:PB_?6)-\&*A:U "%V&N(BI?A>7J=L;EEJQ$U1@HO+#6HPS@\VYKJ::Z7-C5,_/GKF>G-_ MM@W9[]/Q*LAWJ(#F^33!C/SL#H5A3J.8>P-#9-4LM_GH6$OBXG (IK;G4YJ_=[?-P6<=^*FM_$XB#L$ZR M$'[5D#::('E(F%3\I[NL7!$P2BH",:59>BH_2DW^\N;LHA77$KC(7R@/S+H_ MP^U#<23F[- $@]ES1%S-[_S M5R:G\X&&[,_;#+ZR4CU?+G.Z#$JXPL0F[T4<6H*5X,"%L .B:11MNJ]*D[JX M"$1%KNU3LM=E]%=9*II2NL?6^^_[6QI,AG @IKQI_>T+""I]E1N-TF.]7+%I MU?:6%ZT''*#U[V>=L3&48^H-VUAQ2#.72X]9NQL ,9=)9W[ZM?AK(8^H#&[70CQ[1:'=17*R.QJT%2&,*B-) KA>DT4&$$B*T M>+U'WX0BFJ^%-)+A8U4\(XU89TE8_X0'?O5$? M/F3Y5UJ6"7]C.0:HV40;+O*W496AO CB0G?]$:Z:%K5B5#%OW%L#7+ VL L0 M?ZV&T,*^,?/@PNC+/S]B,U9X>Z5%EL01Y*24\;*"A(UXI;5<+@]B^T0;^NU:G\)VQ65]0*R9]")0&=A"OUF5QO4:71 M(.,]97&Q.@S4G']\=F=9Z@Q*(&/'$:[&$WTB($AJ22)$Y=37YW+FC!6D M298&PVS9B^*B:1#G.C^U !Y:KMCO0;'B0+J!/<%])35$"AZ4P$62*URM+V7I M*4\))>+(KL>5I4+8R_CW,8A32!=XG8HDSK=Y !N57VE8Y7$94WW_;E "%V>N M<- M0ORUM__]Z>U_GHOHGV*J0QEWT5D0?K],(STU:6=69"MJ;/.=3#;[P38337,Y M7";3#U*;8/+2!(J?LO+^DZK.HR"?)W1A#P&FE<#5_C9XVHD(*T>@H/^X7CS" M:I-8IA4E[@N-*+WG7FW,,&S[YR/E^.H@[G-C065=E.K4VS/K5L5I\L@>/C&LQ(5YU6>TVYP/&.!;^^\ MMW _+FWFP4O-B"SGM9'MK8NN60?:TU,SJJ,_MI;K,5B]%*+F[0&GI9EJBOJV MWQ:4@1;'V=0N;>RI:7G,S5661#0OQ &FJ87U4M]^1M/0/>",$49ET7\3>6 [ M+T5N6S[K*#.(>H_"U.=IY,;.D S.3M$/M:>G<#=]4=P32?66KMS--8Y*6B%$ M--BQ:;<1ZRUH5=1WFW]*P^R>PDYM;ZLWQ3"VNP&=O>5%87("Q=]X:GZ5?T): MP36$3S*UOZD<(@)ZX>D)MV4B#5EZ1GAY3PQ<96G6-1_#8=E@841<#&,T'(]E M6J^00KXZQA4MF\[ MRNTA_]US)%##U*A?THN?6)K3( $7)W&QYB)>0G8ML9D8ZJXE ^6QL.0*4W,! MZY?S-+:"1P.XF_(-E>:VD[H.91I$!T00C9:N2/5MLV$0Z?%U3\_U/*7J,/01SUK-V'9!!U+V>H^M:*=(0] M4:)O($.#E"9^WEGV6L&,)RVSW'( U2N FBX33D>N6J)H>()AN^GSO(I-) &A7H M2+P)7L8S*(5>!7WK6,=R)^71$*>"?OT1EZOSJBBS>YH;0P-,5(&:5#?DCA0K M9>2):2-*W8S4"M%P#EM"%5NC]E^Z<9%#S6X/7/=>"QJ(_UL\IHF=.!J1 \H5 M-9X[N M>.Z-Q].?]9K=9G.1$9QQ!FE$K$T /;+'U:K\]SA "?_! MR/X8))3O,Q9E'D,\6?B!O4"Z7[1*WM \SB)]Z27SH5X^LXE=NJ1?@I)>\@B8 M)AO9+P)$=N:IXEI8.J9X)JRUI7]&FD>+'^']O_Y=1T! (H;%--P+4CER%3(" MT(C ]AIMOZ[115P\9$60?,RSZH%)\*M1$+>SHI%<8&:I<73Q*&\%\@]%B!"?4Y7-"WB1]K-I/%P?Y+3S#0H;*( MWL"#$/6-8BG WG8B"*C_8*#U/H!MV>_ E:LL(NY&0]8V/;H;'-W]#83\?DI+ M!A]"H8A(!VP1$9?T,QLO(H'1W D'A! QZH[5X(TG)8F*JB&$3[DT0C(_!''. M$[7\RB;(54X;PW7HK<["B,@=CWF=9-! N K2TH&0VZ_574'_JABXR\'1 M<;+)WOE;&HCAF$;*;[HG2*"K+"*V1D,V^E0V&F:DI:/V-?<=:G#M0JD$,X?P M[FEHY]-!#!&58]!:@R+YO;+0M49U'"EO9/>%VG$21,35.+R#?4XIF-6WUST' MT=EM'F611,JX#[.'YR(RH[U6UQA(YO0.5)/VXTGK^7!YIEU.8B 04/S/&GV&P:[?>)AV["IHONWWA8*+PD@]YC*7A^0 M/4' LJ$]O#Y]CBR7K1*0WY#8=YA\ L]UK-K0VC;L]]_4.DZ[)SSX]& M8+>^:KRW05:A(1(.47B(CZ6B=M_90*9]RMV_?V'O^:#H]V4.LI M=EZX&KK PZ,F(6OBT_Q$(#LOZ MIU1\Q[8O(>&U_-TNB/9SCK0)"@1S>P25W]M*%=%QT+:65+_3 BJ4\DP:$)7D M-H.OQIT*>0>#H!_@:8-=KGH%.N'R)?%!G$?X>FU)7*,D-4SR^DZ/W$G9[PG2 M=G$AZ#XHFV/;+Y8MX?/TJA'AU>J00K?!,T1=^T)!-$Z4 M3P2^;C^U&I6)EBD2H>NZJL !5RKCD?!"ZLU/Z8(N:)XS2PV>1324C[DU69^I M)"(2!P#J+BVB."=)18+A(EBH@,% C$ JCH(3+[H89I)ZT#HQ5LLWT2:P\-?* MYV&)!#(@@IDW"U(GSLR9,=I??69_L:_55^P?F+>R;_X&4$L#!!0 ( $19 M#4^$%8V-QU@ ,09!@ 5 =&%U9RTR,#$Y,#8S,%]P&UL[7WI<^,X MLN?WC=C_0=L;&V_>A^JNH^]]LQL^JSUC6U[;-;VS7RIH$K+PFB(U(.FR^Z]? M@-3! T>"(I2@2Q/OS;@D)(3,7^)*Y/$?__MY$4^>",MHFOSUFW??OOUF0I(P MC6CR^-=O/MV].;H[N;CX9I+E01(%<9J0OWZ3I-_\[__U7__+A/_G/_[;FS>3 M0/H]Q\DB5+VZ?9BT^\\SY>_?O?=ER]?ODW2I^!+ MRO[(O@U36'=W:<%"LNGK_NC3Q\G_>'\Z>?_VW2]O?_SP=O+N[?^9_)]WD]/S MZV^?9YR9TR#G[<37O-G;G_E_O?MP_^[[7S_\].L/[_X?\$?S("^RS8^^??[Y M[=L?W_+_5.3_$=/DCU_%?ST$&9EPB)+LU^>,_O6;&JM?/GR;LL?OWK]]^^Z[ M_WMU>1?.R2)X0Q,!54B^65.)7F1T[W[YY9?ORF_733LMGQ]8O/Z-#]^MA[/I MF7]+->UK(\GHKUDYO,LT#/)2TXP_,U&V$/]ZLV[V1GSTYMW[-Q_>??N<1=^L MA5]*D*4QN26SB?A?KC";7\V#@M''@.O(XCOQW7<4@ Q23BPA$LNELNA1K$$?"*# ]U; # MF\[N\C3\8Y[&$5\ S_Y5<*TY)3,:TAP\3$ ?>QNTE1;T[G!PY3@)LOEYG'ZQ MTHT.T4"3*J-6ZJHD&$9*Q6(1L!>.$'U,*(AEDX!?)$X\B*_#.6"BRUL/M%[WWBCWL3OR.?)$Q17F/&47_-ZT M(/?!LUE@!K+!EL(L+W >[$L@I1?TMSA>0 V+@BM ML[,!;(AF2@?G!-C0=#2#;].P(:DIW.Z4L-$!R5WNFF"E,Q,/O8/"EQ(I@;O= M%#8P *F;:^PIR0,:9][FM@.UZ<3CP-QLUU0ZI'S^6G3L[QMBB8].'LT'7%%HS MGCZLV/7LX.QFBP>,VL% :Y*Z"G+>-'_9[$JK)I*!Q>4X" 3+8#[AEM_G% M29I!%:Y_C_MD:##4]HA5V]QHOZG#Z >_%]D.%$([^"!KF-8_Y@OC27=^O)AVY';X==TX7?QR_S:>13R MGXAVF;;EP.O2;$L]F,"-F1S=>W?)+# M#]5#=+\G5KD&$<9(Q#]O;/R[6CS6Q\SAH%TZ"&VS!#5IQ?)/0N$+^4= M"<49GX(/$;OWC,R@U?%AX)]Q9V[=&C:$$VN0O&3G- F2D 9Q-1'X*6=]%^"# M7)%&1_FFMVER*WA@G)G2V G4!YS1.'ANM9W*,&HGS['VAE\8O6ZP2T8R3EMR M>\D_:)"0YYPD$8G6'8E1[^;4RC\67;RM_O-N\F:RIJK_&231I.IB4N]C-?#U MT.,T;(PV%LZ^*3-)37A@AX_"'&\>-.'@@<=G]9T$+(_VNSV"%9#,N MVM+_."/AMX_ITW<1H=\)!L0?)2=OWKY;>1__=_[1YVH0M^21BM].*[9;E6O@GG--ZHT(RE"UM9 MKN26&ABIBY)ZG+>$05]@UA-.4L1")212_U5E.@^#_X*'XIUR@X'/'A1&)(YW'P M*)=_JPE0[M_[)'K 45$ P?G) M/W#T,D $IXR2/>&S^+$6GR+#I-40",7/_D$AY1@1@;M%$,?'1483DFF7K%9# M( *_^(> E&-$!,X6A#WR%?,C2[_D\Y5Y2X>$@@!\C_,/$JT(,*%YON>7_(P* M)JI3MQ8726LH*![>KM7,8RY7S?G MG&?3(B\S9O#9JSWP:NF@^'AU'8<+!-5&4EV8J@E\SC]3;/*:YE!TO+JT&]GW M !1QBP5#4FL,!<2K^[N!=0D<__%=A[M+_H&K1R1Y'I'&J]'[R9O))D,"__LD MY=TG&8G$7UD:TTAX44U6/4U67?75KK5RS8+LH02JR-X\!L&RTC 2Y]GZD[:J MK3[^7$M L7DNO4FK+5WSUK0BAU'WGCR[L[=Z^34RTFZ']>YD)=?F!%)P,MQ2 M-A0:*]L"%)1.<[37*+V$93 H6/4##9&\1?BA\O\13G9/04R$VV!^$C#VPL\F MI4^$&AT@.=HK%@B(M ]+/H%8L5>&%BW3+(CY_;A87B1A7(CCI33@2&W?;(BL M7Y]HKV8]X-Y==I[H0!5/F=V2D'"E%0[E)#>CK*5">X7K@R. ?S^0ZCCNJ>&1 M-$5[D^N!B9)3/X"8YG/"))E>NCAT6Z*]P/6 0<6G'RAL0I3Y?%4CT&R%]L36 M0_HR_OR0_ TCRX!&9\]+<3GE9YY241J\J0$!$:.]O_7 R4(:?L '!*H?),,_ MR/4^FZF%S\=>15U<5EPK1U@.+T_S("Y;XNXZC3#96_HXYQ?\3UD5B:K9@O1D M>*]Z-A=B$.]^S*YU.H";.*ALF.N< -IM2D^%]\IG Q*$"]'?:%08FB MU^;>>OH!X\E1VACO41$NZM3,AD^@K$U74%Q4[:'0.#-*6$.CY]P/=$JG6)+E M4'14[:'H.#-:6*.CY]P/=+@&L8)$7=ZTTT=% L7(F<&BSPS2\^\'3+7Q#?M, MM7/'4,B=&42L(1](EKLJAB)N>9/WZSQE-:>W^_287&19062NL8(00 =^1<:' M"LB13U-4D;[-. --=%#4G!D]K"<83!)^H+;..W-+G@B?[4:T5.VA*#DSD5BC MI.?<#W1LCB4[G$?>.S-L[+(YO6J[_695N$Z3L.<262>%(NVK 00L'>\F)FA& MP@':A]UC1PO5:YF1?8S* YB1W^_#?M('XK$8CVN'89-[::YM3FHP.%R9DH9X$CR6@Z? MIK-:?[\&.,[[,,;L>-?0RF90'< , Y7GW&W$A'[H$Q,Z^4NCYW\_Q(CNX4[" M13YEY8"C\L!^0U@9L@^ZIJB)QQM-:B$;/_;93K*%HR*?IXS^*7U]ZG+9)<(. M-QT&/94P/$5-GS-$Q5Z?C"'.-M(A<8-E#-GS-KAAL%&C4KX%?@_; K==3M+9 M9-OIY"^?DJ#@EW,286Z$U25C,TCSWJS+\?Q.\_E)D>5\ MK.SL>>5(('R2^?]%VFMGK\Z0MT,#BAV+0F]Q^;*V9GP)6K&A6TP;S;!W/3N0 MI#SZ(?Z/+,VR&Y;.=,:X1B/LCLN@K8'T0,\RB)CJ*RCEZV';0:)Q,==MH#L_A3*WY\PNR6BY*/0618.>4K M=9R6D65&R QDV$D1;!$#2<$/P#Z2A/,6EZJUH$E9ST0DB#9"9B3$3J%@"QI0 M$G[ =DJX./EMLQ0F'_%"I%O_LU'I2.8]N@+/8U$7[7H+S@_YK08:"9&2OA8SYX% M^P7-YM6[RBEYT!G5S*3HV2/ZP@H6BQ\H2H,2MSJXCF0L8QJ[#;T/UCYZ+ MHJ\^#"M@5_&AY5C.GL-YD#R6+RK'>2@!M8R@E+=%3T%A#9"&&:?"EJWUI_2Q M]& MIXS0QV2M8F71)%%K;[M$'Y,9;Z/=XZPZ0<]FT1?9'J+R V,EPST,!AZDINA] MWS")8>P&HJW):^T2PL]2G-FMLU*EH%4[KJ8DX^=S%G#$:!*PEXN<+#(1&RN< M2=(X+N547=U-?D2.?A0]MX:=46H/ /BQHDB/ZDWNI4U:[%O>FOK\ 'J>#SL- M&EBP?FA+Y8*C/Q+6VZ!G_;##K,O>V#<2?NG>ZMQ1GC/Z4.0BV=I]:KL]].@* M/;V(Y4M$7V&]"M,WY%FQU0P]J<@.^+[.&?X4T+C2V)I[_RHV[CC(J,P2)M5^ M0$?H&4MVF=U@08U=/\PGV1O"2HZ%LQB-"[X>&<+1=N@2/07*T-< @_#\.+;U M/8NN3?;6&N+L!]'3L^SG$@ 4O!_:]3L1=39(=/3$1_](KHO% V'362>HS+#_ M6':#GOC%3A-Z"Q@D&[P([ MH+_79+.5D!_ RA]B35CJJ;"C^_O !Y&#'XCM*2FM^R-'Y^;G/A?MDC":1GP$ M+,=_2;2P)?J<*<\((\ 2B(*B(@:C&F]5\>L\9:(:Z4F:/'$EY))=FZY5=1!$ M#S8=>'->4:)HRY%W2V4U[-."<=6[J32G9&?+P73V*:&ZNN2V_7AS?@$ML=8" M\@CD/88<>/;/2,,NNIRB*C"+;,WSU%S_V7219SHK2P6>1 M%DG^3HTCO ?T#$Q@)&VE,A(LZP> 71!M]8.>0FDX7*42.?!4 M3N^/)4>KHKLP.Y*Q$_2\2+V,24#9> %4U7H0N-9=H29P&^0Z6-"J\OC,4E*WV)1 7>]&YZ3 M("\8*>=JF6[^(2;"B*^":)<.T=,3@6_=.\K,$9CRA^BCZ#^++!=<*2 SDZ%G M%X(! ^7?D?A/*B<.^D2.9C,2\FE\%*7+2DTN29")\(@D"I@L7$=T8$&/GBX( M!HBU1/RX,;E*K8%OB]!FU<"V&O5V3/G\WH.4-#OXIHCQ=]#HX]=PEGB0OV(7 MWQ0;)/'M!M+A.P+2PT W0"7D'YU&O?E9,OD0!7>(@CM$P8TS"BYC>0T!_J^V M]/E'GV]%4F=%E!O_OO;U&&3<'+&3J#6X5)7.X^M10OW$'4NV*32Y0-=#W5:W MW;-$KVA"%\5")]-6$S3'X+;,.A*5\N+D[@(3;?!L%&VS"9JWKEFT,EX8/(,D)#>,AF0Z:_H$*XPC($J@D'&-(A8RV!\*]ZG&,4XQZCJ-_Y$A ";V M+W3^/T]\X#=Q$!*-A19(ZW]P1#&.H7"YIOG_K/4R:>8,YIPK^7FS"Z MK$"Z&4?01E_Q[&_JK/_1VT-BQS[]#],8@$E/0-4\R=MVXG^P11^NE#AA&0TS MKE!!-C^/TR];!AN&P9\L#8.9L R*/B=EI_[EOMKP:V7LDU#AYB\6 [IAZ1/E MH!^_?,J$%]RF^NM1F-.GLOP.H#AJC[Y\.;YKT.PF,NXI,3_>W9SF&G=7,K6_ MU.VRD*.FHEE[+63WJ? XX0>MF#0&?)\.-EO=_!KV?60P/7$)AB?J%H:,E+@L M4I;3/U?A1&5&Y$*DOTBB&T86M%AD%\D360E#HU ]^\.^'SE%NI/U90>18]:Y MT+B?<BPKUO[4 N@*+R%?UMKLU_QT=T*CSJ[LNT+ M>J#XQE_?YI3P@8>T C")ZJN?>C_1$F%'U^]QTP (K[?KT1-A#VE&?-"0AYPS M5YE!MC5?S25PC838L?I[U120$,>_GK2.3YSM]1%J=7S2G%+-I-B) /9Y((4* MTH\KR_9YHG3IXKK^>\!$>IJLEL5BRD[B@.I\HRR[PL45"$"' MGB-A7[<@L S'?V[IL+:] ?Z6QN(K\X'7I@_T? Q[7&OL93M^?>)29,)2=$JJ M_ZW++.F[7FQ(T=.:](0&NF*T9#3^E[HNJ\*17,CF=YK/ M3_B,XG.'Z7SQE3(S=(2><\61JH#D]QH51[A#%9R-K>PLEY(.-7I*&'>KB4)2 MKU$OUFF\5FLGWY'M[JQ=:O0$,X[T0BVI\>L%W)57K1TV?4!UQ)EY'_.4F#I*U MD^E2D;^B)2]('U M<68&&EQ+X)(;O[; A3?$L04TF@FS7JZWU% M=M]9:<]:7=/G':LY\&Y9/E!P_>/GT5!F0_N MBV7YJ>.OK/Q0L5Q6Z3&#>"WML^H#2&Y&$#4X'9%'&F4C%S]N)UM_%AH9W'Y: M#:'XN$M';B/LME^/E&M?(!'.T/?!L[C0&E'IMH4"X\[>N@LP*M[]P&;-SBJ' MV/;5((DDUU*Q%<1I5C!B7A1W[QF*N_N\YW9;\!#RW$?EWC)%W,9-6)P-Z..< M\_HI(V60RY$(8R!+18ZM3E%;J^Z@V#JSO X&E*K&;P_INO.*6I4(:;X2B%1@ ME5?P>OLX3YG>M+YR+.K9'11T9Y9:%Z#O*EU'H$\9?>0LQ66E\'5*IFG2&N$I M>>!2*]3%T^V[@8+LS%SK N2^TMS',E[/N059IYOMH7 YLU0Z7XAE\G&'2QQD M&9W1<)40;9K/B9CU7*QSDF3TB=1# X^BJ!QD$(O#X45R$BR%BZ :Q6%ZAV+N MS'[G"/,A93]P],.>BVH[*O22=!$DVVQ*B>QO+8*?/L!I#B MNE#+1VUV MB%/JDF09:970@ESI3'3(TT:.1&N.P'C'GQ47O)ODD8H'ES(1HWQ>?-^]O:W) M)BLZ/#7[F*;1%QK'?"5JN=29W0U-18!]\=)B(:E-YO6DN"6Q")J] M"5BN,M^_^[$]+59$DS459HCU9O@O]RQ(,@Y%>0\V3A$S)6KDN'QP5A/(JA/D M207%L1-+;BTG_"E7>E+-TY@+-*N*%IZ2&0VIPESQ4^?QK$;_;Y.JA\E?5GW\ M.^)DK(9BGGKM=I@/8QTLQ)9O-9')\VD]BMA+!GU!E;+)P9CQ/6!!^('=HYF&R(=8"LL[E(X*_=',B(\JJ,+KJ23+ MZM:8/AU7CCH%[KOL:A2*H7T6>QK=9(7L)=8H&_()P'E/TCB MR10(Q1/72\+[C?2)H M)R7QI$&--W*"TB1)L$S?X02]@G/IYR$8/MJ@8RS##2NF3%,*TV11@UMED%@ED[ M&M1"+/ASZJYXR,B_"M[;V9-Z:^JX?&S))BLZS#P.318@N1M4%*CI*)J#@IA. MU"3($\>$22?EA(%W'R8*Q']?Z\?_ON.Y ??CG_QE_1>FA=(+EWYUQ',DZO%& MVZ@2$DEB2,I1O.AFURK"MU]OHW'AWXE+Y:Q$>>SA:T9!1 )-64TT,]Z;QQ"[ M?J U"/&A[LG@," KINM=$)/LELR*) ).22T%N,H?.AA&5GR:6Y]$$9.S+*<+ MOA1H @W;[<"I]M'A4##@$PBK+&[M[)O0=0U(#DY5Y@MD5F+Q \FM;7-KU:P& MK(9/1P/$S%EN%6O,S +P ZB3-,NO2#X7Z6TW)FH34EHB(%3.,J383R^S"/S M:A-.!UX1U11 E)PE1K%&R<3\^ MZ*@,YP'##>P#"[ZZVO"W\ML(9OSJT7:;Y M;97FY)(^DH)CZ8ZOJ*RT_L&Z[*%D"#"2'HNJ/ M5)9.\"^C2RL!I@\S[95DPMS4LKL2I37X_Y:2[9D> MT]C96'-F J7DAR&C'+%P[H-#J2# #H XJ5EUP],6BE812%)H656 ;4V?6!' M2X"0LQ<*_B96SY&IV\(Z690:F3)]V,!>019[7X/&.,7BVS*RCK'=C89ZRY'D?UO M5XGY<1ZIL2'U0RR9JYP1LU7-3O#-8(B^L4^>MKJPHQ#Q%VE%BDC-$OVAD\Y* MG2C2A^7Y566,W*K>V6Q&A&Z1S5!O@YR(6LE)R*^LI6[8S]P^O:*_I=EFG!Q" MB+XMYZ>K1W?.0N5?>I1$:^L%7C\6)^_P@REO_'SHPCSV2IA&TVK]*-6W:&OUX/E%NTA1?QI*TT]1Z&JOAW->K;,F*9C3;F>9R1]6=3.E!X>W4 MU6AR7(_)]@$PO@:0"_ZG)DF6K*T?P,G53H5 ;?B;AT)<%.[Y#TQG1\*V^E@. M\>B9:H!0-!\1%@H.:M=G1#1JPQ([\W6:!-M/ZF6FKLCB@3 U3M8=^8&@5AM; M0%JSN#V5#1D@>"8*+_##1,[H0U%*ZY&1<@Q*C 2=F0S;TZ"G+M;#!J&R<94H M,RWR^7F<,KZ7WI)'_OOV.%GV@9X*<'?0>DG-$8+7*N:YW='<08*.,)TFY)\D8##85(WQT]+L#HU>$*[6Q+]?]E@$#43X M66,&6/9 @G&$RN\TB18TCG\C09S/[0&RH,?//+ [5M;B<@2;,*_SV_H381D8 M*@,-]-3G\U0"B<41)+^E"7GYDJ:1+2X00B@X/A_OX )RA% YS!D!'@"4K:%8 MN$N'LSL6!E$X<8'(6%ZS1_!_M6T1_*//]\)<+A[[(OI$HR*(%58AWE;1U ][ M@MXBI!Y][6Z-+7E19Z(L-BY4:4Z7]^E9D@M7WW014%GN/QE7IDZ0T5(#80;, MQ)H;J\\5NPKF))M?DC_^".) NX0IVJ(ES.XCQ>[:I96 HZWC*KLF)*:+ "1V M16.\=(<#"5XK!+P]8[/6WH6$;X4T5>\9BJ8CV3,4HZ\59MFWY%?C^)1D2Q+2 M&261;G?0-,??![1:5 =!S82;%5],5)K,FFLZ,EH_']G++\ MY?Y+>C]/BRS@AT'>(B0C*QZ++)\F9"@\ M ?WAI5$?"DZPT(;8H++U.IF1\-O'].F[B-!JF>1_M%=(_M'G2_(8Q-7&JMB5 M>*M.HS'L1[)QUQZ9]B=BPZV$-_'JRB&36T>R^[A)W 7T[XQF\R2XO#S16^%E M+='JKG3$(S&IJUES;?TSR5+6$,_T"I"EFC-7SW1+DMS/"0N6I,AIJ/8X*9^R M%(VA(AW^L0$@4CV'GL0?-7.$"O\8O8.6DF ,FYF)AUI1/K\P46Y[:HX\V0=- M(H<"-- FZ00AD[.P3<_HS_CM%M!#S=.#,D*R!OG&SE;_IX7/[_' M?-8%"E4YC1M7!4#,RP)&P8XTJ2RVP%X''3^M_"#A^JL&Q^OCSV9U$]JLOQ7?0)6?X MRA%ZN35E7!NP3Q?4HR\!B\S7TE:S,:PP\I'7[&G>U06M>R0=OVS;W 0O92R- MX&3+3A*)W,;7P<)\>W7R:W[H@%1_015%=^7?43C2IUM]W-'V>^"Z]\&9#[U+ M+6Z$(;5EXN@(?%L&C-\P&I(;PD2TA0($64/DG +J:-RZ)-4<.A+I#4M#0J+L MG(^7_QT587Y*8OI$F*P^IB#14F G48))&<"T'YM_F8?O(LL*$IT6(EE$58>W MG+/9+1%N^6$9<<2;E5/V(TLS;9AWO_ZP0R7-L.[(H-N;>T+NZ8*M5L56)9)5]58^SH6)A\]:SZL8^>\EW@J4PQ M=$_88CH[21-CSG@5!9ICH.U>:&+:U%,]KU4K]=7SZH?AB@JZRFM\$;,I*OJ(R2Y]Y"H"( MT?,E@&>#A2R\ Z^:R4=%/D\9_5-ZH.IRV25"3Z?0!RP5[WZ U*TI<4M$]#.I MQKZ,I;:Z^JW=1(P75M;+" &3A4?@J:TFK;'WMR]U.X*"BG@Q[\N:8TNX,%IR M(5TDTR+/\B 1::2KP2AMXCH2*!#(EWD(WW[,*6D9XH\!32[3+)LFZ^+%91GC M;L-KDD]G]\&SYH(Z4/_HZ6K@]]E!)>J)EC0RN51_\=/819+EK"A?XQ;"+>&= MSE ![0&*M ^6"SNIU+#D3%6E,"XK22E'7@Z;]_N09J1LBZH'U3'ABO##7;2M M +!QE]/:4%9]6'2![W@-U01KN?@QK6M%'-2 -1I!(<&WIDAX\T/H5S1)187C MBR0G7'HR+3E^N2EEH0;%JA/PLR@Z:#UDX^KE:?.#T]FGA#SS?U+A?)*R*OWZ MJ@SA?;HQ)ZU>%H01FR;"5G&41"=!$I*X?A!7O5TY^SDH^-B^#H[EO0W M&Y;.:/Z1).(TIWQ(,Q&AY_ZSATS-NQ^+[CI+P4FZ>!#:4IW71&ELSH$HM$"C MU0%\4XE>O?CVZ@PO2L1V$=Y!5GZ K;"!E+;CX;R13-VA)XGCA?4? M :/"&_LH28H@/B?$^#ZKI4#/$@E;4@%<^S'%+@G?@L^>E[1:"$XY$'L9)"^H"T:K)M 79+1A=Y MFRL_9'T4EO&&V2T)"7T21Q-^TU,+7M$W515X/8: 2% M#M\'1<*;JX21*?N#[U0GP9+F0:RXCK0;006)'"$AY\V/Q>B>!>4S^J9^M5J' M)4VA .#?QY5\#KP [;E([UVQ6 3L93J[HX\)G=$P2/+5>BML#FE,0\XKK'+O M]^W*O:O.1>W>6O>3;?^3]0]X5M"W*P%SE5X=#:K=;I2?U:YM"DPMTH#JT_25Z%3S3 M1;'0R;35!"W$KRVSCD2EO+RJ-XG#BP2650C?'.&G44CJN'J1\(,^$3ZN(EV% MM,DQF:6,5 WMG8;[_,!H$D(,+-+Q6ZI.BBSG/+%;,BN2:.-H<%(PO6.H0 Y/YGUK#CQR<$O72UQW?%V,73?J1;H6 SX7V_:)_> MFJU&D_U#QIP?$_"4+-.,YD=91G3A$:UF_F<"D8_;)\G?S1W>^T9*/) P)B?]Q/09M9#WOM^:']VK.A]^PQ9\O79K3FUQPMD0\/ M":-\S@% <7C/\>6MP?5[SJ%0)*10Y$Z/.X="D7LJ%'DO-M./Q>+^2IO@N]L, MS>H-J,&G8LK)@?10K:I;K>K]H5J5=76@/56K&O0Z:[[)PB^QZ#>E-D^OY%+T MYBZ=+@M'6Y+A]O2X;8T<(P42Y>$ MY2^B)DM^E$3":E]:L8Y?[E],-:) Q"/""<2/$_^ZX7 3 S65AP(1^X&;A7Y" MP:PS>;CXV]LLNW-L[<(.NAJB'X*_0D_#UY8,'EV'G.>" M]^(:]683V:^]9LEO5S]#;U>-&'_3%>QP\=HSTY4?::D!VZ%=)&%&Y6!Y\\4:='@3'Q5.AS?Q MPYLX1EATNE@6.6&;$2J-C2L*)0%V'H$>;^HFEGRZ,9P2+M"05N),1(@]R^F? M@3Z7N99H+&9' .>]#8VYJ/Z);V;<&L#N N'DVM#EC5JJ<8;28U_NX*EKK03B MYS6MYK2LN<5)+V_?OP5>WIK.S(8;WN%>=[C7'>YUAWO=X5YWN-<=[G6^WNL4 M'B'K2THVG$G!(0HU[RC$4/371C<6@PK5WOCZ2V4T2\BC& 2^ M^57)HC:234\UFD3;$.;[V]?3/(@]!OA31F9%?$EG&LL=B!C[]6MWN+NBP#>K MMTO7 OR>OG_7-IUO.IF4O7CF\%2.">#ZVF[G@Y5UE"9ON< /]FU?; ?^V[>/ MHO\LJM@740[XFGRI%4IC:<+_#,N19WI+MV4W(\+.DC,_K-_"H#B='45I61O= MY 8C;^T'1KWTLUUQ4\J?%RY+6VZX,B91P*+LTS+B:LG;__CVO0DY(#GV=4ZG MCO(2S3"!X-FW-DO'1Y(^LF YIV$0JTW>FN9^3#.C"5S# 9Y)_(X\MH>D"]'6 M-,?S^XD EU]*;Y#JT1A(]/: M>+VRQ'[AVXK9>Z/5; P+M7SD-7L-YGUOSOD[YO?52#QHDR1;28Z)QY?R"'?\ MLFUS$[R4KEN"DRT[221,/=?!PNC"X>;7_- !J?ZVKYQ.^'?C#G+VZ5;KZ%'[ M'GR2=6:;=*C%=:>/CDS\6#I7)_DMN_HE5-'2>_Y4%81ER;+Q'VG;D!X):;6SOB;8LNEGKKLF7?Z;LCY.4+5/&]:_R MZ2KMN-HU$$ '71N=O=OT5,?ZL@<6SZ[+H0*>8]XCB?G H;CH"*" .*MY.@ @ M9H'XL3$U7]=NZ>,\G\X^9:1,LJ%>^ QD8_&# 7$__@Q6338W59.A\-8(L"VB M/9'ML.S'Y#LE#_E%DN6L$"Q=)#GAXLQO.8MGLQD)Q;,T),V<93>C\4KI)1X_ MD+TD? 4A326\)VPQG9VDB?&5WTP[&E<3N"!>VS)KK,RJ:(YF]=UMB5578AWR MG/DI"2JW1*X;L .+(#-2H?FG@V4.8L.O%;!2"EHEU3KE#+XS>#9U6J/YMMNO MXHUOY6 M]/_UG;Q&<^/!F8Y#77:&QV3]I"'4%@1"D\#O4XMI]#[M7=U5"FJVMT("]WRA M9O(KV'E@EH#O=]M^ON+;OV*]*PML%'S>1PHX%,L>@,[[/0?,^U[VFG.:!$G( M_P7>;%H48]MMI S[N-VLKP+0+6?;?H3;3IM9S,0QJBR+568<^K1R,]E&8':# M+$N>%+.I1S]^WVM[,N7OS-N#)YPS-XT>07=!5 MUR\;:6HN!9_7:1+VQ+E.BNUDL@O471$,/*7W?)F[X-TDC_0AK@PS&2S;TP_M M6]NVFTG5CV?YGCZF:?2%QO%1$G4XWO!AOKA9=N-#SJ)19HOJ!= M)Y,Z1(?ZE 3J$!TZNNC0\I?X8>?HD1%B+("@;(UMXAH@[M @";S,3],O"6'9 MG"[5V9Y:3?R8#<8,3ZU1XV5UV@Q$E\NITP@_@Y-4,V0"=IM-@U^QDOLYOV8M M29'34+VZKTS-TL9H*XA,3E(+N89'5^\0ZW'I)=INA6;0SBLX3?BE\4JRMOU6DTAO55-NXATC)9B[@:@')EY4V:+9"% M*Y-;1[+-$7N[JGY^C[@8=,0$753%J'UZ^;BB22JB%M9..)OU:QM"??QR$^C- MJ5:=C"4)1 _)8#Z<*";:=K#3V:>$//-_4I%)2[BVIA1X6-)N78Y]M%=/D_PBBQ'92@*V[%D+P8T+> MY6GXQT66%22J[\S5]GW+%9'1D.\89;,R.:FA:&#?_K =$\!3=3>!>0WZ/X*X M(,-A;NIN-+DV=A*7)XB7ZEGQ<,/'*W*)E9]I4%63C"8+AY%M_#0/UVE.LIO@ M11@$81Y /[8]@,HN)JL^///^$6GM;-Q\5.U]/V6>?CW4FP MI'D0BXU6^Z8C;8ENX]5K2OWZJN'4D8V67Y"?",N%DVEYC-&*5]48W7X'E["> M7SR/I5OA>:7V5JI][C],0CLBDTN4"]JHNI-<54 M$RTKWZ=JD^Z.A"*?'25];5B ?L?R%CR,_/PP<(B5=SMD4+)1#0GZEFV3-5[+ MMA_HK+T-5C8*8\2BJKW_CZ\&!GP"I:D[JSE.HFT1@J.%B''6)+*&]X!^0NLW MHH*IY=2J?RS7)-,SOOZ3W\[3(^*&('\'.1"IC0A+8&YQ-3^B&I1YO=/:2VB-V5_Q7YLTQ M7?-=L!=Z@+[0[4N[X0>6UEX1?!D,/T-/Z*:C7=$#26J/V/VM2,A X)F[0C<3 M[88>5%9^V(SJ1@GU^;#9:BSOD3+>_)!ZT\!8*TVZ3GMM?-&"]X!^=.QG=34+ M9?RY.>L*:D10OF)*=A$,L-\S\[,\Q/_M+X^8.A_F"H/QCJT9$X&.H/AOJ#H7Z$AOKK MC7<.+2,C'S@W?"W5VB\,-.@W*[BA L3]?D(R;"(R+"7M+D"X=T#&OB4,4^PA MM-J'MPOW.GU(*=D0NB:EY$[A,(>4DGM**7F2+I9!\F)8'1IMT*P3@/214G8< MK;)G-)O3Y"()M<+KM$)[S@"(3\'2/E\%K1__L(\$ +&:&?7C&>*6Q,* *D;Y M4L^0?_Q2_T9_0[3I8PP[7 ^VALBI/"R8IFNDK*T?X-BKI 8XUUMIDA5Q'A@* M9G2;8;LGJ#6E=;:6LN?'TM5\+-0O4;*V?F@[:"F2#;^F(MZ &U@\?BR'S;7]/ A) ME3P >MRJ4XS%A]/$LX_(K(.3;SF/):,1) ^]31_H+X_]X(,(QD= KX)&]:B<,/!&]8&A(29>><:9B3NYK"?_],(PL=:/9>YL%EYJ=J M_P_[I8%J$6-;YW;,"245Q?AQ_\COL-EEFF4DFR;MJACZ3"< 4O20(RCF8#&, M/SBBN><(?Q#H?ENU'4TN&S6C?NRDRFQ(]_Q7LGD:1_7J8&42R#([TCVCCX\Z M.\#.'8^FXL= (O1''_:>&A._]L=(4F,J5>V8)&1&0QK$6R[.B3C*@R^ET-Z MF#HS#>T^+P'"YH%>F8)] M,^V,9#V41!5#89*2XCM+#Q9=[1]LGB43?H=OWSED$W:<3?C=(9VPRTE;KY^W MR]1M]0,%%]]^TT]"XS??[3EA_SM\J\Y8,O;+GW7Z/&W!T?'-("/CW ^$Z@\Z MS6 WS>31$D$QPC>X 'CW R1MW9MK\J7\JF]]H!H]NLO-,)6 .A(9__:FJ^C< M7P':Y&!W 5_QE\OC%<"/40W;G0^QTW+8@SC#!]D\)EGV>^GQI\S!U6T&%2VB MN48^<)^VN_6HCI+H5J0%SJ9%GN5!$O%YKG^F-5-" <(WQ4"EX/"9@$^Y)*3+ M(*ZL/B=!$I(XWF9&DQA-U"10R7M@(#'Q[<&#: MT/&+GPBP.:Y5DKUK,8E%IOK-.!O)_7YI)_=;=3)9];))UC?9=(29ID\5.VM. MV&>F]"%QW"A3]T%!.23Q\RP6ZY#$SR,L#DG\]HB(OTG\]I=*SH?*'DY3R1TB M=!U$Z.Z4 ^T0H7N(T$6(T'6VTHTM0/>0YA&2YG&G+%>'-(][2O/X-S*;$9:E MR5W.YTN^RO-ARK=GI/(Y%22093_.38?,>T-FWD-.@W7(O*=DSGE5$Z$,D%?G 7\NU2ZK&[T,%(X)_3T,%(<# 2[..,_/J,!$=? M A:)4%W](M9JYLD4@2Q=K9%[XENT'I1IF>HT]$/R4JU1"=[M\]4Y/_P'\3]) MP.Z_I/?SM,B")+KFQX:KN)V:98S^E"4LH)!H2?!WVUV1P,B%$=X5+F6V\[%>D ,-.AI6H9PO(:( MQ14DZ"[Q[YVE#QN;3WP_C[%[\=XQG5TD$7VB41'$BN,:;ZMHZL=&KS^JJ4?O MQ"VUG^1_I_F\?+H62C6GR_OT3.]2+^/*U DR6FH@S("96'-S'!/A?+]5#W[: M)4W2#JU421_I=5=XJ]4_1.(B+D4:Z788WE+:$"^?WNZ J'ARNKV+#+8D MHF76TR>2<3+]'-"TQSMI#3,9C*)P!,$T6>>J'Q4?P-KKB$X M3]F",# "BN90 'R= R9!.)+_YM?TBT^W&=B/RE-YJQCWP]"[.7%77B\GZ6*9 M)N5E2>^PH"<;PVT"QHD?$0ZML9E>!!7-/4-%IW$MD!0,>>&VP$>U$#&P:?B' MR?PN:0I.MHS:[_%-RV ]ES4%.[RC2E<]_GU)]_Y+"I5N MK2EZ*9X^TNVPBG<-OA5F2+6AKO:U9PNWRCA7&W&MUB>&5'5&A48#?$-:1PO: M AWHG;*_1*]H0A?%0B?35A/@RN#DBBK!OR91*2]X2\!5\&P4;;,)4+1.+I\& MT:H)\.:8)&D"9HNB3)_9RP8$F*G(9Z6XBJ,?3@A9(52,^AH[/L MQ[M5]B$1+9H0EIE2E>@(\%+B \1KYM0/NU+MR%T5K3@J\GG*1/U+T/VX2S26 MX'( YS6(1EJ I<-D59/$ MHUP6B"T@TL>SKM:D4R+,!I4*%'U/1&2,*\'S!I MRW7=$N&<%^8D*IN5SN4?69KU+6BFZ6\T,>J["8OMN I!]TSYEAUGVE MA# U0Q=V:F1$Z+^P(M)<"$?Q=M2O*[Q'.S#F_9ES^KBGVV\&04[?$Q0XY#K- M.TC)E<=_Z9XG?EO4BU[;@*K5-5.CQ]S \@-S[<0XZBLO.237/ MC_F>'PFW2I)DI5C/GL6?Y)KDT]E]\*S>"&W[@6*);QOK)R%',^NZ$ _^T]GO M92Q[GO%?ITQ9AE[9&BI]1-.4=OP^S:#FR5F4&X5>&ZJV>%&MN]T1ZIR._T*@ MSEM>WU/A%T(5/7K&D@$RN:=P1L%DOXD=)=$L?YWG= M1T._:IHIH5CAVUF@4O #LY,XR++-_CMEY9#/G@D+:4;*!][MYKSZ-GNG\3;J MUQT477RCR4[RB;B,Q+'RK-AMAN<-:W5(5/'G\0Q:GVNWQO&30 S] M^.4L".?-MI:SR:YK*,3X/D&#R=$/M9#?)6LIRXY?MDUN@IMT M9,*R4WYL<"L:])>@2N.).Y(#*4MTR)>Z.&_NPCF)BKBVT1R%.7TJ6Y2U;39, M-"KEO+.LE,,;K'YHDLXFZY^:K']K4TGG4#_'\EWJ4#\'6?*=1>50/V?/I0]$ MTF= P8EMLQ')OC5R3RKDF/;)3+51;ME)HILX2*Z#A;FXCI-?\T,'I/IK>RKI MQ;\7&7%6YP!3-IQ6,_1 ,(?J+S?_^!BWV?NP?)TFTV7Y%%8]?&XLD77;5G55 M_.YXHZ;T X,JSU^D!E]_&5K-&6&*45X_2>19A M(/Z'H]V!<_@>.>R*H5ZN@ZKLXMN1M[^N8 M(>W>R.J5ZJG)W]2+D8T@/M\;68U83YN73>_N6C;#&T$" ;\$=C I5&*Y)<(M M@7\N\C<)][PBB$7 R7L?UF?-X,82A.^)N%[K*NV7^O8=ZD@R&/@IO#&K]N,C M*]^'+SA3-,EH6&;GP-%=U5A&DA0 %:FOTJ#;G+!>Z3)L9"-(L>"-K!R=ESV, MCZIJ+I9R@\5(O=\I1JIL/%G]WB%0"LO]9 7 /ER3U3^%[(<,B]-R)6'L/=0/ M!2P?TK*+I$JC8JKXX.+'L%V,]Z*%&C&/W(]NQ6#-AW7-I3L]DOX8M@?Q7O1( M(V9/]$B7OK-^U($X\_;H"]M%%QA[W%=(GH \XE//9[C]RYDM%^?@\UEFO'H% MSQ!=?O?A> O]56PO6[VN[44$/BB==PN?Y?/O\(N"WZZU^UXBQ^!&BYUE07J7 M<:3'0PX"VYEV&%T>'I;QI\O=66B2^Q220EN/!-L#=S]:W1.@@VIO[H[XBFTU M#G2?W7WI=0]TO@*M?B4': LK@SNO7I_.T%^K\6&?7KZ[C07=I1?14N&_[^Z MR^^#68 /UI/=QC&ROO+L>S#H?KSP11D')Y>.C7OE2%8 8+.(['LDZ!ZWP,45 M!R'_=:Z7L_ >-+#ON-#KGNU5'W=#[W6\N?Z#9()G(8DE"?F?]ZGXJ)=W^$!7 MAQV&A.Y*NY>[UF!H!<, (EAAX=>MT[ M]^:(@9$<>[#$#4N?:,;[.4_91<(_)O?!,\E6@0G7(F5Y3I^V[#:"(CZT@R(V MO4UF*9M4_4W*#C>Q#I--GYA1#QM6M\,WAT!HB7PH7S+*PC$ * Y59/8'Q]BK MR&S4Z:C(YRD3NXFVG(RJ_8C04+'@1X&9[NA,16+4%'Z HEG]3\$,#_5@%E]_/G3G02"U9?B.^P8(9/BK 5=&[)# MVU'&\IK.\W^U]9U_]/E6'$(5ZPW_OO:U'YJL7UZ:(ZZ%\F!(55E7:#U*:$4A MQY)M"DTNT/50O:C;-.4W$2ZB% M1/W#6[^[?Y) %3P!)\=>P&&9#VS%X6DT M5F,Z2.?8(9!@W <4I:--]!,7VS.)S@(F7I$S48.1I3.:JX$49$8J[,!!V)8) M9-Z1Z%>_,DTVC_C'02P6=X70->V!XG;F$ $3MY%A_)KP"C-^+>.1?$IK;^8[VOQ8K=%$_)X7*8]>E?'_U>QZSLU(X/<%-[O?2(-'(,(HEU&^"UWR M8<2UY6+=],+<._8%V8U^ M0*4Z'CTYY0>&L/3*V$TCZOU@WZW=8-^5%&:Q6L7% ,+(Q6+))3&=B2\)/T4N MCJ2'+M%?_^ZP[]D6.K ;HV.;\&MS7]L,F'4MA;NM"%8_A'WI=[-D])"USXHD M @5H4O#+]^K!H,>N(>\#VP@Q%/PZ"8W!0M%15*UQXH?>QHGU[Y1&B>J7#F:) MH9GI@-GGF=FJD]&9&7J(R)%%MS,2,8!IPCE9IED03V?G])E$U5>*PYI=%R.Z MP-LSY]->VAFYX'GUF7" 3S+2<*-/HF.2D!G-,[F?_4F::18C-[\VOMN\2ZGO M:PGXE# 2Q/1/$GT,:))-F=!YPK7^(GDB65ZFVX&N!;"^1G1SWX%+KU<'0RIZ M5?L1W;<-G.QHM<_3/(CQ;?8[7:]?Z96YWS5X[Z8U1PIP28,'&M.S^V+\^U'KR+U*OQ]I"+X,PR1O2.A%P* D3( M)1G>AP\!9".-X[,%ZA#6YTNDAV;X@X3U=>*4(D(K!/@?;<'SCSY?\ITT/DMR M=?@>;]5I- 91R\8]1*">M8BK 2AC\7B39@MDX5K!&FC0[J, "8/8=23JW]*$O'Q)TT@KW$XKO/2- 'DJ>'(DP;\7T9]I:E+/ M3BN\S&\ "2IX(D\-G>*Z(Y-E,.!45SSU#1:5S;YT'. MD!R55M)4^S'4*UFM5!0[2> MRK/-0+=%ZQFI35 O(%HG-;[G/VG:J/54?D $43XE8#*VW%AF/K*49'D'3BL\ZY=,--VE0,&6'\<6L8I-9[7LO/KSBJ+Y M&!8*/0>UDRXB&O52>4=)=)TFP?:3>_Y7%E1!9J8+E'5'?B"HU<86D-8LNEFT M-N9M?BYXXO-^'J3<. MLFPZ6YGAINQ6E#6J%0_06'Z-E&/)G F5@1\+KG2TC6*3FR^SU;>9K(B8CGES M=]A&_MW A8IK_.ENUJSQ]:?BK:;75T%>E&FHM3F3X#U@!S:!=<)6*'Y,_-*< M/T]C+L2L>@FX)>*$2,HO[I8QU;@,@XBQ'X[ %J( G,*J]ZABD41E\;1FX*% MDYG$.5Y#E1WXBY&?Z.QKSCTH?F*@,U ((6$T*E3IRV0D;.3B"HLHB4C-S M*^0N:0<5,N+=43%RIQ+=IF!89VAYI'D0GQ3\%I.$+V?/89D432%G,#54^H@7 M/RM^G&*RC0MM_;X"!4U[O*=X*[D;.?;#/E(9 JY(/D^C[9 W[@3\Y!X*X4JG M2\/!$M0%^ELCO/B%K5S&;_74Y_3I!GAC1C39PJG/OC-2P$1&J+:&:J!3-(>" MB'@/UC/@UHK#R)5P+M@FBM%9'96MH4)&OB$;N,5/(%H#OI8T=/OIA3AGBA>) M;<();0+1GW0Y4-Y,&BE#MU]-:#)9_Y \]9$HY9$KQ 97.0G/(E'+( ME'+(E/*U94KYR A)+I(D?:J2D5_F^L03FO8^YTPQLOGJ$J<,;]?R/''*L6AR M,@_8(S_WG:1:$2O:HKV3 T2K96\_(EV[&-F(MDV#]JIK+V(YNXY$??22%\JU?"+0D M>/9\R'( X-;5OA9D04)SL08=']T=Z?5L\LRQD(]/QYTIY^7#)$[FD,[*& M].CDMW_HM5=/ Y4QSFX&X=>1K$])6%91.J7!8Y)FXI1]>G:B7RD,-% _=Y0] M#L2O'P^V'?NVOAJ+HOE8HHRTW/H!R"IR+;M/C\)_%921SIA_(W$T2QG=6'S5 MBH\#K?F-6J7"<:34 1@'4_IJUBH-;XC"%XR,2!3[AP/DHL% M8CO.VUKYK$MM(2H8M?^A25;L^ Y?L_Z9/8 R>O\#GRP94H(X&F^:FU)N<\)O M2D&\8:CA6O.S$]>:R5\:/WUPM=D+JP=7FX.KS<'5YN!JLQ\1'UQM^EEM]^]J M@_)T]O6YVJ!4A/DZ7&UPZA5A^-KLUP'D/8I<7[L'R(?AH]2]]@"Q<0#IZ__Q M <4Y03[X4,B7Y=#R.92OTK:66;S U;MZY*,P5!AYL*/:GWU<9FR1H:%2K_D MN6,;G/B1M7D?!?JE0G6][ZW3F!0,6OY/:?(>J SM4'4"N"'>H.O#5 M5QU0'*IOB;@PA7DY5N/6)$BT%/@)R1QJ>OUP#I";DP475)]MLU#=A20)&$W5 ME? 43?V8;,:*>(K1XU7&6X_C4Y(M^?5M1DFDJY&G:8Z,@%JX71#43+A9LXX# M/CU#9S+JE8Q=OE;D52ZIZ9:E]/9+5I#9B)V7R MX%)5:O1ZE)Z4LVL*32[0@F8/ M<9>G4:LB]9.),7G(2).:=CS.MP[TOZ6Q^,H<6QV@C88UR\6-G\CADTH. MV-U")GV:IB[#T/%C6Z%QZ*]ET85'X0%(QQO0"HB_&RGBXH3!R)PD&7T2CI+I M@ER3?#J[#YZUSZ)JHM&$Q@)8=^1%M85JKTG;&%T.M!0HF67M(4,*@0_(!M5>6[$&@V[ M\8=_=E%Y\D:BU%J:!+%D>S#MC5!BM,RE5ONCG2C\F+U[3Z^"6:S1Q(*WD\Q\ M\M(5*053X^6R'?@<.FA-TP%=R;*++"M(9*HG7??)D9- D<*WOACY'O]]O++^ ME7JX5LTZUQ>&"J%K05GU@N\P!E: 'M+Q9,IN1PZ=L4H*O)#F'?!R4@!^Y*G[ M/*AO:9>[SY)%\2K@TO_#AYR2Y*1YB&DYG?)B<+7V1/LM. MH* BVFGZL.74TEDM .L[Z/I,I0!$U1C/%]R%@T E>2X'N]]!#U."3 M^IZSZIT'E)5#NB*!2'VWRJ]7+!8!>REO',L@>ILFMV*Q%E/X.,BHOJ[E+^WD>Z*;2=G/I#XL_LUJ8"(-WVIH M_Y9--H.;5*.;!$DTJ8UOW4DT"?)ZWVDRV8QR4@[3BZJ8&R%N90)(SJ>G\L'; M;Y3I^"!@'!+P^>I?>3EP KX!)_?QR^;/WRAA7 CSETOR1&*]$RR4?D1H05D: M(KW?@ #6=Z;NN$WNLI;=^ &GG?*J8(9Q[$44_F9X%\FRR+.2Q7>F:' M$;:W M7R_U52&IEHH?-A/90-_W@>^];6C_V.![/Q;X/O2![X,E?,YLR*[@^S \?(=< MPY!I&R-YLP"D*:!13\VPL[[A\6+SXB#AG9^V\D)\^&Y7+Q379%\GD:UX@YJ M"!7-L6\.%B[K&G8'?J?;L[7\)$U"WA6KQD8W*>;/K!-#[?TNP/8=[_Q,?(^+@26&D8 YD/9L]1FI]!$D)D9/ZS-W7&N1VG,T6JD] ,NJ$(: 6RS MYX4!^2@,A0-+=DM"0I^$0IKL5VH*[ ,@5!?;>2X-(G#H<\)_\XDDA5KF:S>- M=D-L.Z&MJ%5\^'2)E4QT,TK!E N%@T_+L!.NQ3:NE2^9;A9)@ M3'BH>/##<"49GK$:A)K$$UST>F8&R"O35&M\)KN4HCGV[<.H9WI4?#PHGY*' M_"+AVV%1EIS0KF2RMIY,%L@B)AN^']:0YL@@Q6S4%'X HE8K+2@#5I89[![Y M1%A.N5:)D9JKHTF;8Z];)OWJ7B#53#NRG)R)5$S;BVIM"+C)+I.DV#[22U#CWJ9 M7+]OVW;D!X):;6P_X=NRZ.:1[)2*4GH/12FH1T:J >G+>FM)L*.Y>NI@H_8W M0";.H@/6CMKKY!:; 1CB!(QTV.>_ 8 !2^<0K+6O8*V=RCP>@K7V%*SU-R)R M/V4BSR4K"QDN:1[$EYU\CNQ2 MLN7D-G HMPLOMXM0+/-0;GJ M=H6QZ0"M'H5M55Y[J?AAKA"6F"R[6Z*6VN"[BT'!J[#EZLX748?:1+$I8JLSW*G)"I"OAJ<\^'?L#0D M))+)MXQ^A=.C.[W!ZH=82\2/>\IZ5&*$+;=E]=30$D'QPK?M '@?_TFT5H5R M]5)=+>ZW'!7VQ%4S9>=%7C B%#=(0LW.UJ,KJ#+@VXEZR\F/>=P\A]\$+^OC M.#@$ZM?@L]F,A"+.?C<3@;0;*(Z^F8J \GE5ZW.UX&S? MG$$K<9<("CF^90C NQ]SMWY2*"--5J9GV!&I20&%!]^V8^)Z_),/AF4__/"- M-:\3L^8^<4JRD-&EOG:UA@2*)KY-QLCWP-"JTQFMOA'_]1!DA'_R_P%02P$" M% ,4 " !$60U/N_UA5)B4 0"UUP\ $0 @ $ =&%U M9RTR,#$Y,#8S,"YX;6Q02P$"% ,4 " !$60U/!+;OB1X8 "-%@$ $0 M @ ''E $ =&%U9RTR,#$Y,#8S,"YX&UL4$L! A0#% @ 1%D-3TVSOU'70@ ]Y0$ !4 M ( !SL$! '1A=6&UL4$L%!@ & 8 B@$ ' )#A @ $! end